Physical and Chemical Aspects of PET Radiopharmaceuticals

International Nuclear Information System (INIS)

2004-09-01

On the Workshop 23 contributions were presented. This proceedings includes 21 presentations delivered at the workshop. The topics discussed included: Cyclotron and Target Constructions; Target Chemistry; Radiopharmaceuticals Synthesis; Quality Control of Radiopharmaceuticals; GLP-GMP Design; PET Imaging. Each presentation has been indexed separately

Annual report 1985 Chemistry Department

International Nuclear Information System (INIS)

1987-01-01

This annual report describes the activities carried out in 1985 by the Chemistry Department in the following fields: Chemistry, Inorganic Chemistry, Physicochemistry (Interphases, Surfaces), General Chemical Analysis, Active Materials Analysis, X Ray Fluorescence Analysis, Mass Spectroscopy (Isotopic Analysis, Instrumentation) and Optical Spectroscopy. A list of publications is enclosed. (M.E.L.) [es

Shanghai institute of nuclear research, academia sinica annual report 1991

International Nuclear Information System (INIS)

1992-01-01

The Annual Report is a comprehensive review of achievements made by Shanghai Institute of Nuclear Research (SINR), Academia Sinica in 1991, Which concerns nuclear physics (theories, experimentation, and application), nuclear chemistry (radiochemistry, radiopharmaceuticals, labelled compounds, analytical chemistry), radiation chemistry, accelerator physics and technology, nuclear detectors, computer application and maintenance, laboratory engineering, radiation protection and waste treatment. The maintenance, reconstruction and operation of its major facilities are also described

Radiopharmacy and radiopharmaceutical products

International Nuclear Information System (INIS)

Galy, Gerard; Fraysse, Marc; Hammadi, Akli; Tafani, Mathieu

2012-01-01

Written by two radio-pharmacist doctors, this book presents all the theoretical and practical knowledge necessary to radio-pharmacists in charge of the management, the preparation, the control and the delivery of radiopharmaceutical medicines. It presents the scientific, regulatory and technical foundations for the implementation and operation of radiopharmacy in hospitals, addressing themes such as the fundamentals and theories about nuclear physics and radioactivity (production of artificial radionuclides, detectors and measuring instruments, radio-chemistry), radio-biology and radiation protection (biological effects of ionizing radiations, radioprotection, regulations concerning the use of radiopharmaceutical products by medical personnel), the application domains of radiopharmaceutical medicines and products (diagnosis, therapy, biological assessment), and the management of radiopharmacy in a hospital (design, implementation, organizing, operation)

Computational chemistry and metal-based radiopharmaceuticals

International Nuclear Information System (INIS)

Neves, M.; Fausto, R.

1998-01-01

Computer-assisted techniques have found extensive use in the design of organic pharmaceuticals but have not been widely applied on metal complexes, particularly on radiopharmaceuticals. Some examples of computer generated structures of complexes of In, Ga and Tc with N, S, O and P donor ligands are referred. Besides parameters directly related with molecular geometries, molecular properties of the predicted structures, as ionic charges or dipole moments, are considered to be related with biodistribution studies. The structure of a series of oxo neutral Tc-biguanide complexes are predicted by molecular mechanics calculations, and their interactions with water molecules or peptide chains correlated with experimental data of partition coefficients and percentage of human protein binding. The results stress the interest of using molecular modelling to predict molecular properties of metal-based radiopharmaceuticals, which can be successfully correlated with results of in vitro studies. (author)

Radiopharmaceuticals for neurotransmitter imaging

Energy Technology Data Exchange (ETDEWEB)

Oh, Seung Jun [Asan Medical Center, University of Ulsan College of Medicine, Seoul (Korea, Republic of)

2007-04-15

Neurotransmitter imaging with radiopharmaceuticals plays major role for understanding of neurological and psychiatric disorders such as Parkinson's disease and depression. Radiopharmaceuticals for neurotransmitter imaging can be divided to dopamine transporter imaging radiopharmaceuticals and serotonin transporter imaging radiopharmaceuticals. Many kinds of new dopamine transporter imaging radiopharmaceuticals has a tropane ring and they showed different biological properties according to the substituted functional group on tropane ring. After the first clinical trials with [{sup 123}I] {beta} -CIT, alkyl chain substituent introduced to tropane ring amine to decrease time for imaging acquisition and to increase selectivity. From these results, [{sup 123}I]PE2I, [18F]FE-CNT, [{sup 123}I]FP-CIT and [{sup 18}F]FP-CIT were developed and they showed high uptake on the dopamine transporter rich regions and fast peak uptake equilibrium time within 4 hours after injection. [{sup 11}C]McN 5652 was developed for serotonin transporter imaging but this compound showed slow kinetics and high background radioactivity. To overcome these problems, new diarylsulfide backbone derivatives such as ADAM, ODAM, AFM, and DASB were developed. In these candidates, [{sup 11}C]AFM and [{sup 11}C]DASB showed high binding affinity to serotonin transporter and fast in vivo kinetics. This paper gives an overview of current status on dopamine and serotonin transporter imaging radiopharmaceuticals and the development of new lead compounds as potential radiopharmaceuticals by medicinal chemistry.

Institute of Bioinorganic and Radiopharmaceutical Chemistry. Annual report 1993

International Nuclear Information System (INIS)

Johannsen, B.

1994-02-01

The subjects of the present report are described in this volume in 41 reports dealing with various aspects of radiotracers for nuclear medicine. This first part describes synthetic work on 11 C-tracers and precursors. The papers on technetium/rhenium chemistry describes the efforts to gain a deeper insight into the reactions taking place in intricate Tc/Re-ligand systems, to design more suitable and variable chelate units, and to start functionalizing these complexes in order to make them mimics of biochemical substrates or drugs. Progress has been achieved in the complexation of SH-containing peptides, mainly by the introduction of N-alkylation, which remarkably influences the properties of the complexes, by systematic alteration of the peptide chain length and derivatization. (orig./EF)

International symposium on trends in radiopharmaceuticals (ISTR-2005). Book of extended synopses

International Nuclear Information System (INIS)

2005-01-01

Radiopharmaceuticals, along with imaging instrumentation, are the pillars that support the edifice of clinical nuclear medicine and the former is the major driver enabling investigations of molecular phenomena for better understanding of human disease and developing effective treatments. The growth of nuclear medicine has been intimately linked to availability of new radioisotopes and the discovery of new radiopharmaceuticals. The field of radiopharmaceuticals has witnessed continuous evolution thanks to the immense contributions of scientists from diverse disciplines such as radiochemistry, inorganic chemistry, organic chemistry, biochemistry, physiology and pharmacology. Several milestones can be cited in the trajectory of this growth, which include continuing development of a plethora of 99 mTc radiopharmaceuticals, automated synthesis of 18 F labelled compounds, labelled peptides for accurate mapping of metastasis and the advances in radionuclide therapy. The International Symposium on Trends in Radiopharmaceuticals, ISTR-2005, under the auspices of International Atomic Energy Agency, will provide scientists and professionals working in the field of radiopharmaceuticals and related sciences an opportunity to review the exciting developments in the field. The International Atomic Energy Agency has been organizing such Symposia on Radiopharmaceuticals since 1973 and the last one was held in Lisbon, Portugal, in 1998

International symposium on trends in radiopharmaceuticals (ISTR-2005). Book of extended synopses

Energy Technology Data Exchange (ETDEWEB)

NONE

2005-07-01

Radiopharmaceuticals, along with imaging instrumentation, are the pillars that support the edifice of clinical nuclear medicine and the former is the major driver enabling investigations of molecular phenomena for better understanding of human disease and developing effective treatments. The growth of nuclear medicine has been intimately linked to availability of new radioisotopes and the discovery of new radiopharmaceuticals. The field of radiopharmaceuticals has witnessed continuous evolution thanks to the immense contributions of scientists from diverse disciplines such as radiochemistry, inorganic chemistry, organic chemistry, biochemistry, physiology and pharmacology. Several milestones can be cited in the trajectory of this growth, which include continuing development of a plethora of {sup 99}mTc radiopharmaceuticals, automated synthesis of {sup 18}F labelled compounds, labelled peptides for accurate mapping of metastasis and the advances in radionuclide therapy. The International Symposium on Trends in Radiopharmaceuticals, ISTR-2005, under the auspices of International Atomic Energy Agency, will provide scientists and professionals working in the field of radiopharmaceuticals and related sciences an opportunity to review the exciting developments in the field. The International Atomic Energy Agency has been organizing such Symposia on Radiopharmaceuticals since 1973 and the last one was held in Lisbon, Portugal, in 1998.

Molecularly targeted therapeutic radiopharmaceuticals

International Nuclear Information System (INIS)

Saw, M.M.

2007-01-01

Full text: It is generally agreed that current focus of nuclear medicine development should be on molecular imaging and therapy. Though, the widespread use of the terminology 'molecular imaging' is quite recent, nuclear medicine has used molecular imaging techniques for more than 20 years ago. A variety of radiopharmaceuticals have been introduced for the internal therapy of malignant and inflammatory lesions in nuclear medicine. In the field of bio/medical imaging, nuclear medicine is one of the disciplines which has the privilege of organized and well developed chemistry/ pharmacy section; radio-chemistry/radiopharmacy. Fundamental principles have been developed more than 40 years ago and advanced research is going well into postgenomic era. The genomic revolution and dramatically increased insight in the molecular mechanisms underlying pathology have led to paradigm shift in drug development. Likewise does in the nuclear medicine. Here, the author will present current clinical and pre-clinical therapeutic radiopharmaceuticals based on molecular targets such as membrane-bound receptors, enzymes, nucleic acids, sodium iodide symporter, etc, in correlation with fundamentals of radiopharmacy. (author)

Teaching and research in radiopharmaceuticals

Energy Technology Data Exchange (ETDEWEB)

Wiebe, L I [Noujaim Institute for Pharmaceutical Oncology Research, University of Alberta, Edmonton (Canada)

1998-08-01

Radiopharmaceuticals comprise a critical element of diagnostic and therapeutic clinical nuclear medicine. As well they contribute to more basic pre-clinical and clinical diagnostic studies such as the evaluation of new drugs and new drug formulations. Their development and utilization is based on the complex interaction of a number of disciplines including medicine, pharmacy, biochemistry, pharmacology, chemistry, physics and engineering. This technically-complex multidisciplinary base has impeded the development of a uniform curriculum of training for basic scientists and professionals who work with radiopharmaceuticals. the range of technical knowledge required is very broad; it ranges from chemical synthesis and radiolabelling, through a maze of biochemistry, pharmacology and now molecular biology, to GMP manufacture, dispensing and clinical consultation concerning use and interpretation of data. Clearly, no single discipline can (nor should) be expected to undertake in-depth training of radiopharmaceutical scientists, but equally clearly, there is need for the development of curricula that will develop specific components of the essential knowledge base. The `radiopharmaceutical` or `product` orientation of both teaching and research can be used to provide a focus for academic and professional organizations to develop `radiopharmacy` curricula that effectively train radiopharmaceutical practitioners for specific roles within the clinical, academic, government and industrial interests of radiopharmaceutical scientists. Currently, there is a plethora of segmented training programs, many of which are inadequately positioned to be of great value to the field or its practitioners. Efforts to re-focus radiopharmacy programs and to build professional recognition for them are bringing about harmonization of performance objectives, and leading to didactic and experiential curricula. The impact and evolution of regulatory processes will demand new and better

Teaching and research in radiopharmaceuticals

International Nuclear Information System (INIS)

Wiebe, L.I.

1998-01-01

Radiopharmaceuticals comprise a critical element of diagnostic and therapeutic clinical nuclear medicine. As well they contribute to more basic pre-clinical and clinical diagnostic studies such as the evaluation of new drugs and new drug formulations. Their development and utilization is based on the complex interaction of a number of disciplines including medicine, pharmacy, biochemistry, pharmacology, chemistry, physics and engineering. This technically-complex multidisciplinary base has impeded the development of a uniform curriculum of training for basic scientists and professionals who work with radiopharmaceuticals. the range of technical knowledge required is very broad; it ranges from chemical synthesis and radiolabelling, through a maze of biochemistry, pharmacology and now molecular biology, to GMP manufacture, dispensing and clinical consultation concerning use and interpretation of data. Clearly, no single discipline can (nor should) be expected to undertake in-depth training of radiopharmaceutical scientists, but equally clearly, there is need for the development of curricula that will develop specific components of the essential knowledge base. The 'radiopharmaceutical' or 'product' orientation of both teaching and research can be used to provide a focus for academic and professional organizations to develop 'radiopharmacy' curricula that effectively train radiopharmaceutical practitioners for specific roles within the clinical, academic, government and industrial interests of radiopharmaceutical scientists. Currently, there is a plethora of segmented training programs, many of which are inadequately positioned to be of great value to the field or its practitioners. Efforts to re-focus radiopharmacy programs and to build professional recognition for them are bringing about harmonization of performance objectives, and leading to didactic and experiential curricula. The impact and evolution of regulatory processes will demand new and better

Radiochemistry in nuclear medicine. Radiopharmaceuticals

International Nuclear Information System (INIS)

Samochocka, K.

1999-01-01

Radionuclides and radiopharmaceuticals play a kay role in nuclear medicine, both in diagnostics and therapy. Incorporation of radionuclides into biomolecules, and syntheses of radiolabelled compounds of high biological selectivity are a task for radiochemists working in the multidisciplinary field of radiopharmaceutical chemistry. The most commonly used radionuclide, 99m Tc, owes this popularity to its both nearly ideal nuclear properties in respect to medical imaging, and availability from inexpensive radionuclide generators. Also numerous other radionuclides are widely used for medical imaging and therapy. Labelling of biomolecules with radioiodine and various positron emitters is getting increasingly important. This review describes some chemical and radiochemical problems we meet while synthesizing and using 99m Tc-radiopharmaceuticals and radioiodine-labelled biomolecules. Also represented are the recent developments in the design and use of the second generation radiopharmaceuticals based on bifunctional radiochelates. Several principal routes of fast chemical synthesis concerning incorporation of short-lived positron emitters into biomolecules are outlined as well. The search for chemical structures of high biological selectivity, which would be activated by slow neutrons, is related to the method of Neutron Capture Therapy, an interesting option in nuclear medicine. (author)

Dimethylsulfide Chemistry: Annual, Seasonal, and Spatial Impacts on Sulfate

Science.gov (United States)

We incorporated oceanic emissions and atmospheric chemistry of dimethylsulfide (DMS) into the hemispheric Community Multiscale Air Quality model and performed annual model simulations without and with DMS chemistry. The model without DMS chemistry predicts higher concentrations o...

Technetium in chemistry and nuclear medicine

International Nuclear Information System (INIS)

Deutsch, E.; Nicolini, M.; Wagner, H.N.

1983-01-01

This volume explores the potential of technetium radiopharmaceuticals in clinical nuclear medicine. The authors examine the capabilities of synthetic inorganic chemists to synthesize technetium radiopharmaceuticals and the specific requirements of the nuclear medicine practitioner. Sections cover the chemistry of technetium, the production of radiopharmaceuticals labeled with technetium, and the use of technetium radiopharmaceuticals in nuclear medicine

Radiopharmaceuticals in China. Current status and prospects

Energy Technology Data Exchange (ETDEWEB)

Jia, Hong-Mei; Liu, Bo-Li [Beijing Normal Univ. (China). Key Laboratory of Radiopharmaceuticals

2014-04-01

The review provides an overview of the current status of radiopharmaceuticals in China for in vivo clinical use and also describes some important advances in the past three decades. Development of the diagnostic and therapeutic radiopharmaceuticals as well as basic research on radiopharmaceutical chemistry are being introduced. The radiotracers developed in China include: (1) Brain perfusion imaging agents and CNS radiotracers for β-amyloid plaques, σ{sub 1} receptors, and dopamine D{sub 2} or D{sub 4} receptors; (2) {sup 99m}Tc- and {sup 18}F-labeled myocardial perfusion imaging agents; (3) tumor imaging agents including integrin-targeting radiotracer, novel sentinel lymph node imaging agents, hypoxia imaging agents, {sup 99m}Tc-labeled glucose derivatives, σ{sub 2} receptor imaging agents, folate receptor imaging agents, and potential radiotracers for imaging of human telomerase reverse transcriptase expression; (4) Potential infection imaging agents; (5) Potential asialoglycoprotein receptor imaging agents; (6) Other imaging agents. Moreover, some prospects of research and development of radiopharmaceuticals in the near future are discussed. (orig.)

Proceedings of the 17. Annual Meeting of the Brazilian Chemistry Society; 7. National Symposium on Inorganic Chemistry. Abstracts

International Nuclear Information System (INIS)

1994-01-01

These 17. Annual Meeting of the Brazilian Chemistry Society and 7. National Symposium on Inorganic Chemistry present several subjects of different interests for the participants, including sections about inorganic chemistry; organic chemistry; environmental chemistry; technological chemistry; electrochemistry; physical chemistry; photochemistry; chemical education; natural products; analytical chemistry and biological chemistry. (C.G.C.)

Radiopharmaceuticals for diagnosis. Final report

Energy Technology Data Exchange (ETDEWEB)

1994-03-01

In the period 1969-1986, this project was directed to the evolution of target-specific labeled chemicals useful for nuclear medical imaging, especially radioactive indicators suited to tracing adrenal functions and localizing tumors in the neuroendocrine system. Since 1986, this project research has focused on the chemistry of positron emission tomography (PET) ligands. This project has involved the evaluation of methods for radiochemical syntheses with fluorine-18, as well as the development and preliminary evaluation of new radiopharmaceuticals for positron emission tomography. In the radiochemistry area, the ability to predict fluorine-18 labeling yields for aromatic substitution reactions through the use of carbon-13 NMR analysis was studied. Radiochemical yields can be predicted for some structurally analogous aromatic compounds, but this correlation could not be generally applied to aromatic substrates for this reaction, particularly with changes in ring substituents or leaving groups. Importantly, certain aryl ring substituents, particularly methyl groups, appeared to have a negative effect on fluorination reactions. These observations are important in the future design of syntheses of complicated organic radiopharmaceuticals. In the radiopharmaceutical area, this project has supported the development of a new class of radiopharmaceuticals based on the monoamine vesicular uptake systems. The new radioligands, based on the tetrabenazine structure, offer a new approach to the quantification of monoaminergic neurons in the brain. Preliminary primate imaging studies support further development of these radioligands for PET studies in humans. If successful, such radiopharmaceuticals will find application in studies of the causes and treatment of neurodegenerative disorders such as Parkinson`s disease.

Research laboratories annual report 1993

International Nuclear Information System (INIS)

1994-08-01

The 1993 annual report of the Israel Atomic Energy Commission presents, in brief and concise form, recent results and achievements of the well established program of the basic and applied research carried out by the scientists and engineers of the Israel Atomic Energy Commission in collaboration with colleagues at the other institutions in Israel and abroad. In terms of contents, the report presents the usual combination of topical basic applied research. Much of the work has been published or submitted for publication in the international scientific or technical literature. The main headings in the report are: theoretical physics and theoretical chemistry; optics and lasers; solid states and nuclear physics; materials sciences; chemistry; environmental studies and radiopharmaceuticals; radiation effects, dosimetry and radioprotection; and instrumentation and techniques

Harvard-MIT research program in short-lived radiopharmaceuticals

Energy Technology Data Exchange (ETDEWEB)

Adelstein, S.J.

1991-01-01

This report presents research on radiopharmaceuticals. The following topics are discussed: antibody labeling with positron-emitting radionuclides; antibody modification for radioimmune imaging; labeling antibodies; evaluation of technetium acetlyacetonates as potential cerebral blood flow agents; and studies in technetium chemistry. (CBS)

Report on the Technical Meeting on Therapeutic Radiopharmaceuticals

International Nuclear Information System (INIS)

2009-01-01

The purpose of the TM was to provide an experts' platform to facilitate exploring the current status and future directions on therapeutic radiopharmaceuticals. The invited talks and presentations in the TM were in the following topics: - Radionuclide Production; - Production and availability of alpha emitters and their radiopharmaceuticals; - Therapeutic radiopharmaceutical chemistry; - Targets and biological evaluation; - Medical physics and dosimetry; - Clinical applications including radioimmunotherapy and clinical needs; - Peptide receptor mediated therapy Panel discussions: - Radionuclide therapy using alpha emitters; - Regulatory challenges with therapeutic radiopharmaceuticals; - International activities in radionuclide therapy. he technical meeting generated a large interest among scientists and physicians working in the field of targeted therapy using radiopharmaceuticals. Participants from both developed and developing MS reported on recent developments on the research work and clinical studies going on in the field and provided their views on the future developments in this field. The unexpected high number of participants and the high number of presentations with exceptional quality underlines the great interest of scientists and professionals in therapeutic applications using radiolabelled drugs / biomolecules. The intensive discussions including panels specified the challenges in the future on developing novel agents and to finally use them for the benefit of patients. The IAEA can play as vital role in streamlining developments and to provide tools to overcome scientific, professional and regulatory challenges in the field of therapeutic radiopharmaceuticals

Report on the Technical Meeting on Therapeutic Radiopharmaceuticals

Energy Technology Data Exchange (ETDEWEB)

NONE

2009-07-01

The purpose of the TM was to provide an experts' platform to facilitate exploring the current status and future directions on therapeutic radiopharmaceuticals. The invited talks and presentations in the TM were in the following topics: - Radionuclide Production; - Production and availability of alpha emitters and their radiopharmaceuticals; - Therapeutic radiopharmaceutical chemistry; - Targets and biological evaluation; - Medical physics and dosimetry; - Clinical applications including radioimmunotherapy and clinical needs; - Peptide receptor mediated therapy Panel discussions: - Radionuclide therapy using alpha emitters; - Regulatory challenges with therapeutic radiopharmaceuticals; - International activities in radionuclide therapy. he technical meeting generated a large interest among scientists and physicians working in the field of targeted therapy using radiopharmaceuticals. Participants from both developed and developing MS reported on recent developments on the research work and clinical studies going on in the field and provided their views on the future developments in this field. The unexpected high number of participants and the high number of presentations with exceptional quality underlines the great interest of scientists and professionals in therapeutic applications using radiolabelled drugs / biomolecules. The intensive discussions including panels specified the challenges in the future on developing novel agents and to finally use them for the benefit of patients. The IAEA can play as vital role in streamlining developments and to provide tools to overcome scientific, professional and regulatory challenges in the field of therapeutic radiopharmaceuticals

Eighteenth annual West Coast theoretical chemistry conference

Energy Technology Data Exchange (ETDEWEB)

NONE

1997-05-01

Abstracts are presented from the eighteenth annual west coast theoretical chemistry conference. Topics include molecular simulations; quasiclassical simulations of reactions; photodissociation reactions; molecular dynamics;interface studies; electronic structure; and semiclassical methods of reactive systems.

Radiopharmaceuticals

International Nuclear Information System (INIS)

Theobald, A.E.

1989-01-01

This book is a review of the latest developments in radiopharmaceuticals. It covers the development of radiopharmaceutical compounds, the theory and practice of their synthesis, and examples of their application. Also covers safe handling of radiopharmaceuticals, legislation affecting their use, radiation monitoring, radiochromatography, and computer techniques

Sixth international symposium on radiopharmaceutical chemistry: Abstracts: Final report

International Nuclear Information System (INIS)

1986-01-01

The 113 abstracts are arranged under the following section headings: alkyl spiperone derivatives labeled with fluorine, synthesis of compounds labeled with positron emitters, technetium compounds, positron emitters (target design and synthesis), indium and gallium, halogens, labeled proteins and antibodies, radiopharmaceuticals for brain and SPECT, general, and receptor radioligands

Lung radiopharmaceuticals

International Nuclear Information System (INIS)

Gonzalez, B.M.

1994-01-01

Indication or main clinical use of Lung radiopharmaceuticals is presented and clasification of radiopharmaceuticals as ventilation and perfusion studies. Perfusion radiopharmaceuticals, main controls for administration quality acceptance. Clearence after blood administration and main clinical applications. Ventilation radiopharmaceuticals, gases and aerosols, characteristics of a ideal radioaerosol, techniques of good inhalation procedure, clinical applications. Comparison of several radiopharmaceuticals reflering to retention time as 50% administered dose, percent administered dose at 6 hours post inhalation, blood activity at 30 and 60 minutes post inhalation, initial lung absorbed dose, cumulated activity.Kinetic description of two radiopharmaceuticals, 99mTcDTPA and 99mTc-PYP

Dimethylsulfide chemistry: annual, seasonal, and spatial impacts on SO_4^(2-)

Science.gov (United States)

We incorporated oceanic emissions and atmospheric chemistry of dimethylsulfide (DMS) into the hemispheric Community Multiscale Air Quality model and performed annual model simulations without and with DMS chemistry. The model without DMS chemistry predicts higher concentrations o...

Incorporation of radiohalogens via versatile organometallic reactions: applications in radiopharmaceutical chemistry

Energy Technology Data Exchange (ETDEWEB)

Srivastava, P.C.; Goodman, M.M.; Knapp, F.F. Jr.

1985-01-01

Factors that must be considered for the design of radiohalogenated radio-pharmaceuticals include the stability and availability of the substrate, the physical half-life of the radiohalogen and the in vivo stability of the radiolabel. Vinyl and phenyl radiohalogen bonds show more in vivo stability than the alkyl radiohalogen bonds. Consequently, a variety of methods suitable for the synthesis of tissue specific radiopharmaceuticals bearing a vinyl or phenyl radiohalogen have been developed involving the synthesis and halogenation of metallovinyl and phenyl intermediates. The halogens and metallation reactions include iodine and bromine and alanation, boronation, mercuration, stannylation, and thallation, respectively. 19 refs., 1 fig., 1 tab.

Current directions in radiopharmaceutical research

Energy Technology Data Exchange (ETDEWEB)

Mather, S J [Department of Nuclear Medicine, St. Bartholomew` s Hospital, London (United Kingdom)

1998-08-01

Much of current radiopharmaceutical research is directed towards the development of receptor-binding tracers which are targeted towards biochemical processes. These may be extra or intracellular in nature and hold promise for an imaging approach to tissue characterisation in-vivo. Many of these products are based on proteins which range in size from large monoclonal antibodies to small neuropeptides and share a radiolabelling chemistry based on the use of bifunctional chelating agents. Although developed initially for use with indium-111, considerations of cost and isotope availability have continued to direct the efforts of many researchers towards the use of technetium-99m. While polypeptide-based radiopharmaceuticals may be useful for imaging peripheral cell-surface receptors, access to sites of interest within the cell, or in the brain, requires the development of small lipophilic molecules with retained ability to interact with intracellular targets. The design and synthesis of these compounds presents a particular challenge to the radiopharmaceutical chemist which is being met through either a pendant or integrated approach to the use of technetium coordination with particular emphasis on technetium (v) cores. Progress continues to be made in the application of targeted radionuclide therapy particularly in the development of radiopharmaceuticals for the treatment of malignant bone disease. methods for labelling antibodies with a great variety of cytotoxic radionuclides have now been refined and their use for radioimmunotherapy in the treatment of haematological malignancies shows great promise. The major medical areas for application of these new radiopharmaceuticals will be in oncology, neurology and inflammation but the increasingly difficult regulatory climate in which drug development and health-care now operate will make it essential for researchers to direct their products toward specific clinical problems as well as biological targets. (author) 36 refs

Current directions in radiopharmaceutical research

International Nuclear Information System (INIS)

Mather, S.J.

1998-01-01

Much of current radiopharmaceutical research is directed towards the development of receptor-binding tracers which are targeted towards biochemical processes. These may be extra or intracellular in nature and hold promise for an imaging approach to tissue characterisation in-vivo. Many of these products are based on proteins which range in size from large monoclonal antibodies to small neuropeptides and share a radiolabelling chemistry based on the use of bifunctional chelating agents. Although developed initially for use with indium-111, considerations of cost and isotope availability have continued to direct the efforts of many researchers towards the use of technetium-99m. While polypeptide-based radiopharmaceuticals may be useful for imaging peripheral cell-surface receptors, access to sites of interest within the cell, or in the brain, requires the development of small lipophilic molecules with retained ability to interact with intracellular targets. The design and synthesis of these compounds presents a particular challenge to the radiopharmaceutical chemist which is being met through either a pendant or integrated approach to the use of technetium coordination with particular emphasis on technetium (v) cores. Progress continues to be made in the application of targeted radionuclide therapy particularly in the development of radiopharmaceuticals for the treatment of malignant bone disease. methods for labelling antibodies with a great variety of cytotoxic radionuclides have now been refined and their use for radioimmunotherapy in the treatment of haematological malignancies shows great promise. The major medical areas for application of these new radiopharmaceuticals will be in oncology, neurology and inflammation but the increasingly difficult regulatory climate in which drug development and health-care now operate will make it essential for researchers to direct their products toward specific clinical problems as well as biological targets. (author)

Molecular Engineering of Technetium and Rhenium Based Radiopharmaceuticals

International Nuclear Information System (INIS)

Zubieta, J.

2003-01-01

The research was based on the observation that despite the extraordinarily rich coordination chemistry of technetium and rhenium and several notable successes in reagent design, the extensive investigations by numerous research groups on a variety of N 2 S 2 and N 3 S donor type ligands and on HYNIC have revealed that the chemistries of these ligands with Tc and Re are rather complex, giving rise to considerable difficulties in the development of reliable procedures for the development of radiopharmaceutical reagents

Institute of Nuclear Chemistry and Technology annual report 1994

Energy Technology Data Exchange (ETDEWEB)

NONE

1996-12-31

This annual report is a collection of short communications being a review of scientific activity of the Institute of Nuclear Chemistry and Technology, Warsaw, Poland in 1994. The papers are gathered into several branches as follows: radiation chemistry and physics (16 papers); radiochemistry, stable isotopes, nuclear analytical methods, chemistry in general (17 papers); radiobiology (6 papers); nuclear technologies and methods (30 papers). The annual report of INCT-1994 contains also a general information about the Institute, the full list of papers published in 1994, information about Nukleonika - the International Journal of Nuclear Research being edited in INCT, the list of patent granted and patent applications in 1994, information about conferences organized by the Institute, the list of Ph.D. and D.Sc. finished in 1994 as well as the list of research projects and contracts being realized in INCT during 1994.

Institute of Nuclear Chemistry and Technology annual report 1994

International Nuclear Information System (INIS)

1995-01-01

This annual report is a collection of short communications being a review of scientific activity of the Institute of Nuclear Chemistry and Technology, Warsaw, Poland in 1994. The papers are gathered into several branches as follows: radiation chemistry and physics (16 papers); radiochemistry, stable isotopes, nuclear analytical methods, chemistry in general (17 papers); radiobiology (6 papers); nuclear technologies and methods (30 papers). The annual report of INCT-1994 contains also a general information about the Institute, the full list of papers published in 1994, information about Nukleonika - the International Journal of Nuclear Research being edited in INCT, the list of patent granted and patent applications in 1994, information about conferences organized by the Institute, the list of Ph.D. and D.Sc. finished in 1994 as well as the list of research projects and contracts being realized in INCT during 1994

Institute of Nuclear Chemistry and Technology annual report 1994

Energy Technology Data Exchange (ETDEWEB)

NONE

1995-12-31

This annual report is a collection of short communications being a review of scientific activity of the Institute of Nuclear Chemistry and Technology, Warsaw, Poland in 1994. The papers are gathered into several branches as follows: radiation chemistry and physics (16 papers); radiochemistry, stable isotopes, nuclear analytical methods, chemistry in general (17 papers); radiobiology (6 papers); nuclear technologies and methods (30 papers). The annual report of INCT-1994 contains also a general information about the Institute, the full list of papers published in 1994, information about Nukleonika - the International Journal of Nuclear Research being edited in INCT, the list of patent granted and patent applications in 1994, information about conferences organized by the Institute, the list of Ph.D. and D.Sc. finished in 1994 as well as the list of research projects and contracts being realized in INCT during 1994.

Cyclotron targets and production technologies used for radiopharmaceuticals in NPI

Czech Academy of Sciences Publication Activity Database

Fišer, Miroslav; Kopička, Karel; Hradilek, Pavel; Hanč, Petr; Lebeda, Ondřej; Panek, T.; Vognar, M.

2003-01-01

Roč. 53, č. 2 (2003), s. A737-A743 ISSN 0011-4626 R&D Projects: GA AV ČR KSK4055109 Keywords : cyclotron * radiopharmaceuticals Subject RIV: CH - Nuclear ; Quantum Chemistry Impact factor: 0.263, year: 2003

Harvard--MIT research program in short-lived radiopharmaceuticals. Progress report, September 1, 1977--April 30, 1978

International Nuclear Information System (INIS)

Adelstein, S.J.; Brownell, G.L.

1978-05-01

Progress is reported on the following studies: chemistry studies designed to achieve a more complete understanding of the fundamental chemistry of technetium in order to facilitate the design of future radiopharmaceuticals incorporating the radionuclide /sup 99m/Tc; the development of new radiopharmaceuticals intended to improve image quality and lower radiation doses by the use of short-lived radionuclides and disease-specific agents; the development of short-lived positron-emitting radionuclides which offer advantages in transverse section imaging of regional physiological processes; and studies of the toxic effects of particulate radiation

Hospitable radiopharmaceuticals

International Nuclear Information System (INIS)

Gonzalez, M.B.

1994-01-01

Two types of hospitalary radiopharmaceutical was given in Nuclear Medicine: the centralized and hospitalary radiopharmaceuticals. The good practice in the use, instrumentation and quality control of radiopharmaceuticals are used in nuclear medicine for diagnostic and therapy diseases

Annual Report of Institute of Nuclear Chemistry and Technology 1999

International Nuclear Information System (INIS)

2000-06-01

The INCT 1999 Annual Report is the review of scientific activities in all branches being developed in the Institute of Nuclear Chemistry and Technology, Warsaw. The studies are connected in general with the following fields: radiation chemistry and physics, radiation technologies, radiochemistry, stable isotopes, nuclear analytical methods, chemistry in general, radiobiology, process engineering, material engineering, structural studies and diagnostics and nucleonic control systems and accelerators

Annual Report of Institute of Nuclear Chemistry and Technology 2002

International Nuclear Information System (INIS)

2003-06-01

The INCT 2002 Annual Report is the review of scientific activities in all branches being developed in the Institute of Nuclear Chemistry and Technology, Warsaw. The studies are connected in general with the following fields: radiation chemistry and physics, radiation technologies, radiochemistry, stable isotopes, nuclear analytical methods, chemistry in general, radiobiology, process engineering, material engineering, structural studies and diagnostics, nucleonic control systems and accelerators

Annual Report of Institute of Nuclear Chemistry and Technology 2002

Energy Technology Data Exchange (ETDEWEB)

NONE

2003-06-01

The INCT 2002 Annual Report is the review of scientific activities in all branches being developed in the Institute of Nuclear Chemistry and Technology, Warsaw. The studies are connected in general with the following fields: radiation chemistry and physics, radiation technologies, radiochemistry, stable isotopes, nuclear analytical methods, chemistry in general, radiobiology, process engineering, material engineering, structural studies and diagnostics, nucleonic control systems and accelerators.

Annual Report of Institute of Nuclear Chemistry and Technology 1999

Energy Technology Data Exchange (ETDEWEB)

NONE

2000-06-01

The INCT 1999 Annual Report is the review of scientific activities in all branches being developed in the Institute of Nuclear Chemistry and Technology, Warsaw. The studies are connected in general with the following fields: radiation chemistry and physics, radiation technologies, radiochemistry, stable isotopes, nuclear analytical methods, chemistry in general, radiobiology, process engineering, material engineering, structural studies and diagnostics and nucleonic control systems and accelerators.

Innovative radiopharmaceuticals in oncology and neurology

CERN Document Server

Barbet, Jacques; Chérel, Michel; Guilloteau, Denis

2017-01-01

The aim of this Research Topic was to assemble a series of articles describing basic, preclinical and clinical research studies on radiopharmaceuticals and nuclear medicine. The articles were written by attendees of the third Nuclear Technologies for Health Symposium (NTHS, 10th-11th March 2015, Nantes, Frances) under the auspices of the IRON LabEx (Innovative Radiopharmaceuticals for Oncology and Neurology Laboratory of Excellence). This French network, gathering approximately 160 scientists from 12 academic research teams (Funded by “investissements d’Avenir”), fosters transdisciplinary projects between teams with expertise in chemistry, radiochemistry, radiopharmacy, formulation, biology, nuclear medicine and medical physics. The 12 articles within this resulting eBook present a series of comprehensive reviews and original research papers on multimodality imaging and targeted radionuclide therapy; illustrating the different facets of studies currently conducted in these domains.

New radiopharmaceuticals

International Nuclear Information System (INIS)

Payoux, P.; Esquerre, J.P.; Alonso, M.; Tafani, M.

2008-01-01

With the development of positron emission tomography, the significant increase in prescriptions of [ 18 F]F.D.G. has underlined the interest for molecular imaging in many pathologies. Facing the demand of 'new' radiopharmaceuticals (frequently clinically validated in the last century) for more and more specific diagnosis, the nuclear physician is confronted with a sparse offer of the radiopharmaceutical companies and a particularly complicated radiopharmaceutical legislation. This paper briefly reports on the radiopharmaceutical statutes encountered in France nowadays; it emphasizes that is essential to deeply modify the conditions to obtain a marketing authorization for radiopharmaceuticals if we want to propose to our patients the kind of right they have to expect from nuclear medicine. (authors)

Annual Report of Institute of Nuclear Chemistry and Technology 2001

International Nuclear Information System (INIS)

2002-06-01

The INCT 2001 Annual Report is the review of scientific activities in all branches being developed in the Institute of Nuclear Chemistry and Technology in Warsaw. The studies are connected in general with the following fields: radiation chemistry and physics, radiation technologies, radiochemistry, stable isotopes, nuclear analytical methods, chemistry in general, radiobiology, process engineering, material engineering, structural studies and diagnostics, nucleonic control systems and accelerators and nuclear analytical methods

Annual Report 2004 of Institute of Nuclear Chemistry and Technology

International Nuclear Information System (INIS)

Michalik, J.; Smulek, W.; Godlewska-Para, E.

2005-06-01

The INCT 2004 Annual Report is the review of scientific activities in all branches being developed in the Institute of Nuclear Chemistry and Technology Warsaw. The studies are connected in general with the following fields: radiation chemistry and physics, radiation technologies, radiochemistry, stable isotopes, nuclear analytical methods, chemistry in general, radiobiology, process engineering, material engineering, structural studies and diagnostics, nucleonic control systems and accelerators, radiobiology and nuclear analytical methods

Annual Report 2004 of Institute of Nuclear Chemistry and Technology

Energy Technology Data Exchange (ETDEWEB)

Michalik, J; Smulek, W; Godlewska-Para, E [eds.

2005-06-01

The INCT 2004 Annual Report is the review of scientific activities in all branches being developed in the Institute of Nuclear Chemistry and Technology Warsaw. The studies are connected in general with the following fields: radiation chemistry and physics, radiation technologies, radiochemistry, stable isotopes, nuclear analytical methods, chemistry in general, radiobiology, process engineering, material engineering, structural studies and diagnostics, nucleonic control systems and accelerators, radiobiology and nuclear analytical methods.

Annual Report of Institute of Nuclear Chemistry and Technology 2001

Energy Technology Data Exchange (ETDEWEB)

NONE

2002-06-01

The INCT 2001 Annual Report is the review of scientific activities in all branches being developed in the Institute of Nuclear Chemistry and Technology in Warsaw. The studies are connected in general with the following fields: radiation chemistry and physics, radiation technologies, radiochemistry, stable isotopes, nuclear analytical methods, chemistry in general, radiobiology, process engineering, material engineering, structural studies and diagnostics, nucleonic control systems and accelerators and nuclear analytical methods.

Radiopharmaceuticals

International Nuclear Information System (INIS)

Ganatra, R.D.

1992-01-01

Today there are an estimated ten million nuclear imaging procedures, performed each year, in just the United States, and the number is still growing. More than 30,000 therapy procedures are performed in the USA each year using radiopharmaceuticals. Moreover, while the numbers continue to grow, so also do the variety of the procedures being employed. A weakness of nuclear medicine is related also to one of its strengths. Unlike other types of imaging where only an instrument and the patient are required (e.g., with ultrasonics); nuclear medicine requires a radiopharmaceutical. At the same time, the variety of radiopharmaceuticals offers the ability to trace one or more particular functions of the human body. This provides nuclear medicine with great variety in detecting specific pathologies. Various nuclear medicine studies are possible because of the localization of radiopharmaceuticals in different organs

Universitaet Mainz, Institut fuer Kernchemie. Annual report 2005

International Nuclear Information System (INIS)

Kratz, J.V.

2006-11-01

Compiled by the employees of the institute, the present 2005 annual report gives an overview of the scientific activities of the working groups of the Institute for Nuclear Chemistry. It is also intended as a account to all those who have promoted us financially and idealistically on the use of what has been not an insubstantial amount of public funds. The report again covers three main fields of research: nuclear chemistry in terms of fundamental problems; radiopharmaceutical chemistry and the use radiochemical methods for medical purposes; and highly sensitive and selective analyses for environmental, technical and biological problems. The report also describes the status of the institute's technical facilities and new technical developments. Finally it gives an account of the institute's output in terms of publications, conference contributions, dissertations, diploma theses, state examination theses and on the contributions of its teaching staff to study and advanced training programs

Harvard-MIT research program in short-lived radiopharmaceuticals. Progress report, March 1, 1983-February 29, 1984

International Nuclear Information System (INIS)

Adelstein, S.J.; Brownell, G.L.

1984-02-01

This report describes research efforts towards the achievement of a clearer understanding of the solution chemistry of technetium in order to facilitate the design of future clinical agents labeled with Tc-99m, the development of new receptor binding radiopharmaceuticals for the in vivo assessment of insulin receptors and for imaging the adrenal medulla and the brain, the examination of the utility of monoclonal antibodies and liposomes in the design of radiopharmaceuticals for diagnosis and therapy, and the synthesis of short-lived positron-emitting radiopharmaceuticals for transverse imaging of regional physiological processes

Annual Report 2003 of the Institute of Nuclear Chemistry and Technology

Energy Technology Data Exchange (ETDEWEB)

NONE

2004-07-01

The INCT 2003 Annual Report is the review of scientific activities in all branches being developed in the Institute of Nuclear Chemistry and Technology Warsaw. The studies are connected in general with the following fields: radiation chemistry and physics, radiation technologies, radiochemistry, stable isotopes, nuclear analytical methods, chemistry in general, radiobiology, process engineering, material engineering, structural studies, nucleonic control systems and accelerators.

Annual Report 2003 of the Institute of Nuclear Chemistry and Technology

International Nuclear Information System (INIS)

2004-01-01

The INCT 2003 Annual Report is the review of scientific activities in all branches being developed in the Institute of Nuclear Chemistry and Technology Warsaw. The studies are connected in general with the following fields: radiation chemistry and physics, radiation technologies, radiochemistry, stable isotopes, nuclear analytical methods, chemistry in general, radiobiology, process engineering, material engineering, structural studies, nucleonic control systems and accelerators

Gallium and copper radiopharmaceutical chemistry

International Nuclear Information System (INIS)

Green, M.A.; John, E.K.; Barnhart, A.J.

1990-01-01

Several isotopes of gallium and copper exhibit nuclear properties that make them attractive for applications in nuclear medicine, most notably Ga-67, Ga-68, Cu-67 and Cu-62. Of these, gamma-emitting Ga-67 has historically found the greatest clinical use, based on the observation that tracer gallium(III) citrate rapidly produces Ga-67 transferrin upon intravenous injection and then slowly affords selective Ga-67 localization in sites of abscess and certain tumors. Copper-67 has received attention as a potential label for tissue-selective monoclonal antibodies, since its associated γ-photons can be used for external imaging and its β - -emissions could be used for radiation therapy. Positron-emitting gallium-68 and copper-62, being available from parent/daughter generator systems, have attracted interest as potential labels for radiopharmaceuticals used in positron emission tomography (PET) because they could reduce the dependence of this imaging technology on hospital-based cyclotrons. The 10 min. half-life of Cu-62 is particularly well-suited to the time frame of PET studies of tissue perfusion, an application for which Cu(II)-bis(thiosemicarbazone) derivatives appear promising. The 68 min. half-life of Ga-68 makes it appropriate for PET studies over longer imaging time spans

Institute of Nuclear Chemistry and Technology annual report 1995

International Nuclear Information System (INIS)

1996-01-01

The report is a collection of short communications being a review of scientific activity of the Institute of Nuclear Chemistry and Technology (INCT), Warsaw, in 1995. The papers are gathered in several branches as follows: radiation chemistry and physics (15); radiochemistry, stable isotopes, nuclear analytical methods, chemistry in general (23); radiobiology (7); nuclear technologies and methods (21); nucleonic control systems (5). The Annual Report of INCT - 1995 contains also a general information about the staff and organization of the Institute, the full list of scientific publications and patents, conferences organized by INCT, thesis and list of projects granted by Polish and international organizations

Institute of Nuclear Chemistry and Technology annual report 1995

Energy Technology Data Exchange (ETDEWEB)

NONE

1996-12-31

The report is a collection of short communications being a review of scientific activity of the Institute of Nuclear Chemistry and Technology (INCT), Warsaw, in 1995. The papers are gathered in several branches as follows: radiation chemistry and physics (15); radiochemistry, stable isotopes, nuclear analytical methods, chemistry in general (23); radiobiology (7); nuclear technologies and methods (21); nucleonic control systems (5). The Annual Report of INCT - 1995 contains also a general information about the staff and organization of the Institute, the full list of scientific publications and patents, conferences organized by INCT, thesis and list of projects granted by Polish and international organizations.

Institute of Nuclear Chemistry and Technology annual report 1995

Energy Technology Data Exchange (ETDEWEB)

NONE

1997-12-31

The report is a collection of short communications being a review of scientific activity of the Institute of Nuclear Chemistry and Technology (INCT), Warsaw, in 1995. The papers are gathered in several branches as follows: radiation chemistry and physics (15); radiochemistry, stable isotopes, nuclear analytical methods, chemistry in general (23); radiobiology (7); nuclear technologies and methods (21); nucleonic control systems (5). The Annual Report of INCT - 1995 contains also a general information about the staff and organization of the Institute, the full list of scientific publications and patents, conferences organized by INCT, thesis and list of projects granted by Polish and international organizations.

Annual Report of the Institute of Nuclear Chemistry and Technology 2000

Energy Technology Data Exchange (ETDEWEB)

NONE

2001-06-01

The INCT 2000 Annual Report is the review of scientific activities in all branches being developed in the Institute of Nuclear Chemistry and Technology Warsaw. The studies are connected in general with the following fields: radiation chemistry and physics, radiation technologies, radiochemistry, stable isotopes, nuclear analytical methods, chemistry in general, radiobiology, process engineering, material engineering, structural studies and diagnostics and nucleonic control systems and accelerators.

Annual Report of the Institute of Nuclear Chemistry and Technology 2000

International Nuclear Information System (INIS)

2001-06-01

The INCT 2000 Annual Report is the review of scientific activities in all branches being developed in the Institute of Nuclear Chemistry and Technology Warsaw. The studies are connected in general with the following fields: radiation chemistry and physics, radiation technologies, radiochemistry, stable isotopes, nuclear analytical methods, chemistry in general, radiobiology, process engineering, material engineering, structural studies and diagnostics and nucleonic control systems and accelerators

Harvard-MIT research program in short-lived radiopharmaceuticals. Final report

International Nuclear Information System (INIS)

Adelstein, S.J.

1995-02-01

The Harvard-MIT Research Program in Short-lived Radiopharmaceuticals was established in 1977 to foster interaction among groups working in radiopharmaceutical chemistry at Harvard Medical School, the Massachusetts Institute of Technology, and the Massachusetts General Hospital. To this was added a group at The Childrens Hospital. From these collaborations and building upon the special strengths of the participating individuals, laboratories and institutions, it was hoped that original approaches would be found for the design of new, clinically useful, radiolabeled compounds. The original thrust of this proposal included: (a) examination of the coordination chemistry of technetium as a basis for rational radiopharmaceutical design, (b) development of an ultrashort-lived radionuclide generator for the diagnosis of congenital heart disease in newborns, (c) synthesis of receptor-site-directed halopharmaceuticals, (d) improved facile labeling of complex molecules with positron-emitting radionuclides. The authors' 1986 proposal was oriented toward organs and disease, emphasizing radiolabeled agents that delineate specific functions and the distribution of receptors in brain, heart, and tumors. In 1989, they further refined their purposes and focused on two major aims: (a) synthesis and utilization of neutral technetium and rhenium complexes of high specific activity, and (b) development of new approaches to the radiolabeling of proteins, peptides, immunoglobulins, and their fragments. In 1992, the authors amended this proposal to concentrate their efforts on biologically active peptides and proteins for targeted radiodiagnosis and therapy

Harvard-MIT research program in short-lived radiopharmaceuticals. Final report

Energy Technology Data Exchange (ETDEWEB)

Adelstein, S.J. [Massachusetts Inst. of Tech., Cambridge, MA (United States). Office of Sponsored Programs

1995-02-01

The Harvard-MIT Research Program in Short-lived Radiopharmaceuticals was established in 1977 to foster interaction among groups working in radiopharmaceutical chemistry at Harvard Medical School, the Massachusetts Institute of Technology, and the Massachusetts General Hospital. To this was added a group at The Childrens Hospital. From these collaborations and building upon the special strengths of the participating individuals, laboratories and institutions, it was hoped that original approaches would be found for the design of new, clinically useful, radiolabeled compounds. The original thrust of this proposal included: (a) examination of the coordination chemistry of technetium as a basis for rational radiopharmaceutical design, (b) development of an ultrashort-lived radionuclide generator for the diagnosis of congenital heart disease in newborns, (c) synthesis of receptor-site-directed halopharmaceuticals, (d) improved facile labeling of complex molecules with positron-emitting radionuclides. The authors` 1986 proposal was oriented toward organs and disease, emphasizing radiolabeled agents that delineate specific functions and the distribution of receptors in brain, heart, and tumors. In 1989, they further refined their purposes and focused on two major aims: (a) synthesis and utilization of neutral technetium and rhenium complexes of high specific activity, and (b) development of new approaches to the radiolabeling of proteins, peptides, immunoglobulins, and their fragments. In 1992, the authors amended this proposal to concentrate their efforts on biologically active peptides and proteins for targeted radiodiagnosis and therapy.

Annual Report of Institute of Nuclear Chemistry and Technology 1997

Energy Technology Data Exchange (ETDEWEB)

NONE

1998-10-01

The report is the collection of short communications being the review of the scientific activity of Institute of Nuclear Chemistry and Technology - Warsaw in 1997. The papers are gathered in several branches as follows: radiation chemistry and physics; radiochemistry, stable isotopes, nuclear analytical methods, chemistry in general; radiobiology; nuclear technologies and methods. The annual report of INCT-1997 contains also the general information about INCT as well as the full list of scientific papers being published by the staff in 1997

Annual Report of Institute of Nuclear Chemistry and Technology 1997

International Nuclear Information System (INIS)

1998-06-01

The report is the collection of short communications being the review of the scientific activity of Institute of Nuclear Chemistry and Technology - Warsaw in 1997. The papers are gathered in several branches as follows: radiation chemistry and physics; radiochemistry, stable isotopes, nuclear analytical methods, chemistry in general; radiobiology; nuclear technologies and methods. The annual report of INCT-1997 contains also the general information about INCT as well as the full list of scientific papers being published by the staff in 1997

Radiopharmaceuticals

International Nuclear Information System (INIS)

1981-01-01

The catalogue offers a wide-spread product range which meets the requirements of the international trend of in vivo application of radiopharmaceuticals. It includes: (1) conditions of sale and delivery, (2) delivery schedule for radiopharmaceuticals, (3) technical information, (4) product specifications, and (5) the complete delivery programme

Harvard-MIT research program in short-lived radiopharmaceuticals. Technical progress report, 1991

Energy Technology Data Exchange (ETDEWEB)

Adelstein, S.J.

1991-12-31

This report presents research on radiopharmaceuticals. The following topics are discussed: antibody labeling with positron-emitting radionuclides; antibody modification for radioimmune imaging; labeling antibodies; evaluation of technetium acetlyacetonates as potential cerebral blood flow agents; and studies in technetium chemistry. (CBS)

Lung radiopharmaceuticals; Radioformacos pulmonares

Energy Technology Data Exchange (ETDEWEB)

Gonzalez, B M [Instituto Nacional de Pediatroa (Mexico)

1994-12-31

Indication or main clinical use of Lung radiopharmaceuticals is presented and clasification of radiopharmaceuticals as ventilation and perfusion studies. Perfusion radiopharmaceuticals, main controls for administration quality acceptance. Clearence after blood administration and main clinical applications. Ventilation radiopharmaceuticals, gases and aerosols, characteristics of a ideal radioaerosol, techniques of good inhalation procedure, clinical applications. Comparison of several radiopharmaceuticals reflering to retention time as 50% administered dose, percent administered dose at 6 hours post inhalation, blood activity at 30 and 60 minutes post inhalation, initial lung absorbed dose, cumulated activity.Kinetic description of two radiopharmaceuticals, 99mTcDTPA and 99mTc-PYP.

Radiopharmaceuticals generalities

International Nuclear Information System (INIS)

Leon Cabana, A.S.

1994-01-01

Many applications in nuclear medicine used as diagnostic techniques, images methods with direct and indirect labelled compounds in organs. A brief description about scintillator counters or gamma counters SPECT(single photon emission computed tomography) and PECT (positron emission computed tomography), as well as therapeutic proceedings,radiopharmaceutical classification, labell steps,administration form in the body,physical form and the best radiopharmaceutical ideal classification. Two tables was used contain radiopharmaceuticals more used in diagnostic and more used in therapic uses. Tabs

Annual Report of Institute of Nuclear Chemistry and Technology 1998

International Nuclear Information System (INIS)

1999-04-01

Actual edition of Annual Report is a full review of scientific activities of the Institute of Nuclear Chemistry and Technology (INCT), Warsaw, in 1998. The abstracts are presented in the following group of subjects: radiation chemistry and physics, radiation technologies (26); radiochemistry, stable isotopes, nuclear analytical methods, chemistry in general (25); radiobiology (11); nuclear technologies and methods - process engineering (5); material engineering, structural studies and diagnostics (9); nucleonic control systems (7). The edition also included the list of INCT scientific publications and patents as well as information on conferences organized or co-organized by the INCT in 1998

Technetium chemistry

International Nuclear Information System (INIS)

Burns, C.; Bryan, J.; Cotton, F.; Ott, K.; Kubas, G.; Haefner, S.; Barrera, J.; Hall, K.; Burrell, A.

1996-01-01

Technetium chemistry is a young and developing field. Despite the limited knowledge of its chemistry, technetium is the workhorse for nuclear medicine. Technetium is also a significant environmental concern because it is formed as a byproduct of nuclear weapons production and fission-power generators. Development of new technetium radio-pharmaceuticals and effective environmental control depends strongly upon knowledge of basic technetium chemistry. The authors performed research into the basic coordination and organometallic chemistry of technetium and used this knowledge to address nuclear medicine and environmental applications. This is the final report of a three-year Laboratory-Directed Research and Development (LDRD) project at the Los Alamos National Laboratory (LANL)

The development of cyclotron radiopharmaceuticals

Energy Technology Data Exchange (ETDEWEB)

Yang, Seung Dae; Chun, K. W.; Suh, Y. S.; Lee, J. D.; Ahn, S. H. and others

1999-03-01

The purpose of this project is to developthe radiopharmaceuticals and automatic synthetic unit for labelled compounds, and to establish mass production system of radiopharmaceuticals. These will contribute to the early diagnosis of the disease hard to cure. The contents of this project are as follows, the development of the radiopharmaceutical for imaging of cancer, the development of automatic synthesizer for the synthesis of radio-pharmaceuticals, the development of hormone derivatives labelled with {sup 12}'3I, the development of the radiopharmaceuticals for therapy of cancer labelled with cyclotron produced radionuclides, the development of radiopharmaceuticals for therapy of cancer labelled with cyclotron produced radionuclides, the development of radiopharmaceuticals for imaging of myocardial metabolism.

The development of cyclotron radiopharmaceuticals

International Nuclear Information System (INIS)

Yang, Seung Dae; Chun, K. W.; Suh, Y. S.; Lee, J. D.; Ahn, S. H. and others

1999-03-01

The purpose of this project is to develop the radiopharmaceuticals and automatic synthetic unit for labelled compounds, and to establish mass production system of radiopharmaceuticals. These will contribute to the early diagnosis of the disease hard to cure. The contents of this project are as follows, the development of the radiopharmaceutical for imaging of cancer, the development of automatic synthesizer for the synthesis of radio-pharmaceuticals, the development of hormone derivatives labelled with 12 '3I, the development of the radiopharmaceuticals for therapy of cancer labelled with cyclotron produced radionuclides, the development of radiopharmaceuticals for therapy of cancer labelled with cyclotron produced radionuclides, the development of radiopharmaceuticals for imaging of myocardial metabolism

Fluorine-18 radiopharmaceuticals beyond [F-18]FDG for use in oncology and neurosciences

NARCIS (Netherlands)

Coenen, H. H.; Elsinga, P. H.; Iwata, R.; Kilbourn, M. R.; Pillai, M. R. A.; Rajan, M. G. R.; Wagner, H. N.; Zaknun, J. J.

2010-01-01

Positron emission tomography (PET) is a rapidly expanding clinical modality worldwide thanks to the availability of compact medical cyclotrons and automated chemistry for the production of radiopharmaceuticals. There is an armamentarium of fluorine-18 (F-18) tracers that can be used for PET studies

Cyclotron produced radiopharmaceuticals

International Nuclear Information System (INIS)

Kopicka, K.; Fiser, M.; Hradilek, P.; Hanc, P.; Lebeda, O.

2003-01-01

Some of the cyclotron-produced radionuclides may serve as important materials for the production of radiopharmaceuticals. This lecture deals with basic information relating to various aspects of these compounds. In comparison with radionuclides /compounds used for non-medical purposes, radiopharmaceuticals are subject to a broader scale of regulations, both from the safety and efficacy point of view; besides that, there are both radioactive and medical aspects that must be taken into account for any radiopharmaceutical. According to the regulations and in compliance with general rules of work with radioactivity, radiopharmaceuticals should only be prepared/manufactured under special conditions, using special areas and special equipment and applying special procedures (e.g. sterilisation, disinfection, aseptic work). Also, there are special procedures for cleaning and maintenance. Sometimes the requirements for the product safety clash with those for the safety of the personnel; several examples of solutions pertaining to these cases are given in the lecture. Also, the specific role of cyclotron radiopharmaceuticals is discussed. (author)

Aptamer-based radiopharmaceuticals for diagnostic imaging and targeted radiotherapy of epithelial tumors

International Nuclear Information System (INIS)

Missailidis, Sotiris; Perkins, Alan; Santos-Filho, Sebastiao David; Fonseca, Adenilson de Souza da; Bernardo-Filho, Mario

2008-01-01

In the continuous search for earlier diagnosis and improved therapeutic modalities against cancer, based on our constantly increasing knowledge of cancer biology, aptamers hold the promise to expand on current antibody success, but overcoming some of the problems faced with antibodies as therapeutic or delivery agents in cancer. However, as the first aptamer reached the market as an inhibitor against angiogenesis for the treatment of macular degeneration, aptamers have found only limited applications or interest in oncology, and even less as radiopharmaceuticals for diagnostic imaging and targeted radiotherapy of tumours. Yet, the chemistry for the labelling of aptamers and the options to alter their pharmacokinetic properties, to make them suitable for use as radiopharmaceuticals is now available and recent advances in their development can demonstrate that these molecules would make them ideal delivery vehicles for the development of targeted radiopharmaceuticals that could deliver their radiation load with accuracy to the tumour site, offering improved therapeutic properties and reduced side effects. (author)

Aptamer-based radiopharmaceuticals for diagnostic imaging and targeted radiotherapy of epithelial tumors

Energy Technology Data Exchange (ETDEWEB)

Missailidis, Sotiris [The Open University, Milton Keynes (United Kingdom). Dept. of Chemistry and Analytical Sciences]. E-mail: s.missailidis@open.ac.uk; Perkins, Alan [University of Nottingham (United Kingdom). Dept. of Medical Physics; Santos-Filho, Sebastiao David; Fonseca, Adenilson de Souza da; Bernardo-Filho, Mario [Universidade do Estado do Rio de Janeiro (UERJ), RJ (Brazil). Inst. de Biologia Roberto Alcantara Gomes. Dept. de Biofisica e Biometria

2008-12-15

In the continuous search for earlier diagnosis and improved therapeutic modalities against cancer, based on our constantly increasing knowledge of cancer biology, aptamers hold the promise to expand on current antibody success, but overcoming some of the problems faced with antibodies as therapeutic or delivery agents in cancer. However, as the first aptamer reached the market as an inhibitor against angiogenesis for the treatment of macular degeneration, aptamers have found only limited applications or interest in oncology, and even less as radiopharmaceuticals for diagnostic imaging and targeted radiotherapy of tumours. Yet, the chemistry for the labelling of aptamers and the options to alter their pharmacokinetic properties, to make them suitable for use as radiopharmaceuticals is now available and recent advances in their development can demonstrate that these molecules would make them ideal delivery vehicles for the development of targeted radiopharmaceuticals that could deliver their radiation load with accuracy to the tumour site, offering improved therapeutic properties and reduced side effects. (author)

Harvard--MIT research program in short-lived radiopharmaceuticals. Progress report, September 1, 1977--April 30, 1978. [/sup 99m/Tc, positron-emitting radionuclides

Energy Technology Data Exchange (ETDEWEB)

Adelstein, S.J.; Brownell, G.L.

1978-05-01

Progress is reported on the following studies: chemistry studies designed to achieve a more complete understanding of the fundamental chemistry of technetium in order to facilitate the design of future radiopharmaceuticals incorporating the radionuclide /sup 99m/Tc; the development of new radiopharmaceuticals intended to improve image quality and lower radiation doses by the use of short-lived radionuclides and disease-specific agents; the development of short-lived positron-emitting radionuclides which offer advantages in transverse section imaging of regional physiological processes; and studies of the toxic effects of particulate radiation.

Analytical chemistry department. Annual report, 1977

International Nuclear Information System (INIS)

Knox, E.M.

1978-09-01

The annual report describes the analytical methods, analyses and equipment developed or adopted for use by the Analytical Chemistry Department during 1977. The individual articles range from a several page description of development and study programs to brief one paragraph descriptions of methods adopted for use with or without some modification. This year, we have included a list of the methods incorporated into our Analytical Chemistry Methods Manual. This report is organized into laboratory sections within the Department as well as major programs within General Atomic Company. Minor programs and studies are included under Miscellaneous. The analytical and technical support activities for GAC include gamma-ray spectroscopy, radiochemistry, activation analysis, gas chromatography, atomic absorption, spectrophotometry, emission spectroscopy, x-ray diffractometry, electron microprobe, titrimetry, gravimetry, and quality control. Services are provided to all organizations throughout General Atomic Company. The major effort, however, is in support of the research and development programs within HTGR Generic Technology Programs ranging from new fuel concepts, end-of-life studies, and irradiated capsules to fuel recycle studies

Radiopharmaceutical licensing

International Nuclear Information System (INIS)

Mather, S.J.

1992-01-01

Recent health service legislation, and especially the loss of crown immunity has once again focussed attention on the arrangements for licensing of radiopharmaceuticals. The aim of the article is to describe in general terms the UK licensing system and in particular to provide guidance to those responsible for the supply of radiopharmaceuticals in hospitals. (author)

Research laboratories annual report 1992

International Nuclear Information System (INIS)

1993-07-01

The report book presents the various research activities within the Israel Atomic Energy Commission, during 1992 calendar year. The discipline reported here are (by chapters): theoretical physics and theoretical chemistry, optics and lasers, solid states and nuclear physics, material sciences, chemistry, radiopharmaceuticals, labelled compounds and environmental studies, radiation effects, dosimetry and protection, instrumentation and techniques

A new approach to the analysis of radiopharmaceuticals. Final technical report, January 15, 1987--June 30, 1991

International Nuclear Information System (INIS)

Jones, A.G.; Davison, A.; Costello, C.E.

1998-03-01

The objective of this research was to investigate analytical techniques that could be used in the study of both the basic chemistry and the radiopharmaceutical chemistry of 99m Tc. First funded in 1981, the work focused initially upon the use of high performance liquid chromatography (HPLC) and various forms of mass spectrometry for the identification of technetium species. This funding allowed the authors to combine HPLC and mass spectrometry to identify radiopharmaceuticals which, although in clinical use, had not previously been characterized. Other techniques that have been examined include resonance Raman spectroscopy and, more significantly, 99 Tc nuclear magnetic resonance spectroscopy (NMR), with the latter not only being used in purely chemical experiments but also in biologic studies. In 1985 a grant to the Department of Chemistry at MIT from DOE allowed the purchase of an X-ray diffractometer and access to this instrument has enabled them to broaden the analytical base with routine structural determinations

Annual report of Institute of Nuclear Chemistry and Technology 1996

International Nuclear Information System (INIS)

1997-06-01

The report is a collection of short communications being a review of the scientific activities of the Institute of Nuclear Chemistry and Technology, Warsaw in 1996. The papers are gathered in several branches as follows: radiation chemistry and physics (17); Radiochemistry, stable isotopes, nuclear analytical methods,chemistry in general (20); radiobiology (9); nuclear technologies and methods (28).The last and biggest chapter has been divided in four smaller groups; process engineering; material engineering,structural studies,diagnostics; radiation technologies; nucleonic control systems. The annual report of INCT-1996 contains also a general information of Institute, the full list of scientific publications and patents, conferences organized by INCT, Ph.D. and D.Sc. thesis, a list of projects granted by Polish Committee of Scientific Research and other organizations

Annual report of Institute of Nuclear Chemistry and Technology 1996

Energy Technology Data Exchange (ETDEWEB)

NONE

1997-06-01

The report is a collection of short communications being a review of the scientific activities of the Institute of Nuclear Chemistry and Technology, Warsaw in 1996. The papers are gathered in several branches as follows: radiation chemistry and physics (17); Radiochemistry, stable isotopes, nuclear analytical methods,chemistry in general (20); radiobiology (9); nuclear technologies and methods (28).The last and biggest chapter has been divided in four smaller groups; process engineering; material engineering,structural studies,diagnostics; radiation technologies; nucleonic control systems. The annual report of INCT-1996 contains also a general information of Institute, the full list of scientific publications and patents, conferences organized by INCT, Ph.D. and D.Sc. thesis, a list of projects granted by Polish Committee of Scientific Research and other organizations.

Radiopharmaceutical development

International Nuclear Information System (INIS)

Zielinski, F.W.; Robinson, G.D. Jr.; MacDonald, N.S.

1976-01-01

Progress is reported in the following areas of research: compact cyclotron production of 123 I iodide for radiopharmaceutical synthesis; synthesis of 123 I-labeled compounds for myocardial imaging and evaluation of kidney and liver functions; 62 Cu: a short-lived, generator-produced, positron emitting radionuclide for radiopharmaceuticals; dry radioaerosols for lung airway imaging; and improved particulate agents for perfusion imaging

Harvard-MIT research program in short-lived radiopharmaceuticals. Progress report, March 1, 1985-February 28, 1986

International Nuclear Information System (INIS)

1986-03-01

The Harvard-MIT Research Program in Short-Lived Radiopharmaceuticals was established in 1977 to foster interaction among groups working at Harvard Medical School, the Massachusetts Institute of Technology and the Massachusetts General Hospital in fields related to radiopharmaceutical chemistry. From these collaborations and building upon the special, but different, strengths of the participating individuals, laboratories and institutions, it was hoped that original approaches would be found for the design of new, clinically useful, labeled compounds. We believe that examination of the record demonstrates that this has been a fruitful alliance

Regulatory aspects of radiopharmaceuticals

International Nuclear Information System (INIS)

Kristensen, K.

1985-01-01

Regulatory systems in the field of radiopharmaceuticals have two main purposes: efficacy and safety. Efficacy expresses the quality of the diagnostic and therapeutic process for the patient. Safety involves the patient, the staff, and the environment. The world situation regarding regulations for radiopharmaceuticals is reviewed on the basis of a survey in WHO Member States. The main content of such regulations is discussed. The special properties of radiopharmaceuticals compared with ordinary drugs may call for modified regulations. Several countries are preparing such regulations. Close co-operation and good understanding among scientists working in hospital research, industry and regulatory bodies will be of great importance for the fast and safe introduction of new radiopharmaceuticals for the benefit of the patient. Before introducing new legislation in this field, a radiopharmaceutical expert should analyse the situation in the country and the relationship to the existing regulations. It is expected that the most important factor in promoting the fast introduction of new, safe and effective radiopharmaceuticals will be the training of people working within the regulatory bodies. It is foreseen that the IAEA and WHO will have an important role to play by providing expert advice and training in this area. (author)

Occupational exposure in the production of radiopharmaceuticals in Cuba

International Nuclear Information System (INIS)

Amador, Z. H.; Soria, M. A.

2016-01-01

The aim of this paper is to show the experiences in controlling occupational exposure production of radiopharmaceuticals in the Isotope Center (CENTIS) of the Republic of Cuba. data corresponding period 1996-2014 to 896 records are processed. The percentage distributions of the annual effective dose (E), the equivalent dose in the hands (Hp (0.07)) and the equivalent dose in crystalline (Hp (3)), are presented. The annual performance of the average values ​​of these dose quantities is plotted. The results of the internal dosimetry are processed. Annual activities manipulated radioisotopes greater contribution and its relation to the distribution of the collective dose directly linked S of staff, they are evaluated. The ALARA principle is implemented and maintained, based on qualitative and quantitative analysis, as appropriate. The (63-98)% of workers are monitored to E and the (80-100)% for Hp (0.07) and Hp (3), receives less than 10% of annual exposure limits. Groups of workers Radiopharmacy and Inspection and Testing are the greatest contribution to the collective dose, whose S to E equal to or greater than 2 mSv is the (9-62)% of total annual S. The maximum value of S is 98.3 mSv recorded man-1 and this occurs in 2011, however the highest value of 99Mo activity is handled in 2012 and a later year for 131I. They are identified as the most effective means for optimizing radiation safety the use of electronic dosimeters, internal shields process in hot cells and glove boxes and shields for collection of radioactive waste. a reduction in personnel exposure between (10-27)% is obtained. It is shown that exposure of workers in the production of radiopharmaceuticals in Cuba is acceptably low. (author)

World Radiopharmaceutical Therapy Council: A report on the 5th International Radiopharmaceutical Therapy Colloquium and the Final Planning Meeting of the World Radiopharmaceutical Therapy Council held at Santiago, Chile, 29 September, 2002

International Nuclear Information System (INIS)

Turner, J.V.

2003-01-01

-stenosis of coronary arteries following balloon angioplasty was presented by Achim Kropp of Dresden, Amalia Peix of Havana, and June-Key Chung from Seoul who also reported encouraging radiation synovectomy results. Hans Biersack described preliminary studies from Bonn with 188Re MAG3 RC-160 and 188Re-DOTATOC radiopeptides and the potential clinical applications of other 188Re radiopharmaceuticals for radiopeptide therapy and radioimmunotherapy were contemplated, given the daily on-site supply of radionuclide from the 188W/188Re generator. The Final Planning Meeting of the World Radiopharmaceutical Therapy Council, chaired by Harvey Turner, was held during the last session of the Colloquium and discussion was facilitated by a panel of members of the International Task Force of the Council comprising Horacio Amaral, Suresh Srivastava and Alan Perkins. A Preliminary Draft Charter of the World Radiopharmaceutical Therapy Council had been prepared by the Task Force with notable contributions from Sandy McEwan and Chaitanya Divgi and had been circulated to all attendees of the Foundation Planning Meeting of the Council held during the Annual Scientific Meeting of the Society of Nuclear Medicine, June 2001 in Toronto. This draft document was presented for detailed discussion at the Final Planning Meeting in Chile and embodied the principles of global cooperation in therapeutic nuclear medicine outlined in the first issue of the Journal. A Consensus Draft Charter subsequently prepared by the International Task Force was then submitted to the Assembly of Delegates of the World Federation of Nuclear Medicine and Biology on 1st October 2002. The proposal that the World Radiopharmaceutical Therapy Council become an affiliated body of the World Federation of Nuclear Medicine and Biology was adopted without dissent, having been proposed by the President, Horacio Amaral and supported by the Incoming President, Myung Chul Lee. The World Radiopharmaceutical Therapy Council will become an

18F based radiopharmaceuticals and automation of synthesis. New 18F radiopharmaceuticals

International Nuclear Information System (INIS)

Garg, P.K.; Garg, S.

2007-01-01

Fluorine-18 is one of the most commonly used positron emitting isotopes for clinical and research needs with a physical half-life of 110 min. PET isotopes deposit higher radiation absorbed dose than nuclear medicine isotopes. Because of their relatively short half-life, larger quantities of these isotopes are used at the start of synthesis. Therefore, increased shielding and remote automated synthesis are essential for their safe handling. Unlike other radiopharmaceuticals, it is not practical to produce PET radiopharmaceuticals at a central location for subsequent distribution to clinical and research facilities around the country. This limitation compels various academic and research facilities to manufacture their own PET radiopharmaceuticals for in-house use. For multiple reasons, 18 F fluorodeoxyglucose ([ 18 F]FDG) is one of the most commonly used radiopharmaceuticals. The synthesis of [ 18 F]FDG has been optimized and automated, thus allowing independent laboratories to produce this radiopharmaceutical safely. Nonetheless, these laboratories should acquire resources and expertise to fulfil ever increasing regulatory requirements for the safe production and usage of PET radiopharmaceuticals. In addition to [ 18 F]FDG, a wide array of new and novel radiotracers is being developed to explore various biological processes. This paper emphasizes the fact that it is possible to accomplish research and fulfil clinical needs within an academic setting with modest resources. A careful assessment of the need for due diligence in radiation safety issues is very important for the longevity of any PET research endeavour. (author)

Specific GMP guidelines for radiopharmaceutical products

International Nuclear Information System (INIS)

2000-01-01

These guidelines are intended to complement those provided in ''Good manufacturing practices for pharmaceutical products'', as well as the GMP for sterile pharmaceutical products. The regulatory procedures necessary to control radiopharmaceutical products are in large part determined by the sources of products and methods of manufacture. Manufacturing procedures within the scope of these guidelines include: preparation of radiopharmaceuticals in hospital radiopharmacies, preparation of radiopharmaceuticals in centralized radiopharmacies, production of radiopharmaceuticals in nuclear centres, institutes or industrial manufacturers, preparation and production of radiopharmaceuticals in Positron Emission Tomography (PET) centres

Determination of Sn in 99mTc Radiopharmaceutical Kits by Polarographic Methods

International Nuclear Information System (INIS)

Castro, M.; Cruz, J.; Sanchez, M.

2009-01-01

Kits of 99 m Tc radiopharmaceuticals are used in nuclear medicine for diagnosis of different diseases. Sn (II) is one of the essential components in their formulations, which is used for reduction 99 m Tc-pertechnetate in cold kits for on-site preparation 99 m Tc-pertechnetate radiopharmaceuticals. Usually, these cold kits contain different additives (complexing agents, antioxidants, buffers, etc.) and the amount of Sn (II) varies from kit to kit. The determination of Sn in these products is essential in assessing their quality. We report here the development of a new polarographic method for the determination of Sn (II) and total Sn in representative radiopharmaceuticals kits (for the content of Sn and chemical composition) produced at the Center of Isotopes of Cuba (CENTIS). These methods were validated by analysis of variance and recovery techniques. From the results of the validation, the characteristic functions of uncertainties and fits are considered for the established methods, which give the necessary evidences to demonstrate the usefulness of these methods according to the current trends in Analytical Chemistry. This work provides practical results of great importance for CENTIS. After the speciation of Sn in the MAG3 radiopharmaceuticals kit is inferred that the production process is affected by uncontrolled factors that influence in the product stability, which demonstrates the necessity for analytical tools for the characterization of products and processes. (Author) 57 refs.

A study of effluent control technologies employed by radiopharmaceutical users and suppliers

International Nuclear Information System (INIS)

Leventhal, L.; Slider, J.; Chakoff, E.; Chen, J.I.; Savage, E.

1980-01-01

The quantities of radiopharmaceuticals produced for in-vivo diagnostic and therapy procedures has been estimated to be growing at the rate of 16% per year, based on 1978 sales figures. Nuclear medicine facilities are experiencing an average annual growth rate of 5% per year. The principle radionuclides produced and used for nuclear medicine are 131 I, 131 Xe, and sup(9m)Tc. Of particular concern is that amount of these radionuclides which might become airborne and escape into the environment during the process of manufacture or during aliquotting or administration by hospital personnel. Therefore, a study was made of the effluent control technology employed by radiopharmaceutical suppliers and users. Generally, the means used to control airborne radioactive effluents fall into two classes according to function. The controls either dilute and direct the effluent to a specific point of release or hold up the effluent to reduce by decay the amount of radioactivity released. Radiopharmaceutical suppliers and hospitals were contacted, and a survey made of the control technology used. The classes and types of effluent control equipment and their general characteristics, cost and effectiveness were determined. It was concluded that control equipment was readily available, reliable, and effective in reducing radioactive releases from radiopharmaceutical facilities. (author)

Drug-radiopharmaceutical interactions

International Nuclear Information System (INIS)

Hladik, W.B.; Ponto, J.A.; Stathis, V.J.

1985-01-01

Patients seen in the nuclear medicine department have a wide variety of disorders and, consequently, may be receiving any number of therapeutic drugs. For this reason, nuclear medicine professionals should be aware of the potential effects that these pharmacologic agents may have on the bio-distribution of subsequently administered radiopharmaceuticals, commonly referred to as ''drug-radiopharmaceutical interactions.'' Compared with the quantity of literature written about interactions between various therapeutic drugs, the information available on drug-radiopharmaceutical interactions is scarce. However, there has been increasing interest in this subject, particularly during the past five years. Some of the reported interactions are used intentionally to add a new dimension to the nuclear medicine study and increase its diagnostic capabilities, i.e., pharmacologic intervention. These beneficial ''interactions'' are discussed in detail in several other chapters of this book. Other interactions, however, cause changes in the normal distribution of radiopharmaceuticals, which may interfere with the diagnostic utility of various nuclear medicine procedures. The latter group of interactions is the focus of this chapter

Saclay Center of Nuclear Studies, Direction of Materials and Nuclear Fuels, Department of Physico-Chemistry, Division of Physical Chemistry. 1968 Annual report

International Nuclear Information System (INIS)

Schmidt, M.; Clerc, M.; Le Calve, J.; Bourene, M.; Lesigne, B.; Gillois, M.; Devillers, C.; Arvis, M.; Gilles, L.; Moreau, M.; Sutton, J.; Faraggi, M.; Desalos, J.; Tran Dinh Son; Barat, F.; Hickel, B.; Chachaty, C.; Forchioni, A.; Shiotani, M.; Larher, Y.; Maurice, P.; Le Bail, H.; Nenner, T.

1969-03-01

This document is the 1968 annual report of research activities at the Physico-Chemistry Department (Physical Chemistry Division), part of the Directorate of Materials and Nuclear Fuels of the CEA Saclay center of nuclear studies. The report is divided into two main parts: radiolysis and photolysis studies (gaseous phase, condensed phase), and general physico-chemical studies (sorption, molecular jets)

Chemistry of Technetium

International Nuclear Information System (INIS)

Omori, Takashi

2001-01-01

Since the late 1970's the coordination chemistry of technetium has been developed remarkably. The background of the development is obviously related to the use of technetium radiopharmaceuticals for diagnosis in nuclear medicine. Much attention has also been denoted to the chemical behavior of environmental 99 Tc released from reprocessing plants. This review covers the several aspects of technetium chemistry, including production of radioisotopes, analytical chemistry and coordination chemistry. In the analytical chemistry, separation of technetium, emphasizing chromatography and solvent extraction, is described together with spectrophotometric determination of technetium. In the coordination chemistry of technetium, a characteristic feature of the chemistry of Tc(V) complexes is referred from the view point of the formation of a wide variety of highly stable complexes containing the Tc=O or Tc≡N bond. Kinetic studies of the preparation of Tc(III) complexes using hexakis (thiourea) technetium(III) ion as a starting material are summarized, together with the base hydrolysis reactions of Tc(III), Tc(IV) and Tc(V) complexes. (author)

Therapeutic applications of radiopharmaceuticals

International Nuclear Information System (INIS)

Baker, W.J.; Datz, F.L.; Beightol, R.W.

1987-01-01

Whether a radiopharmaceutical has diagnostic or therapeutic application depends on both the isotope and pharmaceutical used. For diagnostic applications, the isotope should undergo only γ-decay, since usually only γ-radiation is detected by nuclear medicine cameras. The half-life should be just long enough to allow the procedure to be performed. In contrast, the isotope needed for therapeutic purposes should have particulate radiation, such as a β-particle (electron), since these are locally absorbed an increase the local radiation dose. γ-Radiation, which penetrates the tissues, produces less radiation dose than do Β-particles. Several references dealing with radioactive decay, particulate interactions, and diagnostic and therapeutic applications of radiopharmaceuticals are available. Radiopharmaceuticals can legally be used only by physicians who are qualified by specific training in the safe handling of radionuclides. The experience and training of these physicians must be approved by the Nuclear Regulatory Commission or Agreement State Agency authorized to license the use of radiopharmaceuticals. A list of all byproduct material and procedures is available in the Code of Federal Regulations. Of the many radiopharmaceuticals available for diagnostic and therapeutic use, only those commonly used are discussed in this chapter

Quality control of radiopharmaceuticals

International Nuclear Information System (INIS)

Kristensen, K.

1981-01-01

Quality assurance was introduced in the pharmaceutical field long before it was used in many other areas, and the term quality control has been used in a much broader sense than merely analytical quality control. The term Good Manufacturing Practice (GMP) has been used to describe the system used for producing safe and effective drugs of a uniform quality. GMP has also been used for the industrial production of radiopharmaceuticals. For the preparation and control of radiopharmaceuticals in hospitals a similar system has been named Good Radiopharmacy Practice (GRP). It contains the same elements as GMP but takes into account the special nature of this group of drugs. Data on the assessment of the quality of radiopharmaceuticals in relation to present standards are reviewed. The general conclusion is that the quality of radiopharmaceuticals appears comparable to that of other drugs. It seems possible to establish the production of radiopharmaceuticals, generators and preparation kits in such a way that analytical control of the final product at the hospital may be limited provided the final preparation work is carried out in accordance with GRP principles. The elements of GRP are reviewed. (author)

Radiopharmaceuticals 1994. Nil desperandum

International Nuclear Information System (INIS)

Cox, P.H.; Meyer, G.J.

1995-01-01

On the basis of the discussions at a symposium held in Duesseldorf and attended by representatives of various interested bodies, European legislation as it affects radiopharmaceuticals is reviewed. Due consideration is given to the new, centralised and decentralised, registration procedures, effective since 1 January 1995. The dossier required to support an application for marketing authorisation is discussed, separate consideration being given to single-photon emitters, therapeutic radio-nuclides and positron-emitting radiopharmaceuticals. The role of the European Pharmacopoiea is also considered. It is concluded that the new, modified procedures for the registration of medicinal products in the European Union may actually inhibit free availability of radiopharmaceuticals within the Community, and that there is a strong case for modification of the European Directives so that radiopharmaceuticals are placed in a separate category to therapeutic drugs, with less stringent registration requirements. (orig.)

Radiopharmaceuticals for therapy

International Nuclear Information System (INIS)

Lazarus, C.R.; Maisey, M.N.

1985-01-01

Several factors influencing the choice of radiopharmaceutical used in the treatment of benign and malignant disease are discussed. A brief review is given of the routine clinical uses of radiopharmaceuticals including treatments for hyperthyroidism, thyroid cancer, polycythaemia rubra vera and intracavitary therapy. Finally clinical situations using radionuclides under evaluation including the treatment of bone disease, adrenal tumours and monoclonal antibodies are discussed. (UK)

Annual report 1993

International Nuclear Information System (INIS)

Hillebrand, G.

1994-01-01

In the Austrian Research Centre Seibersdorf the main research fields are: economy and environment, instrumentation and information technology, process and environmental technologies, engineering, life sciences and systems research. Moreover radiopharmaceuticals are produced and there are the working areas like radioanalysis, radiation chemistry, treatment of low-level radioactive waste, production of isotopes and waste disposal. (Suda)

Annual report 1993

Energy Technology Data Exchange (ETDEWEB)

Hillebrand, G [ed.; Oesterreichisches Forschungszentrum Seibersdorf, 2444 Seibersdorf (Austria)

1994-12-31

In the Austrian Research Centre Seibersdorf the main research fields are: economy and environment, instrumentation and information technology, process and environmental technologies, engineering, life sciences and systems research. Moreover radiopharmaceuticals are produced and there are the working areas like radioanalysis, radiation chemistry, treatment of low-level radioactive waste, production of isotopes and waste disposal. (Suda)

Supply of radiopharmaceuticals in Japan

International Nuclear Information System (INIS)

Genka, Tsuguo

2006-01-01

Detailed statistics of the application of radiopharmaceuticals in nuclear medicine in Japan are summarized. They are the amount of supply in terms of monetary value and radioactivity, categorized usages of in vivo and in vitro, number of facilities using the radiopharmaceuticals for the time span of 5 years (1998-2002). Obvious tendency of decrease for in vitro use can be seen while the total amount of radiopharmaceuticals is almost unchanged. (author)

AINSE conference on radiation biology and chemistry. Conference handbook

Energy Technology Data Exchange (ETDEWEB)

NONE

1994-12-31

The conference handbook contains 60 oral and poster presentations dealing with recent advances in radiation chemistry applied to biological studies, radiopharmaceuticals, radiosensitizers as well as to solid state chemical physics.

AINSE conference on radiation biology and chemistry. Conference handbook

International Nuclear Information System (INIS)

1994-01-01

The conference handbook contains 60 oral and poster presentations dealing with recent advances in radiation chemistry applied to biological studies, radiopharmaceuticals, radiosensitizers as well as to solid state chemical physics

Radiopharmaceuticals good practices handbook: ARCAL XV radiopharmaceuticals control and production

International Nuclear Information System (INIS)

Verdera Presto, Silvia

1998-01-01

A safety practice of the therapeutics diagnostic proceeding in nuclear medicine require a permanent provide high quality radiopharmaceuticals manufacture. This work treat to give a guide for all radio pharmacies laboratories that produce,control, fraction and or dispense radiopharmaceuticals products, with attention hospitable radiopharmacy laboratory. Three chapters with recommendations in manufacture good practice in Hospital radiopharmacy, industrial centralized, bibliography and three annexe's about clean area classification,standards work in laminar flux bell, and guarantee and cleaning areas

The radiopharmaceutical industry and European Union regulations

International Nuclear Information System (INIS)

Fallais, C.J.; Sivewright, S.; Ogle, J.R.

1997-01-01

After a brief historical introduction to Council Directives relating to the manufacture of radiopharmaceuticals the work of the Association of Radiopharmaceuticals Producers - Europe (ARPE) is discussed. ARPE has played a significant role as an officially recognized interlocutor with the EEC, influencing decisions on the registration of radiopharmaceuticals and labelling; this role is reviewed and difficulties identified. The future of radiopharmaceuticals is then considered; it is emphasized that harmonization of national laws by the European Council would represent a first step to enabling radiopharmaceutical manufacturers to access the largest possible market for their products. (orig.)

Investigation on chemistry of model compounds of technetium radiopharmaceuticals

International Nuclear Information System (INIS)

Muenze, R.; Hartmann, E.

1983-01-01

The report summarized experimental and theoretical results concerning the chemical structures and the biodistribution of hydrophilic technetium chelates with hydroxycarboxylic and aminopolycarboxylic acids, thiol compounds and aliphatic and aromatic nitrogen compounds as ligands. Methods which are suitable for synthesizing and characterizing defined chelates of Tc(V), Tc(IV) and Tc(III) have been developed for crystlline substances and species in solution, respectively. For certain types of technetium chelates three dimensional structure models were calculated from atomic parameters. The electron energies and electron distribution of Tc(V) thiol compounds were calculated by quantum chemical methods in order to interprete physical properties of these substances. Biodistribution studies revealed relationships between the osteotropic behaviour and the structure of phosphorous and non-phosphorous technetium chelates and between the kidney uptake and ligand exchange ability of Tc(V) hydroxycarboxylates. Important parameters for the production of technetium-99m kits have been elaborated and used for the optimization of radiopharmaceuticals (bone-, kidney and hepatobiliaer agents). (author)

Radiopharmaceuticals and applications; Preparacoes radiofarmaceuticas e suas aplicacoes

Energy Technology Data Exchange (ETDEWEB)

Oliveira, Rita [Universidade Fernando Pessoa, Porto (Portugal). Fac. de Ciencias da Saude; Santos, Delfim; Ferreira, Domingos; Coelho, Pedro [Universidade do Porto (Portugal). Fac. da Farmacia; Veiga, Francisco, E-mail: fveiga@ci.uc.pt [Universidade de Coimbra (Portugal). Fac. de Farmacia

2006-04-15

Radiopharmaceuticals are substances without pharmacological activity that are used in Nuclear Medicine for diagnosis and therapy for several diseases. Diagnosis radiopharmaceuticals generally emit {gamma} radiation or positrons ({beta}+), because their decay originates penetrating electromagnetic radiation that can cross the tissues and be externally detected. Therapeutic radiopharmaceuticals must include in their composition ionized particles emission nucleus ({alpha}, {beta}{sup -} or Auger electrons), since their action is based in selective tissue destruction. There are two main methods for image acquisition: SPECT (Single Photon Emission Computerized Tomography) that uses {gamma} emission radionuclides ({sup 99m}Tc, {sup 123}I, {sup 67}Ga, {sup 201}Tl) and PET (Positron Emission Tomography) that uses positron emission radionuclides like {sup 11}C, {sup 13}N, {sup 15}O, {sup 18}F. Radiopharmaceuticals can be classified into perfusion radiopharmaceuticals (first generation) or specific radiopharmaceuticals (second generation). Perfusion radiopharmaceuticals are transported in the blood e reach the target organ in the direct proportion of the blood stream. Specific radiopharmaceuticals contain a biologically active molecule that binds to cellular receptors that must remain biospecific after binding to the radiopharmaceutical. For this type of radiopharmaceuticals, tissue or organ uptake is determined by the biomolecule capacity of recognizing receptors in those biological structures. Radiopharmaceuticals are produced ready to use, in cold kits or in autologal preparations. According to the preparation type there is a different quality control procedure. Most of the radiopharmaceuticals used nowadays are of the perfusion type. Research focus in the development of specific radiopharmaceuticals that can provide information, at the molecular level, of biochemical alterations associated to different pathologies. (author)

Annual Report 1984. Chemistry Department

DEFF Research Database (Denmark)

Funck, Jytte; Nielsen, Ole John

This report contains a brief survey of the main activities in the Chemistry Department. All articles and reports published and lectures given in 1984 are presented. The facilities and equipment are mentioned briefly. The activities are divided into the following groups: radioisotope chemistry, an......, analytical- and organic chemistry, environmental chemistry, polymer chemistry, geochemistry and waste disposal, radical chemistry, positron annihilation, mineral processing, and general.......This report contains a brief survey of the main activities in the Chemistry Department. All articles and reports published and lectures given in 1984 are presented. The facilities and equipment are mentioned briefly. The activities are divided into the following groups: radioisotope chemistry...

Annual report 1984 Chemistry Department

International Nuclear Information System (INIS)

Funck, J.; Larsen, E.; Nielsen, O.J.

1985-03-01

This report contains a brief survey of the main activities in the Chemistry Department. All articles and reports published and lectures given in 1984 are presented. The facilities and equipment are mentioned briefly. The activities are divided into the following groups: radioisotope chemistry, analytical- and organic chemistry , environmental chemistry, polymer chemistry, geochemistry and waste disposal, radical chemistry, positron annihilation, mineral processing, and general. (author)

Annual report 1987 Chemistry Department

International Nuclear Information System (INIS)

Funck, J.; Larsen, E.; Nielsen, O.J.

1988-04-01

This report contains a brief survey of the main activities in the Chemistry Department. The names and abstracts of all articles and reports published and lectures given in 1987 are presented. The facilities and equipment are mentioned briefly. The activities are divided into the following groups: radioisotope chemistry, analytical- and organic chemistry, environmental chemistry, polymer chemistry, radical chemistry, mineral processing, and general. 13 ills., (author)

Annual report 1985 Chemistry Department

International Nuclear Information System (INIS)

Funck, J.; Larsen, E.; Nielsen, O.J.

1986-03-01

This report contains a brief survey of the main activities in the Chemistry Department. All particles and reports published and lectures given in 1985 are presented. The facilities and equipment are mentioned briefly. The activities are divided into the following groups: radioisotope chemistry, analytical- and organic chemistry, environmental chemistry, polymer chemistry, geochemistry and waste disposal, radical chemistry, positron annihilation, mineral processing, and general. (author)

Annual report 1982 chemistry department

International Nuclear Information System (INIS)

Larsen, E.; Nielsen, O.J.

1983-04-01

The work going on in the Risoe National Laboratory, Chemistry Department is briefly surveyed by a presentation of all articles and reports published in 1982. The facilities and equipment are barely mentioned. The papers are divided into eight activities: 1. neutron activation analysis 2. analytical- and organic chemistry 3. environmental chemistry 4. polymer chemistry 5. geochemistry 6. radical chemistry 7. poitron annihilation 8. uranium process chemistry. (author)

Radiopharmaceuticals drug interactions: a critical review

International Nuclear Information System (INIS)

Santos-Oliveira, Ralph; Smith, Sheila W.; Carneiro-Leao, Ana Maria A.

2008-01-01

Radiopharmaceuticals play a critical role in modern medicine primarily for diagnostic purposes, but also for monitoring disease progression and response to treatment. As the use of image has been increased, so has the use of prescription medications. These trends increase the risk of interactions between medications and radiopharmaceuticals. These interactions which have an impact on image by competing with the radiopharmaceutical for binding sites for example can lead to false negative results. Drugs that accelerate the metabolism of the radiopharmaceutical can have a positive impact (i.e. speeding its clearance) or, if repeating image is needed, a negative impact. In some cases, for example in cardiac image among patients taking doxirubacin, these interactions may have a therapeutic benefit. The incidence of drug-radiopharmaceuticals adverse reactions is unknown, since they may not be reported or even recognized. Here, we compiled the medical literature, using the criteria of a systematic review established by the Cochrane Collaboration, on pharmaceutical-drug interactions to provide a summary of documented interactions by organ system and radiopharmaceuticals. The purpose is to provide a reference on drug interactions that could inform the nuclear medicine staff in their daily routine. Efforts to increase adverse event reporting, and ideally consolidate reports worldwide, can provide a critically needed resource for prevention of drug-radiopharmaceuticals interactions. (author)

Nuclear Chemistry Division annual report FY83

International Nuclear Information System (INIS)

Struble, G.

1983-01-01

The purpose of the annual reports of the Nuclear Chemistry Division is to provide a timely summary of research activities pursued by members of the Division during the preceding year. Throughout, details are kept to a minimum; readers desiring additional information are encouraged to read the referenced documents or contact the authors. The Introduction presents an overview of the Division's scientific and technical programs. Next is a section of short articles describing recent upgrades of the Division's major facilities, followed by sections highlighting scientific and technical advances. These are grouped under the following sections: nuclear explosives diagnostics; geochemistry and environmental sciences; safeguards technology and radiation effect; and supporting fundamental science. A brief overview introduces each section. Reports on research supported by a particular program are generally grouped together in the same section. The last section lists the scientific, administrative, and technical staff in the Division, along with visitors, consultants, and postdoctoral fellows. It also contains a list of recent publications and presentations. Some contributions to the annual report are classified and only their abstracts are included in this unclassified portion of the report (UCAR-10062-83/1); the full article appears in the classified portion (UCAR-10062-83/2)

Annual report 1986 chemistry department

International Nuclear Information System (INIS)

Funck, J.; Larsen, E.; Nielsen, O.J.

1987-03-01

This report contains a brief survey of the main activities in the Chemistry Department. All articles and reports published and lectures given in 1986 are presented. The facilities and equipment are mentioned briefly. The activities are divided into the following groups: radioisotope chemistry, analytical- and organic chemistry, environmental chemistry, polymer chemistry, radical chemistral, mineral processing, and general. (author)

Radiopharmaceuticals for nuclear cardiology

International Nuclear Information System (INIS)

Leon Cabana, Alba

1994-01-01

One of the diagnostic technique periodically used in Nuclear Medicine is the angiographic studi e, employee for detect cardiovascular diseases. The radiopharmaceutical more used in the angiographic ones is 99mTc. Between thetopics described in the present work it find: myocardial infarction, radiopharmaceuticals classification for cardiac studies, labelled proceedings, cardiovascular diseases

Development of European regulations on radiopharmaceuticals

International Nuclear Information System (INIS)

Kristensen, K.

1990-01-01

Separate regulatory systems are being developed on the use of radiopharmaceuticals including radiation protection of patients and personnel and on the quality including safety and efficacy of radiopharmaceuticals. Radiation protection legislation has been introduced in most western European Economic Community (EEC). Within the drug field radiopharmaceuticals have been excepted up till now. However, new EEC directive on radiopharmaceuticals will soon come into force. The work done on the preparation of regulations and guidelines will be discussed. This discussion will focus on the problems faced when radiation protection aspects shall be balanced to traditional requirements of pharmaceutical aspects

Annual report 1988 Chemistry Department

International Nuclear Information System (INIS)

Funck, J.; Neve Larsen, Aa.; Larsen, E.; Nielsen, O.J.

1989-05-01

This report contains a brief survey of the main activities in the Chemistry Department. The names and abstracts of all articles and reports published and lectures given in 1988 are presented. The facilities and equipment are mentioned briefly. The activities are divided into the following groups: radioisotope chemistry, analytical- and organic chemistry, environmental chemistry, polymer chemistry, chemical reactivity, mineral processing, and general. (author)

Annual report 1989 Chemistry Department

International Nuclear Information System (INIS)

Funck, J.; Neve Larsen, Aa.; Larsen, E.; Nielsen, O.J.

1990-03-01

This report contains a brief survey of the main activities in the Chemistry Department. The names and abstracts of all articles and reports published and lectures given in 1989 are presented. The facilities and equipment are mentioned briefly. The activities are divided into the following groups: radioisotope chemistry, analytical- and organic chemistry, environmental chemistry, polymer chemistry, chemical reactivity, mineral processing, and general. (author)

Radiopharmaceuticals

International Nuclear Information System (INIS)

Kristensen, K.

1988-01-01

Different forms of radiopharmaceuticals such as radioactive gases, aerosols and colloids used for diagnostic techniques and radiotherapy and methods of labelling them are discussed. Some reference is made to their documentation, handling and quality control. (U.K.)

Production And Quality Control Of Radiopharmaceutical 18F-FDG

International Nuclear Information System (INIS)

Dinh Thi Bich Lieu; Nguyen Van Si; Vu Van Tien

2011-01-01

18 F-FDG is a radiopharmaceutical for imaging diagnosis with PET/CT in Nuclear Medicine. Criteria of injection pharmaceuticals are the highest standards. So, quality assurance and quality control must be followed very strictly. The selection of the procedure for 18 F-FDG has based on several criteria: high chemical efficiency, short synthesis time, toxic component free and etc. The quality control of 18 F-FDG consist many fields such as: nuclear physic (nuclear purity), radiochemistry (radionuclear purity, radiochemical purity), chemistry (chemical purity), radiation measurement (half life), microbiology (pyrogen, endotoxin), etc. which is following USP, BP or EP. (author)

Radiochemical syntheses further radiopharmaceuticals for positron emission tomography and new strategies for their production

CERN Document Server

Kilbourn, Michael R; Kilbourn, Michael R

2015-01-01

This book describes methods and procedures for preparing PET radiopharmaceuticals, and highlights new methods for conducting radiochemical reactions with carbon-11 (C11) and fluorine-18 (F18), which are two of the most commonly used radionuclides in positron emission tomography (PET) imaging.     Provides reliable methods for radiochemical syntheses and reactions, including all essential information to duplicate the procedure     Eliminates the time-consuming process of searching journal articles and extracting pertinent details from lengthy experimental sections or supporting information     Focuses on an emerging and important area for pharmaceutical and medical applications     Encompasses technical, regulatory, and application aspects     Includes solid-phase radiochemistry, transition-metal catalyzed radiochemistry, microfluidics, click chemistry, green radiochemistry and new strategies for radiopharmaceutical quality control.

Annual report 1983 Chemistry Department

International Nuclear Information System (INIS)

Funck, J.; Larsen, E.; Nielsen, O.J.

1984-05-01

This report contains a brief survey of the main activities in the Chemistry Department. All articles and reports published and lectures given in 1983 are presented. The facilities and equipment are barely mentioned. The activities are divided into nine groups: 1. radioisotope chemistry 2. analytical- and organic chemistry 3. environmental chemistry 4. polymer chemistry 5. geochemistry and waste disposal 6. radical chemstry 7. positron annihilation 8. mineral processing 9. general. (author)

6. Radiopharmaceuticals

International Nuclear Information System (INIS)

Schiller, P.; Havranek, E.; Majer, J.

1981-01-01

Radionuclides commonly used in medicine are surveyed and their nuclear characteristics are presented. The methods are given of their preparation, most frequent use and detection. The list is given of radiopharmaceuticals included in the Czechoslovak Pharmacopoeia CsL 3 , ie., sodium chromate( 51 Cr), sodium iodide( 131 I), hippuran( 131 I), sodium phosphate( 32 P), colloidal gold( 198 Au), rose bengal sodium salt( 131 I), and sodium pertechnetate(sup(99m)Tc) injections. Characteristics, chemical preparation, identification tests, packaging, storage, application and dosage are shown for each preparation. Also listed are important unofficial radiopharmaceuticals, their main characteristics and data on their preparation and application. (B.S.)

Recent advances in radiopharmaceuticals

International Nuclear Information System (INIS)

Smith, S.

2000-01-01

Full text: Radiopharmaceuticals in Nuclear Medicine may be divided into diagnostic and therapeutic agents. The diagnostic area is perceived to be mature, while the therapeutic side of nuclear medicine is still evolving. There are over 100 diagnostic radiopharmaceutical products available, the greatest number applied in cardiology followed by oncology and neurology. The greatest success in therapeutic nuclear medicine has been achieved in thyroid cancer, hyperthyroidism and bone pain palliation. Those in the field believe the future of nuclear medicine resides in the growth potential of the emerging therapeutic market, hence much of the recent research has been focussed in the development of therapeutic agents for targeting cancers. Radiopharmaceuticals under development or in clinical trials involve the use of radionuclides such as Y-90, Pd-103, Ir-192, Re-188, I-131, Sm-153, Sn-114, Sr-90, Cu-64 and In-111. Advances in cyclotron and camera technology as well as automation has enhanced and widened the potential use of positron emitting radiopharmaceuticals such as F-18 Fluorodeoxyglucose (FDG). However the relationship between FDG uptake and glucose consumption in normal and diseased tissue is still to be defined. Many challenges remain for the nuclear medicine community to apply new knowledge of human biochemistry in the development of new radiopharmaceuticals. A better understanding of effects of radiation and its role in the design of therapeutic agents is undoubtedly pivotal for advancing therapeutic Nuclear Medicine into the future

Radiopharmaceuticals for bone scintillators

International Nuclear Information System (INIS)

Rey, A.M.

1994-01-01

One of the diagnostic techniques used in nuclear medicine is the bone scintiscanning with labelled compounds for obtain skeletal images. The main sections in this work are: (1) bone composition and anatomy;(2)skeletal radiopharmaceutical development;(3)physical properties of radionuclides;(4)biological behaviour and chemical structures;(5)radiopharmaceuticals production for skeletal scintillation;(6)kits;(7)dosimetry and toxicity.tabs

The use of transducers for automated radiopharmaceutical synthesis procedures

International Nuclear Information System (INIS)

Ruth, T.J.; Adam, M.J.; Morris, D.; Jivan, S.; Tyldesley, S.

1991-01-01

There are essentially two reasons why a synthetic procedure for producing a radiopharmaceutical is automated. The First is to reduce radiation exposure and the second is to increase reliability. Reducing radiation exposure can be accomplished in a number of ways. The most common approaches include the use of: hotcells with manipulators, remotely controlled solenoid valves behind shielding, either a PC or a PLC to control the solenoid valves, or robotics. The question of reliability impacts on each of these methods differently. The use of a hotcell with manipulators requires a highly skilled operator and in general is not suitable for microchemistry and very short half-lives. The remotely controlled system is prone to operator error, for example activating the wrong valving sequence. The computer controlled system is dependent on a feedback system if it is to operate open-quotes intelligentlyclose quotes; and finally the robotic system is dependent on feedbacks, as well as, careful, set-up within the robotic coordinate system. The remainder of this paper will discuss the feedback loops, required for the automated/robotic chemistry associated with the synthesis of positron emitting radiopharmaceuticals

Radiopharmaceuticals for thrombus detection

International Nuclear Information System (INIS)

Knight, L.C.

1990-01-01

Most of the components of the thrombotic and fibrinolytic systems have at some time been evaluated as a means of carrying a radiolabel specifically to thrombi, although very few have been promising enough to emerge from investigational status to routine clinical use. New approaches are being explored, including improved methods of labeling platelets, chemically modified forms of previously tested plasma proteins, and new biomolecules, including monoclonal antibodies specific for fibrin and platelets. The current goal is to find one or more radiotracers that bind specifically and rapidly to thrombi, and that also have a rapid blood disappearance rate, permitting a clear diagnosis within a few hours after injection. Because this test may be needed to assess the course of therapy in an anticoagulated patient, the ideal radiopharmaceutical should be able to locate thrombi without interference by anticoagulants. Until a suitable thrombus-specific radiopharmaceutical becomes generally available, many hospitals will continue to attempt to make a diagnosis with nonspecific radiopharmaceuticals that can at best provide blood pool images to indicate filling defects. Several of the new approaches seem likely to provide the radiopharmaceutical sought, although clinical trials are at an early stage.137 references

Audits of radiopharmaceutical formulations

International Nuclear Information System (INIS)

Castronovo, F.P. Jr.

1992-01-01

A procedure for auditing radiopharmaceutical formulations is described. To meet FDA guidelines regarding the quality of radiopharmaceuticals, institutional radioactive drug research committees perform audits when such drugs are formulated away from an institutional pharmacy. All principal investigators who formulate drugs outside institutional pharmacies must pass these audits before they can obtain a radiopharmaceutical investigation permit. The audit team meets with the individual who performs the formulation at the site of drug preparation to verify that drug formulations meet identity, strength, quality, and purity standards; are uniform and reproducible; and are sterile and pyrogen free. This team must contain an expert knowledgeable in the preparation of radioactive drugs; a radiopharmacist is the most qualified person for this role. Problems that have been identified by audits include lack of sterility and apyrogenicity testing, formulations that are open to the laboratory environment, failure to use pharmaceutical-grade chemicals, inadequate quality control methods or records, inadequate training of the person preparing the drug, and improper unit dose preparation. Investigational radiopharmaceutical formulations, including nonradiolabeled drugs, must be audited before they are administered to humans. A properly trained pharmacist should be a member of the audit team

The current situation and future prospects of radiopharmaceuticals

International Nuclear Information System (INIS)

Ando, Atsushi

2001-01-01

Radiopharmaceuticals play an important role in nuclear medicine. In this paper, nuclear medicine relating to radiopharmaceuticals was briefly described. And I would like to focus on the current situation and future prospects of radiopharmaceuticals. Nuclear medicine in this century should take the following directions. Firstly, cancer treatment by radionuclides will be one of the promising fields in oncology. Secondly, in order to achieve evidence-based medicine, sensitive, quantitative imaging using the nuclides will be necessary in nuclear medicine. Under these circumstances, it is important to develop radiopharmaceuticals for sensitive, quantitative imaging and therapeutic radiopharmaceuticals. (author)

Nuclear Chemistry Division annual report FY83

Energy Technology Data Exchange (ETDEWEB)

Struble, G. (ed.)

1983-01-01

The purpose of the annual reports of the Nuclear Chemistry Division is to provide a timely summary of research activities pursued by members of the Division during the preceding year. Throughout, details are kept to a minimum; readers desiring additional information are encouraged to read the referenced documents or contact the authors. The Introduction presents an overview of the Division's scientific and technical programs. Next is a section of short articles describing recent upgrades of the Division's major facilities, followed by sections highlighting scientific and technical advances. These are grouped under the following sections: nuclear explosives diagnostics; geochemistry and environmental sciences; safeguards technology and radiation effect; and supporting fundamental science. A brief overview introduces each section. Reports on research supported by a particular program are generally grouped together in the same section. The last section lists the scientific, administrative, and technical staff in the Division, along with visitors, consultants, and postdoctoral fellows. It also contains a list of recent publications and presentations. Some contributions to the annual report are classified and only their abstracts are included in this unclassified portion of the report (UCAR-10062-83/1); the full article appears in the classified portion (UCAR-10062-83/2).

Radiopharmaceuticals for cerebral studies

International Nuclear Information System (INIS)

Leon Cabana, Alba

1994-01-01

For obtain good brain scintillation images in nuclear medicine must be used several radiopharmaceuticals. Cerebral studies give a tumors visual image as well as brain anomalities detection and are helpful in the diagnostic diseases . Are described in this work: a cerebrum radiopharmaceuticals classification,labelled compounds proceeding and Tc 99m good properties in for your fast caption, post administration and blood purification for renal way

Radiopharmaceuticals - current state and trends

International Nuclear Information System (INIS)

Muenze, R.

1981-07-01

The current state as well as the tendencies of modern radiopharmaceutical development and application is reviewed. After an evaluation of the fundamental preconditions of decay characteristics and pharmaceutical properties the problems concerning sup(99m)Tc-radiopharmaceuticals, metabolizable compounds and the use of specific biological interactions are discussed. (author)

Cyclotrons and positron emitting radiopharmaceuticals

International Nuclear Information System (INIS)

Wolf, A.P.; Fowler, J.S.

1984-01-01

The state of the art of Positron Emission Tomography (PET) technology as related to cyclotron use and radiopharmaceutical production is reviewed. The paper discusses available small cyclotrons, the positron emitters which can be produced and the yields possible, target design, and radiopharmaceutical development and application. 97 refs., 12 tabs

Radiochemical stability of radiopharmaceutical preparations

International Nuclear Information System (INIS)

Martins, Patricia de A.; Silva, Jose L. da; Ramos, Marcelo P.S.; Oliveira, Ideli M. de; Felgueiras, Carlos F.; Herrerias, Rosana; Zapparoli Junior, Carlos L.; Mengatti, Jair; Fukumori, Neuza T.O.; Matsuda, Margareth M.N.

2011-01-01

The 'in vitro' stability studies of the radiopharmaceutical preparations are an essential requirement for routine practice in nuclear medicine and are an important parameter for evaluating the quality, safety and efficacy required for the sanitary registration of pharmaceutical products. Several countries have published guidelines for the evaluation of pharmaceutical stability. In Brazil, the stability studies should be conducted according to the Guide for Conducting Stability Studies published in the Resolution-RE n. 1, of 29th July 2005. There are also for radiopharmaceutical products, two specific resolutions: RDC-63 regulates the Good Manufacturing Practices for Radiopharmaceuticals and RDC-64 provides the Registration of Radiopharmaceuticals, both published on the 18th December 2009. The radiopharmaceutical stability is defined as the time during which the radioisotope can be safely used for the intended purpose. The radiochemical stability can be affected by a variety of factors, including storage temperature, amount of radioactivity, radioactive concentration, presence or absence of antioxidants or other stabilizing agents. The radiochemical stability studies must be established under controlled conditions determined by the effective use of the product. The aim of this work was to evaluate the radiochemical stability of labeled molecules with 131 I, 123 I, 153 Sm, 18 F, 51 Cr, 177 Lu and 111 In as well as 67 Ga and 201 Tl radiopharmaceuticals. Radiochemical purity was evaluated after production and in the validity period, with the maximum activity and in the recommended storage conditions. The analyses were carried out by thin-layer silica gel plate, paper chromatography and gel chromatography. The experimental results showed to be in accordance with the specified limits for all the analysed products. (author)

Cyclotrons and positron emitting radiopharmaceuticals

Energy Technology Data Exchange (ETDEWEB)

Wolf, A.P.; Fowler, J.S.

1984-01-01

The state of the art of Positron Emission Tomography (PET) technology as related to cyclotron use and radiopharmaceutical production is reviewed. The paper discusses available small cyclotrons, the positron emitters which can be produced and the yields possible, target design, and radiopharmaceutical development and application. 97 refs., 12 tabs. (ACR)

Considerations and controversies in the selection of radiopharmaceuticals

International Nuclear Information System (INIS)

Chilton, H.M.; Cowan, R.J.

1987-01-01

When a radiopharmaceutical is selected for a specific study, multiple factors must be considered to ensure that optimum clinical information will be provided with minimum radiation exposure to the patient and laboratory personnel. In this endeavor, certain questions must be considered. What are the nuclear properties of the available radiopharmaceuticals? For the organ to be studied, are there multiple radiopharmaceutical localization pathways? If so, which is best suited to provide the desired diagnostic information? Does the presence of certain clinical factors preclude the use of some radiopharmaceuticals and require the use of others? Do certain radiopharmaceuticals have overriding radiopharmacologic properties which limit their usefulness for the evaluation of certain clinical situations? Finally, how significant are non-clinical properties such as cost, availability, and product formulation? In this chapter, some of these areas and several situations which illustrate the radiopharmaceutical selection process are discussed

Placental transfer of selected radiopharmaceuticals

International Nuclear Information System (INIS)

Wegst, A.V.

1992-01-01

This paper reviews animal experiments carried out to determine the transfer of radiopharmaceuticals from mother to fetus. Animal data are compared to any human data available. The radiopharmaceuticals included in the discussion are Tc-99m pertechnetate, Tc-99m DTPA, Ga-67 citrate and Tl-201 chloride. (6 tab., 5 refs.)

Annual report 1979/1980

International Nuclear Information System (INIS)

Muenze, R.

1981-11-01

The annual report concentrates result of investigations in the field of the production of radioisotopes, the synthesis of radioactive compounds and their characterization. Main topics are the production of 99 Mo and the application of radioactive compounds in nuclear medicine especially as radiopharmaceuticals. A list of publications and lectures is enclosed. (author)

Clean room installations in a radiopharmaceutical facility

International Nuclear Information System (INIS)

2000-01-01

The standards of radiopharmaceuticals on the facility, working environment and preparation control strategy are yet to be generated. In general, radiopharmaceuticals have short half-lives and emit gamma radiation. Due to its unique characteristics, its preparation has to be made in the fume hood and hot cell to avoid radiation exposure to workers. Considering radiation protection, the working environment has to be maintained under negative pressure so that dispersion of radiopharmaceuticals should be avoided. On the contrary, a positively pressurized working environment gives clean atmosphere and prevents contamination with harmful microorganisms during preparation. Hence, it is required to harmonize for mentioned contradictory conditions in preparation of radiopharmaceuticals for the safety of workers and its quality assurance as well. Therefore, it is reasonable that good manufacturing practice for radiopharmaceutical production facility should be constituted according to the standards for production of biological agents accompanied with a radiation shielding

First Human Use of a Radiopharmaceutical Prepared by Continuous-Flow Microfluidic Radiofluorination: Proof of Concept with the Tau Imaging Agent [18F]T807

Directory of Open Access Journals (Sweden)

Steven H. Liang

2014-10-01

Full Text Available Despite extensive preclinical imaging with radiotracers developed by continuous-flow microfluidics, a positron emission tomographic (PET radiopharmaceutical has not been reported for human imaging studies by this technology. The goal of this study was to validate the synthesis of the tau radiopharmaceutical 7-(6-fluoropyridin-3-yl-5H-pyrido[4,3-b]indole ([18F]T807 and perform first-in-human PET scanning enabled by microfluidic flow chemistry. [18F]T807 was synthesized by our modified one-step method and adapted to suit a commercial microfluidic flow chemistry module. For this proof of concept, the flow system was integrated to a GE Tracerlab FXFN unit for high-performance liquid chromatography purification and formulation. Three consecutive productions of [18F]T807 were conducted to validate this radiopharmaceutical. Uncorrected radiochemical yields of 17 ± 1% of crude [18F]T807 (≈ 500 mCi, radiochemical purity 95% were obtained from the microfluidic device. The crude material was then purified, and > 100 mCi of the final product was obtained in an overall uncorrected radiochemical yield of 5 ± 1% (n = 3, relative to starting [18F]fluoride (end of bombardment, with high radiochemical purity (≥ 99% and high specific activities (6 Ci/μmol in 100 minutes. A clinical research study was carried out with [18F]T807, representing the first reported human imaging study with a radiopharmaceutical prepared by this technology.

Preparation of radiopharmaceutical formulations

International Nuclear Information System (INIS)

Simon, J.; Garlich, J.R.; Frank, R.K.; McMillan, K.

1998-01-01

Radiopharmaceutical formulations for complexes comprising at least one radionuclide complexed with a ligand, or its physiologically-acceptable salts thereof, especially 153 samarium-ethylenediaminetetramethylenephosphonic acid, which optionally contains a divalent metal ion, e.g. calcium, and is frozen, thawed, and then administered by injection. Alternatively, the radiopharmaceutical formulations must contain the divalent metal and are frozen only if the time before administration is sufficiently long to cause concern for radiolysis of the ligand. 2 figs., 9 tabs

Radiopharmaceuticals

Energy Technology Data Exchange (ETDEWEB)

Hunt, F C; Wilson, J G

1980-03-13

The claim describes a reducing metal complex of a compound in a suitable form for labelling with technetium-99m for radiopharmaceutical purposes, the compound being a complex derived from an indene heterocycle structure. The indene heterocycle structure is selected from the group consisting of iminodiacetic acid derivates of benzimidazole, benzthiazole and benzoxazole.

Radiopharmaceuticals For Detection Of Inflammation And Infection

International Nuclear Information System (INIS)

Nurlaila, Z.

2002-01-01

Feeling of pain in the body could be caused by reaction of inflantation and infection as well. One of the methods could be used to detect the reaction is nuclear technique using radiopharmaceutical as radiotracer. Some radiopharmaceuticals having specific accunulation mechanism to diagnose the presence of inflamations and infections with satisfactory results. Among those radiophannaceuticals are technetium-99m-hexamethylpropileneamine-white blood cell ( 99m Tc-HMPAO-WBC), indium-111-oxine-white blood cell ( 111 In-oksin-WBC). technetium-99m-immunoglobuline G ( 99m Tc-lgG) and technetium-99m-infecton ( 99m Tc-infecton). In visualization using this method. the information of a serial previous medical treatment of the patient should be known, because cer1ain medicament, could influence the biological characteristic of radiopharmaceuticals and hence. a missed diagnosis could be resulted. This review discusses several radiopharmaceuticals for inflamation and infection, diagnoses their accumulation, mechanism in the body. Besides, the radiopharmaceuticals interaction with several drugs are also reviewed

Radiopharmaceutical drug review process

International Nuclear Information System (INIS)

Frankel, R.

1985-01-01

To ensure proper radioactive drug use (such as quality, diagnostic improvement, and minimal radioactive exposure), the Food and Drug Administration evaluates new drugs with respect to safety, effectiveness, and accuracy and adequacy of the labeling. The IND or NDA process is used for this purpose. A brief description of the process, including the Chemical Classification System and the therapeutic potential classification, is presented as it applies to radiopharmaceuticals. Also, the status of the IND or NDA review of radiopharmaceuticals is given

The hospital preparation of radiopharmaceuticals

International Nuclear Information System (INIS)

The subject is covered in sections: introduction; preparation ((general - sterilization), production areas (laboratories), working methods for injections, working methods for oral preparations and iodination procedures); analytical testing (general, standards common to injections and oral preparations, standards for injections, standards for oral preparations); reliable methods of preparing sup(99m)Tc-radiopharmaceuticals and 51 Cr-red cells; commercial radiopharmaceutical kits. (U.K.)

NUCLEAR CHEMISTRY ANNUAL REPORT 1970

Energy Technology Data Exchange (ETDEWEB)

Authors, Various

1971-05-01

Papers are presented for the following topics: (1) Nuclear Structure and Nuclear Properties - (a) Nuclear Spectroscopy and Radioactivity; (b) Nuclear Reactions and Scattering; (c) Nuclear Theory; and (d) Fission. (2) Chemical and Atomic Physics - (a) Atomic and Molecular Spectroscopy; and (b) Hyperfine Interactions. (3) Physical, Inorganic, and Analytical Chemistry - (a) X-Ray Crystallography; (b) Physical and Inorganic Chemistry; (c) Radiation Chemistry; and (d) Chemical Engineering. (4) Instrumentation and Systems Development.

Uncertainty sources in radiopharmaceuticals clinical studies

International Nuclear Information System (INIS)

Degenhardt, Aemilie Louize; Oliveira, Silvia Maria Velasques de

2014-01-01

The radiopharmaceuticals should be approved for consumption by evaluating their quality, safety and efficacy. Clinical studies are designed to verify the pharmacodynamics, pharmacological and clinical effects in humans and are required for assuring safety and efficacy. The Bayesian analysis has been used for clinical studies effectiveness evaluation. This work aims to identify uncertainties associated with the process of production of the radionuclide and radiopharmaceutical labelling as well as the radiopharmaceutical administration and scintigraphy images acquisition and processing. For the development of clinical studies in the country, the metrological chain shall assure the traceability of the surveys performed in all phases. (author)

Database setup insuring radiopharmaceuticals traceability

International Nuclear Information System (INIS)

Robert, N.; Salmon, F.; Clermont-Gallerande, H. de; Celerier, C.

2002-01-01

Having to organize radiopharmacy and to insure proper traceability of radiopharmaceutical medicines brings numerous problems, especially for the departments which are not assisted with global management network systems. Our work has been to find a solution enabling to use high street software to cover those needs. We have set up a PC database run by the Microsoft software ACCESS 97. Its use consists in: saving data related to generators, isotopes and kits reception and deletion, as well as the results of quality control; transferring data collected from the software that is connected to the activimeter (elutions and preparations registers, prescription book). By relating all the saved data, ACCESS enables to mix all information in order to proceed requests. At this stage, it is possible to edit all regular registers (prescription book, generator and radionuclides follow-up, blood derived medicines traceability) and to quickly retrieve patients who have received a particular radiopharmaceutical, or the radiopharmaceutical that has been given to a particular patient. This user-friendly database provides a considerable support to nuclear medicine department that don't possess any network management for their radiopharmaceutical activity. (author)

Recent Progress toward Microfluidic Quality Control Testing of Radiopharmaceuticals

Directory of Open Access Journals (Sweden)

Noel S. Ha

2017-11-01

Full Text Available Radiopharmaceuticals labeled with short-lived positron-emitting or gamma-emitting isotopes are injected into patients just prior to performing positron emission tomography (PET or single photon emission tomography (SPECT scans, respectively. These imaging modalities are widely used in clinical care, as well as in the development and evaluation of new therapies in clinical research. Prior to injection, these radiopharmaceuticals (tracers must undergo quality control (QC testing to ensure product purity, identity, and safety for human use. Quality tests can be broadly categorized as (i pharmaceutical tests, needed to ensure molecular identity, physiological compatibility and that no microbiological, pyrogenic, chemical, or particulate contamination is present in the final preparation; and (ii radioactive tests, needed to ensure proper dosing and that there are no radiochemical and radionuclidic impurities that could interfere with the biodistribution or imaging. Performing the required QC tests is cumbersome and time-consuming, and requires an array of expensive analytical chemistry equipment and significant dedicated lab space. Calibrations, day of use tests, and documentation create an additional burden. Furthermore, in contrast to ordinary pharmaceuticals, each batch of short-lived radiopharmaceuticals must be manufactured and tested within a short period of time to avoid significant losses due to radioactive decay. To meet these challenges, several efforts are underway to develop integrated QC testing instruments that automatically perform and document all of the required tests. More recently, microfluidic quality control systems have been gaining increasing attention due to vastly reduced sample and reagent consumption, shorter analysis times, higher detection sensitivity, increased multiplexing, and reduced instrumentation size. In this review, we describe each of the required QC tests and conventional testing methods, followed by a

Synthesis of the radiopharmaceuticals for positron emission tomography

International Nuclear Information System (INIS)

Biricova, V.; Kuruc, J.

2007-01-01

In this paper is shown a short overview of the biogenic positron radiopharmaceuticals production and a brief summary of some PET preparation synthesis. At the end the overview of some forward-looking positron radionuclides, which can be used for a preparation of the PET radiopharmaceuticals is said. A short review of diagnostic use of PET radiopharmaceuticals is presented (authors)

Radiopharmaceuticals in Czechoslovakia

International Nuclear Information System (INIS)

Hron, M.; Kronrad, L.; Svoboda, K.; Melichar, F.

1986-01-01

The history is briefly described of the production of radiopharmaceuticals in Czechoslovakia for nuclear medicine purposes. 131 I-labelled orthoiodohippurate and rose Bengal were first produced. Currently, 99m Tc is the most frequently requested radionuclide for radiopharmaceutical labelling. The preparation of 99m Tc is described in detail, a flow chart is shown and the network of 99m Tc distribution to hospitals outlined. In addition of 99m Tc and 131 I, UJV Rez produces other radionuclides for nuclear medicine, such as 113m In, 67 Ga, 35 S, 32 P, 203 Hg, 85 Sr. The methods are being developed of the production of 201 Tl, 125 I and 131 I-labelled bromosulfophthalein. (E.S.)

Quality assurance of radiopharmaceuticals

International Nuclear Information System (INIS)

Frier, M.; Hesslewood, S.R.

1980-01-01

A practical guide has been composed for all persons involved in the preparation and use of radiopharmaceuticals on methods used in quality assurance and their applications. These methods include the calibration of ionization chamber assay calibrators, the determination of radionuclide purity, radiochemical purity and chemical purity, particle size analysis and the measurement of pH. Quality assurance procedures are described for products not described in Compendial Monographs, or where the monograph exists, additional useful information is provided; such radiopharmaceuticals include technetium, indium-labelled and iodine-labelled products. (U.K.)

Coordination chemistry of technetium as related to nuclear medicine

International Nuclear Information System (INIS)

Srivastava, S.C.; Richards, P.

1982-01-01

Significant advances have been made in the area of technetium coordination chemistry during the last five years. The main driving force behind this recent surge of interest in the field has been due to the practical application of technetium-99m in the rapidly growing speciality of nuclear medicine. Technetium-99 is one of the products of nuclear fission reactions, but it was the development of the molybdenum-99-technetium-99m generator about two decades ago that provided the basis for the development of radiopharmaceuticals routinely used in modern diagnostic applications. The chemistry of this element has proven to be quite rich owing to its multiple oxidation states and variable geometry. This can be attributed to its position in the middle of the periodic table. Diagnostic radiopharmaceuticals comprise predominantly III, IV and V oxidation states of Tc and involve a variety of coordination complexes. Even though the chemistry of Tc has been slow to evolve, recent synthetic advances have provided a more scientific basis for the study of a number of compounds with diverse coordination geometries and structures. Ligands with oxygen, nitrogen and sulfur donor atoms have been utilized to elucidate various aspects of the coordination chemistry of Tc. Single crystal X-ray structural analysis has been extensively used to characterize Tc complexes and thus construct a firm foundation for the study of synthetic and mechanistic aspects of the chemistry of this element. (author)

Exposure of croatian population to radiopharmaceuticals

International Nuclear Information System (INIS)

Prlic, I.; Suric Mihic, M.; Marovic, G.; Mestrovic, T.; Mrcela, I.; Cerovac, Z.; Golubovic, D.; Hajdinjak, M.

2010-01-01

The aim of this paper is to call attention to the exposure of Croatian population to open sources of ionising radiation used in medical diagnostics, radiopharmaceuticals in particular, whose initial activity is very high. Without proper exposure monitoring, it is not possible to establish the effective dose per capita, but we have estimated it to be between 6.8 μSv and 7.0 μSv for this type of internal exposure, based on a very loose assumption that about 35,000 diagnostic procedures with radiopharmaceuticals are performed in Croatia every year. This calls for further research that would eventually lead to limiting the doses received through exposure to radiopharmaceuticals. (authors)

Radiopharmaceutical scanning agents

International Nuclear Information System (INIS)

1976-01-01

This invention is directed to dispersions useful in preparing radiopharmaceutical scanning agents, to technetium labelled dispersions, to methods for preparing such dispersions and to their use as scanning agents

Recent developments in 99mTc and 123I-radiopharmaceuticals for SPECT imaging

International Nuclear Information System (INIS)

Kulkarni, P.V.

1991-01-01

Availability of 123 I of high radionuclidic purity has encouraged the development of 123 I-based radiopharmaceuticals for the assessment of myocardial fatty acid metabolism, myocardial neuronal activity, and for receptor and antibody imaging. Advances in the chemistry of technetium have resulted in the development of novel agents for myocardial and cerebral perfusion and renal function studies. Monoclonal antibodies labeled with 99m Tc show promise for imaging neoplastic lesions, myocardial infarcts, and thrombus localization. Recent developments in 123 I and 99m Tc agents for myocardial and brain imaging studies are discussed. (author)

Application of a small molecule radiopharmaceutical concept to improve kinetics

International Nuclear Information System (INIS)

Jeong, Jae Min

2016-01-01

Recently, large molecules or nanoparticles are actively studied as radiopharmaceuticals. However, their kinetics is problematic because of a slow penetration through the capillaries and slow distribution to the target. To improve the kinetics, a two-step targeting method can be applied by using small molecules and very rapid copper-free click reaction. Although this method might have limitations such as internalization of the first targeted conjugate, it will provide high target-to-non-target ratio imaging of radiopharmaceuticals. The majority of radiopharmaceuticals belong to small molecules of which the molecular weight is less than 2000 Da, and the molecular size is smaller than 2 nm generally. The outstanding feature of the small molecule radiopharmaceuticals compared to large molecules is with their kinetics. Their distribution to target and clearance from non-target tissues are very rapid, which is the essential requirement of radiopharmaceuticals. In conclusion, the small molecule radiopharmaceuticals generally show excellent biodistribution properties; however, they show poor efficiency of radioisotope delivery. Large molecule or nanoparticle radiopharmaceuticals have advantages of multimodal and efficient delivery, but lower target-to-non-target ratio. Two-step targeting using a bio-orthogonal copper-free click reaction can be a solution of the problem of large molecule or nanoparticle radiopharmaceuticals. The majority of radiopharmaceuticals belong to small molecules of which the molecular weight is less than 2000 Da, and the molecular size is smaller than 2 nm generally. The outstanding feature of the small molecule radiopharmaceuticals compared to large molecules is with their kinetics. Their distribution to target and clearance from non-target tissues are very rapid, which is the essential requirement of radiopharmaceuticals

Application of a small molecule radiopharmaceutical concept to improve kinetics

Energy Technology Data Exchange (ETDEWEB)

Jeong, Jae Min [Dept. of Nuclear Medicine, Seoul National University College of Medicine, Seoul (Korea, Republic of)

2016-06-15

Recently, large molecules or nanoparticles are actively studied as radiopharmaceuticals. However, their kinetics is problematic because of a slow penetration through the capillaries and slow distribution to the target. To improve the kinetics, a two-step targeting method can be applied by using small molecules and very rapid copper-free click reaction. Although this method might have limitations such as internalization of the first targeted conjugate, it will provide high target-to-non-target ratio imaging of radiopharmaceuticals. The majority of radiopharmaceuticals belong to small molecules of which the molecular weight is less than 2000 Da, and the molecular size is smaller than 2 nm generally. The outstanding feature of the small molecule radiopharmaceuticals compared to large molecules is with their kinetics. Their distribution to target and clearance from non-target tissues are very rapid, which is the essential requirement of radiopharmaceuticals. In conclusion, the small molecule radiopharmaceuticals generally show excellent biodistribution properties; however, they show poor efficiency of radioisotope delivery. Large molecule or nanoparticle radiopharmaceuticals have advantages of multimodal and efficient delivery, but lower target-to-non-target ratio. Two-step targeting using a bio-orthogonal copper-free click reaction can be a solution of the problem of large molecule or nanoparticle radiopharmaceuticals. The majority of radiopharmaceuticals belong to small molecules of which the molecular weight is less than 2000 Da, and the molecular size is smaller than 2 nm generally. The outstanding feature of the small molecule radiopharmaceuticals compared to large molecules is with their kinetics. Their distribution to target and clearance from non-target tissues are very rapid, which is the essential requirement of radiopharmaceuticals.

Trends in radiopharmaceutical dispensing in a regional nuclear pharmacy

International Nuclear Information System (INIS)

Basmadjian, G.P.; Barker, K.; Johnston, J.; Stinchcomb, R.; Tarman, B.; Ice, R.D.

1983-01-01

In the last five years, the practice of nuclear medicine has undergone changes due to the advent of new imaging technologies and radiopharmaceuticals. These changes have had an impact upon the number and the type of radiopharmaceuticals dispensed in centralized nuclear pharmacies. With the advent of Computerized Axial Tomography Scanners (CAT), sophistication and wider acceptance of the Ultrasound imaging modality, nuclear medicine has had to change directions from utilizing radiopharmaceuticals for static organ imaging to functional type imaging and to resort to the use of new radiopharmaceuticals or to find other uses for the existing radiopharmaceuticals. The following trends in radiopharmaceutical dispensing in a regional nuclear pharmacy are evident: Brain procedures have declined by about 67% while nuclear cardiology studies have increased by over 2000%. Bone scans have increased by 72% while liver, renal and lung studies have shown no significant increase. These changes will continue as the practice of nuclear medicine concentrates more on functional studies and relegates other studies to newer imaging modalities

Rational development of radiopharmaceuticals for HIV-1

International Nuclear Information System (INIS)

Lau, Chuen-Yen; Maldarelli, Frank; Eckelman, William C.; Neumann, Ronald D.

2014-01-01

The global battle against HIV-1 would benefit from a sensitive and specific radiopharmaceutical to localize HIV-infected cells. Ideally, this probe would be able to identify latently infected host cells containing replication competent HIV sequences. Clinical and research applications would include assessment of reservoirs, informing clinical management by facilitating assessment of burden of infection in different compartments, monitoring disease progression and monitoring response to therapy. A “rational” development approach could facilitate efficient identification of an appropriate targeted radiopharmaceutical. Rational development starts with understanding characteristics of the disease that can be effectively targeted and then engineering radiopharmaceuticals to hone in on an appropriate target, which in the case of HIV-1 (HIV) might be an HIV-specific product on or in the host cell, a differentially expressed gene product, an integrated DNA sequence specific enzymatic activity, part of the inflammatory response, or a combination of these. This is different from the current approach that starts with a radiopharmaceutical for a target associated with a disease, mostly from autopsy studies, without a strong rationale for the potential to impact patient care. At present, no targeted therapies are available for HIV latency, although a number of approaches are under study. Here we discuss requirements for a radiopharmaceutical useful in strategies targeting persistently infected cells. The radiopharmaceutical for HIV should be developed based on HIV biology, studied in an animal model and then in humans, and ultimately used in clinical and research settings

Radiopharmaceuticals for thyroid imaging: a review

International Nuclear Information System (INIS)

Nishiyama, H.

1979-01-01

A review of radiopharmaceuticals which have been used for thyroid imaging was made with special emphasis on palpable thyroid nodules. An attempt was made to evaluate cold nodules derived from imaging methods using radioiodine or Tc-99m pertechnetate, followed by a successive application of another radiopharmaceutical. An attempt was also made to understand the patho-physiology of various thyroid disorders. The latter was based on the accumulated cases with discordant images between radioiodine and Tc-99m pertechnetate, and also on the iodine content within the gland by means of fluorescent techniques. Better radiopharmaceuticals are anxiously awaited in order to realize the distinction between benign and malignant thyroid disorders at the preoperative decision-making stage

Radiopharmaceutical prescription in nuclear medicine departments

International Nuclear Information System (INIS)

Biechlin-Chassel, M.L.; Lao, S.; Bolot, C.; Francois-Joubert, A.

2010-01-01

In France, radiopharmaceutical prescription is often discussed depending to which juridical structure the nuclear medicine department is belonging. According to current regulation, this prescription is an obligation in a department linked to hospital with a pharmacy department inside. But situation remains unclear for independent nuclear medicine departments where physicians are not constrained to prescribe radiopharmaceuticals. However, as radiographers and nurses are only authorized to realize theirs acts in front of a medical prescription, one prescription must be realized. Nowadays, computerized prescription tools have been developed but only for radiopharmaceutical drugs and not for medical acts. In the aim to achieve a safer patient care, the prescription regulation may be applied whatever differences between nuclear medicines departments. (authors)

Aptamers as radiopharmaceuticals for nuclear imaging and therapy

International Nuclear Information System (INIS)

Gijs, Marlies; Aerts, An; Impens, Nathalie; Baatout, Sarah; Luxen, André

2016-01-01

Today, radiopharmaceuticals belong to the standard instrumentation of nuclear medicine, both in the context of diagnosis and therapy. The majority of radiopharmaceuticals consist of targeting biomolecules which are designed to interact with a disease-related molecular target. A plethora of targeting biomolecules of radiopharmaceuticals exists, including antibodies, antibody fragments, proteins, peptides and nucleic acids. Nucleic acids have some significant advantages relative to proteinaceous biomolecules in terms of size, production, modifications, possible targets and immunogenicity. In particular, aptamers (non-coding, synthetic, single-stranded DNA or RNA oligonucleotides) are of interest because they can bind a molecular target with high affinity and specificity. At present, few aptamers have been investigated preclinically for imaging and therapeutic applications. In this review, we describe the use of aptamers as targeting biomolecules of radiopharmaceuticals. We also discuss the chemical modifications which are needed to turn aptamers into valuable (radio-)pharmaceuticals, as well as the different radiolabeling strategies that can be used to radiolabel oligonucleotides and, in particular, aptamers.

Radiopharmaceutical regulation and Food and Drug Administration policy.

Science.gov (United States)

Rotman, M; Laven, D; Levine, G

1996-04-01

The regulatory policy of the Food and Drug Administration (FDA) on radiopharmaceuticals flows from a rigid, traditional, drug-like interpretation of the FDC Act on the licensing of radiopharmaceuticals. This contributes to significant delays in the drug-approval process for radiopharmaceuticals, which are very costly to the nuclear medicine community and the American public. It seems that radiopharmaceuticals would be better characterized as molecular devices. Good generic rule-making principles include: use of a risk/benefit/cost analysis; intent based on sound science; performance standards prepared by outside experts; a definite need shown by the regulatory agency; to live with the consequences of any erroneous cost estimates; and design individual credential requirements so that additional training results in enhanced professional responsibility. When these common elements are applied to current FDA policy, it seems that the agency is out of sync with the stated goals for revitalizing federal regulatory policies as deemed necessary by the Clinton administration. Recent FDA rulings on positron-emission tomography, Patient Package inserts, and on medical device service accentuate the degree of such asynchronization. Radiopharmaceutical review and licensing flexibility could be dramatically improved by excluding radiopharmaceuticals from the drug category and reviewing them as separate entities. This new category would take into account their excellent record of safety and their lack of pharmacological action. Additionally, their evaluation of efficacy should be based on their ability to provide useful scintiphotos, data, or responses of the physiological system it portends to image, quantitate, or describe. To accomplish the goal of transforming the FDA's rigid, prescriptive policy into a streamlined flexible performance-based policy, the Council on Radionuclides and Radiopharmaceuticals proposal has been presented. In addition, it is suggested that the United

Report of a Technical Meeting on ''Alpha emitting radionuclides and radiopharmaceuticals for therapy''

International Nuclear Information System (INIS)

2013-01-01

Considering the high potential of α-emitters for future development of radionuclide therapy, the International Atomic Energy Agency (IAEA) organized a Technical Meeting on ‘Alpha Emitting Radionuclides and Radiopharmaceuticals for Therapy’, from June 24 to 28, 2013, at IAEA Headquarters in Vienna with the purpose of gathering eminent Experts in the field and discuss with them the status and future perspectives of the field. Sixteen Experts and two External Observers from ten different countries, and four IAEA Technical Officers attended this meeting. Outstanding lectures have been presented covering all relevant aspects of α-therapy, which were followed by extensive discussions and analysis. Selected arguments encompassed production methods and availability of alpha-emitting radionuclides, labelling chemistry of alpha-emittting radioelements, design and development of target-specific radiopharmaceuticals, physical principles of alpha-particle dosimetry and advanced dosimetric models, biological effects of alpha radiation at the cellular level, on-going preclinical and clinical studies with new radiopharmaceuticals, results of clinical trials on the use of radium-223 chloride solutions for the treatment of metastatic bone cancer. The broad scientific background of invited components of the Experts’ panel conferred a strong interdisciplinary trait to the overall discussion and stimulated a critical analysis of this emerging unexplored field. Results of this comprehensive overview on alpha therapy, including recommendations to the Agency on suitable initiatives that may help to promote and spread the knowledge to Members States on this emerging therapeutic modality, are summarized in the present Report

Progress report on nuclear science and technology in China (Vol.3). Proceedings of academic annual meeting of China Nuclear Society in 2013, No.4--Nuclear chemistry and radiation chemistry sub-volume

International Nuclear Information System (INIS)

2014-05-01

Progress report on nuclear science and technology in China (Vol. 3) includes 24 articles which are communicated on the third national academic annual meeting of China Nuclear Society. There are 10 books totally. This is the fourth one, the content is about Nuclear chemistry and radiation chemistry sub-volume

Chirality plays important roles in radiopharmaceuticals

International Nuclear Information System (INIS)

Shen Yumei

2006-01-01

The paper introduces the basic concept of chirality, target specific selectivity and their relationship in radiopharmaceuticals. If the ligands labeled by radionuclides have chiral center, the enantiomers must be separated, or the target specific selectivity will not be good. Chirality is one of the most important factors which must be considered in the study of the structure-activity relationship of radiopharmaceuticals. (authors)

Applications and development trend of radiopharmaceuticals

International Nuclear Information System (INIS)

Kim, J.R.

1978-01-01

Present status of radiopharmaceuticals applications and the trend of the development are extensively reviewed and discussed. The followings are manifested: a) Among the various radionuclides, those of short lived, accelerator produced, and having moderate radiation energies are becoming popular. b) Diagnosis using various labelled molecules are considered to be the most active field in nuclear medicine. c) Development of radiopharmaceuticals for tumor localization studies is one of the trends. d) The use of various convenient kits of both in-vitro radioligand assay, and in-vivo instant labelling is now an enormous domain in nuclear medicine. A great stride is also made in the development of automation technique. Upon it, an urgent development of some new radiopharmaceuticals having local characteristics is proposed. (author)

Quality control in 99m technetium radiopharmaceuticals

International Nuclear Information System (INIS)

Leon Cabana, Alba

1994-01-01

This work means about the quality control in Tc radiopharmaceuticals preparation at hospitalary levels. Several steps must be used in a Nuclear Medicine Laboratory, such as proceeding,radiopharmaceuticals kits preparation, and dispensation materials,glasses,stopper,physical aspects,identification,ph control,storage,and reactif kits

Preparation and control of radiopharmaceuticals in hospitals

International Nuclear Information System (INIS)

Kristensen, K.

1979-01-01

This guidebook covers the work commonly organized as part of the work in the hospital. It does not cover the manufacture of radiopharmaceuticals on an industrial scale. The work is characterized by the small scale on which manufacture and preparation of radiopharmaceuticals take place

Research advancements and applications of carboranes in nuclear medicinal chemistry

International Nuclear Information System (INIS)

Chen Wen; Wei Hongyuan; Luo Shunzhong

2011-01-01

Because of their uniquely high thermal and chemical stabilities, carboranes have become a subject of study with high interest in the chemistry of supra molecules, catalysts and radiopharmaceuticals. In recent years, the role of carboranes in nuclear medicinal chemistry has been diversified, from the traditional use in boron neutron capture therapy (BNCT), to the clinical applications in molecular radio imaging and therapy. This paper provides an overview of the synthesis and characterization of carboranes and their applications in nuclear medicinal chemistry, with highlights of recent key advancements in the re- search areas of BNCT and radio imaging. (authors)

The Chemistry of Re-188 Radiopharmaceuticals: Could Re-188 Play the Same Role in Therapy as Tc-99m in Diagnostics?

International Nuclear Information System (INIS)

Duatti, A.

2009-01-01

Radiopharmaceuticals incorporating the β-emitting radionuclide Re-188 are still attracting much interest for their potential application in nuclear medicine as therapeutic agents. There are many advantages of employing this class of radioactive compounds as briefly summarized in the following. (1) Re-188 emits a high-energy β- particle (2.1 MeV) that can be efficiently used to deliver high-dose radiation to the target. (2) Re-188 concomitantly emits a 155-keV γ photon that can be conveniently employed to obtain good-quality SPECT images of the biodistribution of Re-188 radiopharmaceuticals and, ultimately, following in vivo the course of the therapy. (3) Re-188 has a relatively short half-life (17 hours) that may allow multiple treatments of the same patient's disease. (4) Re-188 is a radiometal belonging to the same group of Tc-99m in the transition metal series of the Periodic Table, and shares with its cogener similar (though not identical) chemical properties that could be useful for designing a broad class of Re-188 radiopharmaceuticals having the same biodistribution properties of the corresponding Tc-99m analogues. (5) Similarly to Tc-99m, the radionuclide Re-188 is produced in high-specific activity through the 188 W/ 188 Re transportable generator system. A first challenge encountered in the attempt to develop efficient labeling procedures for Re-188 was related to the low radiochemical yield usually observed in tracer-level preparations of Re-188 radiopharmaceuticals starting from generator-produced [ 188 ReO 4 ]-. This drawback is commonly associated with the low value of the standard reduction potential of the tetraoxo anion as compared to the corresponding Tc-99m pertechnetate anion. In recent years, we reported a simple and efficient procedure for overcoming this problem based on a general chemical principle called 'expansion of the coordination sphere' and involving the addition to the reaction vial of an ancillary ligand (usually, chelating hard

Characterization of atmospheric emissions of a radiopharmaceutical' s production unit

Energy Technology Data Exchange (ETDEWEB)

Siqueira, Gessilane M.; Barreto, Alberto A.; Maletta, Paulo G.M.; Alves, Thaís A.N., E-mail: gessilane.siqueira@cdtn.br, E-mail: aab@cdtn.br, E-mail: pgmm@cdtn.br, E-mail: aryadnenasc@gmail.com [Centro de Desenvolvimento da Tecnologia Nuclear (CDTN/CNEN-MG), Belo Horizonte - MG (Brazil)

2017-07-01

Cyclotrons are radiative facilities capable of synthesizing radioisotopes that will be used for the production of radiopharmaceuticals. The increasing use of these substances in diagnostic therapies and procedures in nuclear medicine implies the need to increase the production of radiopharmaceuticals. In this context, it is fundamental, from the point of view of environmental radioprotection, to characterize atmospheric emissions from this type of production, in order to make feasible studies of radiological impacts, especially with a view to human health and environmental preservation. It is premise that facilities must ensure the radiological safety of exposed individuals through the control of discharges into the environment. This work aims to characterize the atmospheric emissions behavior of a Radiopharmaceutical Research and Production Unit (RRPU). The emission data for the radionuclides C-11, F-18, and N-13, associated to the production of radiopharmaceuticals ({sup 18}F-FES, {sup 18}F-FDG, {sup 18}FCOL, {sup 18}F-FLT, Na{sup 18}F) during the year 2016 were analyzed. Emissions data are collected every 10 seconds from a sensor installed in the unit's exhaust system. The pre-processing of these data was done by spreadsheets (Excel®) and exported to a statistical package (Minitab16®) to characterize the behavior of these emissions. The results of this study aim to contribute: to the study of atmospheric dispersion of radionuclides in the region of interest; to evaluate the operational control measures of the investigated facility; and to evaluate the radiological impacts in the region neighboring the facility. This methodology has been used in atmospheric dispersion modeling studies in the RRPU and the results showed that the annual doses from the emissions are within the limits established by the radioprotection norms of the Brazilian National Nuclear Energy Commission. Additionally, it is believed that the information generated in this study

Radiopharmaceuticals for palliative therapy pain

International Nuclear Information System (INIS)

Gaudiano, Javier

1994-01-01

Dissemination to bone of various neoplasms is cause of pain with poor response by major analgesics.Indications. Radiopharmaceuticals,description of main characteristics of various β emitter radionuclides.Choose of patients for worm indication of pain palliative therapy with β emitter radiopharmaceuticals is adequate must be careful . Contraindications are recognized.Pre and post treatment controls as clinical examination and complete serology are described.It is essential to subscribe protocols,keep patient well informed,included the physician in charge of the patient as part of the team.Bibliography

Studies of quality control procedures for radiopharmaceuticals

International Nuclear Information System (INIS)

Zivanovic, M.; Trott, N.G.

1983-01-01

In this paper, a short description is given of a radiopharmaceutical preparation suite set up at the Royal Marsden Hospital and an account is presented of methods used for quality control of radiopharmaceuticals and of the results obtained over a period of about two and a half years

Shanghai institute of nuclear research, academia sinica annual report (1993-1994)

International Nuclear Information System (INIS)

1996-01-01

This report is a comprehensive review of achievements made by Shanghai Institute of Nuclear Research (SINR), Academia Sinica in the period of 1993-1994, which concerns nuclear physics (theories, experimentation, and application), nuclear chemistry (radiochemistry, radiopharmaceuticals, labelled compounds, analytical chemistry), radiation chemistry, nuclear detectors, development and industrialization of nuclear techniques. The maintenance, reconstruction and operation of its major facilities are also described. There are keywords in each paper. In addition, a series of lists concerning awarded scientific technologies, scientific exchanges, scientific publications, academic activities and etc, is also included in the appendix

Annual report 1990

International Nuclear Information System (INIS)

Gaeggeler, H.W.; Lorenzen, R.

1991-04-01

This annual report of the chemistry laboratory gives an overview of research performed during 1990 in the field of geochemistry, trace analysis, aerosol chemistry, heavy elements, cement chemistry and analytical chemistry. figs., tabs., refs

Trends in radiopharmaceutical dispensing in a regional nuclear pharmacy

International Nuclear Information System (INIS)

Basmadjian, G.P.; Johnston, J.; Barker, K.; Ice, R.D.

1982-01-01

Dispensing trends for radiopharmaceuticals at a regional nuclear pharmacy over a 51-month period were studied. dispensing records of a regional nuclear pharmacy were analyzed with a forecasting procedure that uses univariate time data to produce time trends and autoregressive models. The overall number of prescriptions increased from 3500 to 5500 per quarter. Radiopharmaceuticals used in nuclear cardiology studies increased from less than 0.1% to 17.5% of total prescriptions dispensed, while radiopharmaceuticals used for brain imaging showed a steady decline from 29% to 11% of total prescriptions dispensed. The demand for other radiopharmaceuticals increased in areas such as renal studies, bone studies, lung studies, liver-function studies, and 67 Ga tumor-uptake studies, and declined slightly for static liver studies. Changes in dispensing trends for radiopharmaceuticals will continue as the practice of nuclear medicine concentrates more on functional studies and as newer imaging techniques become used for other purposes

Chemistry and Materials Science Department annual report, 1988--1989

Energy Technology Data Exchange (ETDEWEB)

Borg, R.J.; Sugihara, T.T.; Cherniak, J.C.; Corey, C.W. [eds.

1989-12-31

This is the first annual report of the Chemistry & Materials Science (C&MS) Department. The principal purpose of this report is to provide a concise summary of our scientific and technical accomplishments for fiscal years 1988 and 1989. The report is also tended to become part of the archival record of the Department`s activities. We plan to publish future editions annually. The activities of the Department can be divided into three broad categories. First, C&MS staff are assigned by the matrix system to work directly in a program. These programmatic assignments typically involve short deadlines and critical time schedules. A second category is longer-term research and development in technologies important to Laboratory programs. The focus and direction of this technology-base work are generally determined by programmatic needs. Finally, the Department manages its own research program, mostly long-range in outlook and basic in orientation. These three categories are not mutually exclusive but form a continuum of technical activities. Representative examples of all three are included in this report. The principal subject matter of this report has been divided into six sections: Innovations in Analysis and Characterization, Advanced Materials, Metallurgical Science and Technology, Surfaces and Interfaces, Energetic Materials and Chemical Synthesis, and Energy-Related Research and Development.

Prenatal radiation doses from radiopharmaceuticals

International Nuclear Information System (INIS)

Rojo, A.M.; Gomez Parada, I.M.; Di Trano, J.L.

1998-01-01

The radiopharmaceutical administration with diagnostic or therapeutic purpose during pregnancy implies a prenatal radiation dose. The dose assessment and the evaluation of the radiological risks become relevant due to the great radiosensitivity of the fetal tissues in development. This paper is a revision of the available data for estimating fetal doses in the cases of the more frequently used radiopharmaceuticals in nuclear medicine, taking into account recent investigation in placental crossover. The more frequent diagnostic and therapeutic procedures were analyzed according to the radiation doses implied. (author) [es

Fluorine-18 radiopharmaceuticals beyond [18F]FDG for use in oncology and neurosciences

International Nuclear Information System (INIS)

Coenen, H.H.; Elsinga, P.H.; Iwata, R.; Kilbourn, M.R.; Pillai, M.R.A.; Rajan, M.G.R.; Wagner, H.N.; Zaknun, J.J.

2010-01-01

Positron emission tomography (PET) is a rapidly expanding clinical modality worldwide thanks to the availability of compact medical cyclotrons and automated chemistry for the production of radiopharmaceuticals. There is an armamentarium of fluorine-18 ( 18 F) tracers that can be used for PET studies in the fields of oncology and neurosciences. However, most of the 18 F-tracers other than 2-deoxy-2-[18F]fluoro-D-glucose (FDG) are in less than optimum human use and there is considerable scope to bring potentially useful 18 F-tracers to clinical investigation stage. The International Atomic Energy Agency (IAEA) convened a consultants' group meeting to review the current status of 18 F-based radiotracers and to suggest means for accelerating their use for diagnostic applications. The consultants reviewed the developments including the synthetic approaches for the preparation of 18 F-tracers for oncology and neurosciences. A selection of three groups of 18 F-tracers that are useful either in oncology or in neurosciences was done based on well-defined criteria such as application, lack of toxicity, availability of precursors and ease of synthesis. Based on the recommendations of the consultants' group meeting, IAEA started a coordinated research project on 'Development of 18 F radiopharmaceuticals (beyond [ 18 F]FDG) for use in oncology and neurosciences' in which 14 countries are participating in a 3-year collaborative program. The outcomes of the coordinated research project are expected to catalyze the wider application of several more 18 F-radiopharmaceuticals beyond FDG for diagnostic applications in oncology and neurosciences.

Quality controls of radiopharmaceuticals used in nuclear medicine

International Nuclear Information System (INIS)

Gomez de Castiglia, S.I.; Fraga de Suarez, A.H.; Mitta, A.E.A.

1981-01-01

Chromatographic quality controls for Tc-99m; In-113m; I-131; Tl-201 and Ga-67 radiopharmaceuticals are described. Moreover, a chromatographic system which allows to separate different radiopharmaceuticals from In-113m is pointed out. (author) [es

Radiopharmaceuticals for diagnosis of ischemic heart disease

Energy Technology Data Exchange (ETDEWEB)

Komarek, P; Chalabala, M [Institut pro Dalsi Vzdelavani Lekaru a Farmaceutu, Prague (Czechoslovakia)

1982-01-01

Radiopharmaceuticals used for diagnosing ischemic heart disease in the experimental and clinical practice are reviewed. The mechanism of their retention by the heart muscle is briefly described. The respective radiopharmaceuticals are divided into preparations imaging disorders in the blood supply of the cardiac muscle, diagnosing the myocardial infarction, and evaluating the contractility of the heart.

Nuclear Chemistry Institute, Mainz University. Annual Report 1995

International Nuclear Information System (INIS)

Denschlag, H.O.

1996-03-01

The annual report of the Institut fuer Kernchemie addresses inter alia three main research activities. The first belongs to the area of basic research, covering studies in the fields of nuclear fission, chemistry of the super-heavy elements and of heavy-ion reactions extending from the Coulomb barrier to relativistic energies, and nuclear astrophysics in connection with the ''r process''. By means of laser technology, high-precision data could be measured of the ionization energies of berkelium and californium. Studies of atomic clusters in the vacuum of an ionization trap revealed interesting aspects. The second major activity was devoted to the analysis of environmental media, applying inter alia neutron activation analysis and resonance ionization mass spectroscopy (RIMS). The third activity resulted in the development of novel processes, or the enhancement of existing processes or methods, for applications in basic research work and in environmental analytics. Another item of interest is the summarizing report on the operation of the TRIGA research reactor. (orig./SR) [de

A study on bacterial endotoxins test of radiopharmaceuticals with limulus agent

Energy Technology Data Exchange (ETDEWEB)

Suozhen, Bai; Kai, Luyu; Cheng, Luo [Academia Sinica, Beijing, BJ (China). Inst. of Atomic Energy; Ruiting, Zhang; Zhenmin, Xia [National Inst. for the Control of Pharmaceutical and Biological Products (China)

1989-08-01

The feasibility of endotoxins test of radiopharmaceuticals with limulus agent and the approach to take off the inhibition/enhancement effect of radiopharmaceuticals on limulus agent have been studied. Results of the test for 8 radiopharmaceuticals have been given.

Detection of sentinel nodes with radiopharmaceuticals

International Nuclear Information System (INIS)

Yokoyama, Kunihiko; Michigishi, Takatoshi; Kinuya, Seigo; Konishi, Shota; Nakajima, Kenichi; Tonami, Norihisa

2000-01-01

Sentinel lymph nodes have been found to be an indicator of lymph node metastasis in breast cancer. In Japan, the theory and concept of sentinel lymph nodes in breast cancer have begun to be applied to carcinomas of the digestive system. Based on clinical experience in the detection of sentinel lymph nodes with radiopharmaceuticals, differences and similarities between the radiopharmaceuticals, methods, and techniques used to detect sentinel lymph nodes have been assessed in relation to breast cancer and carcinomas of the digestive system (including carcinomas of the esophagus and large intestine). The greatest difference between the methods used for breast and digestive cancers is the site of administration of the radiopharmaceutical. In breast cancer, the radiopharmaceutical is administered into a superficial organ (i.e., the mammary gland), whereas in carcinomas of the digestive system, it is administered into a deep organ (i.e., digestive tract). Another obvious difference is in lymph flow, i.e., the flow of the mammary glands is subcutaneous whereas lymph flow in the digestive tract is submucosal. Two radionuclide diagnostic methods are available to detect sentinel lymph nodes: sentinel lymphoscintigraphy with a gamma camera and a method that involves the use of a gamma probe intraoperatively. Radiopharmaceuticals used to detect sentinel lymph nodes must be smoothly transferred from the site of administration into the lymph, and uptake by the sentinel lymph node must continue for a long time without excessive flowing to lower reaches. The optimal particle size remains a matter of controversy, and no radiopharmaceuticals appropriate for lymphoscintigraphy have ever been approved in Japan. The authors compared the pharmacokinetics of three different radiopharmaceuticals used for sentinel lymphoscintigraphy in breast cancer ( 99m Tc-labeled albumin, 99m Tc-labeled tin colloid, and 99m Tc-labeled phytic acid) and founded that the detection rate was lowest with

Kinetic model for the dosimetry of radiopharmaceuticals contaminated by Mo-99

International Nuclear Information System (INIS)

Shearer, D.R.; Pezzullo, J.C.

1986-01-01

Radiopharmaceuticals tagged with Tc-99m may become contaminated with breakthrough products from the Mo-99/Tc-99m generator. If a fraction of the contaminant becomes bound to the radiopharmaceutical, the dose to the radiopharmaceutical target organ from the contaminant must be considered. The dose to the contaminant target organ may then be calculated as the sum of the doses from a) the initially unbound contaminant, and b) the contaminant later released by degradation of the radiopharmaceutical. This paper presents a model which takes the above processes into account. The model is illustrated with clinical data derived from Mo-99 contaminated radiopharmaceuticals. 5 references, 2 figures, 6 tables

Annual report 1994

International Nuclear Information System (INIS)

Johannsen, B.

1995-02-01

Our main objectives are derived from an awareness of the very important role modern nuclear medicine is playing, as expressed explicitly in the synonym in vivo biochemistry. Radiopharmaceuticals are the molecular probes used for the diagnosis and cure of disease. For full exploitation of its potential, this discipline of in vivo biochemistry requires great commitment to interdisciplinary research into tracers. The emphasis is on fundamentals on the molecular level, leading to new approaches in tracer design: the tracer chemistry and structure-biodistribution relationships. The goals imply exploiting technetium coordination chemistry. New classes of complexes of technetium or thenium, the convenient model nuclide for radioactive technetium, have been synthesized and characterized. Technetium has an intricate coordination chemistry that does not go well with the organic nature of biochemical substrates. One of the main achievements of the year was the successful approach to make complexes of technetium biochemically reactive by functionalization of a coordinate ligand. Functionalization is focused on two areas. The first is specific binding, as in ligand-receptor interactions. The second is enzymatic hydrolysis in the target or a nontarget. The studies also constitute a contribution to applied bio-inorganic chemistry. (orig.)

Consequences of radiopharmaceutical extravasation and therapeutic interventions: a systematic review

Energy Technology Data Exchange (ETDEWEB)

Pol, Jochem van der; Voeoe, Stefan [Maastricht University Medical Centre (MUMC+), Department of Radiology and Nuclear Medicine, Postbox 5800, Maastricht (Netherlands); Bucerius, Jan; Mottaghy, Felix M. [Maastricht University Medical Centre (MUMC+), Department of Radiology and Nuclear Medicine, Postbox 5800, Maastricht (Netherlands); University Hospital, RWTH Aachen University, Department of Nuclear Medicine, Aachen (Germany)

2017-07-15

Radiopharmaceutical extravasation can potentially lead to severe soft tissue damage, but little is known about incidence, medical consequences, possible interventions, and effectiveness of these. The aims of this study are to estimate the incidence of extravasation of diagnostic and therapeutic radiopharmaceuticals, to evaluate medical consequences, and to evaluate medical treatment applied subsequently to those incidents. A sensitive and elaborate literature search was performed in Embase and PubMed using the keywords ''misadministration'', ''extravasation'', ''paravascular infiltration'', combined with ''tracer'', ''radionuclide'', ''radiopharmaceutical'', and a list of keywords referring to clinically used tracers (i.e. ''Technetium-99m'', ''Yttrium-90''). Reported data on radiopharmaceutical extravasation and applied interventions was extracted and summarised. Thirty-seven publications reported 3016 cases of diagnostic radiopharmaceutical extravasation, of which three cases reported symptoms after extravasation. Eight publications reported 10 cases of therapeutic tracer extravasation. The most severe symptom was ulceration. Thirty-four different intervention and prevention strategies were performed or proposed in literature. Extravasation of diagnostic radiopharmaceuticals is common. {sup 99m}Tc, {sup 123}I, {sup 18}F, and {sup 68}Ga labelled tracers do not require specific intervention. Extravasation of therapeutic radiopharmaceuticals can give severe soft tissue lesions. Although not evidence based, surgical intervention should be considered. Furthermore, dispersive intervention, dosimetry and follow up is advised. Pharmaceutical intervention has no place yet in the immediate care of radiopharmaceutical extravasation. (orig.)

Melanin-binding radiopharmaceuticals

International Nuclear Information System (INIS)

Packer, S.; Fairchild, R.G.; Watts, K.P.; Greenberg, D.; Hannon, S.J.

1980-01-01

The scope of this paper is limited to an analysis of the factors that are important to the relationship of radiopharmaceuticals to melanin. While the authors do not attempt to deal with differences between melanin-binding vs. melanoma-binding, a notable variance is assumed

Metabolic radiopharmaceutical therapy in nuclear medicine

International Nuclear Information System (INIS)

Reguera, L.; Lozano, M. L.; Alonso, J. C.

2016-01-01

In 1986 the National Board of Medical Specialties defined the specialty of nuclear medicine as a medical specialty that uses radioisotopes for prevention, diagnosis, therapy and medical research. Nowadays, treatment with radiopharmaceuticals has reached a major importance within of nuclear medicine. The ability to treat tumors with radiopharmaceutical, Radiation selective therapy has become a first line alternative. In this paper, the current situation of the different therapies that are sued in nuclear medicine, is reviewed. (Author)

Radioisotopes and radiopharmaceuticals catalogue

International Nuclear Information System (INIS)

2002-01-01

The Chilean Nuclear Energy Commission (CCHEN) presents its radioisotopes and radiopharmaceuticals 2002 catalogue. In it we found physical characteristics of 9 different reactor produced radioisotopes ( Tc-99m, I-131, Sm-153, Ir-192, P-32, Na-24, K-42, Cu-64, Rb-86 ), 7 radiopharmaceuticals ( MDP, DTPA, DMSA, Disida, Phitate, S-Coloid, Red Blood Cells In-Vivo, Red Blood Cells In-Vitro) and 4 labelled compounds ( DMSA-Tc99m, DTPA-Tc99m, MIBG-I131, EDTMP-Sm153 ). In the near future the number of items will be increased with new reactor and cyclotron products. Our production system will be certified by ISO 9000 on March 2003. CCHEN is interested in being a national and an international supplier of these products (RS)

The progress on researching method and metabolism of positron radiopharmaceutical

International Nuclear Information System (INIS)

Gan Hongmei; Qiao Jinping; Kong Aiying; Zhu Lin

2010-01-01

Positron radiopharmaceuticals are mainly used for PET studies, which are used in the field of nuclear medicine as tracers in the diagnosis and treatment of many diseases. They have important position and function in the clinical diagnosis and treatment. Metabolism or biotransformation will happen when PET radio-pharmaceuticals enter into the body. Understanding the metabolic fate of radiopharmaceutical probes is essential for an accurate analysis and interpretation of positron emission tomography imaging. The recent research progress on PET radiopharmaceuticals metabolism was reviewed in this paper, including the metabolism characteristics, research methods, analytical techniques and so on. (authors)

Evaluation of quality control of radiopharmaceuticals in Nuclear Medicine service

International Nuclear Information System (INIS)

Tavares, Jamille A. Lopes; Lira, Renata F. de; Santos, Marcus Aurelio P. dos

2014-01-01

Radiopharmaceuticals are a type of pharmaceutical preparation associated with radionuclides with purpose of diagnosis and therapy. Nuclear Medicine Services (NMS) should perform quality control of radiopharmaceuticals according to the recommendations of the manufacturer and scientific evidences accepted by the National Agency Sanitary Surveillance ( Brazilian ANVISA). This study evaluated the quality of the main radiopharmaceuticals in a NMS of the state of Pernambuco in relation to pH and radiochemical purity. The results showed that 96.8% of the radiopharmaceuticals showed radiochemical purity and all pH values were within the range recommended by the American pharmacopoeia. The study found that the quality control when inserted into the NMS, provides important data that allows exclusion of radiopharmaceuticals with low radiochemistry purity, favoring a reliable diagnosis and ensuring good radiation protection practices and biosecurity for patient and occupationally exposed individuals

Analytics of radiochmical impurities in radiopharmaceutics. Pt. 4

International Nuclear Information System (INIS)

Heide, L.; Stamm, A.; Boegl, W.

1981-01-01

The radiopharmaceutics have been compiled in the present volume in the form of a medicament encyclopaedia. The term radiopharmaceutic has been very broadly covered so that one can find pharmaceutics which are applied in clinical routine as well as for veterinary tests or are being or have been tested. Preparates for radio-immuno assays are also recorded. All analysis methods are considered even if these only slightly differ from one another. Methods described in the literature are given which have resulted in a bad or no separation of the radiopharmaceutics from the impurities. (orig./MG) [de

The application of the 'ten-day rule' in radiopharmaceutical investigations

International Nuclear Information System (INIS)

Ellis, R.E.; Nordin, B.E.C.; Tothill, P.; Veall, N.

1977-01-01

The working party first classified subjects who are investigated using radiopharmaceuticals into three groups, being (a) patients and other subjects who are asked to volunteer as controls for research studies, (b) patients on whom research investigations are being conducted which are relevant to their clinical condition but which are not strictly necessary for their management, and (c) patients on whom investigations are required for their proper management. The application of the 'ten-day rule' in relation to the use of radiopharmaceuticals is complicated by the fact that the total radiation dose is received over a time given by the effective life of the radiopharmaceutical in the organ, which may be a substantial part or even longer of the menstrual cycle. The activities of the radiopharmaceuticals normally administered are tabulted together with their effective half-lives and resulting gonad doses, and those radiopharmaceuticals requiring consideration of the implementation of the 'ten-day rule' for patients in groups (b) and (c) are identified. When the administration of therapeutic quantities of radiopharmaceuticals is being contemplated it is particularly important to take into account the applicability or otherwise of the 'ten-day rule'. It is recommended that the 'ten-day rule' should be strictly applied to all radiopharmaceutical administrations to women of child-bearing age who are volunteers for research purposes (group(a)). (U.K.)

Interactive radiopharmaceutical facility between Yale Medical Center and Brookhaven National Laboratory. Progress report, October 1976-June 1979

Energy Technology Data Exchange (ETDEWEB)

Gottschalk, A.

1979-01-01

DOE Contract No. EY-76-S-02-4078 was started in October 1976 to set up an investigative radiochemical facility at the Yale Medical Center which would bridge the gap between current investigation with radionuclides at the Yale School of Medicine and the facilities in the Chemistry Department at the Brookhaven National Laboratory. To facilitate these goals, Dr. Mathew L. Thakur was recruited who joined the Yale University faculty in March of 1977. This report briefly summarizes our research accomplishments through the end of June 1979. These can be broadly classified into three categories: (1) research using indium-111 labelled cellular blood components; (2) development of new radiopharmaceuticals; and (3) interaction with Dr. Alfred Wolf and colleagues in the Chemistry Department of Brookhaven National Laboratory.

Interactive radiopharmaceutical facility between Yale Medical Center and Brookhaven National Laboratory. Progress report, October 1976-June 1979

International Nuclear Information System (INIS)

Gottschalk, A.

1979-01-01

DOE Contract No. EY-76-S-02-4078 was started in October 1976 to set up an investigative radiochemical facility at the Yale Medical Center which would bridge the gap between current investigation with radionuclides at the Yale School of Medicine and the facilities in the Chemistry Department at the Brookhaven National Laboratory. To facilitate these goals, Dr. Mathew L. Thakur was recruited who joined the Yale University faculty in March of 1977. This report briefly summarizes our research accomplishments through the end of June 1979. These can be broadly classified into three categories: (1) research using indium-111 labelled cellular blood components; (2) development of new radiopharmaceuticals; and (3) interaction with Dr. Alfred Wolf and colleagues in the Chemistry Department of Brookhaven National Laboratory

Design and Development of New Radiopharmaceuticals

Energy Technology Data Exchange (ETDEWEB)

Wagner, Jr., H. N.; Stern, H. S.; Rhodes, B. A.; Reba, R. C.; Hosain, F.; Zolle, I. [Johns Hopkins Medical Institutions, Baltimore, MD (United States)

1969-05-15

The major factors in the design of a new radiopharmaceutical for radioisotope scintigraphy are the photon energy of the radionuclide, the ability to incorporate the radionuclide insuitable chemical and biological form, the radiation dose to the patient, and the cost of production of the radiopharmaceutical. In this laboratory, the radionuclides, indium-113m and ytterbium-169, and technetium-99m, have been incorporated into a variety of radiopharmaceuticals. These include particles suitable for lung and liver studies, chelates for brain and kidney studies, and ionic forms for blood pool imaging. Studies in experimental animals and man indicate that these agents offer certain advantages over previously available radiopharmaceuticals. By providing larger numbers of photons, they permit more precise temporal and spatial resolution. The longer half-life of the tin-113 parent radionuclide from which indium-113m can be eluted makes indium-113m readily available, even at sites distant from the source of production. The tin-indium generator system need be purchased only every five months rather than weekly as in the case of the widely used molybdenum-technetium system. The ytterbium-radionuclide in the chemical form of a chelate is particularly useful as an inexpensive agent that provides high photon yields for renal and brain imaging. The rapid and complete biological excretion results in low radiation dose while the longer physical half-life greatly extends the shelf-life. (author)

Legal aspects of the production and application of radiopharmaceuticals in Germany

International Nuclear Information System (INIS)

Kuwert, T.; Prante, O.; Meyer, G.

2009-01-01

This article deals with the regulation of the production and use of radiopharmaceuticals in Germany. As in other countries, radiopharmaceuticals may be used when licensed by the German equivalent of the Federal Drug Agency or in clinical trials. Furthermore, non-licensed radiopharmaceuticals can be administered to patients for diagnosis when they are produced in the same institution and not more than 20 doses per week and radiopharmaceutical are given. A prerequisite for these three ways of use is the production of the radiopharmaceutical in question according to the guidelines of the good manufacturing practice (GMP) which creates considerable problems for the usually small PET centers installed in the German university hospitals. German law offers a further possibility to apply non-licensed radiopharmaceuticals for clinical purposes: their administration to patients is not forbidden when performed by a physician who produces the substance himself or is at least responsible for its synthesis. This regulation has, however, been met with criticism by government agencies. (orig.)

Good Practice for Introducing Radiopharmaceuticals for Clinical Use

International Nuclear Information System (INIS)

2016-02-01

The use of new radiopharmaceuticals can provide extremely valuable information in the evaluation of cancer, as well as heart and brain diseases. Information that often times cannot be obtained by other means. However, there is a perceived need in many Member States for a useful reference to facilitate and expedite the introduction of radiopharmaceuticals already in clinical use in other countries. This publication intends to provide practical support for the introduction of new radiotracers, including recommendations on the necessary steps needed to facilitate and expedite the introduction of radiopharmaceuticals in clinical use, while ensuring that a safe and high quality product is administered to the patient at all times

The safe and effective use of radiopharmaceuticals

International Nuclear Information System (INIS)

Trott, N.G.

1982-01-01

In the medical applications of radionuclides, we have to arrange effective radiation protection of patients, staff and general public, maintain high standards of pharmaceutical safety and ensure that the radiopharmaceuticals are effective in use. The influence of the 1976 Council of the European Communities Euratom Directive in producing legislation in the United Kingdom controlling medical work with radioactivity is discussed. Attention is drawn to current studies in the dosimetry of radiopharmaceuticals, and some of the problems that continue to arise in evaluating the dosimetry and possible hazards of isotopes of iodine are discussed. Developments in facilities for preparing radiopharmaceuticals in hospital laboratories are considered and a short report is given of an extensive study of quality control procedures which showed that it was difficult to justify their use as a routine on established products. (Author)

Fetal absorbed doses by radiopharmaceutical administration

International Nuclear Information System (INIS)

Rojo, Ana M; Gomez Parada, Ines M.; Di Trano, Jose L.

2000-01-01

The radiopharmaceutical administration with diagnostic or therapeutic purpose during pregnancy implies a prenatal radiation dose. The dose assessment and the evaluation of the radiological risks become relevant due to the great radiosensitivity of the fetal tissues in development. This paper is a revision of the available data for estimating fetal doses in the cases of the more frequently used radiopharmaceuticals in nuclear medicine, taking into account recent investigation in placental crossover. The more frequent diagnostic and therapeutic procedures were analyzed according to the radiation doses implied. (author)

Results of quality control studies of technetium 99m labelled radiopharmaceuticals prepared from kits

International Nuclear Information System (INIS)

McLean, J.R.; Rockwell, L.J.; Welsh, W.J.

1978-01-01

This report summarizes the results of quality control studies of Tc 99m labelled normal serum albumin and macro-aggregated albumin radiopharmaceuticals prepared from commercially available kits. It includes all analyses performed since the inception of the program in 1976 until the end of 1977. The results presented herein were obtained through the application of various in vitro tests and animal (mouse) bio-distribution studies. It is hoped that a similar report will be published annually for the benefit of hospital nuclear medicine departments and kit manufacturers. (auth)

F-18 Radiopharmaceuticals

International Nuclear Information System (INIS)

2001-12-01

This document includes 8 presentations delivered at the symposium. The topics discussed include: optimization of accelerator production of 18 F- and 18 F 2 -fluorodeoxyglucose; radiopharmaceuticals synthesis, synthesis modules, pharmacopoeia and GLP; quality control; radiation safety of production and application; PET imaging in human medicine. Each presentation has been indexed separately

Radiopharmaceuticals for nuclear cardiology; Radiofarmacos para cardiologica nuclear

Energy Technology Data Exchange (ETDEWEB)

Leon Cabana, Alba [Universidad de la Republica, Facultad de Quimica (Uruguay)

1994-12-31

One of the diagnostic technique periodically used in Nuclear Medicine is the angiographic studi e, employee for detect cardiovascular diseases. The radiopharmaceutical more used in the angiographic ones is 99mTc. Between thetopics described in the present work it find: myocardial infarction, radiopharmaceuticals classification for cardiac studies, labelled proceedings, cardiovascular diseases.

Chemistry and Materials Science Directorate 2005 Annual Report

International Nuclear Information System (INIS)

Diaz De La Rubia, T; Fluss, M J; Rath, K; Rennie, G; Shang, S; Kitrinos, G

2006-01-01

In 1952, we began laboratory operations in the barracks building of the Naval Air Station with approximately 50 employees. Today, the Chemistry and Materials Science (CMS) Directorate is a major organization at the Lawrence Livermore National Laboratory with more than 500 employees who continue to contribute to our evolving national security mission. For more than half a century, the mission of the Laboratory revolved primarily around nuclear deterrence and associated defense technologies. Today, Livermore supports a broad-based national security mission, and our specialized capabilities increasingly support emerging missions in human health and energy security. In the future, CMS will play a significantly expanded role in science and technology at the intersection of national security, energy and environment, and health. Our world-class workforce will provide the science and technology base for radically innovative materials to our programs and sponsors. Our 2005 Annual Report describes how our successes and breakthroughs follow a path set forward by our strategic plan and four organizing research themes, each with key scientific accomplishments by our staff and collaborators. Organized into two major sections-research themes and dynamic teams, this report focuses on achievements arising from earlier investments that address future challenges. The research presented in this annual report gives substantive examples of how we are proceeding in each of these four theme areas and how they are aligned with our national security mission. Research Themes: (1) Materials Properties and Performance under Extreme Conditions--We are developing ultrahard nanocrystalline metals, exploring the properties of nanotubes when exposed to very high temperatures, and engineering stronger materials to meet future needs for materials that can withstand extreme conditions. (2) Chemistry under Extreme Conditions and Chemical Engineering to Support National-Security Programs--Our recent

Chemistry and Materials Science Directorate 2005 Annual Report

Energy Technology Data Exchange (ETDEWEB)

Diaz De La Rubia, T; Fluss, M J; Rath, K; Rennie, G; Shang, S; Kitrinos, G

2006-08-08

In 1952, we began laboratory operations in the barracks building of the Naval Air Station with approximately 50 employees. Today, the Chemistry and Materials Science (CMS) Directorate is a major organization at the Lawrence Livermore National Laboratory with more than 500 employees who continue to contribute to our evolving national security mission. For more than half a century, the mission of the Laboratory revolved primarily around nuclear deterrence and associated defense technologies. Today, Livermore supports a broad-based national security mission, and our specialized capabilities increasingly support emerging missions in human health and energy security. In the future, CMS will play a significantly expanded role in science and technology at the intersection of national security, energy and environment, and health. Our world-class workforce will provide the science and technology base for radically innovative materials to our programs and sponsors. Our 2005 Annual Report describes how our successes and breakthroughs follow a path set forward by our strategic plan and four organizing research themes, each with key scientific accomplishments by our staff and collaborators. Organized into two major sections-research themes and dynamic teams, this report focuses on achievements arising from earlier investments that address future challenges. The research presented in this annual report gives substantive examples of how we are proceeding in each of these four theme areas and how they are aligned with our national security mission. Research Themes: (1) Materials Properties and Performance under Extreme Conditions--We are developing ultrahard nanocrystalline metals, exploring the properties of nanotubes when exposed to very high temperatures, and engineering stronger materials to meet future needs for materials that can withstand extreme conditions. (2) Chemistry under Extreme Conditions and Chemical Engineering to Support National-Security Programs--Our recent

Molecular design of 99Tcm labelled radiopharmaceuticals. Pt.2

International Nuclear Information System (INIS)

Wang Xuebin; Chu Jinfeng

2003-01-01

The structure-activity relationship of 99 Tc m labelled radiopharmaceuticals and the correlative contents of computer aided drug design are introduced. Of them, quantitative structure-activity relationship and its application to design 99 Tc m labelled radiopharmaceuticals are narrated on emphases

Radiation Protection, double-blind studies with radiopharmaceuticals

International Nuclear Information System (INIS)

Pujadas, M. C.; Camacho, C.; Guasp, M.; Villaescusa, J. I.

2009-01-01

In a double-blind randomized controlled clinical trial (RCT) subjects and researchers do not know the assignment to treatment groups to ovoid the appearance of subjective biases of information. The employment of radiopharmaceuticals in double-blind RCTs raises a dilemma from the point ov view of the radiological protection. On the one hand, the obligation to act in cases of contamination and/or risk of irradiation exists, but on the other hand the duty of keeping the blind study also exists. In this paper some of the possible problems that arise when conducting a double-blind RCT with radiopharmaceuticals from the point of view of the radiological protection are presented. We comment our experience with the radiopharmaceutical Alpharadin and, in addition, we propose useful recommendations based on the randomness of the decontamination process. (Author) 7 refs.

Report of the Task Force on radiopharmaceuticals

International Nuclear Information System (INIS)

Lacker, D.K.; Porter, B.J.; Watkins, G.

1975-01-01

The procedures for evaluation of IND and NDA applications were reviewed by FDA and the state members of the Task Force believe that there is significant progress being made toward expeditious handling of these items. Progress toward publication of the final rule on radiopharmaceuticals has reduced the need for state regulatory activity in investigational aspects of radiopharmaceutical research to the point that the original concept for the training is no longer valid

Pain palliative Radiopharmaceuticals

International Nuclear Information System (INIS)

Gonzalez, B. M.

1994-01-01

A pain relieving agents based on β emitters mainly and in some cases a complex preparation are being given for bone metastasis in relation with breast,prostate and lung carcinoma with good performance in clinical practice.Several radionuclides and radiopharmaceuticals are mentioned giving strength to those newly proposed, 153Sm and 186Re.Bibliography

The role of mathematical models in the optimization of radiopharmaceutical therapy

International Nuclear Information System (INIS)

Divgi, C.

2001-01-01

Mathematical models have been used in radiopharmaceutical therapy for over five decades. These have served to determine the amount of radioactivity required to treat disease, as in the therapy of hyperthyroidism with iodine-131, or, more frequently, to determine the largest amount of radioactivity that can be safely administered. Mathematical models are especially useful in the determination of fractionated radiopharmaceutical therapy. This review will briefly outline the historical development and current utility of mathematical models in radiopharmaceutical therapy, including thyroid disorders and radioimmunotherapy; and describe the potential of modeling in fractionated therapy. The extended application of such models to currently used radiopharmaceutical therapy based on indices of body mass or surface area, to alleviate toxicity and increase radiation dose to tumour, will be proposed. Finally, future applications of mathematical models in radiopharmaceutical therapy will be outlined. (author)

Quality control of radiopharmaceuticals

International Nuclear Information System (INIS)

Verdera, E.S.

1994-01-01

The quality control of radiopharmaceuticals is based in physics, physics-chemical and biological controls. Between the different controls can be enumerated the following: visual aspect,side, number of particle beams,activity,purity,ph,isotonicity,sterility,radioinmunoessay,toxicity,stability and clinical essay

Biweekly list of papers on radiation chemistry and photochemistry. Annual cumulation with keyword and author indexes. Volume 16. 1983

International Nuclear Information System (INIS)

Carmichael, I.C.; Helman, W.P.; Hug, G.L.; Ross, A.B.

1983-01-01

The Biweekly List of Papers on Radiation Chemistry and Photochemistry is a current-awareness service published by the Radiation Chemistry Data Center (RCDC), with special emphasis on the kinetics and other properties of transient ions, radicals, and excited species. Papers are included on the radiation chemistry and photochemistry of organic and inorganic systems, biological molecules and polymers, with references to ESR and luminescence studies. Complete coverage is attempted only for those studies which are initiated by light or ionizing radiation, and which provide quantitative physical chemical data such as quantum yields, specific rates, G values, etc. No attempt is made to cover topics such as mechanistic and preparative photochemistry, photosynthesis, photography, and irradiation of metals. The references listed herein are obtained from scanning about 60 current journals as well as Chemical Abstracts, INIS Atomindex and several other publications listing current references. The reference lists, which are issued biweekly, are cumulated annually with the addition of keyword and author indexes. Indexed cumulations were published semiannually for Vol. 4-6 (1971-73) and are published annually for Vol. 7+ (1974+); back copies are available from the National Technical Information Service (NTIS)

Breast feeding's interruption following radiopharmaceutical administration to nursing mothers

International Nuclear Information System (INIS)

Rojo, A.M.; Gomez Parada, I.M.; Dubner, D.; Gisone, P.; Perez de Serrano, M.

1995-01-01

The radiopharmaceutical administration to lactating women for therapeutic or diagnostic purpose can achieve a radiological risk to the breast feeding child due to levels of radioactivity in the breast milk. International recommendations regarding safe assumption of nursing mother after radiopharmaceutical administration were analysed. We examined the formula proposed by Rommey et al. to establish objective guidelines in case of the administration of radiopharmaceutical to nursing mothers. The ICRP 54 metabolic model for iodine was modified in order to calculate the suppression breast feeding's period according to the radioactivity measured in the breast milk. (author). 6 refs., 1 fig., 1 tab

Active and passive vectorization of technetium99m and 188rhenium radiopharmaceuticals for medical imaging and radiotherapy

International Nuclear Information System (INIS)

Lepareur, N.

2003-11-01

Research for new molecules for nuclear medicine is a field in constant development. Over the past few years, development of new radiopharmaceuticals for radiotherapy has renewed interest for rhenium chemistry. Indeed, its two isotopes 186 Re and 188 Re, owing to their ideal properties and their similitude with 99m Tc, which is widely used as a radiotracer for diagnostic imaging, seem very promising for the preparation of radiopharmaceuticals. In the first part of this manuscript, the synthesis of rhenium and technetium-99 complexes, [M(RPhCS3)2(RPhCS2)] (M = Re, Tc), is described. The preparation of technetium 99m based radiopharmaceuticals, analogues to the pondered complexes, is also described. The stability/reactivity of these complexes has been studied by exchange reactions with potential ligands, specially dithiocarbamates, and also by UV-visible absorption spectroscopy and thermogravimetry. The reactivity of the complexes towards dithiocarbamates leads to the possibility to bind biomolecules to the metallic core, via the dithiocarbamate moiety. This method represents a potential alternative to current ones using the so-called bifunctional approach. In the second part of this manuscript, a new kit formulation for the 188 Re labeling of lipiodol is described, using a complex analogous to those described in the previous part. The labeled oil is a potential cure for hepatocellular carcinoma. The in vitro and in vivo stability of this 188 Re-SSS lipiodol and of its analogue 99m Tc-SSS lipiodol has been studied, and also their in vivo behavior in healthy pigs. This study has shown the quasi-exclusive hepatic fixation of the radiopharmaceutical, and has proven its good stability. Its selectivity for tumors remains to be shown before trying it on humans. (author)

Sixth international radiopharmaceutical dosimetry symposium: Proceedings. Volume 2

Energy Technology Data Exchange (ETDEWEB)

S.-Stelson, A.T. [ed.] [comp.; Stabin, M.G.; Sparks, R.B. [eds.; Smith, F.B. [comp.

1999-01-01

This conference was held May 7--10 in Gatlinburg, Tennessee. The purpose of this conference was to provide a multidisciplinary forum for exchange of state-of-the-art information on radiopharmaceutical dosimetry. Attention is focused on the following: quantitative analysis and treatment planning; cellular and small-scale dosimetry; dosimetric models; radiopharmaceutical kinetics and dosimetry; and animal models, extrapolation, and uncertainty.

Use of radiopharmaceuticals for treating bone metastases

International Nuclear Information System (INIS)

Alberti Ramírez, Alejandro; Morín Zorrilla, José; Cruz Arencibia, Jorge

2016-01-01

Cancer prevalence is estimated at around 2% of the population and on average between 64-80% of patients with solid tumors develop bone metastases, being breast tumors, lung and prostate those who do more frequency. In this paper an estimate of the prevalence of bone pain from metastases, with reference to the data reported in the literature is presented. the different treatment techniques are summarized for pain management with special emphasis on Radionuclidic therapy, analyzing the different factors to consider for the selection of suitable radiopharmaceutical. cost data and cost-benefit of some radiopharmaceuticals for the purpose to take into account during their selection are provided. It is concluded that although the treatment of metastatic bone disease requires multidisciplinary therapies, Radionuclidic therapy is not sufficiently used, particularly by inadequate perception of risks and costs of radiopharmaceuticals, despite the undeniable support of its efficacy and tolerability. (author)

Quality assurance of radiopharmaceuticals - specifications and test procedures

International Nuclear Information System (INIS)

Baldas, J.; Bonnyman, J.; Colmanet, S.F.; Ivanov, Z.; Lauder, R.A.

1990-10-01

The authors report on a Radiopharmaceutical Quality Assurance Test Programme carried out by the Australian Radiation Laboratory in which radiopharmaceuticals used in nuclear medicine in Australia are tested for compliance with specifications. Where the radiopharmaceutical is the subject of a monograph in the British Pharmacopoeia or the European Pharmacopoeia, then the specifications given in the Pharmacopoeia are adopted. In other cases the specifications given have been adopted by this Laboratory and have no legal status. In some cases test procedures described have been taken from various Pharmacopoeias or methods published in the literature. In other cases test methods described have been developed at this Laboratory. It should be noted that, unless stated otherwise, specifications listed apply at all times up until product expire

Experimental nuclear medicine radiopharmaceutical development

International Nuclear Information System (INIS)

Harper, P.; Lathrop, K.

1980-01-01

This report summarizes progress that has been made on the preparation and biological accumulation of various radiopharmaceuticals including C-hexamethonium, C-cholic acid, Mn-51 and labeled amino acids

Quality assessment of radiopharmaceuticals in nuclear medicine services at Northeast states, Brazil

International Nuclear Information System (INIS)

Andrade, Wellington Gomes de

2012-01-01

The radiopharmaceuticals are used in the field nuclear medicine services (NMS) as tracer in the diagnoses and treatment of many diseases. Radiopharmaceuticals used in nuclear medicine and usually have a minimum of pharmacological effect. The procedures for labelling Radiopharmaceuticals should be observed in order to minimize risks to patients, employees and individuals from the public, and to be administered in humans, must be sterile and free of pyrogens and possess elements all measures of quality controls required a conventional drug. The 'Agencia Nacional de Vigilancia Sanitaria (ANVISA)' in its 'Resolucao de Diretoria Colegiada' (RDC) No. 38 of June 4 th 2008, decided that the NMS must perform quality control in the generators eluate and radiopharmaceuticals according to recommendations of manufacturers and scientific evidence accepted by ANVISA. Thus, this study proposes to evaluate the quality of the generator 99M o- 99m Tc eluate and radiopharmaceuticals labeled with 99m Tc used in most NMS of some states in the Northeast, in relation to radionuclide, chemical, radiochemical purity and pH and promote the inclusion of procedure for quality control of radiopharmaceuticals in routine NMS. The results show that 90% radionuclidic purity, 98.2% purity chemical and radiochemical purity of 46% and 100% of the eluates are in agreement with international pharmacopoeias; already radiopharmaceuticals showed 82.6% purity and all radiochemical pH values are also in accordance with international pharmacopoeias. Even with so many positive results, staff the majority of MNS was not able to perform the quality control of the eluates and radiopharmaceuticals. Showing the importance of implementing of quality control programs of the eluates and radiopharmaceuticals in nuclear medicine. (author)

Characterization of in vivo chemistry of cations in the heart

International Nuclear Information System (INIS)

Mousa, S.A.; Williams, S.J.; Sands, H.

1987-01-01

A variety of laboratory procedures can be used to define the chemistry and pharmacokinetics of myocardial cationic imaging agents. These methods are utilized to define the in vivo chemistry of cationic heart agents, in order to understand the kinetics and mechanisms of: tissue and cellular transport, subcellular distribution, and intracellular localization. Transport across cell membranes can be active, passive or facilitated. Studies performed in erythrocytes, heart cells, slices and isolated perfused hearts using methods for separation of metabolites have shown a high degree of myocardial specificity for [99mTc]hexakis alkyl isonitrile by an uptake mechanism different from 201 Tl. These studies demonstrate the importance of in vivo chemistry and pharmacokinetics in the development of new radiopharmaceuticals. 31 references

Bio-organic chemistry at BARC

International Nuclear Information System (INIS)

Sharma, A.; Ghosh, S.K.; Chattopadhyay, S.

2009-01-01

Bioorganic chemistry plays a pivotal role of co-ordination amongst the research and developmental activities of physical, biological, material and nuclear sciences. Understandably, the domain of bioorganic chemistry encompasses overlapping scientific fields, and often involves multi-disciplinary subjects. The research activities of bioorganic research at BARC are, therefore directed with reference to deliverables, relevant to various nuclear and non-nuclear programmes of the department. Also, the activities of the division are fine tuned to address the contemporary needs. It is now well recognized that organic compounds are essential in various programmes of nuclear technology. These include solvents and membranes for the back-end process, carrier molecules for radiopharmaceuticals, optoelectrical materials and sensors for high tech applications etc. Coupled with this, bioorganics also form integral part of the departmental mission-oriented societal programmes in the areas of health and agriculture

Radiation decomposition of technetium-99m radiopharmaceuticals

International Nuclear Information System (INIS)

Billinghurst, M.W.; Rempel, S.; Westendorf, B.A.

1979-01-01

Technetium-99m radiopharmaceuticals are shown to be subject to autoradiation-induced decomposition, which results in increasing abundance of pertechnetate in the preparation. This autodecomposition is catalyzed by the presence of oxygen, although the removal of oxygen does not prevent its occurrence. The initial appearance of pertechnetate in the radiopharmaceutical is shown to be a function of the amount of radioactivity, the quantity of stannous ion used, and the ratio of /sup 99m/Tc to total technetium in the preparation

Present status and prospect of copper radiopharmaceuticals

International Nuclear Information System (INIS)

Chen Huawei; Li Hongfeng; Liu Boli

1996-01-01

In the past decade most of the efforts of copper radiopharmaceuticals research has been focused on bis(thiosemicarbazonato) copper complexes for use in myocardial and brain imaging agents. In the present work, the analogs of bis(thiosemicarbazone) is studied in labeling antibodies and tumors. The retention mechanism of Cu-PTSM is investigated. Other kinds of ligands, BAT (N 2 S 2 ) for example, can be used to prepare neutral copper complexes in order to obtain brain radiopharmaceuticals in future. (60 refs.)

Influence of Storage Temperature on Radiochemical Purity of 99mTc-Radiopharmaceuticals.

Science.gov (United States)

Uccelli, Licia; Boschi, Alessandra; Martini, Petra; Cittanti, Corrado; Bertelli, Stefania; Bortolotti, Doretta; Govoni, Elena; Lodi, Luca; Romani, Simona; Zaccaria, Samanta; Zappaterra, Elisa; Farina, Donatella; Rizzo, Carlotta; Giganti, Melchiore; Bartolomei, Mirco

2018-03-15

The influence of effective room temperature on the radiochemical purity of 99m Tc-radiopharmaceuticals was reported. This study was born from the observation that in the isolators used for the preparation of the 99m Tc-radiopharmaceuticals the temperatures can be higher than those reported in the commercial illustrative leaflets of the kits. This is due, in particular, to the small size of the work area, the presence of instruments for heating, the continuous activation of air filtration, in addition to the fact that the environment of the isolator used for the 99m Tc-radiopharmaceuticals preparation and storage is completely isolated and not conditioned. A total of 244 99m Tc-radiopharmaceutical preparations (seven different types) have been tested and the radiochemical purity was checked at the end of preparation and until the expiry time. Moreover, we found that the mean temperature into the isolator was significantly higher than 25 °C, the temperature, in general, required for the preparation and storage of 99m Tc-radiopharmaceuticals. Results confirmed the radiochemical stability of radiopharmaceutical products. However, as required in the field of quality assurance, the impact that different conditions than those required by the manufacturer on the radiopharmaceuticals quality have to be verified before human administration.

Radiopharmaceuticals for cerebral studies; Radiofarmacos para Estudios Cerebrales

Energy Technology Data Exchange (ETDEWEB)

Leon Cabana, Alba [Universidad de la Republica, Facultad de Quimica (Uruguay)

1994-12-31

For obtain good brain scintillation images in nuclear medicine must be used several radiopharmaceuticals. Cerebral studies give a tumors visual image as well as brain anomalities detection and are helpful in the diagnostic diseases . Are described in this work: a cerebrum radiopharmaceuticals classification,labelled compounds proceeding and Tc 99m good properties in for your fast caption, post administration and blood purification for renal way.

Guidelines on current good radiopharmacy practice (cGRPP) in the preparation of radiopharmaceuticals

International Nuclear Information System (INIS)

Dumas, Cecile

2010-07-01

Preparation of radiopharmaceuticals for injection involves adherence to regulations on radiation protection as well as to appropriate rules of working under aseptic conditions, which are covered by these guidelines on Good Radiopharmacy Practice (GRPP). The handling of radiopharmaceuticals is potentially hazardous. The level of risk depends in particular upon the types of radiation emitted and the half-lives of the radioactive isotopes. Particular attention must be paid to the prevention of cross-contamination, and to waste disposal. A continuous assessment of the effectiveness of the Quality Assurance system is essential to prove that the procedures applied in the Radiopharmacy Department lead to the expected quality. Clinical trials with new radiopharmaceuticals should follow these regulations on cGRPP as well as the Guideline on Good Clinical Practice. As there is a considerable difference in complexity in preparing 'classical' radiopharmaceuticals in 'kit' procedures and producing radiopharmaceuticals by distinct chemical procedures (Positron Emission Tomography (PET) Radiopharmaceuticals, in house prepared radiopharmaceuticals including in house prepared kits) these guidelines have been divided in two parts (A and B) respecting these differences

Radiopharmaceutical potential of I-131 labelled diazepam

International Nuclear Information System (INIS)

Yurt, F.; Unek, P.; Asikoglu, M.; Baggi, S.; Erener, G.; Ozkilic, H.; Uluc, F.; Tuglular, I.

1998-01-01

In this study, diazepam is a derivative of the 1.4 benzodiazepine family that the most widely used drug as anticonvulsant agent has been labeled with I-131, as a new radiopharmaceutical and its radiopharmaceutical potential has been determined. Labeling of diazepam has been performed by iodogen method and optimum labeling conditions have been determined. Optimum reaction conditions are 1 mg for iodogen amount; 1-5 mg for diazepam amount, 15-20 minutes for reaction time and room temperature for reaction temperature. Specific activity of labeled compound was 0,15 Ci/mmol level. N-octanol/water ratio was found 1.9 for 131 IDZ ( 131 I labeled diazepam). In vivo experiments have been carried out to determine radiopharmaceutical potentials of labeled compound. Biodistribution studies on rats showed that 131 IDZ have accumulated in kidneys, liver, lungs and brain tissues. Scintigraphic results taken with gamma camera on rabbits agree with biodistribution results of rats. (author)

Molecular target in oncology. Opportunity for radiopharmaceuticals development

International Nuclear Information System (INIS)

Navarro Marques, Fabio Luiz

2016-01-01

Cancer is a cellular multifactorial disease, regulated by changes in phenotype characteristics, such as adhesion, invasion, migration, and tumorigenesis; genotypic status of commonly altered genes (KRAS and p53); microenvironmental conditions, such pH, oxygen and nutrient supply. All these features provide opportunities for radiopharmaceuticals development, both for diagnostic and therapy. For both applications, radiopharmaceuticals molecules can be divided in small synthetic molecules, small peptides (natural or modified), large molecules such as antibody or nanoparticles. The characteristics of those molecules and use will guide the choice of the radionuclide to be used for labeling it. In the presentation, data from literature and research ongoing in the Faculty of Medicine of the University of São Paulo/Brazil will be used for demonstrate the potential for radiopharmaceuticals development. (author)

Radiopharmaceuticals drug interactions: a critical review

Directory of Open Access Journals (Sweden)

Ralph Santos-Oliveira

2008-12-01

Full Text Available Radiopharmaceuticals play a critical role in modern medicine primarily for diagnostic purposes, but also for monitoring disease progression and response to treatment. As the use of image has been increased, so has the use of prescription medications. These trends increase the risk of interactions between medications and radiopharmaceuticals. These interactions which have an impact on image by competing with the radiopharmaceutical for binding sites for example can lead to false negative results. Drugs that accelerate the metabolism of the radiopharmaceutical can have a positive impact (i.e. speeding its clearance or, if repeating image is needed, a negative impact. In some cases, for example in cardiac image among patients taking doxirubacin, these interactions may have a therapeutic benefit. The incidence of drug-radiopharmaceuticals adverse reactions is unknown, since they may not be reported or even recognized. Here,we compiled the medical literature, using the criteria of a systematic review established by the Cochrane Collaboration, on pharmaceutical-drug interactions to provide a summary of documented interactions by organ system and radiopharmaceuticals. The purpose is to provide a reference on drug interactions that could inform the nuclear medicine staff in their daily routine. Efforts to increase adverse event reporting, and ideally consolidate reports worldwide, can provide a critically needed resource for prevention of drug-radiopharmaceuticals interactions.Os radiofármacos desempenham função crítica na medicina moderna, primariamente para fins diagnósticos, mas também no monitoramento da progressão de doenças assim como na avaliação de respostas ao tratamento. O uso da tecnologia por imagem tem crescido e conseqüentemente as prescrições de medicamentos (radiofármacos em especial com esse propósito. Este fato, aumenta o risco de interações entre medicamentos e radiofármacos. Interações que podem ter um impacto na

Radiation dose estimates for radiopharmaceuticals

International Nuclear Information System (INIS)

Stabin, M.G.; Stubbs, J.B.; Toohey, R.E.

1996-04-01

Tables of radiation dose estimates based on the Cristy-Eckerman adult male phantom are provided for a number of radiopharmaceuticals commonly used in nuclear medicine. Radiation dose estimates are listed for all major source organs, and several other organs of interest. The dose estimates were calculated using the MIRD Technique as implemented in the MIRDOSE3 computer code, developed by the Oak Ridge Institute for Science and Education, Radiation Internal Dose Information Center. In this code, residence times for source organs are used with decay data from the MIRD Radionuclide Data and Decay Schemes to produce estimates of radiation dose to organs of standardized phantoms representing individuals of different ages. The adult male phantom of the Cristy-Eckerman phantom series is different from the MIRD 5, or Reference Man phantom in several aspects, the most important of which is the difference in the masses and absorbed fractions for the active (red) marrow. The absorbed fractions for flow energy photons striking the marrow are also different. Other minor differences exist, but are not likely to significantly affect dose estimates calculated with the two phantoms. Assumptions which support each of the dose estimates appears at the bottom of the table of estimates for a given radiopharmaceutical. In most cases, the model kinetics or organ residence times are explicitly given. The results presented here can easily be extended to include other radiopharmaceuticals or phantoms

Factors and pharmaceuticals that affect the radiopharmaceuticals bio distributions

International Nuclear Information System (INIS)

Gonzalez, B.M.

1994-01-01

The pattern of biodistribution of radiopharmaceuticals may be affected by various agents and therapeutical procedures, chemotherapy agents, thyroid hormones, metals, radiotherapy, surgery, anesthetic agents, dialysis other radiopharmaceutical interactions. Recommendations for the detection of altered biodistribution in patients by causes not directly related with the pathology itself was given. pathology itself was given

Annual report 1993 by the Rossendorf Society of Nuclear Engineering and Analysis

International Nuclear Information System (INIS)

Haefele, W.

1994-03-01

The second annual report contains, apart from the business report and the organigram, priorities and results achieved in the special fields of nuclear installations (decommissioning and disposal), nuclear waste management (radioactive wastes), nuclear analyses and rehabilitation, radiopharmaceuticals, and safety and radiation protection. (HP) [de

Chemistry Division : Annual progress report of 1974

International Nuclear Information System (INIS)

1974-01-01

Research and development activities (during 1974) of the Chemistry Division of the Bhabha Atomic Research Centre, Bombay, are described. Some of the activities of particular interest to nuclear science and technology are: (1) chemistry-based problems of the operating power reactors such as development of a decontaminating solution for power reactors, correlation of iodine-131 levels in the primary heat transport system of a reactor with its operation (2) release of fission gases like xenon from ceramic fuels and (3) radiation chemistry of nitrate solutions (M.G.B.)

Regulatory requirements for radiopharmaceutical radiochemistry and radiation dosimetry

International Nuclear Information System (INIS)

Bonnyman, J.

1985-01-01

The Australian Department of Health is responsible for ensuring that radiopharmaceuticals are safe and effective and that their use does not result in unnecessary radiation exposure. Section B1 requirements of New Drug Form 4 (NDF4) fall into the following sections - manufacture, product specifications, quality assurance testing, stability studies and expiry dating. It covers ready to inject pharmaceuticals, radioactive formulations used to prepare a radiopharmaceutical, generators and cold kits

Guidance for nuclear medicine staff on radiopharmaceuticals drug interaction

International Nuclear Information System (INIS)

Santos-Oliveira, Ralph

2009-01-01

Numerous drug interactions related to radiopharmaceuticals take place every day in hospitals many of which are not reported or detected. Information concerning this kind of reaction is not abundant, and nuclear medicine staff are usually overwhelmed by this information. To better understand this type of reaction, and to help nuclear medicine staff deal with it, a review of the literature was conducted. The results show that almost all of radiopharmaceuticals marketed around the world present drug interactions with a large variety of compounds. This suggests that a logical framework to make decisions based on reviews incorporating adverse reactions must be created. The review also showed that researchers undertaking a review of literature, or even a systematic review that incorporates drug interactions, must understand the rationale for the suggested methods and be able to implement them in their review. Additionally, a global effort should be made to report as many cases of drug interaction with radiopharmaceuticals as possible. With this, a complete picture of drug interactions with radiopharmaceuticals can be drawn. (author)

Radiopharmaceuticals for renal studies

International Nuclear Information System (INIS)

Verdera, Silvia

1994-01-01

Between the diagnostic techniques using radiopharmaceuticals in nuclear medicine it find renal studies.A brief description about renal glomerular filtration(GFR) and reliability renal plasma flux (ERPF),renal blood flux measurement agents (RBF),renal scintillation agents and radiation dose estimates by organ physiology was given in this study.tabs

Good radiopharmaceuticals practices

International Nuclear Information System (INIS)

Verdera E, Silvia

1994-01-01

A careful security must be used in the nuclear medicine laboratory concerning to the proceedings, preparation and dispensation of radiopharmaceuticals. Each control laboratory must look after the radiation protection patients,workers and people in general. Between another routinary activities in the present work it find : equipment prearrangement,installations,handling and support of electronic instruments,proceedings,methodology, results and interpretation of analysis , as well as registry maintenance

Radiopharmaceutical therapy in Dominican Republic. Present and future

International Nuclear Information System (INIS)

Johny Osvaldo de los Santos

2005-01-01

Full text: In this paper we present experience in Dominican Republic on Radiopharmaceutical Therapy. In our country, there are 8 Center with Nuclear Medicine Department. Only, 7 centers are working with Radiopharmaceutical Therapy. Radioiodine treatment with I-131 in Thyroid diseases(Thyroid Cancer and Hyperthyroidism). This is only Nuclear Medicine therapy available in Dominican Republic. The objectives of this paper are to analyze and assess the difficulties and facilities for the development of Radiopharmaceutical Therapy in Dominican Republic. We made surveys with the help of Nuclear Medicine Physicians of different Nuclear Medicine departments. 8 Nuclear Physicians accepted the interview. Two of these Nuclear Medicine Centers are Department of a Cancer Center and they have many patients for therapies. In the majority opinion of Physicians, Cost of Radiopharmaceuticals is principal problem to use Therapy in Dominican Republic. In addition the following problems were identified: Lack of awareness about new therapy in Nuclear Medicine among Physicians of other specialties, lack of adequate training in the current trends of radionuclide therapy and finally lack of basic infrastructure, equipment and finances to buy radiopharmaceuticals and introduce radionuclide therapy. For this reason, Nuclear Medicine Centers prefer to work with only I-131 Therapy and they do not have new programs to start other therapies. In the near future, our department of Nuclear Medicine will work with I-131, pain palliation, treatment of metastatic disease and Treatment of benign diseases. We have interest in offering other therapies in the department and we hope that other departments with more resources, have the same interest, to enhance practice of radionuclide therapy in our country. (author)

Development of radiopharmaceutical for radiosinovectomy

International Nuclear Information System (INIS)

Couto, Renata Martinussi

2009-01-01

Radiopharmaceuticals prepared with different radionuclides have been used in diagnostic and therapeutic procedures in Nuclear Medicine. The interest in radionuclidic therapy has been increased in last years, with the introduction of new radiopharmaceuticals applied in the destruction of specific cells or to prevent its undesired proliferation. Radiosinovectomy (RSV) is a therapeutic modality that uses radiopharmaceuticals administered in the intra-articular cavity and represents an alternative to the treatment of different arthropaties and, in particular, the arthropaties derived from rheumatoid arthritis and haemophilic. The objective of the present work was to study the labeling of compounds with 90 Y and 177 Lu in order to improve the production conditions and quality control procedures, study the stability of the labeled compounds and preliminary biodistribution studies of the radiopharmaceuticals with potential for RSV applications. The study of the production of 90 Y citrate colloid ( 90 Y-Cit) was based in a labeling procedure using 90 Y Cl 3 solution (37 - 54 MBq) that was previously dried, followed by the addition of yttrium nitrate and sodium citrate in p H 7 at 37 deg C for 30 minutes. The production of hydroxyapatite (HA) labeled with 90 Y was based in a labeling procedure using mono hydrated citric acid, yttrium nitrate and 90 Y Cl 3 solution (37 - 370 MBq). The reaction mixture was incubated for 30 minutes at room temperature and the HA was introduced in aqueous medium and the reaction proceed for 30 minutes under strong stirring. 177 Lu-HA was produced using 177 Lu Cl 3 solution (296 MBq), in presence of lutetium oxide in NaCl medium, p H 7, under continuous stirring for 30 minutes at room temperature. Several reaction parameters were studied for the three radiopharmaceuticals. Labeling yield was determined after particles were centrifuged and washed with NaCl 0,9%. Radiochemical purity was determined by ascending chromatography using different

Short-lived radiopharmaceutical development at E.R. Squibb and Sons, Inc

International Nuclear Information System (INIS)

Loberg, M.D.

1985-01-01

This paper describes the present status and future plans of E.R. Squibb and Sons, Inc. as they relate to the development of short-lived radiopharmaceuticals. The advantages of short-lived radiopharmaceuticals are summarized as are the problems inherent in their manufacture, quality control, and distribution. The nuclear generator is advocated as the best means of distributing short-lived radiopharmaceuticals. The E.R. Squibb and Sons work with the 82 Sr → 82 Rb generator is summarized

Radiopharmaceuticals for oncology: status and newer trends- an overview

International Nuclear Information System (INIS)

Ramamoorthy, N.; Prabhakar, G.

1997-01-01

Radiopharmaceuticals have provided a powerful means in the diagnosis and follow up of cancer patients. Radiopharmaceuticals for the treatment of metastatic thyroid cancer and palliation of metastatic bone pain are in extensive use. Newer agents are on the anvil for more efficacious diagnosis and therapy. This article gives an overview of the status and trends in this context. (author)

Radiopharmaceuticals based on the scandium or rhodium radionuclides

International Nuclear Information System (INIS)

Majkowska, A.; Pruszynski, M.; Bilewicz, A.

2006-01-01

Radionuclides 103m Rh, 105 Rh emitting β-radiation or 47 Sc (Auger electrons emitter) are suitable for treatment small tumors spread over the human tissues. Presented communication describes preliminary results obtained in the Institute of Nuclear Chemistry and Technology, Warsaw (Poland) in the field of obtaining new complexes containing the aforementioned radionuclides. The radionuclides can be produced in the laboratory scale from simple and cheap generators. 103m Rh and 105 Rh cations were complexed with the thioetheric ligand (1,5,9,13-tetrathiacyclahexadecane-3,11-diole) and in the future, after funcionalization with certain biomolecules, are promising radiopharmaceuticals. 47 Sc cation was complexes by one from the following tri- or tetraaza macoryclic ligands: 1,4,7,10-triazacyclononane-1,4,7-triacetic acid (NOTA), 1,4,7,10-tetraazacyclododecane-1,7-diacetic acid (DO2A) or 1,4,7,10-triazacyclononane-1,4,7-triacetic acid (NOTA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). Composition and the stability constants of the complexes were determined

Production, control and utilization of radioisotopes including radiopharmaceuticals

International Nuclear Information System (INIS)

Muenze, R.

1985-05-01

From April 29th to May 5th, 1984 27 participants from 21 developing countries stayed within an IAEA Study Tour ('Production, Control and Utilization of Radioisotopes including Radiopharmaceuticals') in the GDR. In the CINR, Rossendorf the reactor, the cyclotron, the technological centre as well as the animal test laboratory were visited. The participants were made familiar by 10 papers with the development, production and control of radiopharmaceuticals in the CINR, Rossendorf. (author)

Traceability in the pharmaceutical industry: application to radiopharmaceutical production

International Nuclear Information System (INIS)

Zanette, Camila; Melero, Laura T.U.H.; Araujo, Elaine B. de; Mengatti, Jair; Silva, Katia S. de S.

2011-01-01

The development of tools to promote the traceability of the drugs in the pharmaceutical industry during all the production chain is a necessary requisite. The traceability system is applied to enable the identification of the origin, destination and exact location of the drug. Traceability optimizes the process chain, reduces errors, is a requirement for quality process, promotes safety for the user and assists in pharmacovigilance. The health regulatory agency in Brazil (ANVISA) will implement a tracking system for medicaments with RDC no. 59 of 2009, to control distribution since the producer until the patients in order to prevent the traffic and adulteration of drugs. Thus, this study discusses the importance and impact of the new traceability system proposed by ANVISA in the production and distribution of radiopharmaceuticals from the Nuclear and Energy Research Institute (IPEN-CNEN). The radiopharmaceuticals have a difference track when compared with another drug classes. In this context, this RDC would increase the price of the medicines by up to 10%, since it provides deployment of a single stamp supplied by the Mint. Considering that radiopharmaceuticals are not sold to the final consumer (patients), but only for accredited medical clinics and nuclear medicine physicians, and the transport of radiopharmaceuticals is performed by specialized companies licensed by CNEN (National Nuclear Energy Commission), the use of the stamp to ensure authenticity and prevent falsification should not be appropriated and represents and additional cost for the radiopharmaceuticals. (author)

Stannous ion quantitation in sup(99m)Tc-radiopharmaceutical kits

International Nuclear Information System (INIS)

Chervu, L.R.; Vallabhajosyula, B.; Mani, J.; Chun, S.B.; Blaufox, M.D.

1982-01-01

A simple and inexpensive method for the estimation of stannous ion, Sn(II), in radiopharmaceutical kits is described. The method used is a potentiometric titration of Sn(II) in 1 N HCl medium, using potassium iodate as the oxidizing agent in an atmosphere of nitrogen. The apparatus includes a pH meter, a platinum electrode, and a simple titration cell. Several commonly used radiopharmaceutical kits were analyzed for their Sn(II) content using this method. These studies indicate that the procedure can be used, as a routine quantitative test for the Sn(II) content of various sup(99m)Tc-labeled radiopharmaceuticals. (orig.)

Process for preparing radiopharmaceuticals

International Nuclear Information System (INIS)

Barak, M.; Winchell, H.S.

1977-01-01

A process for the preparation of technetium-99m labeled pharmaceuticals is disclosed. The process comprises initially isolating technetium-99m pertechnetate by adsorption upon an adsorbent packing in a chromatographic column. The technetium-99m is then eluted from the packing with a biological compound to form a radiopharmaceutical

The ARPANSA quality assurance program for radiopharmaceuticals

International Nuclear Information System (INIS)

Baldas, J.; Ivanov, Z.

2003-01-01

Full text: The Australian Radiation Protection and Nuclear Safety Agency (ARPANSA) conducts a radiopharmaceutical quality assurance test program in which radiopharmaceuticals used in nuclear medicine in Australia are tested for compliance with specifications. Where the radiopharmaceutical is the subject of a monograph in the British Pharmacopoeia or the European Pharmacopoeia, then the specifications given in these Pharmacopoeias are adopted. Where a monograph is only available in the US Pharmacopoeia, then this specification is generally adopted. In other cases the specifications quoted have been adopted by this Agency. Animal biodistribution testing was discontinued in 1997 due to resource limitation. Samples for testing were obtained through commercial channels. All technetium-99m cold kits were reconstituted according to the directions in the package insert using Sodium Pertechnetate [ 99m Tc] injection. The results of testing conducted by the ARPANSA during 1984-1999 are summarised. A significant cause of failure to meet full specifications has been due to non-compliance of the vial/package labels. Copyright (2003) The Australian and New Zealand Society of Nuclear Medicine Inc

Intelligent portal monitor for fast suppression of false positives due to radiopharmaceuticals

International Nuclear Information System (INIS)

Johnson, M.W.; Butterfield, K.B.

1985-01-01

Monitoring the movement of radioactive material through secure or sensitive areas may be complicated by the existence of unanticipated sources of radiation carried by individuals passing through the area. Typical of such sources are radiopharmaceuticals prescribed for a medical procedure. We report here on an apparatus designed to quickly discriminate between in-vivo radiopharmaceuticals and other nuclear materials, based on a pattern-recognition algorithm and a microcomputer. Principles of operation are discussed, and the data base for the pattern-recognition algorithm is displayed. Operating experience with the apparatus in a trial location is also discussed. Our apparatus correctly identifies in-vivo radiopharmaceuticals in over 80% of all trials; challenges with radioisotopes other than radiopharmaceuticals have led the apparatus, without exception, to reject the challenge isotope as incompatible with medical practice. The apparatus thus rapidly discriminates between individuals bearing radiopharmaceuticals and those bearing illicit sources, such as special nuclear materials. Examples of applications are presented. 7 refs., 4 figs., 1 tab

Annual report 1994 of the Verein fuer Kernverfahrenstechnik und Analytik, Rossendorf

International Nuclear Information System (INIS)

Haefele, W.

1995-05-01

The annual report 1994 of the VKTA presents reports on the scientific and technical activities and the management activities, and an organigram. The scientific-technical activities focus on the subjects of nuclear facilities, nuclear waste management, radioactivity monitoring and analysis, site decontamination and rehabilititation, radiopharmaceuticals, and safety and radiological protection. (DG) [de

Synthesis of radiopharmaceuticals containing short-lived radionuclides: Comprehensive progress report, March 1, 1986-February 28, 1989

International Nuclear Information System (INIS)

Kabalka, G.W.

1988-06-01

The primary objective of the DOE Nuclear Medicine Program at The University of Tennessee is the creation of new methods for intoducing short-lived isotopes into agents for use in PET and SPECT. A portion of our effort is directed toward the design and in vivo quantitation of boron-containing neutron therapy agents. The uniqueness of the program is its focus on the design of new chemistry (molecular architecture) and technology as opposed to the application of known reactions to the synthesis of specific radiopharmaceuticals. The following topics are outlined in this paper: new isotope incorporation reactions utilizing nitrogen 13, oxygen 15, and carbon 11; technetium-boron complexes; boron-neutron-capture

Towards a harmonized radiopharmaceutical regulatory framework in Europe

International Nuclear Information System (INIS)

Decristoforo, A.; Penuelas, I.

2009-01-01

Despite European unification regarding a common legal framework for many aspects of pharmaceutical production including industrial manufacture of pharmaceuticals, the practice of pharmacy in general, and of radiopharmacy in particular, differs substantially and are mainly regulated at the national level. Herein the authors discuss major European documents relevant for radiopharmacy practice in Europe and recent developments on the national level especially regarding the small-scale preparation of radiopharmaceuticals (R P). Issues related to marketing authorization (and exemptions from it), standards of preparation, quality requirements, regulations of clinical trials and education will be outlined. Standards for the industrial preparation of pharmaceuticals are defined in Good Manufacturing Practice (GMP), not taking into account specific requirements for the small scale, extemporaneous preparation of R P. The European Association of Nuclear Medicine EANM has published several documents based on GMP and called Good Radiopharmaceutical Practice (cGRPP) to specifically address this in an attempt to harmonize R P preparation across Europe. Clinical trials have been hampered by the introduction of directive 2001/20/E C again aimed at the marketing track of industrial production and currently a number of activities are ongoing to counterbalance this problem in radiopharmaceutical research. Additionally, the role of the European Pharmacopoeia in regulating quality requirements and the need for specific education and training in the small scale radiopharmaceutical preparation are also discussed.

Radiation hygiene problems of radiopharmaceutical preparation at nuclear medicine units

International Nuclear Information System (INIS)

Pekarek, J.; Kukacka, R.

1977-01-01

The problems of magistral radiopharmaceuticals preparation are indicated and the layout of a unit for the magistral preparation of radiopharmaceuticals is described. The results are briefly reported of a study of radiation load of laboratory personnel preparing radiopharmaceuticals as against doctors actually applying them. It was found that the exposure of hands to ionizing radiation represents the highest hazard for the laboratory personnel. The most important radiation protection principles are pointed out, such as the use of protective clothing, regular preventive medical examinations, appropriately shielded radionuclides and radionuclide generators to be supplied by manufacturers, and a more frequent rotation of personnel working with active and nonactive preparations. (L.O.)

The radiopharmaceuticals labelled with technetium-99m and the radiopharmacy

International Nuclear Information System (INIS)

Bodenant, V.

1998-01-01

In less than fifty years, the place of nuclear medicine is become primordial. Among all the radiopharmaceuticals used in nuclear medicine, the technetium-99m is the most used because of its physico-chemical properties and its great availability with the molybdenum-99m - technetium-99m generator. Since 1992, the radiopharmaceuticals, the packages, the generators are included in the pharmaceutic monopole. They are now under the reliability of the radio-pharmacist. This thesis has for object to introduce these different radiopharmaceuticals labelled with technetium-99m and to show the primordial place of the radio-pharmacist in a service of nuclear medicine. (N.C.)

In vitro test for pyrogenes in radiopharmaceuticals

Energy Technology Data Exchange (ETDEWEB)

Jovanovic, V; Zmbova, B; Bzenic, J [Institut za Nuklearne Nauke Boris Kidric, Belgrade (Yugoslavia); Berkes, J [Institut za Biohemije, Belgrade (Yugoslavia)

1978-05-01

Procedure and results of determination of pyrogenic substances in radiopharmaceutical preparations by an in vitro method based on the reaction between bacterial endotoxine and Limulus Amebocyte Lysate are presented. The advantage of this method as compared to the test in experimental animals performed so far has also been analyzed and proved by the fact that it enables avoidance of introduction of radioactive materials in experimental animals and of radiation effects on the results obtained in efficiency studies. The in vitro method is a quick one and requires only small quantities of the radiopharmaceutical preparation to be examined.

Development of new radiopharmaceuticals

International Nuclear Information System (INIS)

1989-12-01

The possibilities to design and prepare better and more organ-specific radiopharmaceuticals for diagnostic nuclear medicine has increased dramatically in the recent past with a deeper understanding of the relationships between chemical structure and biological activity. Whereas most of the research is performed in well-funded laboratories of industrialized countries, there are several developing countries with adequate resources and expertise as to undertake fruitful research in the field of radiopharmacy. With the aim of promoting advanced research in radiopharmacy by developing new radiodiagnostics agents, in particular, hepatobiliary imaging agents labelled with 99m Tc, and to facilitate exchange of information, the IAEA has established in 1983 the present Research Co-ordination Programme (CRP) with a duration of five years. The report includes detailed results obtained by all participants as well as novel preparation procedures for some of the newest and more promising radiopharmaceuticals developed under the auspices of the CRP. The extensive bibliographic reference listing is considered another important information of particular value for scientists in developing countries who do not always have access to updated scientific information sources. Refs, figs and tabs

Knowledge-based automated radiopharmaceutical manufacturing for Positron Emission Tomography

International Nuclear Information System (INIS)

Alexoff, D.L.

1991-01-01

This article describes the application of basic knowledge engineering principles to the design of automated synthesis equipment for radiopharmaceuticals used in Positron Emission Tomography (PET). Before discussing knowledge programming, an overview of the development of automated radiopharmaceutical synthesis systems for PET will be presented. Since knowledge systems will rely on information obtained from machine transducers, a discussion of the uses of sensory feedback in today's automated systems follows. Next, the operation of these automated systems is contrasted to radiotracer production carried out by chemists, and the rationale for and basic concepts of knowledge-based programming are explained. Finally, a prototype knowledge-based system supporting automated radiopharmaceutical manufacturing of 18FDG at Brookhaven National Laboratory (BNL) is described using 1stClass, a commercially available PC-based expert system shell

188Re(V) Nitrido Radiopharmaceuticals for Radionuclide Therapy.

Science.gov (United States)

Boschi, Alessandra; Martini, Petra; Uccelli, Licia

2017-01-19

The favorable nuclear properties of rhenium-188 for therapeutic application are described, together with new methods for the preparation of high yield and stable 188 Re radiopharmaceuticals characterized by the presence of the nitride rhenium core in their final chemical structure. 188 Re is readily available from an 188 W/ 188 Re generator system and a parallelism between the general synthetic procedures applied for the preparation of nitride technetium-99m and rhenium-188 theranostics radiopharmaceuticals is reported. Although some differences between the chemical characteristics of the two metallic nitrido fragments are highlighted, it is apparent that the same general procedures developed for the labelling of biologically active molecules with technetium-99m can be applied to rhenium-188 with minor modification. The availability of these chemical strategies, that allow the obtainment, in very high yield and in physiological condition, of 188 Re radiopharmaceuticals, gives a new attractive prospective to employ this radionuclide for therapeutic applications.

188Re(V) Nitrido Radiopharmaceuticals for Radionuclide Therapy

Science.gov (United States)

Boschi, Alessandra; Martini, Petra; Uccelli, Licia

2017-01-01

The favorable nuclear properties of rhenium-188 for therapeutic application are described, together with new methods for the preparation of high yield and stable 188Re radiopharmaceuticals characterized by the presence of the nitride rhenium core in their final chemical structure. 188Re is readily available from an 188W/188Re generator system and a parallelism between the general synthetic procedures applied for the preparation of nitride technetium-99m and rhenium-188 theranostics radiopharmaceuticals is reported. Although some differences between the chemical characteristics of the two metallic nitrido fragments are highlighted, it is apparent that the same general procedures developed for the labelling of biologically active molecules with technetium-99m can be applied to rhenium-188 with minor modification. The availability of these chemical strategies, that allow the obtainment, in very high yield and in physiological condition, of 188Re radiopharmaceuticals, gives a new attractive prospective to employ this radionuclide for therapeutic applications. PMID:28106830

Design of radiopharmaceuticals for monitoring gene transfer therapy

International Nuclear Information System (INIS)

Lambrecht, R.M.; Staehler, P.; Kley, J.; Spiegel, M.; Gross, C.; Graepler, F.T.C.; Gregor, M.; Lauer, U.; Oberdorfer, F.

1998-01-01

The development of radiopharmaceuticals for monitoring gene transfer therapy with emission tomography is expected to lead to improved management of cancer by the year 2010. There are now only a few examples and approaches to the design of radiopharmaceuticals for gene transfer therapy. This paper introduces a novel concept for the monitoring of gene therapy. We present the optimisation of the labelling of recombinant human β-NGF ligands for in vitro studies prior to using 123 I for SPET and 124 I for PET studies. (author)

Peptide radiopharmaceuticals in nuclear medicine

International Nuclear Information System (INIS)

Blok, D.; Vermeij, P.; Feitsma, R.I.J.; Pauwels, E.J.K.

1999-01-01

This article reviews the labelling of peptides that are recognised to be of interest for nuclear medicine or are the subject of ongoing nuclear medicine research. Applications and approaches to the labelling of peptide radiopharmaceuticals are discussed, and drawbacks in their development considered. (orig.)

Fuel Chemistry Division annual progress report for 1990

International Nuclear Information System (INIS)

Vaidyanathan, R.

1993-01-01

The progress report gives brief descriptions of the various activities of the Fuel Chemistry Division of Bhabha Atomic Research Centre, Bombay for the year 1990. The descriptions of activities are arranged under the headings: Fuel Development Chemistry, Chemistry of Actinides, Quality Control of Nuclear Fuels, and studies related to Nuclear Materials Accounting. At the end of the report, a list of papers published in journals and presented at various conferences/symposia is also given. (author). 7 figs., 52 tabs

An intelligent portal monitor for fast suppression of false positives due to radiopharmaceuticals

International Nuclear Information System (INIS)

Johnson, M.W.; Butterfield, K.B.

1985-01-01

Monitoring the movement of radioactive material through secure or sensitive areas may be complicated by the existence of unanticipated sources of radiation carried by individuals passing through the area. Typical of such sources are radiopharmaceuticals prescribed for a medical procedure. The authors report here on an apparatus designed to quickly discriminate between in-vivo radiopharmaceuticals and other nuclear materials, based on a pattern-recognition algorithm and microcomputer. Principles of operation are discussed, and the data base for the pattern-recognition algorithms is displayed. Operating experience with the apparatus in a trial location is also discussed. The apparatus correctly identifies in-vivo radiopharmaceuticals in over 80% of all trials; challenges with radioisotopes other than radiopharmaceuticals have led the apparatus, without exception, to reject the challenge isotope as incompatible with medical practice. The apparatus thus rapidly discriminates between individuals bearing radiopharmaceuticals and those bearing illicit sources, such as special nuclear materials

Radiopharmaceuticals good practices handbook: ARCAL XV radiopharmaceuticals control and production; Manual de buenas practicas radiofarmaceuticas: ARCAL XV produccion y control de radiofarmacos

Energy Technology Data Exchange (ETDEWEB)

Verdera Presto, Silvia [comp.; Universidad de la Republica, Facultad de ciencias, Centro de Investigaciones Nucleares, Montevideo (Uruguay)

1999-12-31

A safety practice of the therapeutics diagnostic proceeding in nuclear medicine require a permanent provide high quality radiopharmaceuticals manufacture. This work treat to give a guide for all radio pharmacies laboratories that produce,control, fraction and or dispense radiopharmaceuticals products, with attention hospitable radiopharmacy laboratory. Three chapters with recommendations in manufacture good practice in Hospital radiopharmacy, industrial centralized, bibliography and three annexe`s about clean area classification,standards work in laminar flux bell, and guarantee and cleaning areas

Leading safety performance indicators for resilience assessment of radiopharmaceuticals production process

International Nuclear Information System (INIS)

Grecco, Claudio H.S.; Santos, Isaac J.A.L.; Carvalho, Paulo V.R.

2011-01-01

Radiopharmaceuticals are radiation-emitting substances used in medicine for radiotherapy and imaging diagnosis. A Research Institute, located in Rio de Janeiro, produces three radiopharmaceuticals: the sodium iodate is used in the diagnosis of thyroid dysfunctions, the meta-iodo-benzyl guanidine is used in the diagnosis of cardiac diseases, and the fluorodeoxyglucose is used in diagnosis in cardiology, oncology, neurology and neuro psychiatry. This paper presents a leading safety performance indicators framework to assess the resilience of radiopharmaceuticals production processes. The organizations that use resilience indicators will be able to pro actively evaluate and manage safety. (author)

Leading safety performance indicators for resilience assessment of radiopharmaceuticals production process

Energy Technology Data Exchange (ETDEWEB)

Grecco, Claudio H.S.; Santos, Isaac J.A.L.; Carvalho, Paulo V.R., E-mail: grecco@ien.gov.b, E-mail: luquetti@ien.gov.b, E-mail: paulov@ien.gov.b [Instituto de Engenharia Nuclear (IEN/CNEN-RJ), Rio de Janeiro, RJ (Brazil). Div. de Instrumentacao e Confiabilidade Humana; Vidal, Mario C.R., E-mail: mvidal@ergonomia.ufrj.b [Coordenacao dos Programas de Pos-Graduacao de Engenharia (PEP/COPPE/UFRJ), Rio de Janeiro, RJ (Brazil). Programa de Engenharia de Producao. Grupo de Ergonomia e Novas Tecnologias (GENTE)

2011-07-01

Radiopharmaceuticals are radiation-emitting substances used in medicine for radiotherapy and imaging diagnosis. A Research Institute, located in Rio de Janeiro, produces three radiopharmaceuticals: the sodium iodate is used in the diagnosis of thyroid dysfunctions, the meta-iodo-benzyl guanidine is used in the diagnosis of cardiac diseases, and the fluorodeoxyglucose is used in diagnosis in cardiology, oncology, neurology and neuro psychiatry. This paper presents a leading safety performance indicators framework to assess the resilience of radiopharmaceuticals production processes. The organizations that use resilience indicators will be able to pro actively evaluate and manage safety. (author)

Annual report of the Osaka Laboratory for Radiation Chemistry, Japan Atomic Energy Research Institute, No. 29. April 1, 1995 - March 31, 1996

International Nuclear Information System (INIS)

1997-03-01

The annual research activities of the Osaka Laboratory for Radiation Chemistry, JAERI, during the fiscal year 1995, are reported. The research activities were conducted under two research programs: the study on laser-induced organic chemical reactions and the study on basic radiation technology for functional materials. Detailed description of the activities are presented as reviews on the following subjects: laser-induced chemical transformation, laser-induced reaction of polymer surface, photochemical separation of stable isotopes, microprocessing by radiation-induced polymerization, preparation of fine metal particles by gamma-ray irradiation, and electron beam dosimetry. The operation report of the irradiation facility is also included. In October 1995, the Osaka Laboratory was dissolved into the Kansai Research Establishment which was newly inaugurated to promote advanced photon research. Therefore, this is the final issue of the annual report of the Osaka Laboratory for Radiation Chemistry. (author)

Evaluation of 4-[18F]fluoro-1-butyne as a radiolabeled synthon for click chemistry with azido compounds

International Nuclear Information System (INIS)

Kim, Dong Hyun; Choe, Yearn Seong; Kim, Byung-Tae

2010-01-01

Click chemistry is a useful approach for the preparation of novel radiopharmaceuticals. In this study, we evaluated 4-[ 18 F]fluoro-1-butyne as a radiolabeled synthon for click chemistry with azido compounds. Our results showed that nucleophilic substitution of 4-tosyloxy-1-butyne with K[ 18 F]F produces vinyl acetylene as well as 4-[ 18 F]fluoro-1-butyne, while the same reaction using 5-tosyloxy-1-pentyne gives exclusively 5-[ 18 F]fluoro-1-pentyne. Thus, ω-[ 18 F]fluoro-1-alkynes with chain lengths longer than four carbons may be better radiolabeled synthons for use in click chemistry.

Drug interactions with radiopharmaceuticals

International Nuclear Information System (INIS)

Hesslewood, S.; Leung, E.

1994-01-01

Considerable information on documented drug and radiopharmaceutical interactions has been assembled in a tabular form, classified by the type of nuclear medicine study. The aim is to provide a rapid reference for nuclear medicine staff to look for such interactions. The initiation of drug chart monitoring or drug history taking of nuclear medicine patients and the reporting of such events are encouraged. (orig.)

The transport of radiopharmaceuticals in the United States

International Nuclear Information System (INIS)

Ferate, F.D.

2004-01-01

Among all the various uses of radioactive materials for peaceful purposes, the creation and use of radiopharmaceuticals to diagnose and treat medical ailments has probably brought the greatest benefit to humanity. The use of radionuclides in medicine has mushroomed over the past 20 years, as has the number of nuclides and procedures which are now routinely used in hospitals and clinics around the globe. Parallel to the growth in the use of radiopharmaceuticals has been the growth in shipments of these nuclides and their compounds to the locations where they are used

New radiopharmaceuticals currently used in clinical nuclear medicine

International Nuclear Information System (INIS)

Hladik, W.B. III

1997-01-01

During 1996 and 1997, six new radiopharmaceuticals have been approved by the U.S. Food and Drug Administration for use in the diagnosis and/or management of patients with various disease states. Four of these new agents are antibody-based diagnostic radiotracers, and one is a therapeutic agent. One radio-pharmaceutical that has been available for several years has been approved for a new, unique indication. Our discussion focuses on the physicochemical and pharmacokinetic properties of these recently released agents as well as their specific role in the management of patients

The transport of radiopharmaceuticals in the United States

Energy Technology Data Exchange (ETDEWEB)

Ferate, F.D. [U. S. Dept. of Transportation, Washington, DC (United States)

2004-07-01

Among all the various uses of radioactive materials for peaceful purposes, the creation and use of radiopharmaceuticals to diagnose and treat medical ailments has probably brought the greatest benefit to humanity. The use of radionuclides in medicine has mushroomed over the past 20 years, as has the number of nuclides and procedures which are now routinely used in hospitals and clinics around the globe. Parallel to the growth in the use of radiopharmaceuticals has been the growth in shipments of these nuclides and their compounds to the locations where they are used.

Determination of Sn in 99{sup m}Tc Radiopharmaceutical Kits by Polarographic Methods; Determinacion de Estano en Radiofarmacos de 99{sup m}Tc mediante Metodos Polarograficos

Energy Technology Data Exchange (ETDEWEB)

Castro, M; Cruz, J; Sanchez, M

2009-07-01

Kits of 99{sup m}Tc radiopharmaceuticals are used in nuclear medicine for diagnosis of different diseases. Sn (II) is one of the essential components in their formulations, which is used for reduction 99{sup m}Tc-pertechnetate in cold kits for on-site preparation 99{sup m}Tc-pertechnetate radiopharmaceuticals. Usually, these cold kits contain different additives (complexing agents, antioxidants, buffers, etc.) and the amount of Sn (II) varies from kit to kit. The determination of Sn in these products is essential in assessing their quality. We report here the development of a new polarographic method for the determination of Sn (II) and total Sn in representative radiopharmaceuticals kits (for the content of Sn and chemical composition) produced at the Center of Isotopes of Cuba (CENTIS). These methods were validated by analysis of variance and recovery techniques. From the results of the validation, the characteristic functions of uncertainties and fits are considered for the established methods, which give the necessary evidences to demonstrate the usefulness of these methods according to the current trends in Analytical Chemistry. This work provides practical results of great importance for CENTIS. After the speciation of Sn in the MAG3 radiopharmaceuticals kit is inferred that the production process is affected by uncontrolled factors that influence in the product stability, which demonstrates the necessity for analytical tools for the characterization of products and processes. (Author) 57 refs.

Fuel Chemistry Division annual progress report for 1989

International Nuclear Information System (INIS)

Singh Mudher, K.D.

1993-01-01

The progress report gives a brief description of the various activities of the Fuel Chemistry Division of Bhabha Atomic Research Centre, Bombay for the year 1989. The descriptions of activities are arranged under the headings: Fuel Development Chemistry, Chemical Quality Control, Chemistry of Actinides, Sol-Gel process for the non Nuclear Ceramics and Studies related to Nuclear Material Accounting.At the end of the report, a list of papers published in journals and presented at various conferences/symposia is also given. (author). 69 tabs., 6 figs

Ensuring quality while going local: IAEA helps Cuba produce radiopharmaceuticals

International Nuclear Information System (INIS)

Jawerth, Nicole

2015-01-01

Cancer and cardiovascular disease are health conditions Cuba will now be able to more readily diagnose and treat thanks to its newly built facility for producing key radiopharmaceuticals. Nuclear medicine requires a constant and reliable supply of these radioactive drugs, prepared according to what the industry calls good manufacturing practices (GMP), and there have so far been limitations in getting them to the island nation. “Through our work with the IAEA, we now have a dedicated GMP compliant facility and the expertise to meet most of our national needs for diagnostic and therapeutic radiopharmaceuticals for helping patients,” said René Leyva Montaña, Director of Production at the Isotope Centre (CENTIS), Cuba’s centre dedicated to radiopharmaceutical production.

Radiopharmaceuticals for diagnosis

International Nuclear Information System (INIS)

Kuhl, D.E.

1990-06-01

During this grant period 1 January 1988--31 December 1990, we have successfully developed a number of new approaches to fluorine-18 labeled compounds, prepared several new radiotracers for both animal studies and eventual clinical trials, and explored the utility of a high-quality industrial robot in radiopharmaceutical applications. The progress during the last grant period is summarized briefly in the following sections. Publications arising from this research are listed below and can be found in Appendix I. 1 fig

Chemistry Division annual progress report for period ending January 31, 1984

Energy Technology Data Exchange (ETDEWEB)

1984-05-01

Progress is reported in the following fields: coal chemistry, aqueous chemistry at high temperatures and pressures, geochemistry, high-temperature chemistry and thermodynamics of structural materials, chemistry of transuranium elements and compounds, separations chemistry, elecrochemistry, catalysis, chemical physics, theoretical chemistry, nuclear waste chemistry, chemistry of hazardous chemicals, and thermal energy storage.

Preparation of radiopharmaceutical formulations; Fremstilling av radioaktive farmasoeytiske blandinger

Energy Technology Data Exchange (ETDEWEB)

Simon, J.; Garlich, J.R.; Frank, R.K.; McMillan, K

1998-03-16

Radiopharmaceutical formulations for complexes comprising at least one radionuclide complexed with a ligand, or its physiologically-acceptable salts thereof, especially {sup 153}samarium-ethylenediaminetetramethylenephosphonic acid, which optionally contains a divalent metal ion, e.g. calcium, and is frozen, thawed, and then administered by injection. Alternatively, the radiopharmaceutical formulations must contain the divalent metal and are frozen only if the time before administration is sufficiently long to cause concern for radiolysis of the ligand. 2 figs., 9 tabs.

Recent radiopharmaceutical research at the AAEC Research Establishment

International Nuclear Information System (INIS)

Wilson, J.G.; Boyd, R.E.

1985-12-01

During the past few years a large part of the radiochemical research carried out at Lucas Heights has been devoted to the synthesis of ligands capable of forming chelate complexes with technetium-99m, as part of a search for tumour-localising radiopharmaceuticals. An account is given of the synthesis and biological evaluation of a range of these compounds and of the investigation of certain biochemical and biological properties affecting the clinical application of both ligands and radiopharmaceuticals. In addition to the search for novel Tc-99m radiopharmaceuticals, major research programs on the development of Tc-99m generating systems have been in progress at Lucas Heights for several years. Work on the AAEC's Mark III Tc-99m technetium generator has been brought to a successful conclusion. A new type of Tc-99m generator, which uses an insoluble zirconium molybdate gel and provides high yields of pertechnetate by a simple elution technique, has also been developed. Studies are in progress on the osmium-iridium generator

Design of GMP compliance radiopharmaceutical production facility in MINT

International Nuclear Information System (INIS)

Anwar Abd Rahman; Shaharum Ramli; M Rizal Mamat Ibrahim; Rosli Darmawan; Yusof Azuddin Ali; Jusnan Hashim

2005-01-01

In 1985, MINT built the only radiopharmaceutical production facility in Malaysia. The facility was designed based on IAEA (International Atomic Energy Agency) standard guidelines which provide radiation safety to the staff and the surrounding environment from radioactive contamination. Since 1999, BPFK (Biro Pengawalan Farmaseutikal Kebangsaan) has used the guidelines from Pharmaceutical Inspection Convention Scheme (PICS) to meet the requirements of the Good Manufacturing Practice (GMP) for Pharmaceutical Products. In the guidelines, the pharmaceutical production facility shall be designed based on clean room environment. In order to design a radiopharmaceutical production facility, it is important to combine the concept of radiation safety and clean room to ensure that both requirements from GMP and IAEA are met. The design requirement is necessary to set up a complete radiopharmaceutical production facility, which is safe, has high production quality and complies with the Malaysian and International standards. (Author)

Isotope and Nuclear Chemistry Division annual report, FY 1983

International Nuclear Information System (INIS)

Heiken, J.H.; Lindberg, H.A.

1984-05-01

This report describes progress in the major research and development programs carried out in FY 1983 by the Isotope and Nuclear Chemistry Division. It covers radiochemical diagnostics of weapons tests; weapons radiochemical diagnostics research and development; other unclassified weapons research; stable and radioactive isotope production, separation, and applications (including biomedical applications); element and isotope transport and fixation; actinide and transition metal chemistry; structural chemistry, spectroscopy, and applications; nuclear structure and reactions; irradiation facilities; advanced analytical techniques; development and applications; atmospheric chemistry and transport; and earth and planetary processes

Isotope and Nuclear Chemistry Division annual report, FY 1983

Energy Technology Data Exchange (ETDEWEB)

Heiken, J.H.; Lindberg, H.A. (eds.)

1984-05-01

This report describes progress in the major research and development programs carried out in FY 1983 by the Isotope and Nuclear Chemistry Division. It covers radiochemical diagnostics of weapons tests; weapons radiochemical diagnostics research and development; other unclassified weapons research; stable and radioactive isotope production, separation, and applications (including biomedical applications); element and isotope transport and fixation; actinide and transition metal chemistry; structural chemistry, spectroscopy, and applications; nuclear structure and reactions; irradiation facilities; advanced analytical techniques; development and applications; atmospheric chemistry and transport; and earth and planetary processes.

Isotope and Nuclear Chemistry Division annual report, FY 1984

International Nuclear Information System (INIS)

Heiken, J.H.

1985-04-01

This report describes progress in the major research and development programs carried out in FY 1984 by the Isotope and Nuclear Chemistry Division. It covers radiochemical diagnostics of weapons tests; weapons radiochemical diagnostics research and development; other unclassified weapons research; stable and radioactive isotope production, separation, and applications (including biomedical applications); element and isotope transport and fixation; actinide and transition metal chemistry; structural chemistry, spectroscopy, and applications; nuclear structure and reactions; irradiation facilities; advanced analytical techniques: development and applications; atmospheric chemistry and transport; and earth and planetary processes. 287 refs

Radioisotope requirements and usage in the radiopharmaceutical industry

International Nuclear Information System (INIS)

Langton, M.A.

1995-01-01

Radioisotopes are used extensively in many different productive and beneficial human endeavors. Amersham International, a U.K.-based company originating in the British Scientific Civil Service during World War II, has been actively involved in many of these activities for more than 50 yr. Today they are one of the world's largest suppliers of radioactive compounds and scaled radiation sources for use in industrial quality and safety assurance, life science research, and medicine. This paper outlines one of these applications: the use of radioisotopes as radiopharmaceuticals. Radiopharmaceuticals are radioactive nuclides and labeled compounds that have been developed for the diagnosis and treatment of (human) disease. They are manufactured via highly controlled processes and have gone through regulatory scrutiny and approval far in excess of other radioisotopes used in other applications. Radiopharmaceuticals can be conveniently split into two categories. One type is simply an active analog that mimics the physiological behavior of its inactive counterpart in the body. The other involves an actual pharmacological compound that exhibits the desired physiological behavior, which is then labeled with a radionuclide suitable for either imaging or the delivery of a therapeutic radiation dose as appropriate but which plays no part in the mechanism of action of the drug. The latter type, which is the more common of the two, can be supplied either as an active compounded product or as a open-quotes cold kit,close quotes which is then labeled with the appropriate radiopharmaceutical-grade radionuclide to yield the final product

The WFNMB Survey on the Introduction of New Radiopharmaceuticals for Clinical Research: Snapshot of the international perspective

International Nuclear Information System (INIS)

Jeong, J.M.; Choe, Y.S.; Knapp, F.F. Jr.

2007-01-01

Development of new radiopharmaceuticals and their introduction into clinical trials ensures continuing improvement in the practice of nuclear medicine. Although it is crucial that safety and efficacy are established prior to use in humans, the characteristics of radiopharmaceuticals are quite different from other drugs since these agents are generally administered in trace, sub-pharmacological amounts. Diagnostic and therapeutic radiopharmaceutical agents are used only in restricted and controlled areas and are administered only by trained personnel. In many cases - as often for PET -- such diagnostic agents are often used in the same institution where they are prepared. Thus, regulations for the preparation and use of radiopharmaceuticals should be different from other drugs. To evaluate the current status of radiopharmaceutical regulations, we surveyed radiopharmaceutical experts and nuclear medicine societies on an international basis. A questionnaire was provided which focused on the regulations required for the in-house non-commercial preparation of new radiopharmaceutical for routine clinical use or for use in clinical trials. Responses were received from participants in 36 countries. Although both government and institutional approval are required for introduction of new radiopharmaceuticals in the majority of countries, some countries require only institutional approval. In the case of therapeutic radiopharmaceuticals, as may be expected, only physician responsibility is more often required compared with similar approval for use of diagnostic agent in these settings. The requirement of current Good Manufacturing Practice (cGMP) for PET agents was higher than with the other agents. This preponderance of cGMP requirements may be interpreted as much higher than may be expected, since many PET radiopharmaceuticals are used in-house and are prepared in the hospital by pharmaceutical compounding and not by manufacturing. Compounding is not regulated by c

EEC directives and guidelines applicable to radiopharmaceuticals - 1993

International Nuclear Information System (INIS)

Cox, P.H.

1993-01-01

The manufacture, scale and supply of radiopharmaceuticals in the EEC is regulated by directives that are incorporated into the national laws of the member states. The situation as of 1 January 1993 was not too optimistic, however, as the processing of licensing applications had been completely misjudged. Not one product had been registered as of 1 January. The costs involved are also high and since the European market for radiopharmaceuticals is relatively small, the market cannot afford this. It would appear that the EEC directives are inadquate and too non-specific, so revision is indicated. (orig.)

The role of high performance liquid chromatography in radiochemical/radiopharmaceutical synthesis and quality assurance

International Nuclear Information System (INIS)

Boothe, T.E.; Emran, A.M.

1990-01-01

The usefulness of HPLC in all areas of radiopharmaceutics has been demonstrated in numerous laboratories, particularly in the development of in-house radiopharmaceuticals for SPECT and PET. HPLC continues to be a powerful tool in preparation and quality assurance (QA) as illustrated in such areas as chemical and radiochemical identification; product separation and isolation; preparative scale purification; and specific activity determination. A review of established HPLC techniques in radiopharmaceutics will be presented. Examples from the literature as well as newer applications will be used in an attempt to assess and define the present-day role of HPLC in the preparation of radiochemicals and radiopharmaceuticals with emphasis on QA

Chemistry Division annual progress report for period ending July 31, 1981

International Nuclear Information System (INIS)

1982-01-01

Research is reported on: chemistry of coal liquefaction, aqueous chemistry at high temperatures, geosciences, high-temperature chemistry and thermodynamics of structural materials, chemistry of TRU elements and compounds, separations chemistry, electrochemistry, nuclear waste chemistry, chemical physics, theoretical chemistry, inorganic chemistry of hydrogen cycles, molten salt systems, and enhanced oil recovery. Separate abstracts were prepared for the sections dealing with coal liquefaction, TRU elements and compounds, separations, nuclear wastes, and enhanced oil recovery

Chemistry Division annual progress report for period ending July 31, 1981

Energy Technology Data Exchange (ETDEWEB)

1982-01-01

Research is reported on: chemistry of coal liquefaction, aqueous chemistry at high temperatures, geosciences, high-temperature chemistry and thermodynamics of structural materials, chemistry of TRU elements and compounds, separations chemistry, electrochemistry, nuclear waste chemistry, chemical physics, theoretical chemistry, inorganic chemistry of hydrogen cycles, molten salt systems, and enhanced oil recovery. Separate abstracts were prepared for the sections dealing with coal liquefaction, TRU elements and compounds, separations, nuclear wastes, and enhanced oil recovery. (DLC)

Water chemistry, seepage investigation, streamflow, reservoir storage, and annual availability of water for the San Juan-Chama Project, northern New Mexico, 1942-2010

Science.gov (United States)

McKean, Sarah E.; Anderholm, Scott K.

2014-01-01

The Albuquerque Bernalillo County Water Utility Authority supplements the municipal water supply for the Albuquerque metropolitan area, in central New Mexico, with surface water diverted from the Rio Grande. The U.S. Geological Survey, in cooperation with the Albuquerque Bernalillo County Water Utility Authority, undertook this study in which water-chemistry data and historical streamflow were compiled and new water-chemistry data were collected to characterize the water chemistry and streamflow of the San Juan-Chama Project (SJCP). Characterization of streamflow included analysis of the variability of annual streamflow and comparison of the theoretical amount of water that could have been diverted into the SJCP to the actual amount of water that was diverted for the SJCP. Additionally, a seepage investigation was conducted along the channel between Azotea Tunnel Outlet and the streamflow-gaging station at Willow Creek above Heron Reservoir to estimate the magnitude of the gain or loss in streamflow resulting from groundwater interaction over the approximately 10-mile reach. Generally, surface-water chemistry varied with streamflow throughout the year. Streamflow ranged from high flow to low flow on the basis of the quantity of water diverted from the Rio Blanco, Little Navajo River, and Navajo River for the SJCP. Vertical profiles of the water temperature over the depth of the water column at Heron Reservoir indicated that the reservoir is seasonally stratified. The results from the seepage investigations indicated a small amount of loss of streamflow along the channel. Annual variability in streamflow for the SJCP was an indication of the variation in the climate parameters that interact to contribute to streamflow in the Rio Blanco, Little Navajo River, Navajo River, and Willow Creek watersheds. For most years, streamflow at Azotea Tunnel Outlet started in March and continued for approximately 3 months until the middle of July. The majority of annual streamflow

Chemistry Division annual progress report for period ending January 31, 1986

Energy Technology Data Exchange (ETDEWEB)

1986-05-01

This report has been indexed by 11 separate chapters. The subjects covered are: coal chemistry, aqueous chemistry at high temperatures and pressures, geochemistry, materials chemistry, chemistry of transuranium elements and compounds, separations chemistry, catalysis, electron spectroscopy, nuclear waste chemistry, heuristic modeling, and special topics. (PLG)

Chemistry Division annual progress report for period ending January 31, 1986

International Nuclear Information System (INIS)

1986-05-01

This report has been indexed by 11 separate chapters. The subjects covered are: coal chemistry, aqueous chemistry at high temperatures and pressures, geochemistry, materials chemistry, chemistry of transuranium elements and compounds, separations chemistry, catalysis, electron spectroscopy, nuclear waste chemistry, heuristic modeling, and special topics

Role of the tunisian central pharmacy in the import of radio-pharmaceutical products

International Nuclear Information System (INIS)

Souissi Jaziri, Camelia; Moulahi, L.

2013-01-01

In Tunisia the centralized organization of the medicine sector has a strategic and economic importance. It presents particular characteristics concerning the importation and the control of drugs. Tcp has a monopoly on the importation of drugs for the country, which enters in the state policy for the control of drug purchasing costs, their availability in different region of the country and their guarantee and quality. The Tcp has a crucial role in the availability of drugs and in the holding safety stock and strategic reserve of the imported pharmaceutical products, either for the public or private sector. The Tcp has to stock up medicaments, chemical and pharmaceutical products, objects of bandages, instruments, accessory tools and other supplies necessary for the human and veterinary medicine. The Tcp packages any specialized or not medicament and all other products or supplies. The Tcp provides medicaments and products entering within the framework of its task to different health groups and hospitals. The Tcp provides distributors, laboratories and pharmacies over the country. In Tunisia the import of radioisotopes used in the medical domain is attributed to the Tcp. The objective is to centralize purchases and to guarantee: the security, the availability as well as the traceability. The Tcp supply radiopharmaceutical products for diagnostic and therapy purposes according to an authorization delivered annually by the National Center of Radiation Protection (NCRP). An authorization of removal used at the customs allows the clearance of products at the level of the air freights by the transit service of the Tcp. Regarding the evolution of purchases of radio-pharmaceutical products, their importation remained stable during the last three years. Indeed, it is approximately around 1MDT annually (954 121 DT in 2010, 939 956 in 2011 and 1047 967 in 2012). Sources of supply are divided between 4 suppliers: International IBA-CISBIO (49.9 pour cent), COVIDIEN EX (TYCO

ANSTO. Annual Report 1992-1993

International Nuclear Information System (INIS)

1993-11-01

Significant events and achievements highlighted in the Annual Reports include: the Research Reactor Review, increase of external revenues by 12.5%, sales of Australian radioisotopes amounting to $8.5 M, regulatory approval for production of thallium-201 in National Medical Cyclotron, completion of first contracts with Wismut GmbH in Germany, production of a database of content of atmospheric particulate matter in air over NSW, word-wide licence agreement signed for further commercialization of blood clot radiopharmaceuticals, collaborative agreement signed with SURPAC Int. for development of geochemical speciation software, complete design of rings in HIFAR for silicon doping. ills., tabs

Fundamental molecular physics and chemistry. Radiological and Environmental Research Division annual report, October 1981-December 1982. Pt. 1

International Nuclear Information System (INIS)

1983-12-01

This document is the twelfth Annual Report of our Fundamental Molecular Physics and Chemistry Program. Scientifically, the work of the program deals with aspects of the physics and chemistry of molecules related to their interactions with photons, electrons, and other external agents. We chose these areas of study in view of our matic goals; that is to say, we chose them so that the eventual outcome of our work meets some of the needs of the US Department of Energy (DOE) and of other government agencies that support our research. First, we endeavor to determine theoretically and experimentally cross sections for electron and photon interactions with molecules, because those cross sections are indispensable for detailed microscopic analyses of the earliest processes of radiation action on any molecular substance, including biological materials. Those analyses in turn provide a sound basis for radiology and radiation dosimetry. Second, we study the spectroscopy of certain molecules and of small clusters of molecules because this topic is fundamental to the full understanding of atmospheric-pollutant chemistry

Fundamental molecular physics and chemistry. Radiological and Environmental Research Division annual report, October 1981-December 1982. Pt. 1

Energy Technology Data Exchange (ETDEWEB)

1983-12-01

This document is the twelfth Annual Report of our Fundamental Molecular Physics and Chemistry Program. Scientifically, the work of the program deals with aspects of the physics and chemistry of molecules related to their interactions with photons, electrons, and other external agents. We chose these areas of study in view of our matic goals; that is to say, we chose them so that the eventual outcome of our work meets some of the needs of the US Department of Energy (DOE) and of other government agencies that support our research. First, we endeavor to determine theoretically and experimentally cross sections for electron and photon interactions with molecules, because those cross sections are indispensable for detailed microscopic analyses of the earliest processes of radiation action on any molecular substance, including biological materials. Those analyses in turn provide a sound basis for radiology and radiation dosimetry. Second, we study the spectroscopy of certain molecules and of small clusters of molecules because this topic is fundamental to the full understanding of atmospheric-pollutant chemistry.

Radiopharmaceuticals - pattern and development and utilisation in India

International Nuclear Information System (INIS)

Iya, V.K.; Mani, R.S.

1990-01-01

The availability of research reactors at an early stage of India's Atomic Energy Programme led to developemental efforts in the field of radiopharmaceuticals. The use of several 125 I-labelled compounds like Rose-Bengal, hippuran, etc. for imaging has been replaced over the years by 99m Tc compounds; the final formulations are prepared at the hospital using generators and cold kits supplied by the Board of Radioisotope Technology. Parallel with the development of short-lived generators in radiopharmaceuticals came advances in imaging and instrumentation techniques, the scanners being replaced by sophisticated gamma cameras, with capabilities for tomography and computerisation. About 40 centres in India have the modern instrumentation and equipment needed for carrying out nuclear medicine procedures. Further growth of nuclear medicine centres in the country has, however, been limited by the need to import such advanced high cost instumentation not currently available from indigeneous sources. Regarding in-vitro radiopharmaceuticals, some RIA and IRMA kits and procedures have been developed. These include assay of T 3 , T 4 and TSH in the thyroid group of hormones. There are over a hundred and fifty medical laboratories carrying out RIA procedures. (author)

Radionuclides, radiotracers and radiopharmaceuticals for in vivo diagnosis

International Nuclear Information System (INIS)

Wiebe, L.I.

1984-01-01

Radioactive tracers for in vivo clinical diagnosis fall within a narrow, strictly-defined set of specifications in respect of their physical properties, chemical and biochemical characteristics, and medical applications. The type of radioactive decay and physical half-life of the radionuclide are immutable properties which, along with the demands of production and supply, limit the choice of radionuclides used in medicine to only a small fraction of those known to exist. In use, the biochemical and physiological properties of a radiotracer are dictated by the chemical form of the radionuclide. This chemical form may range from elemental, molecular or ionic, to complex compounds formed by coordinate or covalent bonding of the radionuclide to either simple organic or inorganic molecules, or complex macromolecules. Few of the radiotracers which are tested in model systems ever become radiopharmaceuticals in the strictest sense. Radionuclides, radiotracers and radiopharmaceuticals in use are reviewed. Drug legislation and regulations concerning drug manufacture, as well as hospital ethical constraints and legislation concerning unsealed sources of radiation must all be satisfied in order to translate a radiopharmaceutical from the laboratory to clinical use. (author)

Radionuclides, radiotracers and radiopharmaceuticals for in vivo diagnosis

Science.gov (United States)

Wiebe, Leonard I.

Radioactive tracers for in vivo clinical diagnosis fall within a narrow, strictly-defined set of specifications in respect of their physical properties, chemical and biochemical characteristics, and (approved) medical applications. The type of radioactive decay and physical half-life of the radionuclide are immutable properties which, along with the demands of production and supply, limit the choice of radionuclides used in medicine to only a small fraction of those known to exist. In use, the biochemical and physiological properties of a radiotracer are dictated by the chemical form of the radionuclide. This chemical form may range from elemental, molecular or ionic, to complex compounds formed by coordinate or covalent bonding of the radionuclide to either simple organic or inorganic molecules, or complex macromolecules. Few of the radiotracers which are tested in model systems ever become radiopharmaceuticals in the strictest sense. Radionuclides, radiotracers and radiopharmaceuticals in use are reviewed. Drug legislation and regulations concerning drug manufacture, as well as hospital ethical constraints and legislation concerning unsealed sources of radiation must all be satisfied in order to translate a radiopharmaceutical from the laboratory to clinical use.

Detection of endotoxins in radiopharmaceutical preparations. III. Limulus test assessment using radiopharmaceutical preparations; correlation with the rabbit pyrogen test

Energy Technology Data Exchange (ETDEWEB)

Cohen, Y; Bahri, F; Bruneau, J; Dubuis, M; Dubuis, N; Merlin, L; Michaud, T; Peysson, S

1986-01-01

Experiments using 17 radiopharmaceuticals containing known amounts of added endotoxin show that none of them inhibits the pyrogenic reaction of the rabbit. Gelation of the Limulus amoebocyte lysate (LAL) is inhibited by 4 of them: colloidal erbium 169Er citrate, colloidal rhenium 186Re sulfide, colloidal technetium /sup 99m/Tc (Re) sulfide for liver scintigraphy and the colloidal technetium /sup 99m/Tc (Re) sulfide for lymphography. This inhibition is cancelled, either by dilution or after neutral pH adjustment. Both controls were performed on 313 batches of various radiopharmaceuticals, 95% of results were identical (93% negative, 2% positive). The remaining 5% correspond to positive LAL tests vs negative rabbit tests on the same batches. No negative LAL test vs positive rabbit test was observed.

A short history of radiopharmaceutical research in Australia

International Nuclear Information System (INIS)

Baker, R.

1989-01-01

A brief summary is given of radiopharmaceuticals research carried out in Australia. Historically, a number of the larger hospital radiopharmacies have been, and still are, involved with 99m Tc-cold kit production. Originally, this scenario evolved because the nuclear medicine community was denied access to state-of-the-art products available overseas. Although the situation has improved in recent times, most such departments continue kit production, having made a large capital investment in sterile facilities, equipment and staff. Australian Nuclear Science and Technology Organization has a leading role in radiopharmaceutical research and some of the topics which have occupied its scientists over the last few years are outlined

Recent developments in the field of 123I-radiopharmaceuticals

International Nuclear Information System (INIS)

Machulla, H.J.; Knust, E.J.

1984-01-01

Due to its advantageous nuclear physical properties iodine-123 is an excellent label for radiopharmaceuticals very well suited for measurements by γ-cameras and single-photon emission tomography. The development of 123 I-radiopharmaceuticals should be based on a clear biochemical concept, reliable labelling procedures and careful pharmacokinetic studies in order to evaluate the physiological behaviour of the radioiodinated compounds being analogues of metabolic substrates. The development of 123 I-labelled fatty acids and biogenic amines clearly proved the successful use of 123 I for labelling compounds applied in medical diagnosis. (orig.) [de

Depyrogenation, sterilization and deproteination of radiopharmaceuticals with an ultrafilter

Energy Technology Data Exchange (ETDEWEB)

Suzuki, K; Tamate, K; Nakayama, T [National Inst. of Radiological Sciences, Chiba (Japan)

1984-01-01

A newly developed filter holder is described for an ultrafiltration method used in the removal of pyrogen, enzyme and bacteria in the preparation of intravenously injectable radiopharmaceuticals. Penetration ratios of bovine serum albumin, glutamate dehydrogenase and Escherichia coli endotoxin through the PTGC ultrafilter (NMWL = 10,000) were measured; these results are useful for estimating penetration ratios of other macromolecules. Attempts to obtain i.v. injectable /sup 13/NH, L- /sup 13/N-glutamate and 3- /sup 123/I-iodotyrosine radiopharmaceuticals were successful; after ultrafiltration, pyrogen, bacteria or protein were not detected.

Calibration and qualification of equipment in the pharmaceutical industry: emphasis on radiopharmaceuticals production

International Nuclear Information System (INIS)

Melero, Laura T.U.H.; Silva, Katia S. da S.; Zanette, Camila; Araujo, Elaine B. de; Mengatti, Jair

2011-01-01

The calibration and qualification of equipment are listed items in RDC number 17 of 2010 which refers about the Good Manufacturing Practice (GMP) of medicaments and RDC number 63 of 2009 which refers about GMP of Radiopharmaceuticals. Both are essential requirements since they are involved in process control to attend the regulatory criteria and are a key part of the validation process. The aim of this work is presenting the importance of calibration and qualification, and the routine use of equipment and facilities in industrial scale production of radiopharmaceuticals in the IPEN/CNEN. The radiopharmacy of IPEN is a pharmaceutical industry that produces radiopharmaceuticals for diagnosis and therapy. It was the pioneer institute in production of radioisotopes and radiopharmaceuticals in Brazil. Currently, 38 products are distributed to the nuclear medicine centers, including primary radioisotopes, labeled molecules and lyophilized reagents for labeling with technetium-99m. To fulfill the GMP requirements for quality assurance of products, several factors must be considered including infrastructure, equipment and raw materials beyond, obviously, the whole production process should be controlled until the release of the final product. Therefore, the calibration and verification of equipment, instruments and other appliances used in the production and quality control should be performed. A program of calibration, qualification and requalification of equipment used in production and quality control of radiopharmaceuticals is necessary for the validation of production processes and analytical methods, and should be established for quality assurance of produced radiopharmaceuticals. (author)

Calibration and qualification of equipment in the pharmaceutical industry: emphasis on radiopharmaceuticals production

Energy Technology Data Exchange (ETDEWEB)

Melero, Laura T.U.H.; Silva, Katia S. da S.; Zanette, Camila; Araujo, Elaine B. de; Mengatti, Jair [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil)

2011-07-01

The calibration and qualification of equipment are listed items in RDC number 17 of 2010 which refers about the Good Manufacturing Practice (GMP) of medicaments and RDC number 63 of 2009 which refers about GMP of Radiopharmaceuticals. Both are essential requirements since they are involved in process control to attend the regulatory criteria and are a key part of the validation process. The aim of this work is presenting the importance of calibration and qualification, and the routine use of equipment and facilities in industrial scale production of radiopharmaceuticals in the IPEN/CNEN. The radiopharmacy of IPEN is a pharmaceutical industry that produces radiopharmaceuticals for diagnosis and therapy. It was the pioneer institute in production of radioisotopes and radiopharmaceuticals in Brazil. Currently, 38 products are distributed to the nuclear medicine centers, including primary radioisotopes, labeled molecules and lyophilized reagents for labeling with technetium-99m. To fulfill the GMP requirements for quality assurance of products, several factors must be considered including infrastructure, equipment and raw materials beyond, obviously, the whole production process should be controlled until the release of the final product. Therefore, the calibration and verification of equipment, instruments and other appliances used in the production and quality control should be performed. A program of calibration, qualification and requalification of equipment used in production and quality control of radiopharmaceuticals is necessary for the validation of production processes and analytical methods, and should be established for quality assurance of produced radiopharmaceuticals. (author)

Enhanced radiosyntheses of [¹¹C]raclopride and [¹¹C]DASB using ethanolic loop chemistry.

Science.gov (United States)

Shao, Xia; Schnau, Paul L; Fawaz, Maria V; Scott, Peter J H

2013-01-01

To improve the synthesis and quality control of carbon-11 labeled radiopharmaceuticals, we report the fully automated loop syntheses of [¹¹C]raclopride and [¹¹C]DASB using ethanol as the only organic solvent for synthesis module cleaning, carbon-11 methylation, HPLC purification, and reformulation. Ethanolic loop chemistry is fully automated using a GE TRACERLab FX(C-Pro) synthesis module, and is readily adaptable to any other carbon-11 synthesis apparatus. Precursors (1 mg) were dissolved in ethanol (100 μL) and loaded into the HPLC loop. [¹¹C]MeOTf was passed through the HPLC loop and then the labeled products were purified by semi-preparative HPLC and reformulated into ethanolic saline. Both [¹¹C]raclopride (3.7% RCY; >95% RCP; SA=20831 Ci/mmol; n=64) and [¹¹C]DASB, both with (3.0% RCY; >95% RCP; SA=15152Ci/mmol; n=9) and without (3.0% RCY; >95% RCP; SA=10931 Ci/mmol; n=3) sodium ascorbate, have been successfully prepared using the described methodology. Doses are suitable for human use and the described methods are now employed for routine clinical production of both radiopharmaceuticals at the University of Michigan. Ethanolic loop chemistry is a powerful technique for preparing [¹¹C]raclopride and [¹¹C]DASB, and we are in the process of adapting it for other carbon-11 radiopharmaceuticals prepared in our laboratories ([¹¹C]PMP, [¹¹C]PBR28 etc.). Copyright © 2013 Elsevier Inc. All rights reserved.

Sterile kits for the preparation of radiopharmaceuticals: some basic quality control considerations

International Nuclear Information System (INIS)

Briner, W.H.

1975-01-01

Quality control concepts involved in the formulation of radiopharmaceutical kits, as well as all other radiopharmaceuticals, are meant to protect both the patients who receive these products and the practitioners of nuclear medicine who use these products in their practice. These concepts include the adequacy of site and facilities in which these products are formulated, the level of training and experience of personnel responsible for the formulation of the products, quality assurance procedures employed to monitor the acceptability of products, and, finally, a professional dedication to excellence in all these matters. The absence of any of these in a nuclear medicine or radiopharmaceutical program will result in almost certain disaster

Annual Report 2005

Energy Technology Data Exchange (ETDEWEB)

Michalik, J; Smulek, W; Godlewska-Para, E [eds.

2006-07-01

The Annual Report of the Institute of Nuclear Chemistry and Technology (Warsaw, Poland) describes the activities of the Institute in 2005. The document consist of four parts: (1) Radiation chemistry and physics, radiation technologies; (2) Radiochemistry, stable isotopes, nuclear analytical methods, general chemistry; (3) Radiobiology; (4) Nuclear technologies and methods. In total - 73 detailed papers prepared by the Institute workers and collaborating scientists are presented. General information on the Institute status, personnel activity and the international cooperation is also listed.

Annual Report 2005

International Nuclear Information System (INIS)

Michalik, J.; Smulek, W.; Godlewska-Para, E.

2006-01-01

The Annual Report of the Institute of Nuclear Chemistry and Technology (Warsaw, Poland) describes the activities of the Institute in 2005. The document consist of four parts: (1) Radiation chemistry and physics, radiation technologies; (2) Radiochemistry, stable isotopes, nuclear analytical methods, general chemistry; (3) Radiobiology; (4) Nuclear technologies and methods. In total - 73 detailed papers prepared by the Institute workers and collaborating scientists are presented. General information on the Institute status, personnel activity and the international cooperation is also listed

Annual reports in inorganic and general syntheses 1974

CERN Document Server

Niedenzu, Kurt

1975-01-01

Annual Reports in Inorganic and General Syntheses-1974 presents an organized annual summary of synthetic developments in inorganic chemistry and its related areas. The book discusses the chemistry of simple and complex metal hydrides of main groups I, II, and III, boron, aluminium, gallium, indium, thallium, silicon, germanium, tin, lead, phosphorus, arsenic, antimony, bismuth, chalcogens, halogens, and pseudohalogens. The text also describes the chemistry of scandium, yttrium, lanthanides, actinides, titanium, zirconium, hafnium, vanadium, niobium, tantalum, chromium, molybdenum, tungsten, ma

Radiation absorbed dose from medically administered radiopharmaceuticals

International Nuclear Information System (INIS)

Roedler, H.D.; Kaul, A.

1975-01-01

The use of radiopharmaceuticals for medical examinations is increasing. Surveys carried out in West Berlin show a 20% average yearly increase in such examinations. This implies an increased genetic and somatic radiation exposure of the population in general. Determination of radiation exposure of the population as well as of individual patients examined requires a knowledge of the radiation dose absorbed by each organ affected by each examination. An extensive survey of the literature revealed that different authors reported widely different dose values for the same defined examination methods and radiopharmaceuticals. The reason for this can be found in the uncertainty of the available biokinetic data for dose calculations and in the application of various mathematical models to describe the kinetics and calculation of organ doses. Therefore, the authors recalculated some of the dose values published for radiopharmaceuticals used in patients by applying biokinetic data obtained from exponential models of usable metabolism data reported in the literature. The calculation of organ dose values was done according to the concept of absorbed fractions in its extended form. For all radiopharmaceuticals used in nuclear medicine the energy dose values for the most important organs (ovaries, testicles, liver, lungs, spleen, kidneys, skeleton, total body or residual body) were recalculated and tabulated for the gonads, skeleton and critical or examined organs respectively. These dose values are compared with those reported in the literature and the reasons for the observed deviations are discussed. On the basis of recalculated dose values for the gonads and bone-marrow as well as on the basis of results of statistical surveys in West Berlin, the genetically significant dose and the somatically (leukemia) significant dose were calculated for 1970 and estimated for 1975. For 1970 the GSD was 0.2 mrad and the LSD was 0.7 mrad. For 1975 the GSD is estimated at < 0.5 mrad and the

Preparation of sup(113m)In-labelled compounds of radiopharmaceutical interest. Part of a coordinated programme on radiopharmaceuticals

International Nuclear Information System (INIS)

Servian, J.; Robles, A.

1975-06-01

Techniques for the preparation and control of already known and new sup(113m)In-radiopharmaceuticals were investigated. New rapid procedures for the control and preparation of a number of radiopharmaceuticals were developed and standardized. After biological distribution studies and clinical tests, new techniques for the preparation of the following indium-113 radiopharmaceuticals were adopted: a) Indium - labelled colloids of: S, Al(OH) 3 , Fe(OH) 3 and AlPO 4 for liver and spleen scintigraphy. b) Indium labelled chelates using the ligands EDTA, DTPA, TTHA (Triethylene-tetramine-hexaacetic acid) and DHPTA (Diamino-hydroxy-propane-tetraacetic acid) for brain scintigraphy. c) Indium labelled Fe(OH) 3 macroaggregates and microspheres for lung scintigraphy. d) Several complexes of sup(113m)In with different ligands (fluoride, tartrate, pyrophosphate, tripolyphosphate, trimetaphosphate, EHDP (or ethane-1-hydroxy-1, 1-diphosphonate), ethylendiamine-pyrophosphate were synthesized and its potential use as bone-scanning agents were evaluated. It was found that the complexes with tartrate, tripolyphosphate and EHDP show appreciable skeletal uptake (bone/muscle ratio are 9.0, 5.5, and 4.7 respectively), although they are inferior to the sup(99m)Tc bone-scanning agents. e) A new simple technique is proposed for the preparation of highly concentrated sup(113m)In solutions. The technique is based on the precipitation of In(OH) 3 , millipore filtration and redissolution in a small volume of 0.05 N HCl

15. workshop on radiation induced chemistry. JECR - 2010. Compilation of summaries

International Nuclear Information System (INIS)

Abidi, Wafa; Agelou, Mathieu; Atinault, Elodie; Balcerzyk, Anna; Baldacchino, Gerard; Barillon, Remi; Belloni, Jacqueline; Berlu, Lilian; Berthon, Laurence; Blain, Guillaume; Boogaerts, Anne; Bouniol, Pascal; Bouteleux, Simon; Canizares, Aurelien; Champion, Christophe; Chatelain, Caroline; Cobut, Vincent; Cochin, Florence; Costa, Cedric; Criquet, Justine; Crumiere, Francis; Damaj, Ziad; Dannoux, Adeline; Dauvois, Vincent; Davidkova, Maria; Delorme, Rachel; Deschanel, Xavier; Devineau, Stephanie; El Omar, Abdel-Karim; Essehli, Rachid; Fattahi, Massoud; Fereira da Silva, Filipe; Fromm, Michel; Gardes-Albert, Monique; Green, Nicholas; Guetat, Philippe; Guimbretiere, Guillaume; Hagen, Cornelius; Hanot, Maite; Hickel, Bernard; Hioul, Mohamed; Incerti, Sebastien; Jore, Daniel; Jung, Jean Marc; Khandal, Dhriti; Karamitros, Mathieu; Karpel, Vel; Leitner, Nathalie; Kovacs, Marie-Paule; Kowandy, Christelle; Krzeminski, Michael; Kuntz, Florent; Labed, Veronique; Lafosse, Anne; Le Caer, Sophie; Le Cocguen, Alexandre; Lehoux, Anais; Leoni, Elisa; Marchioni, Eric; Martin, Violaine; Melo, Rita; Mostafavi, Mehran; Moisy, Philippe; Mozeika-Araujo, Michel; Munier, Melodie; Musat, Raluca; Muzeau, Benoist; Pain, Laurent; Pastina, Barbara; Peyrat, Michel; Pin, Serge; Raffi, Jacques; Raffy, Quentin; Renault, Jean Philippe; Rolland, Severine; Saffre, Dimitri; Samraoui, Khalid; Savin-Martinez, Martine; Sicart-Roselli, Cecile; Sohier, Till; Spotheim-Maurizot, Melanie; Stammose, Denise; Tilquin, Bernard; Toquer, Guillaume; Traboulsi, Ali; Tribet, Magaly; Vandenborre, Johan; Vieira, Abel; Vigneron, Georges; Wasselin-Trupin, Virginie; Wishart, James; Yamashita, Shinichi

2010-05-01

This workshop is the most important international french-speaking meeting dedicated to the study of the effects of ionising radiations on matter; the discussed themes, interdisciplinary, go from primary physical interaction to physico-chemical, chemical and biochemical effects, including applications such as industrial irradiation, radiotherapy and radio-pharmaceutics. Titles of the 9 main sessions are: primary events; extreme conditions; radicalar bio-chemistry; radiolysis of specific molecules; nano-sciences, nano-technologies; dosimetry / direct effect; warehousing / storage; polymers / ionic liquids; astro-radiolysis

Dosimetric aspects of the treatment of metastatic bone pain with radiopharmaceuticals

International Nuclear Information System (INIS)

Garcia, T.; Marti, J. F.; Olivas, C.; Vercher, J. L.; Repetto, R.; Bello, P.

2014-01-01

Within the context of treatment of metastatic bone pain with bone seeking radiopharmaceuticals, this paper expounds the results of an analysis of available molecules (both approved for clinical use or still under study) intended to obtain a detailed comparison of their dosimetric characteristics. These can be used to supplement the list of already know differences between them, such as efficacy, appearance and length of the palliative effect, eventual tumoricidal effect, myelotoxicity, sale price and availability. Seven radiopharmaceuticals have been analysed, five of them are based on beta emission radionuclides: 3 2P, 1 53Sm, 1 86Re and 1 88Re and the other two ones are based on high Linear energy Transference emission radionuclides: 1 17mSn and 2 23Ra a series of estimates of the main dosimetric parameters for each radiopharmaceutical analysed have been obtained. The values obtained might be worth being incorporated to the risk/benefit analysis that precedes every choice of the specific radiopharmaceutical to be used with an individual patient. In this way, we hope these results will be of some help for those Nuclear Medicine specialists interested in the treatment of oncological bone pathologies. (Author)

The anesthetics influence (ethilic-eter and urethane) on renal radiopharmaceuticals

International Nuclear Information System (INIS)

Muramoto, E.; Achando, S.S.; Araujo, E.B. de; Hamada, H.S.; Silva Valente Goncalves, R. da; Pereira, N.P.S. de; Silva, C.P.G. da.

1990-01-01

A comparative study was done using anesthetics like ether ethilic and urethane, in rats (Wistar). A significative variation was observed in the results obtained when renal radiopharmaceuticals were investigated. Using urethane, the renal uptake increase progressivelly due to the inhibition of the renal filtration and it starts to recuperate when the anesthetic effect was eliminated. Using ether ethilic the radiopharmaceuticals are quickly eliminated from the kidneys (tubular or glomerular filtration), showing that the renal function was protected. (author) [pt

Chemistry Division: Annual progress report for period ending March 31, 1987

International Nuclear Information System (INIS)

1987-08-01

This report is divided into the following sections: coal chemistry; aqueous chemistry at high temperatures and pressures; geochemistry of crustal processes to high temperatures and pressures; chemistry of advanced inorganic materials; structure and dynamics of advanced polymeric materials; chemistry of transuranium elements and compounds; separations chemistry; reactions and catalysis in molten salts; surface science related to heterogeneous catalysis; electron spectroscopy; chemistry related to nuclear waste disposal; computational modeling of security document printing; and special topics

Safety and efficacy of radiopharmaceuticals 1987

International Nuclear Information System (INIS)

Kristensen, K.; Norbygaard, E.

1987-01-01

In this text aspects of the development of new radiopharmaceuticals are reviewed with particular reference to products of biological origin such as monoclonal antibodies and human cells. Also included in this survey are the legal aspects of the introduction of new pharmaceuticals and good radiopharmacy practice

In search of scar seeking radiopharmaceuticals

Energy Technology Data Exchange (ETDEWEB)

Salehi, N.; Lawlor, J.M.; Lichtenstein, M.; Allaway, M.; Barencevic, A. [Royal Melbourne Hospital, Melbourne, VIC (Australia). Department of Nuclear Medicine]|[University of Melbourne, VIC (Australia)

1998-03-01

Full text: Sensitive detection of acute peri-osseous scar tissue should be valuable for detection of partial ligamentous, tears and other common rheumatological conditions including back pain and ligamentous scars. Our aim was to investigate acute scar uptake of {sup 99m}Tc(V)-DMSA (dimercapto-succinic-acid), {sup 99m}Tc-DMAD (di- methyl-aminodiphosphonate) compared to {sup 99m}Tc-MDP (methylen-diphosphonate), the standard bone-scanning radiopharmaceutical. New Zealand white rabbits were anaesthetised and had 5-7cm of their mid-line abdominal wall surgically incised. At 24, 48, 72, 96 and 240 hours post surgery, 74 MBq (2 mCi) of the above radiopharmaceuticals were injected intravenously and scintigraphy performed 2.5 hours later. Relative count rate in scar is tabulated. In conclusion, the increased activity in the acute surgical site and lesser bone uptake confirmed that Tc (V)-DMSA and Tc-DMAD are superior to Tc- MDP for detection of new scar tissue in the region of bone. 1 tab.

Chemistry Division: Annual progress report for period ending March 31, 1987

Energy Technology Data Exchange (ETDEWEB)

1987-08-01

This report is divided into the following sections: coal chemistry; aqueous chemistry at high temperatures and pressures; geochemistry of crustal processes to high temperatures and pressures; chemistry of advanced inorganic materials; structure and dynamics of advanced polymeric materials; chemistry of transuranium elements and compounds; separations chemistry; reactions and catalysis in molten salts; surface science related to heterogeneous catalysis; electron spectroscopy; chemistry related to nuclear waste disposal; computational modeling of security document printing; and special topics. (DLC)

Analytical techniques for the determination of radiochemical purity of radiopharmaceuticals prepared from kits. Part II

International Nuclear Information System (INIS)

MacLean, J.R.; Rockwell, L.J.; Welsh, W.J.

The evaluation of efficacy of commercially available kits used for the preparation of radiopharmaceuticals is one aspect of the Radiation Protection Bureau's radiopharmaceutical quality control program. This report describes some of the analytical methodology employed in the program. Many of the tests can be performed rapidly and with a minimum of special equipment, thus enabling the confirmation of radiopharmaceutical purity prior to patient administration

Radiopharmaceutical quality control-Pragmatic approach

International Nuclear Information System (INIS)

Barbier, Y.

1994-01-01

The quality control must be considered in a practical manner. The radiopharmaceuticals are drugs. They must satisfy the quality assurance control. These products are then conform to Pharmacopeia. But sometimes the user must control some data especially radiochemical purity and pH value. On all the administered solutions four controls are compulsory: radionuclide identity, administered radioactivity, organoleptic character and pH

Development, preparation and control of sup(99m)Tc or sup(113m)In labelled stannous hydroxide radiopharmaceuticals. Part of a coordinated programme on radiopharmaceuticals

International Nuclear Information System (INIS)

Alvarez Cervera, J.

1975-01-01

The preparation of different sup(99m)Tc and sup(113m)In radiopharmaceuticals using stannous chloride was investigated. Chemical and radiochemical procedures for the quality control of these preparations were studied. Toxicity and biological controls of the preparation were carried out. Procedures for the preparation and control of the following radiopharmaceuticals have been standardized by the authors; albumin macroaggregates labelled with sup(99m)Tc, sup(113m)In and other isotopes for lung scanning; albumin microspheres labelled with sup(99m)Tc for lung scanning; sup(99m)Tc or sup(113m)In-labelled stannous hydroxide colloid for liver scanning; sup(99m)Tc-stannous phytate for liver scanning; sup(99m)Tc-Sn-dextrose, a new radiopharmaceutical which has been proposed by the authors and is now used in Mexico for renal and cerebral scanning and sup(99m)Tc-Sn pyrophosphate and diphosphonate for bone scanning

Limulus test for pyrogens and radiometric sterility tests on radiopharmaceuticals. Part of a coordinated programme

International Nuclear Information System (INIS)

Gopal, N.G.S.

1976-10-01

Sterility testing of radiopharmaceuticals prepared at BARC were carried out using the radiometric technique (Radiometric detection of the metabolic product 14 Co 2 ). Batches of different radiopharmaceuticals were tested for pyrogen using the limulus lysate method and the results were compared with the rabbit method. The results of sterility test on 202 batches of 19 different radiopharmaceuticals show that the radiometric method can be used for sterility testing of radiopharmaceuticals labelled with 35 S, 51 Cr, 57 Co, 59 Fe, 82 Br, 86 Rb, sup(99m)Tc, sup(113m)In, 125 I and 169 Yb. The radiometric test proves to be more rapid than the conventional one for the sterility testing of such radiopharmaceuticals. Detection time is between 6-21 hours. In the case of 131 I-labelled radiopharmaceuticals and in the case of chlormerodrin-Hg-203, it was found an interference due to volatile species (sup(131m)Xe in the case of 131 I and some volatile mercury form in the case of chlormerodrin). In these cases it would be possible to carry out the radiometric sterility test after separation of the microorganisms from the radioactive material (by filtration). The limulus lysate method can be employed for control of various pyrogen-prone raw materials and radiopharmaceuticals. Such method is the only method at present available for detecting the low level pyrogen contamination in intrathecal injections. The limulus test is more rapid than the rabbit test

Experience in the quality control of commercial and self-labelled radiopharmaceuticals

International Nuclear Information System (INIS)

Strehlau, E.; Weiland, J.

1980-01-01

Different methods of quality control of radiopharmaceuticals checked in the laboratory practice are summarized. Starting from the general organization of quality control in the clinical radiochemical laboratory methods of analysis and working regulations are discussed. The quality tests of sup(99m)Tc-generator eluate, that is the testing for radioactive contaminants and for soluble aluminium as well as the testing of sup(99m)Tc-labelled kits and of different other frequently used radiopharmaceuticals are described in detail. Special conditions of examination and results of chromatography and medium-voltage electrophoresis are also given. Furthermore the routine determination of the output in the labelling of denaturated erythrocytes with sup(99m)Tc is discussed. The clinical practice in the case of preparation deficiencies and of possible incidents following the application of radiopharmaceuticals is outlined. (author)

Annual report of the Osaka Laboratory for Radiation Chemistry Japan Atomic Energy Research Institute, (No. 26)

International Nuclear Information System (INIS)

1994-03-01

The annual research activities of Osaka Laboratory for Radiation Chemistry, JAERI during the fiscal year of 1992 (April 1, 1992 - March 31, 1993) are described. The research activities were conducted under the two research programs: the study on laser-induced organic chemical reactions and the study on basic radiation technology for functional materials. Detailed descriptions of the activities are presented in the following subjects: laser-induced organic synthesis, modification of polymer surface by laser irradiation, radiation-induced polymerization, preparation of fine particles by gamma ray irradiation, and electron beam dosimetry. The operation report of the irradiation facilities is also included. (author)

Modern trends in radiopharmaceuticals for diagnosis and therapy. Proceedings of a symposium

International Nuclear Information System (INIS)

1998-08-01

The IAEA held an International Symposium on Modern Trends in Radiopharmaceuticals for Diagnosis and Therapy in Lisbon, Portugal, from 30 March to 3 April 1998. Two earlier symposia were organized on similar topics in Copenhagen, Denmark in 1973 and in Tokyo, Japan, in 1984. The proceedings of these symposia have been published and widely used as reference sources. To facilitate faster publication and more widespread availability, the IAEA has decided to publish the proceedings of this symposium as a cost-free TECDOC. The symposium was organized into 14 sessions consisting of five on 99m Tc radiopharmaceuticals, two each on therapeutic radiopharmaceuticals and radiohalogens/other isotopes and one each on bioevaluation, radiometric assay, medical isotope production, good radiopharmacy practice and technology transfer. In the proceedings the papers from multiple sessions on the same topic have been grouped together for the convenience of the reader. The papers presented in the symposium reflect current and future developments in diagnostic and therapeutic agents. The largest number of papers presented dealt with 99m Tc, highlighting its continuing importance to nuclear medicine and the role of imaging as an important tool. The emerging interest in therapeutic radiopharmaceuticals based on beta emitting short lived isotopes such as 186 Re and 153 Sm was evident from the papers presented in two sessions devoted to this topic. Also of steady interest was the development of agents labelled with other established isotopes, radioiodine in particular and also 111 In and 67 Ga. Regulation, training and good manufacturing practices are important for ensuring safety in regular use of radiopharmaceuticals and were discussed in a separate session. The production of radiopharmaceuticals has become a regular activity in many developing countries, often facilities were presented at the symposium

Modern trends in radiopharmaceuticals for diagnosis and therapy. Proceedings of a symposium

Energy Technology Data Exchange (ETDEWEB)

NONE

1998-08-01

The IAEA held an International Symposium on Modern Trends in Radiopharmaceuticals for Diagnosis and Therapy in Lisbon, Portugal, from 30 March to 3 April 1998. Two earlier symposia were organized on similar topics in Copenhagen, Denmark in 1973 and in Tokyo, Japan, in 1984. The proceedings of these symposia have been published and widely used as reference sources. To facilitate faster publication and more widespread availability, the IAEA has decided to publish the proceedings of this symposium as a cost-free TECDOC. The symposium was organized into 14 sessions consisting of five on {sup 99m}Tc radiopharmaceuticals, two each on therapeutic radiopharmaceuticals and radiohalogens/other isotopes and one each on bioevaluation, radiometric assay, medical isotope production, good radiopharmacy practice and technology transfer. In the proceedings the papers from multiple sessions on the same topic have been grouped together for the convenience of the reader. The papers presented in the symposium reflect current and future developments in diagnostic and therapeutic agents. The largest number of papers presented dealt with {sup 99m}Tc, highlighting its continuing importance to nuclear medicine and the role of imaging as an important tool. The emerging interest in therapeutic radiopharmaceuticals based on beta emitting short lived isotopes such as {sup 186}Re and {sup 153}Sm was evident from the papers presented in two sessions devoted to this topic. Also of steady interest was the development of agents labelled with other established isotopes, radioiodine in particular and also {sup 111}In and {sup 67}Ga. Regulation, training and good manufacturing practices are important for ensuring safety in regular use of radiopharmaceuticals and were discussed in a separate session. The production of radiopharmaceuticals has become a regular activity in many developing countries, often facilities were presented at the symposium Refs, figs, tabs

Implementation of the Good Practices of Manufacture of PET Radiopharmaceuticals in INOR

International Nuclear Information System (INIS)

Sinconegui Gómez, Belkys; Quesada Cepero, Waldo; González González, Joaquín J.; Calderón Marín, Carlos F.; Varela Corona, Consuelo; Figueroa, Roberto

2016-01-01

The growing advance of new technologies in Nuclear Medicine such as positron emission tomography (PET) allows visualizing biological processes in vivo and provides more sensitive results in the diagnosis of oncological processes in asymptomatic stages of the disease and contribute significantly to improve cancer management. It is significant to note that these technologies include radiopharmaceuticals marked with 90 Y and 177 Lu for the therapy of patients already diagnosed by the PET technique that contribute to a significant improvement in the quality of life of patients with cancer. Our country, taking into account the importance of this technology for Health, has developed in INOR a project for the obtaining, dispensing and quality control of PET radiopharmaceuticals marked with 68 Ga for diagnosis and its therapeutic analogues marked with 177 Lu and 90Y in Conditions of Good Manufacturing Practices (GMP). The objective of the present work is to present our experiences in the implementation of the Good Practices of Manufacture of PET Radiopharmaceuticals according to regulation 16-2012 GUIDELINES ON GOOD PRACTICES OF MANUFACTURE OF PHARMACEUTICAL PRODUCTS, issued by the State Control Center for Medicines, Equipment and Devices Doctors (CECMED), a Cuban regulatory body. The implementation of the regulation considers from the preparation of personnel involved in the activity, moving through the facilities and equipment to the validation and quality control. A system for the quality assurance of the production of PET radiopharmaceuticals was implemented in accordance with Annex 5 of Regulation 16-2012 of the CECMED. This is the first experience in Cuba of the implementation of Good Manufacturing Practices of PET Radiopharmaceuticals in Hospital Radiopharmacy. The acquired experiences will be extended to the practices for the preparation of radiopharmaceuticals for the conventional Nuclear Medicine in the INOR.

Impact of risk considerations on dosimetry of radiopharmaceuticals

International Nuclear Information System (INIS)

Eckerman, K.F.

1981-01-01

Estimates of the absorbed dose from clinical procedures involving the administration of radiopharmaceuticals are used primarily to determine the presumed risk of various procedures so that, in-so-far as possible, the selection of a given procedure can be based on a comparison of risk. Although this has been the basic objective, risk evaluation has generally been separated from the dosimetry considerations. In the recent revision of its radiation protection guidance, the International Commission on Radiological Protection (ICRP) has embodied risk considerations in its recommendations and risk concepts have become an integral part of the dosimetric framework. The impact of these considerations on the dosimetric assessments of radiopharmaceuticals and the resulting need for additional information is discussed

Obligations, precautions and pending issues in regulatory development for radiopharmaceuticals in Brazil

Energy Technology Data Exchange (ETDEWEB)

Gamboa, Maryelle Moreira Lima; Roesch, Heveline Rayane Moura; Lemos, Vanessa Pinheiro Amaral, E-mail: maryellelg@hotmail.com [PPG BioSaude, Universidade Luterana do Brasil, Canoas, RS (Brazil); Rocha, Bruna Oliveira [Faculty of Biology, Universidade Luterana do Brasil, Canoas, RS (Brazil); Santos-Oliveira, Ralph [Institute of Radiopharmacy Research, Universidade Estadual da Zona Oeste, Rio de Janeiro, RJ (Brazil)

2014-04-15

Radiopharmaceuticals are compounds that have a radionuclide and may be gamma-radiation emitter (γ) or positrons emitter (β+), linked to a molecule with specific diagnostic and therapeutic purposes. The progress in the use of radiopharmaceuticals has culminated to a sector in common with other types of drugs: regulation and surveillance. >From 2006 on, production, marketing and use of these drugs were open to the Brazilian market granting much more freedom due to the Constitutional Amendment 49, resulting from the previous Constitutional Amendment 199/03 which removes the Union monopoly for this kind of manipulation and granted this production to other nuclear medicine. From this date on, the amount of this type of sold product have been greatly increased, and the nucleus of surveillance and regulation in Brazil have also advanced in the legislative processes, creating documents that are now more focused on radiopharmaceuticals in the national territory (Resolutions No. 63 and No. 64). In international overview, there is too much to be done in regulatory terms in Brazil, such as adding mainly issues of drugs surveillance to pharmacovigilance practice in radiopharmaceuticals drugs. (author)

Obligations, precautions and pending issues in regulatory development for radiopharmaceuticals in Brazil

International Nuclear Information System (INIS)

Gamboa, Maryelle Moreira Lima; Roesch, Heveline Rayane Moura; Lemos, Vanessa Pinheiro Amaral; Rocha, Bruna Oliveira; Santos-Oliveira, Ralph

2014-01-01

Radiopharmaceuticals are compounds that have a radionuclide and may be gamma-radiation emitter (γ) or positrons emitter (β+), linked to a molecule with specific diagnostic and therapeutic purposes. The progress in the use of radiopharmaceuticals has culminated to a sector in common with other types of drugs: regulation and surveillance. >From 2006 on, production, marketing and use of these drugs were open to the Brazilian market granting much more freedom due to the Constitutional Amendment 49, resulting from the previous Constitutional Amendment 199/03 which removes the Union monopoly for this kind of manipulation and granted this production to other nuclear medicine. From this date on, the amount of this type of sold product have been greatly increased, and the nucleus of surveillance and regulation in Brazil have also advanced in the legislative processes, creating documents that are now more focused on radiopharmaceuticals in the national territory (Resolutions No. 63 and No. 64). In international overview, there is too much to be done in regulatory terms in Brazil, such as adding mainly issues of drugs surveillance to pharmacovigilance practice in radiopharmaceuticals drugs. (author)

Acquisition of biokinetic data for internal dose calculations for some novel radiopharmaceuticals

International Nuclear Information System (INIS)

Smith, T.; Zanelli, G.D.; Crawley, C.W.

1986-01-01

Estimation of radiation dose commitment, expresses as an effective dose equivalent, is a prior requisite to the application for a license to administer radiopharmaceuticals and, therefore, in the case of novel radiopharmaceuticals is leading to an increasing awareness of the need for dosimetry-orientated studies. In this laboratory potential new radiopharmaceuticals are investigated initially by animal studies to assess the possible distribution in man, and subsequently in controlled volunteer studies designed to obtain the maximum possible amount of biokinetic data to allow accurate estimation of radiation dose. A variety of techniques are used for this purpose, including profile counting, partial and whole-body scanning by LFOV gamma camera and whole-body counting, in addition to the analysis of radioactivity in blood and excreta. The use of these techniques is illustrated for the acquisition of biokinetic data and subsequent dosimetry of three novel radiopharmaceuticals: 77 Br-p-bromospiperone (quantification of dopamine receptors in the brain). 99 Tc/sup m/-porphyrins and 99 Tc/sup m/ DEPE (a possible novel blood pool marker for MUGA studies). 14 references, 14 figures, 2 tables

Computational system for activity calculation of radiopharmaceuticals

African Journals Online (AJOL)

STORAGESEVER

2008-12-29

Dec 29, 2008 ... 2National Nuclear Energy Commission, Brazil. Accepted 24 October ... radiopharmaceuticals in use around the world with ... ment with a very important aspects: no profits ends. The tool ... The software interface is showed in ...

Which radiopharmaceuticals for to-morrow. Heart and brain investigations

International Nuclear Information System (INIS)

Maziere, B.

1994-01-01

This paper is a critical review of the various radiopharmaceuticals which have been or are presently designed for functional imaging of brain or heart using positron (PET) or single photon emission tomography. Currently used radiopharmaceuticals have been classified into two broad categories: 'passive' radiotracers intended to visualize the perfusion of the organ and 'active' or 'specific' radiotracers used to investigate metabolism or neurotransmission processes. Moreover, the potential interest of radioactive peptides or oligonucleotides which would be biologically stable in vivo and which could target proteins involved in inter or intra-cellular communications will be reviewed. (authors). 47 refs

Analytical techniques for the determination of radiochemical purity of radiopharmaceuticals prepared from kits

International Nuclear Information System (INIS)

McLean, J.R.; Rockwell, L.J.; Welsh, W.J.

1977-01-01

The evaluation of efficacy of commercially available kits used for the preparation of radiopharmaceuticals is one aspect of the Radiation Protection Bureau's radiopharmaceutical quality control program. This report describes some of the analytical methodology employed in the program. The techniques may be of interest to hospital radiopharmacy personnel as many of the tests can be performed rapidly and with a minimum of special equipment, thus enabling the confirmation of radiopharmaceutical purity prior to patient administration. Manufacturers of kits may also be interested in learning of the analytical methods used in the assessment of their products. (auth)

Radiopharmaceuticals production activities in Egypt

International Nuclear Information System (INIS)

Raieh, M.

1998-01-01

Applications of radiopharmaceuticals and labelled compounds in the field of nuclear medicine in Egypt have increased so rapidly in the last few years. At present, a large number of hospitals are utilizing these radioisotopic techniques for both diagnosis and treatment. The following production activities are taking place in the Egyptian Radioisotope Production laboratories. By utilizing the research reactor a large number of radioisotopes which find wide applications in nuclear medicine were produced, such as iodine-131, phosphorus-32, sodium-24, potassium-42 and molybdenum-99 / technetium-99m generators. Gallium-67, indium-111 and iodine-123 will be produced locally after installation of the cyclotron at the end of 1998. A large number of Tc-99m based kits for diagnostic medical applications have been produced. Also, many radiopharmaceuticals labelled with iodine-131 were produced. The radioisotope production laboratory is able to supply many hospitals with the radioimmunoassay kits of the thyroid related hormones (T4, T3 and TSH). Research and development activities are taking place in the field of monoclonal antibodies and tumor markers with special consideration of AFP, CEA, PSA and βhCG. (author)

Progress on the application of ligand receptor binding assays in radiopharmaceuticals

International Nuclear Information System (INIS)

Zhou Xue; Qian Jinping; Kong Aiying; Zhu Lin

2010-01-01

Receptor binding assay is an important drug screening method, which can quickly and inexpensively study the interactions between the targeted receptor and the potential ligands in vitro and provide the information of the relative binding affinity of ligand-receptor. The imaging of many radiopharmaceuticals is based on highly selective radioligand-receptor binding. The technique plays an important role in the design and screening of receptor-targeting radiopharmaceuticals. (authors)

Radiopharmaceutical projects of CNESTEN (Centre National de l'Energie, des Sciences et des Techniques Nucleaires)

International Nuclear Information System (INIS)

2000-01-01

In nuclear medicine, the prescriptions of isotopic investigations are increasing because they can provide early information about morphological anomalies and permit,so to avoid long and onerous treatments. Until now, Morocco imports the radiopharmaceuticals in spite of the difficulties related to administrative procedures. To facilitate these procedures CNESTEN has launched a project which involves the following activities: - Import and distribution of needed radiopharmaceuticals; - development and production of new radiopharmaceutical kits in cooperation with scientific partners. Priority is given to the most prescribed radiopharmaceuticals. Many kits have been produced with manufacturing protocol modifications aiming to improve and optimize the production processes. The quality of the obtained products is tested and their biodistribution kinetics are studied. (F.M.)

Isotope and Nuclear Chemistry Division annual report, FY 1988

International Nuclear Information System (INIS)

1989-06-01

This report describes some of the major research and development programs of the Isotope and Nuclear Chemistry Division during FY 1988. The report includes articles on weapons chemistry, biochemistry and nuclear medicine, nuclear structure and reactions, and the INC Division facilities and laboratories

Annual Report 2006

Energy Technology Data Exchange (ETDEWEB)

Michalik, J; Smulek, W; Godlewska-Para, E [eds.

2007-07-01

The Annual Report of the Institute of Nuclear Chemistry and Technology (Warsaw, Poland) describes achievements of the Institute in 2006 obtained in seven fields: (1) radiation chemistry and technology, (2) radiochemistry and coordination chemistry, (3) radiobiology, (4) application of nuclear methods in material and process engineering, (5) design of instruments based on nuclear techniques, (6) trace analysis and radioanalytical techniques, (7) environmental research. In total - 83 detailed papers prepared by the Institute workers and collaborating scientists are presented. General information on the Institute status, personnel activity, international cooperation and publications are presented.

Annual Report 2006

International Nuclear Information System (INIS)

Michalik, J.; Smulek, W.; Godlewska-Para, E.

2007-01-01

The Annual Report of the Institute of Nuclear Chemistry and Technology (Warsaw, Poland) describes achievements of the Institute in 2006 obtained in seven fields: (1) radiation chemistry and technology, (2) radiochemistry and coordination chemistry, (3) radiobiology, (4) application of nuclear methods in material and process engineering, (5) design of instruments based on nuclear techniques, (6) trace analysis and radioanalytical techniques, (7) environmental research. In total - 83 detailed papers prepared by the Institute workers and collaborating scientists are presented. General information on the Institute status, personnel activity, international cooperation and publications are presented

Annual Report 2008

International Nuclear Information System (INIS)

Michalik, J.; Smulek, W.; Godlewska-Para, E.

2009-01-01

The Annual Report of the Institute of Nuclear Chemistry and Technology (Warsaw, Poland) describes achievements of the Institute in 2008 obtained in six fields: (1) radiation chemistry and physics, radiation technologies, (2) radiochemistry, stable isotopes, nuclear analytical methods, general chemistry, (3) radiobiology, (4) nuclear technologies and methods: process engineering, (5) nuclear technologies and methods: material engineering, structural studies, diagnostics, (6) nucleonic control systems and accelerators. In total - 76 detailed papers prepared by the Institute workers and collaborating scientists are presented. General information on the Institute status, personnel activity, international cooperation and publications are also given

Radiolabeling of human platelets using four radiopharmaceuticals with Tc-99m

International Nuclear Information System (INIS)

Portillo L, M.C.; Godoy, C.

1991-01-01

The present investigation work has been done in an evaluation of four different radiopharmaceuticals with Tin II (Glucoheptonate, Pyrophosphate, Citrate and DTPA), with the purpose of determining which one of the four would be obtained a higher rate of radiolabeling of platelets with Tc-99m. In order to evaluate the four radiopharmaceuticals it was procede to the separation and labeling of the human platelets. It was worked with samples of blood from five pacients, and the platelets from each one of them were labeled with the radiopharmaceuticals-Tc-99m. Then was observed a significant difference among the four radiopharmaceuticals studied, with a reliable level of 0.05 being the Glucoheptonate-Tc-99m the best to label platelets, obtaining with the same 50.23% of labeling efficiency, while for DTPA, Pyrophosphate and Citrate, It was obtained 33.42%, 29.82% and |2.62% respectively. Also, it was studied the biodistribution of the labeled platelets, using Glucoheptonate-Tc-99m as a radiopharamceutical. The biodistribution was studied in white mice at different times and it was founded that the place of biodistribution of the labeled platelets is given in greater percentage in the liver, spleen, lungs and kydneis. (Author)

Legislative situation of EEC member states and european provisions concerning preparation and use of radiopharmaceuticals

International Nuclear Information System (INIS)

Lalanne, P.

1977-01-01

Radiopharmaceuticals are excluded from the directives on pharmaceutical products and considerable gaps exist in the legislation of many countries. The pharmacopoeia provides standards and methods for the quality control of the final product. According to the same principles, it is proposed that special provisions, taking into consideration the very special nature of radiopharmaceuticals, might be introduced in the european economic community legislation, to secure that all radiopharmaceuticals used are safe and of an uniform quality

Indirect iodometric procedure for quantitation of Sn(II) in radiopharmaceutical kits

International Nuclear Information System (INIS)

Muddukrishna, S.N.; Chen, A.; Sykes, T.R.; Noujaim, A.A.; Alberta Univ., Edmonton, AB

1994-01-01

A method of quantitating stannous ion [Sn(II)] suitable for radiopharmaceutical kits, based on indirect iodometric titration, is described. The method is based on the oxidation of Sn(II) using a known excess of iodine and the excess unreacted iodine determined using thiosulphate by potentiometric titration. The titration cell is a beaker and the titrations are done conveniently under air using an autotitrator in approx. 4 min. The method is accurate and is linear in the range of approx. 10 μg to approx. 6 mg of Sn(II). Several radiopharmaceutical kits were analysed for their Sn(II) content using the method including those containing antibodies or other proteins. The studies indicate that the procedure is rapid, simple and accurate for routine quantitative estimation of Sn(II) in radiopharmaceutical preparations during development, manufacture and storage. (Author)

Annual Report 1978

International Nuclear Information System (INIS)

1979-01-01

The annual report gives the specific scientific results in the fields of nuclear and radiation physics, radiation chemistry, radiochemistry and data processing with a list of publications. (orig.) [de

Fuel Chemistry Division: annual progress report for 1988

International Nuclear Information System (INIS)

Vaidyanathan, S.

1991-01-01

The progress report gives the brief descriptions of various activites of the Fuel Chemistry Division of Bhabha Atomic Research Centre, Bombay for the year 1988. The descriptions of activities are arranged under the headings: Fuel Development Chemistry of Actinides, Quality Control of Fuel, and Studies related to Nuclear Material Accounting. At the end of report, a list of publications published in journals and papers presented at various conferences/symposia during 1988 is given. (author). 13 figs., 61 tabs

Radiopharmaceuticals for diagnosis and treatment of arthritis

International Nuclear Information System (INIS)

Hosain, F.; Haddon, M.J.; Hosain, H.; Drost, J.K.; Spencer, R.P.

1990-01-01

A brief review is given of radiopharmaceuticals for the diagnosis and treatment of arthritis. Topics covered include the pathophysiology of arthritis and the basis for the use of radiotracers, diagnostic procedures and radiotracer applications and therapeutic approaches and radionuclide applications. (UK)

Radiopharmaceutical chelates and method of external imaging

International Nuclear Information System (INIS)

Loberg, M.D.; Callery, P.S.; Cooper, M.

1977-01-01

A chelate of technetium-99m, cobalt-57, gallium-67, gallium-68, indium-111 or indium-113m and a substituted iminodiacetic acid or an 8-hydroxyquinoline useful as a radiopharmaceutical external imaging agent. The invention also includes preparative methods therefor

Approaches to the design of clean air handling facilities for radiopharmaceuticals

International Nuclear Information System (INIS)

2000-01-01

Manufacturing, handling and administering processes of radiopharmaceuticals have to meet the requirements of both the fields viz. ''radio'' activity and ''pharma'' activity. Both these fields often dictate conflicting requirements. A step by step analysis of these conflicts can lead to practices reasonably acceptable to both the fields. The design approaches include engineering concepts of radiation protection, concepts and practices for pharmaceuticals, biologically unsafe products/processes and manufacturing, handling and administering processes of radiopharmaceuticals

Routine clinical use of radiopharmaceuticals in Latin American developing countries

International Nuclear Information System (INIS)

Mitta, A.E.

1985-01-01

The paper describes the routine clinical use of radiopharmaceuticals in the developing countries of Latin America made possible by: (1) the International Atomic Energy Agency (IAEA), which sent experts and equipment to many countries and made a substantial bibliographic contribution on the subject; (2) the Latin American Association of Societies of Nuclear Biology and Medicine (ALASBIMN), which fostered the exchange of data on techniques of radiopharmaceutical preparation and quality control by providing materials for tests, etc., and by publishing quality control manuals in some countries, finally in 1982 producing the Manual of Radiopharmaceutical Quality Control, in collaboration with the Inter-American Nuclear Energy Commission (CIEN) and published by the Organization of American States (OAS); (3) the countries themselves under agreements between their atomic energy commissions; (4) radiopharmacy courses organized by universities, either alone or in collaboration with the IAEA, WHO, etc.; (5) professional workers who established radiopharmaceutical services at private centres. Finally, the societies of nuclear medicine and biology in each country, the World Federation of Nuclear Medicine and Biology, the ALASBIMN, the IAEA, etc. organized symposia and meetings which afforded opportunities to professionals of these countries to receive and exchange information, since in Latin America, given its language and human characteristics, the problems are similar. The countries referred to are Argentina, Brazil, Mexico, Uruguay, Bolivia, Paraguay, Chile, Peru, Ecuador, Colombia, Venezuela, Costa Rica, Guatemala, Puerto Rico, El Salvador and Panama; little is known about Honduras, Nicaragua, the Dominican Republic and Cuba. (author)

Annual Report 1974

International Nuclear Information System (INIS)

1975-01-01

This annual report supersedes the work done in the nuclear physics institute at Lyon. The studied matters are the following: nuclear theory, nuclear reactions, nuclear spectroscopy and nuclear chemistry [fr

Synthesis and formulation of 99m Tc-ECD radiopharmaceutical

International Nuclear Information System (INIS)

Ocampo G, B.E.

1998-01-01

Nuclear medicine is a medical specialty which uses radioactive compounds (radionuclides) for diagnostic and therapeutic purposes. 99m Tc is the more common radionuclide used in many studies in nuclear medicine because its advantages: it has a photopeak of 140 KeV and a half-life of 6 hours; it can be eluted from a Molybdenum 99 generator, so radiopharmaceuticals can be prepared on site. Ethyl cysteine dimer (ECD) labelled with reduced Technetium 99m has been purposed recently as a promising radiopharmaceutical for brain perfusion imaging 99m Tc-ECD is a lipophilic neutral complex which cross the brain blood barrier and show high brain uptake. The objective of this work was synthesize and to design a freeze dried formulation for the instant preparation of 99m Tc-ECD complex useful for brain perfusion imaging. We obtained a freeze dried stable formulation for the preparation of 99m Tc-ECD kit with a radiochemical purity higher than 90 %, which fulfills with the quality control of radiopharmaceuticals. Furthermore, we developed analytic techniques for the determination of the different chemical compounds into the lyophilized kit. (Author)

Stannous ion determination in99mTc - radiopharmaceutical kits

International Nuclear Information System (INIS)

Almeida, M.A.T.M. de; Silva, C.P.G. da.

1989-10-01

Two simple and selective methods for determination of stannous ion in radiopharmaceutical kits are proposed. One of this permits the estimation of stannic ion. The first method used is a potentiometric tiration of Sn +2 in HCl medium using KIO 3 solution under nitrogen gas and a redox platinum electrode. The second method consist of a compleximetric tiration of tin (Sn +2 and Sn +4 ) using EDTA standart solution at pH 5.5-5.6 without use of nitrogen gas. The employed procedures indicates that both the methods can be used for routine quantitative determination of tin in most labeled radiopharmaceuticals. (author) [pt

Radioisotope and radiopharmaceutical generators

International Nuclear Information System (INIS)

Barak, M.; Winchell, H.W.

1975-01-01

A chromatographic column for generating technetium-99m isotopes and technetium-99m labeled pharmaceuticals in a simple two-step process is described. Technetium-99m pertechnetate in a first step is isolated by adsorption upon an adsorbent packing. Then the technetium-99m in a second step is eluted from the packing, either with an immediately labeled biological compound to form a radiopharmaceutical, or by a controlled volume of eluant to produce a 99m-technetium-bearing eluate of a desired specific concentration. (Official Gazette)

Obligations, precautions and pending issues in regulatory development for radiopharmaceuticals in Brazil

Directory of Open Access Journals (Sweden)

Maryelle Moreira Lima Gamboa

2014-04-01

Full Text Available Radiopharmaceuticals are compounds that have a radionuclide and may be gamma-radiation emitter (γ or positrons emitter (β+, linked to a molecule with specific diagnostic and therapeutic purposes. The progress in the use of radiopharmaceuticals has culminated to a sector in common with other types of drugs: regulation and surveillance. From 2006 on, production, marketing and use of these drugs were open to the Brazilian market granting much more freedom due to the Constitutional Amendment 49, resulting from the previous Constitutional Amendment 199/03 which removes the Union monopoly for this kind of manipulation and granted this production to other nuclear medicine. From this date on, the amount of this type of sold product have been greatly increased, and the nucleus of surveillance and regulation in Brazil have also advanced in the legislative processes, creating documents that are now more focused on radiopharmaceuticals in the national territory (Resolutions No. 63 and No. 64. In international overview, there is too much to be done in regulatory terms in Brazil, such as adding mainly issues of drugs surveillance to pharmacovigilance practice in radiopharmaceuticals drugs.

Radiopharmaceuticals to 99mTc

International Nuclear Information System (INIS)

Leon Cabana, Alba

1994-01-01

Studies about 99m Tc had demonstrated that have favorable properties for support diagnostic proceedings in nuclear medicine. This physical and chemical properties used for obtain another radiopharmaceuticals have been employed through re actives kits labelled with Tc 99m . A brief description was given about 99m utilities in diagnostic techniques such as endothelium reticular system,renal and hepatic studies,bone scintillators,cardiac diagnostic and cerebral perfusion

Chemistry Division annual progress report for period ending April 30, 1993

Energy Technology Data Exchange (ETDEWEB)

Poutsma, M.L.; Ferris, L.M.; Mesmer, R.E.

1993-08-01

The Chemistry Division conducts basic and applied chemical research on projects important to DOE`s missions in sciences, energy technologies, advanced materials, and waste management/environmental restoration; it also conducts complementary research for other sponsors. The research are arranged according to: coal chemistry, aqueous chemistry at high temperatures and pressures, geochemistry, chemistry of advanced inorganic materials, structure and dynamics of advanced polymeric materials, chemistry of transuranium elements and compounds, chemical and structural principles in solvent extraction, surface science related to heterogeneous catalysis, photolytic transformations of hazardous organics, DNA sequencing and mapping, and special topics.

Current status of production and research of radioisotopes and radiopharmaceuticals in Indonesia

International Nuclear Information System (INIS)

Soenarjo, Sunarhadijoso; Tamat, Swasono R.

2000-01-01

The use of radioactive preparation in Indonesia has sharply increased during the past years, indicated by increase of the number of companies utilizing radioisotopes during 1985 to 1999. It has been clearly stressed in the BATAN's Strategic Plan for 1994-2014 that the production of radioisotopes and radiopharmaceuticals is one of five main industrial fields within the platform of the Indonesian nuclear industry. Research programs supporting the production of radioisotopes and radiopharmaceuticals as well as development of production technology are undertaken by the Research Center for Nuclear Techniques (RCNT) in Bandung and by the Radioisotope Production Center (RPC) in Serpong, involving cooperation with other research center within BATAN, universities and hospitals as well as overseas nuclear research institution. The presented paper describes production and research status of radioisotopes and radiopharmaceuticals in Indonesia after the establishment of P.T. Batan Teknologi in 1996, a government company assigned for activities related to the commercial application of nuclear technology. The reviewed status is divided into two short periods, i.e. before and after the Chairman Decree No. 73/KA/IV/1999 declaring new BATAN organizational structure. Subsequent to the Decree, all commercial requests for radioisotopes and radiopharmaceuticals are fulfilled by P.T. Batan Teknologi, while demands on novel radioactive preparations or new processing technology, as well as research and development activities should be fulfilled by the Center for the Development of Radioisotopes and Radiopharmaceuticals (CDRR) through non-commercial arrangement. The near-future strategic research programs to response to dynamic public demand are also discussed. The status of research cooperation with JAERI (Japan) is also reported. (author)

Production of PET radiopharmaceutical 18F-FDG using synthesizer automatic module

International Nuclear Information System (INIS)

Purwoko; Chairuman; Adang Hardi Gunawan; Yayan Tahyan; Eny Lestari; Sri Aguswarini Lestiyowati; Karyadi; Sri Bagiawati

2010-01-01

Radiopharmaceutical 2-( 18 F)Fluoro-2-Deoxy-D-Glucose or 18 F(FDG) is an important PET (Positron Emission Tomography) radiopharmaceutical for tumour imaging. In the PET technique glucose metabolism in tumour tissues can be determined quantitatively and used for diagnosis staging and monitoring of treatment tumour or cancer disease in medical oncology. The production of 2-( 18 F)Fluoro-2-Deoxy-D-Glucose 18 F-FDG using compact automated system module TRACERlab MX has been carried out. The modular setup of the apparatus permits reliable for routine synthesis of radiopharmaceuticals 18 F-FDG based on kriptofix mediated nucleophilic fluorination to mannose triflate precursor. Radiochemical yield of 18 F-FDG was 53.895 % (decay time uncorrected) in 40 minutes. The product showed that the colorless and clear solution at pH:6, sterile and pirogen free, kriptofix impurities was low and radiochemical purity was 99.595%. (author)

Chemistry of /sup 99m/Tc labeling kits

International Nuclear Information System (INIS)

Srivastava, S.C.; Meinken, G.; Richards, P.

1976-01-01

Problems have been reported with the use of kit-produced /sup 99m/Tc radiopharmaceuticals. This study was undertaken to understand the chemistry involved in various stannous kit systems. The relation between Tc, tin, and the ligands used to complex the reduced Tc was investigated. It is concluded that for reliable performance, stannous kits should be prepared so that most of the tin is kept in the usable (reducing) form; a solution would be to use minimum tin and a large excess of complexing agent. Oxidation of the Tc complex to free pertechnetate is not a major problem in most kit systems. 5 figures

Radiopharmacy and radiopharmaceuticals in Brazil: sanitarians aspects related to a project of an industry of PET radiopharmaceuticals

International Nuclear Information System (INIS)

Santos-Oliveira, Ralph; Benevides, Clayton Augusto; Hwang, Suy Ferreira; Salvi, Roberto Paulo Camara; Freitas, Ione Maria Acioly Teixeira Ricarte de

2008-01-01

The increasing use of radiopharmaceuticals for PET (Positron Emission Tomography) has come to the attention of nuclear medicine staff and regulatory bodies. The aim of this study is to provide a national reference in radiopharmacy that could help all nuclear medicine staff and specially the Brazilian's regulatory bodies focused on the industrial project. (author)

Annual report 1990

International Nuclear Information System (INIS)

Kyrs, M.

1991-06-01

An account is given of the activities of the Nuclear Research Institute in Rez in 1989 and 1990. In the activities, emphasis was put on solving safety problems of Czechoslovak nuclear power plants, which were approached from various points of view in the divisions of nuclear power and safety, of nuclear reactor physics and nuclear reactor materials. Another important field was radioactive wastes, their solidification and storage, which was dealt with by the nuclear chemistry division. In addition to the activities connected with nuclear power plants, increasing attention was paid to research into new radiopharmaceuticals and their production and to the use of ionizing radiation in various technological processes. Analytical chemistry topics included safeguard analyses for the IAEA, radioactivation analysis for environmental purposes, etc. A new direction in the research consisted in the application of previously developed methods to non-nuclear purposes, such as the application of sophisticated fluorine processes to the purification of Pt and Pb catalysts or the application of the vitrification technology to toxic chemical wastes. After general reconstruction, the experimental reactor was put into operation and now is used for the preparation of radionuclides and for irradiation service. Other experimental and production facilities are also mentioned. (author)

Fourth international radiopharmaceutical dosimetry symposium

International Nuclear Information System (INIS)

Schlafke-Stelson, A.T.; Watson, E.E.

1986-04-01

The focus of the Fourth International Radiopharmaceutical Dosimetry Symposium was to explore the impact of current developments in nuclear medicine on absorbed dose calculations. This book contains the proceedings of the meeting including the edited discussion that followed the presentations. Topics that were addressed included the dosimetry associated with radiolabeled monoclonal antibodies and blood elements, ultrashort-lived radionuclides, and positron emitters. Some specific areas of discussion were variations in absorbed dose as a result of alterations in the kinetics, the influence of radioactive contaminants on dose, dose in children and in the fetus, available instrumentation and techniques for collecting the kinetic data needed for dose calculation, dosimetry requirements for the review and approval of new radiopharmaceuticals, and a comparison of the effect on the thyroid of internal versus external irradiation. New models for the urinary blader, skeleton including the active marrow, and the blood were presented. Several papers dealt with the validity of traditional ''average-organ'' dose estimates to express the dose from particulate radiation that has a short range in tissue. These problems are particularly important in the use of monoclonal antibodies and agents used to measure intracellular functions. These proceedings have been published to provide a resource volume for anyone interested in the calculation of absorbed radiation dose

The development of new radiopharmaceuticals

International Nuclear Information System (INIS)

Britton, K.E.

1990-01-01

The development of new radiopharmaceuticals is the basis of the continuing growth of nuclear medicine. Chemical interactions of electron clouds in their three-dimensional conformations bring together, in the process of molecular recognition, the reaction of antibody and antigen, receptor and ligand, enzyme and substrate, hormone and response site. This convergence enables the computer design of molecules such as ligands to fit computer-displayed conformational models showing active centres, positive and negative charges and other interactions. Indeed, given a particular molecule, a complementary binding structure can be devised. The hybridoma approach to monoclonal antibody production is being superceded by the bacterial bioengineer. The gene for the hypervariable region from the spleen cells of immunized mouse can be coupled with the myeloma gene. The polymerase chain reaction can duplicate the DNA a million times over in 20 min and the result transfected into a bacterial plasmid to produce the antibody. These scientific problems are soluble in principle and are being solved. However, so much damage to this developing biological field is being done by regulatory authorities that one must ask who should or can regulate the regulators. The problems have to be overcome in order to provide the new radiopharmaceuticals that are the food and wine of nuclear medicine. (orig.)

Radiopharmaceuticals used in nuclear cardiology

International Nuclear Information System (INIS)

Costa, H.

1985-01-01

During the last years, since short physical mean life radionuclides have started to be used, radionuclide scanning has been experienced with remarkable culmination. There are detector devices, which jointly with computation equipments, allow to obtain multiple images per second as properly rapid gammagraphic series, in order to obtain whole hemodynamic data or to generate functional images no representing an anatomical structure but reporting about cardiac dynamics at regional level. In these techniques, employed in Nuclear Cardiology, the following radionuclides and radiopharmaceuticals are used: radiolabeled albumin 99m Tc red blood cells, 113m In-transferrin, very short physical mean life radionuclides, such as 195m Au, 178 Ta, 191 Ir. In addition, 113 Xe for coronary flow measurements; radiolabeled microspheres and macroparticles for angiogammagraphy; 129 Cs, 43 K, 81 Rb, 82 Rb and 201 Ti, the most largerly used, for myocardial gammagraphy. It is pointed out that fatty acids are the newest, basically if are radioiodate, and some 99m Tc labeled long chain hydrocarbons. It is expressed that 99m Tc-Sn-pyrophosphate has been used for myocardial infarction. Working on the development of new radiopharmaceuticals, basically fatty acids and 99m Tc chelating agents, for the improvement of these techniques is carried out. (author)

A Study on the Quality Control of 18F-FDG Radiopharmaceutical

International Nuclear Information System (INIS)

Kim, Ssang Tae; Yong, Chul Soon; Han, Eun Ok

2010-01-01

The types of test items which were recorded in this test report of quality control domestic 18 F-FDG radiopharmaceutical which consisted of 13 different types: appearance, half-life, radioactive heterokaryosis, radiochemical Confirmation (measure of Rf value), radiochemical Purity, Ethanol, Acetonitrile, Kryptofix, Aluminium, pH, Endotoxin, aseptic test, and radioactivity·ml-1. The record was fully recorded in 'appearance', 'radioactive heterokaryosis', 'pH', 'Endotoxin', and 'aseptic test'. In 'half-life', 'radiochemical Confirmation (measure of Rf value), 'radiochemical Purity', 'Ethanol', 'Acetonitrile', 'Kryptofix', 'Aluminium', 'radioactivity·ml-1', there were differences in records of each manufacturing business on radioactive medicine and medical supplies. The result of the test showed all 13 items of quality control test were 100% suitable on the basis of recorded data. There were more radiopharmaceutical made in the laboratory than in hospitals and businesses and in for result of suitability test, the laboratory showed higher suitability than did the hospitals or businesses. Domestically, there are differences of the test report items in the safety of radiopharmaceutical of each facility, and since it is not standardized, supplements are needed. To submit standardized test reports of quality guarantee in radiopharmaceutical, GMP of U.S. and CE Mark of Europe should be referred as well as receiving advice from professionals to standardize as suitable domestic standard

Uncertainty sources in radiopharmaceuticals clinical studies; Fontes de incertezas em estudos clinicos com radiofarmacos

Energy Technology Data Exchange (ETDEWEB)

Degenhardt, Aemilie Louize; Oliveira, Silvia Maria Velasques de, E-mail: silvia@cnen.gov.br, E-mail: amilie@bolsista.ird.gov.br [Instituto de Radioprotecao e Dosimetria, (IRD/CNEN-RJ), Rio de Janeiro, RJ (Brazil)

2014-07-01

The radiopharmaceuticals should be approved for consumption by evaluating their quality, safety and efficacy. Clinical studies are designed to verify the pharmacodynamics, pharmacological and clinical effects in humans and are required for assuring safety and efficacy. The Bayesian analysis has been used for clinical studies effectiveness evaluation. This work aims to identify uncertainties associated with the process of production of the radionuclide and radiopharmaceutical labelling as well as the radiopharmaceutical administration and scintigraphy images acquisition and processing. For the development of clinical studies in the country, the metrological chain shall assure the traceability of the surveys performed in all phases. (author)

Report of the consultants meeting on good manufacturing practices and clean room requirements for radiopharmaceuticals

International Nuclear Information System (INIS)

2000-07-01

Radiopharmaceuticals are compounds containing radioisotopes that are used in nuclear medicine for a variety of diagnostic studies and, to a limited extent, for therapy. Almost 80% of the diagnostic studies are carried out with 99m Tc containing radiopharmaceuticals (half-life, six hours). Recently, another class of radiopharmaceuticals contains the ultra short-lived isotopes 11 C, 13 N and 15 O as well as 18 F, which are mostly produced and immediately used in the hospital cyclotron Positron Emission Tomography (PET) facilities. In therapy, 131 I is widely used for thyroid disorders, 32 P for treatment of abnormal increase in circulating red blood cells, while 153 Sm and 89 Sr are used for palliation of pain in patients suffering from bone metastases. They contain very small amounts of chemical ingredients, normally do not have any pharmacological effects, and are administered in small volumes. Radiopharmaceuticals are produced, used and exported both in developing and developed countries. The scale of production is small compared to conventional pharmaceuticals. Monographs on radiopharmaceuticals can be found in many pharmacopoeias, such as BP, USP, EP and other compendia. This field is also marked by active research and development of new products both for diagnosis and therapy. Traditionally, production and supply of radiopharmaceuticals started as research activities of national nuclear laboratories operating reactors and cyclotrons. Certain products found useful and effective were continued to be provided to the clinics as a service from the nuclear centres. In developed countries demand of radiopharmaceuticals is so considerable that production and sale are increasingly taken over by commercial companies. On the other hand, in many developing countries, demand is still limited, and radiopharmaceutical production and supply still remain more of a service operation at the national nuclear centres. Depending on the radioactivity levels handled, production has to

Annual Report 2007

International Nuclear Information System (INIS)

Michalik, J.; Smulek, W.; Godlewska-Para, E.

2008-01-01

The Annual Report of the Institute of Nuclear Chemistry and Technology (Warsaw, Poland) describes achievements of the Institute in 2007 obtained in seven fields: (1) radiation chemistry and physics, radiation technologies; (2) radiochemistry, stable isotopes, nuclear analytical methods, general chemistry; (3) radiobiology; (4) nuclear technologies and methods: process engineering; (5) nuclear technologies and methods: material engineering, structural studies, diagnostics; (6) nuclear technologies and methods: nucleonic control systems and accelerators. In total - 76 detailed papers prepared by the Institute workers and collaborating scientists are presented. General information on the Institute status, personnel activity, international cooperation and publications are also given

Annual Report 2007

Energy Technology Data Exchange (ETDEWEB)

Michalik, J; Smulek, W; Godlewska-Para, E [eds.

2008-07-01

The Annual Report of the Institute of Nuclear Chemistry and Technology (Warsaw, Poland) describes achievements of the Institute in 2007 obtained in seven fields: (1) radiation chemistry and physics, radiation technologies; (2) radiochemistry, stable isotopes, nuclear analytical methods, general chemistry; (3) radiobiology; (4) nuclear technologies and methods: process engineering; (5) nuclear technologies and methods: material engineering, structural studies, diagnostics; (6) nuclear technologies and methods: nucleonic control systems and accelerators. In total - 76 detailed papers prepared by the Institute workers and collaborating scientists are presented. General information on the Institute status, personnel activity, international cooperation and publications are also given.

Procedures of quality control of radiopharmaceutical activity counters

International Nuclear Information System (INIS)

Oliveira, A.E. de; Iwahara, A.; Gaast, H.A. van der; Buckman, S.M.

1999-01-01

The Radionuclides Metrology Supervision-Ionizing Radiation Metrology National Laboratory maintain and distributes the brazilian standards for radioactivity measurements. The Brazilian Institute for Metrology, Regulation and Industrial Quality (INMETRO), which is the brazilian authority for standards verification, is coordinating the enhancement of the standards distribution. Concerning to the nuclear medicine related radioisotopes, this network will provide for calibration of brazilian hospitals and clinics instruments, assuring great accuracy of the radiopharmaceuticals activities. This work gives details of the calibration quality control procedures recommended by the Radionuclides Metrology Supervisory (Brazilian National Nuclear Energy Commission) and the Radioactive Standards Division of the Australian Nuclear Technology and Science Organization (ANSTO). This information can be used as a guide for the brazilian nuclear medicine services guaranty on the accuracy and precision of the radiopharmaceuticals activity measurements measurements

Developments in radioisotope production and labelling of radiopharmaceuticals

International Nuclear Information System (INIS)

Lambrecht, R.M.

1998-01-01

Recent developments in both reactor and accelerator production of radioisotopes finding applications in nuclear medicine and in biomedical research are summarised. The priorities for the production of 48 different cyclotron radioisotopes; and for 42 reactor produced radioisotopes finding biomedical applications are identified. Each includes 5 generator systems. The rapid expansion of cyclotron based radioisotope production and automated synthesis of short-lived radiopharmaceuticals with the position-emitting radionuclides continues to gain momentum. Recent feasibility studies of the cyclotron production of 186 Re, 99m Tc and of 99 Mo are cited as examples of motivation to develop accelerator alternatives to use of nuclear reactors for medical radioisotope production. Examples of SPET and PET radiopharmaceuticals labelled with 131 I, 123 I, 124 I, 18 F, and with therapeutic radionuclides are highlighted. (author)

Urinary excretion and external radiation dose from patients administered with radiopharmaceuticals

International Nuclear Information System (INIS)

Konishi, E.; Abe, K.; Kusama, T.

1994-01-01

Patients who have received radiopharmaceuticals become a source of exposure to those near them, such as nursing staff or visiting relatives. In order to provide quantitative information to propose protective measures for carers attending patients administered diagnostic amounts of 99 Tc, 67 Ga or 201 Tl (the most frequently used radiopharmaceuticals) the dose rate at various distances from 84 patients was measured using an ionising chamber, and the radioactivity of these compounds in urine collected from some patients was also measured. (author)

Improving radiopharmaceutical supply chain safety by implementing bar code technology.

Science.gov (United States)

Matanza, David; Hallouard, François; Rioufol, Catherine; Fessi, Hatem; Fraysse, Marc

2014-11-01

The aim of this study was to describe and evaluate an approach for improving radiopharmaceutical supply chain safety by implementing bar code technology. We first evaluated the current situation of our radiopharmaceutical supply chain and, by means of the ALARM protocol, analysed two dispensing errors that occurred in our department. Thereafter, we implemented a bar code system to secure selected key stages of the radiopharmaceutical supply chain. Finally, we evaluated the cost of this implementation, from overtime, to overheads, to additional radiation exposure to workers. An analysis of the events that occurred revealed a lack of identification of prepared or dispensed drugs. Moreover, the evaluation of the current radiopharmaceutical supply chain showed that the dispensation and injection steps needed to be further secured. The bar code system was used to reinforce product identification at three selected key stages: at usable stock entry; at preparation-dispensation; and during administration, allowing to check conformity between the labelling of the delivered product (identity and activity) and the prescription. The extra time needed for all these steps had no impact on the number and successful conduct of examinations. The investment cost was reduced (2600 euros for new material and 30 euros a year for additional supplies) because of pre-existing computing equipment. With regard to the radiation exposure to workers there was an insignificant overexposure for hands with this new organization because of the labelling and scanning processes of radiolabelled preparation vials. Implementation of bar code technology is now an essential part of a global securing approach towards optimum patient management.

Radiopharmaceuticals and hospital radiopharmacy practices: course manual for accreditation/certification of hospital radiopharmacists

International Nuclear Information System (INIS)

Ramamoorthy, N.; Shivarudrappa, V.; Bhelose, Amita A.

2000-02-01

This manual on hospital radiopharmaceuticals and hospital radiopharmacy practices contains information and recommendations that could be of use to hospital radiopharmacists while the main focus of the book is to impart adequate exposure to basics of radiopharmaceuticals and purity and safety aspects of formulations to be made in hospital radiopharmacy. Papers relevant to INIS are indexed separately

Analytical methods for determination of radiochemical and radionuclidic purity of radiopharmaceuticals containing sup(99m)Tc and sup(113m)In. Part of a coordinated programme on radiopharmaceuticals

International Nuclear Information System (INIS)

Galatzeanu, I.

1974-01-01

The obtained results on radiochemical and radionuclidic purities determination of sup(99m)Tc and sup(113m)In-radiopharmaceuticals proved to be a good tool for small hospital units and laboratories in satisfying their duty to improve the quality control. The complicated behaviour of technetium in aqueous solutions during the preparation of radiopharmaceuticals, needs further research work to elucidate the mechanisms of interaction of reduced species with media and their disproportionation

Annual progress report of the physical chemistry department. Basic research 1987

International Nuclear Information System (INIS)

1988-01-01

Basic research for 1987 in physical chemistry of the French Atomic Energy Commission are reviewed. Topics include molecular chemistry, isotopic geochemistry, molecular photophysics, laser photochemistry, solid and surface physical chemistry. A list of publications and thesis is given [fr

Adverse reactions to radiopharmaceuticals and their reporting

International Nuclear Information System (INIS)

Keeling, D.

1988-01-01

Adverse reactions to radiopharmaceuticals are uncommon and the great majority that do occur are relatively trivial and require little or no treatment. Reporting schemes for such reactions are in operation in a number of countries but they vary in their effectiveness and the best collect only a minority of cases; only 10-15% of total reactions in the United Kingdom, for instance. Radiopharmaceutical reaction reports in the UK for the period 1982-1987 are summarised in a table and then discussed. Reliable incidence figures for such reactions are difficult to obtain. The UK figure is estimated here to be near 1 per 2000. The great majority of reactions reported are of an idiopathic hypersensitivity nature and are related to the chemical form of the material; radiation has very rarely caused recognisable problems since the discontinuance of colloid gold for lymphatic clearance studies. The value of such reaction reports is their role as a forewarning to doctors

Implementation of a metrology programme to provide traceability for radionuclides activity measurements in the CNEN Radiopharmaceuticals Producers Centers

Energy Technology Data Exchange (ETDEWEB)

Andrade, Erica A.L. de; Braghirolli, Ana M.S.; Tauhata, Luiz; Gomes, Regio S.; Silva, Carlos J., E-mail: erica@ien.gov.br [Instituto de Engenharia Nuclear (IEN/CNEN-RJ), Rio de Janeiro, RJ (Brazil); Delgado, Jose U.; Oliveira, Antonio E.; Iwahara, Akira, E-mail: ealima@ird.gov.br [Instituto de Radioprotecao e Dosimetria (IRD/CNEN-RJ), Rio de Janeiro, RJ (Brazil)

2013-07-01

The commercialization and use of radiopharmaceuticals in Brazil are regulated by Agencia Nacional de Vigilancia Sanitaria (ANVISA) which require Good Manufacturing Practices (GMP) certification for Radiopharmaceuticals Producer Centers. Quality Assurance Program should implement the GMP standards to ensure radiopharmaceuticals have requirements quality to proving its efficiency. Several aspects should be controlled within the Quality Assurance Programs, and one of them is the traceability of the Radionuclides Activity Measurement in radiopharmaceuticals doses. The quality assurance of activity measurements is fundamental to maintain both the efficiency of the nuclear medicine procedures and patient and exposed occupationally individuals safety. The radiation doses received by patients, during the nuclear medicine procedures, is estimated according to administered radiopharmaceuticals quantity. Therefore it is very important either the activity measurements performed in radiopharmaceuticals producer centers (RPC) as the measurements performed in nuclear medicine services are traceable to national standards. This paper aims to present an implementation program to provide traceability to radionuclides activity measurements performed in the dose calibrators(well type ionization chambers) used in Radiopharmaceuticals Producer Center placed in different states in Brazil. The proposed program is based on the principles of GM Pand ISO 17025 standards. According to dose calibrator performance, the RPC will be able to provide consistent, safe and effective radioactivity measurement to the nuclear medicine services. (author)

Current status of production and research of radioisotopes and radiopharmaceuticals in Indonesia

Energy Technology Data Exchange (ETDEWEB)

Soenarjo, Sunarhadijoso; Tamat, Swasono R. [Center for Development of Radioisotopes and Radiopharmaceuticals, National Nuclear Energy Agency (BATAN), Kawasan Puspiptek, Serpong, Tangerang (Indonesia)

2000-10-01

The use of radioactive preparation in Indonesia has sharply increased during the past years, indicated by increase of the number of companies utilizing radioisotopes during 1985 to 1999. It has been clearly stressed in the BATAN's Strategic Plan for 1994-2014 that the production of radioisotopes and radiopharmaceuticals is one of five main industrial fields within the platform of the Indonesian nuclear industry. Research programs supporting the production of radioisotopes and radiopharmaceuticals as well as development of production technology are undertaken by the Research Center for Nuclear Techniques (RCNT) in Bandung and by the Radioisotope Production Center (RPC) in Serpong, involving cooperation with other research center within BATAN, universities and hospitals as well as overseas nuclear research institution. The presented paper describes production and research status of radioisotopes and radiopharmaceuticals in Indonesia after the establishment of P.T. Batan Teknologi in 1996, a government company assigned for activities related to the commercial application of nuclear technology. The reviewed status is divided into two short periods, i.e. before and after the Chairman Decree No. 73/KA/IV/1999 declaring new BATAN organizational structure. Subsequent to the Decree, all commercial requests for radioisotopes and radiopharmaceuticals are fulfilled by P.T. Batan Teknologi, while demands on novel radioactive preparations or new processing technology, as well as research and development activities should be fulfilled by the Center for the Development of Radioisotopes and Radiopharmaceuticals (CDRR) through non-commercial arrangement. The near-future strategic research programs to response to dynamic public demand are also discussed. The status of research cooperation with JAERI (Japan) is also reported. (author)

Analytical techniques for the determination of radiochemical purity of radiopharmaceuticals prepared from kits. Pt. III

International Nuclear Information System (INIS)

McLean, J.R.; Rockwell, L.J.; Welsh, W.J.

1982-01-01

The evaluation of efficacy of commercially available kits used for the preparation of radiopharmaceuticals is one aspect of the Radiation Protection Bureau's radiopharmaceutical quality control program. This report describes some of the analytical methodology employed in the program. The techniques may be of interest to hospital radiopharmacy personnel since many of the tests can be performed rapidly and with a minimum of special equipment, thus enabling the confirmation of radiopharmaceutical purity prior to patient administration. Manufacturers of kits may also be interested in learning of the analytical methods used in the assessment of their products

Radiopharmaceuticals for palliative therapy pain; Radiofarmacos para terapia paliativa del dolor

Energy Technology Data Exchange (ETDEWEB)

Gaudiano, Javier [Universidad de la Republica, Montevideo (Uruguay). Centro de Medicina Nuclear

1994-12-31

Dissemination to bone of various neoplasms is cause of pain with poor response by major analgesics.Indications. Radiopharmaceuticals,description of main characteristics of various {beta} emitter radionuclides.Choose of patients for worm indication of pain palliative therapy with {beta} emitter radiopharmaceuticals is adequate must be careful . Contraindications are recognized.Pre and post treatment controls as clinical examination and complete serology are described.It is essential to subscribe protocols,keep patient well informed,included the physician in charge of the patient as part of the team.Bibliography.

A Unique Master's Program in Combined Nuclear Technology and Nuclear Chemistry at Chalmers University of Technology, Sweden

International Nuclear Information System (INIS)

Skarnemark, Gunnar; Allard, Stefan; Ekberg, Christian; Nordlund, Anders

2009-01-01

The need for engineers and scientists who can ensure safe and secure use of nuclear energy is large in Sweden and internationally. Chalmers University of Technology is therefore launching a new 2-year master's program in Nuclear Engineering, with start from the autumn of 2009. The program is open to Swedish and foreign students. The program starts with compulsory courses dealing with the basics of nuclear chemistry and physics, radiation protection, nuclear power and reactors, nuclear fuel supply, nuclear waste management and nuclear safety and security. There are also compulsory courses in nuclear industry applications and sustainable energy futures. The subsequent elective courses can be chosen freely but there is also a possibility to choose informal tracks that concentrate on nuclear chemistry or reactor technology and physics. The nuclear chemistry track comprises courses in e.g. chemistry of lanthanides, actinides and transactinides, solvent extraction, radioecology and radioanalytical chemistry and radiopharmaceuticals. The program is finished with a one semester thesis project. This is probably a unique master program in the sense of its combination of deep courses in both nuclear technology and nuclear chemistry.

Comparison of two methods of radiopharmaceuticals production and evaluation of their quality

International Nuclear Information System (INIS)

Portillo L, M.C.; Rodriguez J, S.

1987-05-01

Two methods for the following five radiopharmaceuticals production were compared: sulfur colloid, diethylenetriamine pentaacetic calcium salt, phyrophosphate sodium, albumin aggregated, glucoheptonate calcium salt. Radiochemical purity was determined by electrophoresis, thin-layer chromatography and bio-distribution test in mice and rats. It was concluded that chromatographic method shows better efficiency and that bio-distribution test should be done only when testing new radiopharmaceuticals because the good correlation of this test with thin-layer chromatography. (author)

Impact of chemistry on production and utilization of radioisotopes and related products

International Nuclear Information System (INIS)

Ramamoorthy, N.

2011-01-01

The year 2011, declared as the International Year of Chemistry (IYC), commemorates the centenary of the award of Nobel Prize in Chemistry to Madam Curie for her pioneering work on the discovery of Radium and Polonium. Her invaluable discovery and her other research pursuits, as well as other subsequent discoveries in nuclear sciences, including by her daughter and son-in-law - Irene Curie and Frederic Joliot - who in 1935 discovered the phenomenon of artificially induced radioactivity (that later bagged the Nobel Prize), led to several noteworthy applications. The author, as a member of 'Indian radioisotope family' and the DAE programmes on radioisotopes and related radiation technology since August 1972, narrates in this article a series of select chemistry-related milestones that enabled vital developments in the production of isotope products and their applications. Ingenious and often simple chemistry-based solutions instituted by the researchers stand out in the enormous progress achieved over the years and highly significant practical applications rendered a reality. Appropriate examples can be cited from both the Indian scenario and international developments over the past nearly four decades. The long list will include inter alia the following: change of eluent from dilute nitric acid to normal saline to obtain medical-grade pertechnetate from molybdate adsorbed an acidic alumina (ushering in 99m Tc generators for (radio)pharmacy use); premixing a reducing agent like stannous chloride with ligand and freeze-drying the mixture - 'lyophilised kit' - (providing an easy access to 99m Tc radiopharmaceuticals); introduction of an iodine atom in place of an aryl hydrogen as a non-isotopic label in organic compound of interest (birth of radioiodinated compounds for biomedical use); bifunctional chelates designed to link radiometals with biological or pharmaceutical compound (radiolabeled biological analogues for medical use); nucleophilic substitution by fluoride

Cerenkov Luminescence Tomography for In Vivo Radiopharmaceutical Imaging

Directory of Open Access Journals (Sweden)

Jianghong Zhong

2011-01-01

Full Text Available Cerenkov luminescence imaging (CLI is a cost-effective molecular imaging tool for biomedical applications of radiotracers. The introduction of Cerenkov luminescence tomography (CLT relative to planar CLI can be compared to the development of X-ray CT based on radiography. With CLT, quantitative and localized analysis of a radiopharmaceutical distribution becomes feasible. In this contribution, a feasibility study of in vivo radiopharmaceutical imaging in heterogeneous medium is presented. Coupled with a multimodal in vivo imaging system, this CLT reconstruction method allows precise anatomical registration of the positron probe in heterogeneous tissues and facilitates the more widespread application of radiotracers. Source distribution inside the small animal is obtained from CLT reconstruction. The experimental results demonstrated that CLT can be employed as an available in vivo tomographic imaging of charged particle emitters in a heterogeneous medium.

Radiopharmaceuticals using radioactive compounds in pharmaceutics and medicine

International Nuclear Information System (INIS)

Theobald, A.

1989-01-01

This review of the latest techniques and developments indicates the importance of radiopharmaceutical techniques in the development of drug compounds. It presents practical demonstrations, offers practical exercises, as well as the underlying theoretical considerations: it will supplement existing (mostly American) texts in this subject, since most industrial pharmaceutical companies have a keen interest in the area and most pharmaceutical courses include the subject at degree level. The authors emphasize the pharmaceutical applications throughout. They review targeting aspects, including cell and protein labelling: and discuss radiotracers in testing dosage forms and formulation studies. Safety and legislation are considered, with reviews of the handling techniques, radiation monitoring, radiochromatography and the use of computer techniques. The latter part of the work discusses standards for radiopharmaceuticals, sterility and pyrogen testing, as well as both radiochromatographic and electrophoretic methods and their importance to quality control. (author)

Preparações radiofarmacêuticas e suas aplicações Radiopharmaceuticals and applications

Directory of Open Access Journals (Sweden)

Rita Oliveira

2006-06-01

ármacos em uso clínico corresponde a agentes de perfusão. Atualmente, o esforço de investigação na área da química radiofarmacêutica centra-se no desenvolvimento de radiofármacos específicos que possam fornecer informação, ao nível molecular, relativa às alterações bioquímicas associadas às diferentes patologias.Radiopharmaceuticals are substances without pharmacological activity that are used in Nuclear Medicine for diagnosis and therapy for several diseases. Diagnosis radiopharmaceuticals generally emit gamma radiation or positrons (beta+, because their decay originates penetrating electromagnetic radiation that can cross the tissues and be externally detected. Therapeutic radiopharmaceuticals must include in their composition ionized particles emission nucleus (a, b- or Auger electrons, since their action is based in selective tissue destruction. There are two main methods for image acquisition: SPECT (Single Photon Emission Computerized Tomography that uses g emission radionuclides (99mTc, 123I, 67Ga, 201Tl and PET (Positron Emission Tomography that uses positron emission radionuclides like 11C, 13N, 15O, 18F. Radiopharmaceuticals can be classified into perfusion radiopharmaceuticals (first generation or specific radiopharmaceuticals (second generation. Perfusion radiopharmaceuticals are transported in the blood e reach the target organ in the direct proportion of the blood stream. Specific radiopharmaceuticals contain a biologically active molecule that binds to cellular receptors that must remain biospecific after binding to the radiopharmaceutical. For this type of radiopharmaceuticals, tissue or organ uptake is determined by the biomolecule capacity of recognizing receptors in those biological structures. Radiopharmaceuticals are produced ready to use, in cold kits or in autologal preparations. According to the preparation type there is a different quality control procedure. Most of the radiopharmaceuticals used nowadays are of the perfusion type

Legal aspects of the production and application of radiopharmaceuticals in Germany; Arzeinmittelrechtliche Aspekte der Herstellung und Anwendung von Radiopharmaka

Energy Technology Data Exchange (ETDEWEB)

Kuwert, T.; Prante, O. [Universitaetsklinikum, Erlangen (Germany). Nuklearmedizinische Klinik; Meyer, G. [Medizinische Hochschule Hannover (Germany). Klinik fuer Nuklearmedizin

2009-06-15

This article deals with the regulation of the production and use of radiopharmaceuticals in Germany. As in other countries, radiopharmaceuticals may be used when licensed by the German equivalent of the Federal Drug Agency or in clinical trials. Furthermore, non-licensed radiopharmaceuticals can be administered to patients for diagnosis when they are produced in the same institution and not more than 20 doses per week and radiopharmaceutical are given. A prerequisite for these three ways of use is the production of the radiopharmaceutical in question according to the guidelines of the good manufacturing practice (GMP) which creates considerable problems for the usually small PET centers installed in the German university hospitals. German law offers a further possibility to apply non-licensed radiopharmaceuticals for clinical purposes: their administration to patients is not forbidden when performed by a physician who produces the substance himself or is at least responsible for its synthesis. This regulation has, however, been met with criticism by government agencies. (orig.)

Radiopharmaceuticals in breast milk

International Nuclear Information System (INIS)

Mountford, P.J.; Coakley, A.J.

1986-01-01

As assessment has been made of the radiological hazards to an infant following the administration of a radiopharmaceutical to a breast feeding mother. Feeding should be discontinued after administration of most I-131 and I-125 compounds, Ga-67 citrate or Se-78 methionine, and for iodinated compounds where it was possible to resume feeding, a thyroid-blocking agent should be administered. For Tc-99m compounds, pertechnetate had the greatest excretion in milk and interruptions of 12hr and 4hr were considered appropriate for pertechnetate and MAA respectively. Other Tc-99m compounds, Cr-51 EDTA and In-111 leucocytes did not justify an interruption just on the grounds of their associated excretion in milk. The ingestion hazard could be minimized by reducing the administered activity, and in some cases, by the substitution of a radiopharmaceutical with lower breast milk excretion. For Tc-99m lung and brain scans, the absorbed dose due to radiation emitted by the mother (i.e. when cuddling) was less than the ingested dose, but for a Tc-99m bone scan the emitted dose was greater. In all three cases, the emitted dose did not exceed 0 x 5 mGy for the infant in close contact to the mother for one-third of the time. For In-111 leucocytes, the emitted dose was about 2mGy, and it was concluded that close contact should be restricted to feeding times during the first 3 days after injection. 36 references, 2 figures, 5 tables

Click chemistry for [99mTc(CO)3] labeling of Lys3-bombesin

International Nuclear Information System (INIS)

Ferro-Flores, G.; Rivero, I.A.; Santos-Cuevas, C.L.; Sarmiento, J.I.; Arteaga de Murphy, C.; Ocampo-Garcia, B.E.; Garcia-Becerra, R.; Ordaz-Rosado, D.

2010-01-01

99m Tc-HYNIC labeled Lys 3 -bombesin has shown specific binding to gastrin-releasing peptide receptors (GRP-r) over-expressed in cancer cells. Click chemistry offers an innovative functionalization strategy for biomolecules such as bombesin. The aim of this research was to apply a click chemistry approach for [ 99m Tc(CO) 3 ] labeling of Lys 3 -bombesin and to compare the in vitro MCF7 breast cancer cell uptake and biodistribution profile in mice with that of 99m Tc-EDDA/HYNIC-Lys 3 -bombesin. The results suggest a higher lipophilicity for 99m Tc(CO) 3 -triazole-Lys 3 -bombesin which explains its higher in vivo hepatobiliary elimination. Pancreas-to-blood ratio for 99m Tc(CO) 3 -triazole-Lys 3 -bombesin was 4.46 at 3 h and both bombesin radiopharmaceuticals showed specific recognition for GRP receptors in MCF7 cancer cells. Click chemistry is a reliable approach for [ 99m Tc(CO) 3 ] labeling of Lys 3 -bombesin.

Radiopharmaceuticals labelled with positron-emitting radioisotopes

International Nuclear Information System (INIS)

Comar, D.; Berridge, M.; Maziere, B.; Crouzel, C.

1982-01-01

This chapter reviews the preparation of radioisotopes for biochemical and physiological studies and the principal methods for their incorporation into radiopharmaceuticals, while pointing out the problems encountered with their use and considering their medical interest in the following areas: distribution and flow of fluids, metabolic and pharmacokinetic studies. Inorganic and organic radiopharmaceuticals presently in use and most probable to be used in the future are reviewed. It is anticipated that three types of products labelled with 15 O, 13 N, 11 C and 18 F will be developed in the future. The first type includes products which trace general phenomena such as fluid movement or metabolism of sugars, fats and proteins. The compromise between physiological accuracy and imaging technology is discussed in relation to the use of 11 C and 18 F. The second type of product is one to measure more specific parameters such as those of molecular transport kinetics, membrane permeability, cellular pH and receptor-ligand interactions, again with particular reference to 11 C and 18 F. The third type of product discussed is that intended for pharmacology studies, particular reference being made to 68 Ga, 82 Rb. Extensive bibliography. (U.K.)

Preparation and quality control of technetium-99m radiopharmaceuticals

International Nuclear Information System (INIS)

Samuels, D.L.

1978-11-01

Appropriate procedures for the production and quality control of technetium-99m based radiopharmaceuticals in hospital radiopharmacy consistent with the recently published Australian Code of Good Manufacturing Practice are discussed

Report on the 1. research coordination meeting on 'Development of therapeutic radiopharmaceuticals based on 177Lu for radionuclide therapy'

International Nuclear Information System (INIS)

2006-01-01

Radionuclide therapy (RNT) employing radiopharmaceuticals labelled with emitting radionuclides is fast emerging as an important part of nuclear medicine. Radionuclide therapy is effectively utilized for bone pain palliation, thus providing significant improvement in quality of life of patients suffering from pain resulting from bone metastasis. Targeting primary diseases by using specific carrier molecules labelled with radionuclides is also widely investigated and efficacious products have been emerging for the treatment of Lymphoma and Neuroendocrine tumours. In order to ensure the wider use of radiopharmaceuticals, it is essential to carefully consider the choice of radionuclides that together with the carrier molecules will give suitable pharmacokinetic properties and therapeutic efficacy. The criteria for the selection of a radionuclide for radiotherapy are suitable decay characteristics and amenable chemistry. However, the practical considerations in selecting a radionuclide for targeted therapy are availability in high radionuclidic purity as well as high specific activity and low production cost and comfortable delivery logistics. 177 Lu is one of the isotopes emerging as a clear choice for therapy. Worldwide, the isotope is under investigation for approximately 30 different clinical applications, including treatment of colon cancer, metastatic bone cancer, non-Hodgkin's lymphoma, and lung cancer. 177 Lu decays with a half-life of 6.71 d by emission of particles with E max of 497 keV (78.6%), 384 keV (9.1%) and 176 keV (12.2%). It also emits photons of 113 keV (6.4%) and 208 keV (11%), that are ideally suited for imaging the in-vivo localization and dosimetric calculations applying a gamma camera. The physical half-life of 177 Lu is comparable to that of 131 I, the most widely used therapeutic radionuclide. The long halflife of 177 Lu provides logistic advantage for production, QA/QC of the products as well as feasibility to supply the products to places

Export of radiopharmaceuticals and establishment of export base of cyclotron

International Nuclear Information System (INIS)

Jung, Kyungil; Kim, Youngsik

2006-01-01

Sam young Unit ech has seized an opportunity to advance into the radiopharmaceuticals market through successful transfer of radiopharmaceuticals manufacturing technology and medical cyclotron, an original technology in nuclear medicine that is the core of less developed areas in nuclear-related fields. The company has continued to push for research development and establishment of market base through industry-academia-research center cooperation with an aim to complement relatively less developed domestic technology and market than in advanced countries, and is making efforts to establish export base in the overseas market based on stabilized supply in the domestic market. As for radiopharmaceuticals, the company is exporting Tc-99m generator to Vietnam, Thailand and the Philippines and preparing itself to export manufacture facilities for Tc-99m generator to Syria and Kazakhstan. In addition, it plans to export 13Mev Cyclotron that has been commercialized after being developed in the domestic market to the U. S. The company plans to grow up to play a pivotal role in the domestic RT area by conducting proactive business activities with an aim to revitalize the domestic market and further domestic original technologies and products in the global market

Preparation of Radiopharmaceuticals Labeled with Metal Radionuclides

Energy Technology Data Exchange (ETDEWEB)

Welch, M.J.

2012-02-16

The overall goal of this project was to develop methods for the production of metal-based radionuclides, to develop metal-based radiopharmaceuticals and in a limited number of cases, to translate these agents to the clinical situation. Initial work concentrated on the application of the radionuclides of Cu, Cu-60, Cu-61 and Cu-64, as well as application of Ga-68 radiopharmaceuticals. Initially Cu-64 was produced at the Missouri University Research Reactor and experiments carried out at Washington University. A limited number of studies were carried out utilizing Cu-62, a generator produced radionuclide produced by Mallinckrodt Inc. (now Covidien). In these studies, copper-62-labeled pyruvaldehyde Bis(N{sup 4}-methylthiosemicarbazonato)-copper(II) was studied as an agent for cerebral myocardial perfusion. A remote system for the production of this radiopharmaceutical was developed and a limited number of patient studies carried out with this agent. Various other copper radiopharmaceuticals were investigated, these included copper labeled blood imaging agents as well as Cu-64 labeled antibodies. Cu-64 labeled antibodies targeting colon cancer were translated to the human situation. Cu-64 was also used to label peptides (Cu-64 octriatide) and this is one of the first applications of a peptide radiolabeled with a positron emitting metal radionuclide. Investigations were then pursued on the preparation of the copper radionuclides on a small biomedical cyclotron. A system for the production of high specific activity Cu-64 was developed and initially the Cu-64 was utilized to study the hypoxic imaging agent Cu-64 ATSM. Utilizing the same target system, other positron emitting metal radionuclides were produced, these were Y-86 and Ga-66. Radiopharmaceuticals were labeled utilizing both of these radionuclides. Many studies were carried out in animal models on the uptake of Cu-ATSM in hypoxic tissue. The hypothesis is that Cu-ATSM retention in vivo is dependent upon the

VII Russian annual conference of young scientists and postgraduate students Physical chemistry and technology of inorganic materials. Collection of materials

International Nuclear Information System (INIS)

Tsvetkov, Yu.V.

2010-01-01

The materials of the VII Russian annual conference of young scientists and postgraduate students Physical chemistry and technology of inorganic materials, held 8-11 November 2010 in Moscow, are presented. Structure and properties of high-strength nanostructured metal and composite materials, development of research methods and simulation of the structure and properties of materials and nanomaterials, functional ceramic and composite nanomaterials - in sight of the participants. The problems of physicochemical principles and processes for new technologies and forming powder materials and nanomaterials, physicochemical bases of production and processing of advanced inorganic materials, physical chemistry and technology of energy-, resource-saving and environmentally friendly processes for ferrous, non-ferrous and rare metals are under consideration. Promising composite coatings and nanostructured films of functional purposes, physicochemical bases of new processes of shaping and forming of materials and nanomaterials are discussed [ru

Effects of radiation exposure from radiopharmaceuticals used in diagnostic studies

International Nuclear Information System (INIS)

Witcofski, R.L.

1981-01-01

In the United States about 90 percent of man-made radiation exposure to the general population is from the use of radiation in diagnostic medicine. Although the doses of radiation from these procedures to individuals are generally quite small, large numbers of people are exposed. Estimates of the radiation doses associated with such use in the healing arts are approximately 15 million person-rem to the general population from diagnostic x ray and 3.3 million person-rem from the diagnostic use of radiopharmaceuticals. The purpose of this paper is to present what is known about the possible effects of radiation from diagnostic radiopharmaceuticals

Study of surface potential contamination in radioisotope and radiopharmaceutical production facilities and alternative solutions

International Nuclear Information System (INIS)

Suhaedi Muhammad; Rimin Sumantri; Farida Tusafariah; Djarwanti Rahayu Pipin Soedjarwo

2013-01-01

Radioisotope and radiopharmaceutical production facilities that exist in their operations around the world in the form of radiological impacts of radiation exposure, contamination of surface and air contamination. Given the number of existing open source in radioisotope and radiopharmaceutical production facility, then the possibility of surface contamination in the work area is quite high. For that to protect the safety and health of both workers, the public and the environment, then the licensee must conduct an inventory of some of the potential that could result in contamination of surfaces in radioisotope and radiopharmaceutical production facilities. Several potential to cause surface contamination in radioisotope and radiopharmaceutical production facilities consist of loss of resources, the VAC system disorders, impaired production facilities, limited resources and lack of work discipline and radioactive waste handling activities. From the study of some potential, there are several alternative solutions that can be implemented by the licensee to address the contamination of the surface so as not to cause adverse radiological impacts for both radiation workers, the public or the environment. (author)

Radiopharmaceuticals in Radiosynoviorthesis

International Nuclear Information System (INIS)

Cruz Arencibia, Jorge; Morin Zorrilla, Jose; Garcia Rodriguez, Enrique; Sagarra Veranes, Marta

2010-01-01

The Radiosynoviorthesis is a procedure of Metabolic Radiotherapy, consisting in the intraarticular injection of a radiopharmaceutical with a beta emitting radionuclide for the treatment of chronic synovitis, frequently present in rheumatoid arthritis, haemophilia and other systemic diseases. As this is a safe, effective and a relatively low-cost procedure, It is ordinarily used in Europe, USA and in some Latin American countries . The existing commercial products are based on 90 Y, 169 Er, 186 Re and 32 P, although research is carried out on the use of 188 Re, 166 Ho, among others radionuclides. In Cuba a suspension of Chromium Phosphate (III) labeled with 32 P, is on trial. The above-mentioned suspension has enough characteristics to become an efficient and safe product in practice. (Author)

The liability of the radiopharmacist and the nuclear physician in the use of radiopharmaceuticals

International Nuclear Information System (INIS)

Coustou, F.

1986-01-01

A brief article examines the traditional aspects of the physician's and pharmacist's liability in general followed by a discussion on the liability of the nuclear physician and the radiopharmacist in the use of radiopharmaceuticals. It is concluded that the liabilities involved in the use of radiopharmaceuticals go well beyond the scope of traditional medicine and pharmacy. (UK)

Annual reports in inorganic and general syntheses 1972

CERN Document Server

Niedenzu, Kurt

1973-01-01

Annual Reports in Inorganic and General Syntheses-1972 presents an organized annual summary of synthetic developments in inorganic chemistry and its related areas. The book discusses alkali and alkaline earth elements, alloys, silver, gold, zinc, cadmium, mercury, boron, aluminum, gallium, indium, thallium, yttrium, scandium, lanthanides, actinides, titanium, zirconium, hafnium, Group V and VI transition elements, manganese, technetium, rhenium, iron, cobalt, nickel, ruthenium, osmium, rhodium, and iridium. The text also describes the chemistry of palladium, platinum, silicon, germanium, tin,

The regional service for the preparation and distribution of radiopharmaceuticals in the west of Scotland

International Nuclear Information System (INIS)

Horton, P.W.

1977-01-01

The centralised preparation of radiopharmaceuticals was begun in 1965 for reasons of radiological safety and cost effectiveness. It enabled the provision of a single specially designed facility to process large quantities of radioactivity safely and avoided the distributed handling of radioactivity. Effective supervision of the safe usage and disposal of radionuclides in hospitals throughout the region became practicable. It also enabled the bulk purchase of radiopharmaceuticals with lower unit costs and their efficient utilisation due to the large number of users. Since 1965, great changes have taken place in the nature of the common radiopharmaceuticals. Most now have short physical half-lives and must be prepared close to their place of use. This has meant improving the pharmaceutical standards of the facilities and working methods. However, the reasons stated above for a centralised service are still applicable and have been reinforced by others arising from the need for good pharmaceutical manufacturing practice in current radiopharmaceutical production

Analysis of residual solvents in PET radiopharmaceuticals by GC

International Nuclear Information System (INIS)

Li Yungang; Zhang Xiaojun; Liu Jian; Tian Jiahe; Zhang Jinming

2013-01-01

The residual solvents in PET radiopharmaceuticals were analyzed by GC, which were acetonitrile, ethanol, N, N-dimethylethanolamine (DMEA), dimethylsulfoxide (DMSO). The standard curves were established with the AT-624 capillary column at GC, and the sensitivity of acetonitrile and ethanol were 0.004-0.320 g/L and 0.010-0.120 g/L respectively. The residual solvents of acetonitrile, ethanol, DMEA and DMSO in PET radio- pharmaceuticals were analyzed by GC. The linearity were 0.9994, 0.9999, 0.9997, 0.999 6 respectively. The residual of acetonitrile were (0.0313±0.0433), (0.0829±0.0668), (0.0156±0.0059), (0.0254±0.0266) g/L in 18 F-FDG, 18 F-FLT, 11 C-CFT, 11 C-PIB respectively. The residual of ethanol was (0.0505±0.00528) g/L in 18 F-FDG. The residual of DMSO were (0.0331±0.0180) g/L, (0.0238±0.0100) g/L in 18 F-W372 and 11 C-DTBZ respectively. The residual of DMEA was (0.0348±0.0022) g/L in 11 C-Choline. The survived of organic solvent in PET radiopharmaceuticals can be analyzed with GC directly. The results showed that the QC should be done in PET radiopharmaceuticals purity with semi-HPLC to avoid the high residual. (authors)

Bone-seeking radiopharmaceuticals in skeletal malignancy: evolution, not revolution

International Nuclear Information System (INIS)

MacFarlane, D.

2003-01-01

Many advanced malignancies are complicated by skeletal metastases, with attendant pain and disability. External beam radiotherapy is still the most effective treatment for isolated lesions. Bone-seeking radiopharmaceuticals were perceived as a means of delivering radiation to multiple lesions simultaneously. A wide variety of radioisotopes have been used in this endeavor, with myelosuppression being the most significant potential adverse effect. Benefits of treatment are modest, including a transient improvement in pain control and perhaps prolongation of the treatment-free period. This is best demonstrated in prostate cancer with lower responses by skeletal metastases from breast and lung cancers. However, the treatment is yet to produce any improvement in patient survival. Experimental approaches to improve treatment efficacy include combination with cytotoxic therapy, and administration earlier in the course of the disease. Bone seeking radiopharmaceuticals have been used in treatment of advanced osteosarcoma in humans and canines and achieved effective palliation. The myelosuppressive effects of these agents have been exploited in patients with multiple myeloma to assist in attaining myeloablation prior to stem cell transplantation. Development of more potent non-radiolabelled bisphosphonates and recognition of their antitumour effect against several tumours has sparked a recrudescence of interest in their use for bone metastases. Set against these developments, the role of bone-seeking radiopharmaceuticals in skeletal metastases may need to be redefined

Annual report 1987

International Nuclear Information System (INIS)

1988-01-01

In this annual report of the Dutch Interfacultary Reactor Institute, summary and detailed reports are presented of current research during 1987 of the departments radiochemistry, radiation chemistry, radiation physics and reactor physics. (H.W.). 61 refs.; 13 figs.; 14 tabs

Pain palliative Radiopharmaceuticals; Radiofarmacos paliativos del dolor

Energy Technology Data Exchange (ETDEWEB)

Gonzalez, B M [Instituto Nacional de Pediatria (Mexico)

1994-12-31

A pain relieving agents based on {beta} emitters mainly and in some cases a complex preparation are being given for bone metastasis in relation with breast,prostate and lung carcinoma with good performance in clinical practice.Several radionuclides and radiopharmaceuticals are mentioned giving strength to those newly proposed, 153Sm and 186Re.Bibliography.

Abbreviated New Drug Applications (ANDAS): Future trend in radiopharmaceuticals

International Nuclear Information System (INIS)

Kishore, R.

1990-01-01

The Drug Price Competition and Patent Term Restoration Act (commonly called Waxman Hatch Amendment) of 1984, to the Federal Food, Drug, and Cosmetic Act provided for abbreviated new drug applications (ANDAs) if the conditions specified in the Code of Federal Regulations (CFR) Title 21, subsection 312.55 are met. Under this subsection, reports of nonclinical laboratory studies and clinical investigations can be omitted. New drugs approved under these regulations are so called generic drugs as opposed to listed or pioneer (innovator) drugs. As the patents on more and more radiopharmaceuticals reach their expiration, the radiopharmaceutical industry is likely to produce more of these generic versions of innovator drugs. The ANDAs are required to contain information specified under subsections 314.50(a), (b), (d)(1) and (3), (e), and (g)

Applying knowledge engineering tools for the personal computer to the operation and maintenance of radiopharmaceutical production systems

International Nuclear Information System (INIS)

Alexoff, D.L.

1990-01-01

A practical consequence of over three decades of Artificial Intelligence (AI) research has been the emergence of Personal Computer-based AI programming tools. A special class of this microcomputer-based software, called expert systems shells, is now applied routinely outside the realm of classical AI to solve many types of problems, particularly in analytical chemistry. These AI tools offer not only some of the advantages inherent to symbolic programming languages, but, as significant, they bring with them advanced program development environments which can facilitate software development and maintenance. Exploitation of this enhanced programming environment was a major motivation for using an AI tool. The goal of this work is to evaluate the use of an example-based expert system shell (1st Class FUSION, 1st Class Expert Systems, Inc.) as a programming tool for developing software useful for automated radiopharmaceutical production

Survey of radiopharmaceuticals used for in vivo studies in medical practice in New Zealand

International Nuclear Information System (INIS)

McEwan, A.C.; Smyth, V.G.

1984-01-01

To obtain up-to-date information on numbers and types of radiopharmaceutical procedures, a survey was undertaken in the last quarter of 1983. In conjunction with this survey dosimetry data for the range of radiopharmaceutical procedures has been reviewed and extended where necessary so that effective dose equivalents could be estimated and mean genetically significant and malignancy significant doses for the population derived

State of the art and perspectives in radiopharmaceutical field since ACOMEN 8. International Conference (Bordeaux May 11-13, 2005)

International Nuclear Information System (INIS)

Vuillez, J.P.; Desruet, M.D.; Desruet, M.D.; Mundler, O.; Karcher, G.

2009-01-01

Since previous ACOMEN conference in 2005 on radiopharmaceuticals, many improvements have been encountered: active research has allowed the development of numerous new tracers of interest, with a large part dedicated for PET; clinical applications of radiopharmaceuticals have resulted in patients care improvement, both for management and survival; therapeutic applications are now fully recognized, as internal targeted radiotherapy could be considered as efficient in several cancer diseases; and regulation, despite remaining difficulties, will certainly become more favourable for radiopharmaceuticals. Thus we could make sure that radiopharmaceuticals use will be even more established in the next years. (authors)

Quality evaluation of radiopharmaceuticals in nuclear medicine services in the states of Alagoas and Sergipe - Brazil

International Nuclear Information System (INIS)

Santos, Poliane Angelo de Lucena; Andrade, Wellington Gomes de; Lima, Fernando Roberto de Andrade; Lima, Fabiana Farias de

2011-01-01

Radiopharmaceuticals are compounds associated with a radionuclide. They can be considered as vectors that have some specificity for an organ or a physiological or pathophysiological function. Assessing the radiopharmaceutical's quality is essential to obtain adequate images, avoiding repetition of examinations and unnecessary absorbed dose to the patient. Resolution no. 8 (RCD 38) of 06/04/2008 by Agencia Nacional de Vigilancia Sanitaria (ANVISA) states the obligation of performing a minimum of tests in the routines of nuclear medicine services (NMS). The aim of this work was to evaluate the radiochemical purity and pH of radiopharmaceuticals used in NMS in states of Alagoas and Sergipe - Brazil. Radiochemical purity was determined by thin layer chromatography where a paper Whatman and TLC were used as steady state and the solvents were used related to the appropriate radiopharmaceutical, both as recommended by the manufacturer's directions. The chromatographic strips were placed in closed containers to avoid contact with the walls. After, the strips were cut in 1cm pieces and the activity was determined in each NMS's activity calibrators. The radiopharmaceuticals pH was evaluated by using universal pH paper (Merck) and the obtained color was compared with its range of colors. It was observed that 33.34% and 2.3% of the tested radiopharmaceuticals showed PRQ (radiochemical purity) and pH values, respectively, are outside of the limits described by the manufacturers. The results show that the radiochemical purity assessment in the NMS's routine can indicate problems with a radioisotope tagging, allowing their exclusion before administration. (author)

Production of radiopharmaceuticals by cyclotrons

International Nuclear Information System (INIS)

Schmitz, F.; Van Naemen, J.; Monclus, M.; Van Gansbeke, B.; Kadiata, M.; Ekelmans, D.; Moray, M.; Penninckx, R.; Goldman, S.

2004-01-01

Companies specialized in the development and installation of accelerator-based systems dedicated to the medical applications brought on the market cyclotrons well fitted to the requests of the industrial community or universities and so covering every segment of the market. These machines are fully automatic, and need reduced maintenance; they are highly specialized for defined tasks. They can produce high beam intensity and realize dual beam irradiation. Also the prices are reducing considerably. The targets and the automatic system follow the same trend. Unfortunately, the flexibility of these devices for new area of research and development has been dramatically reduced. The growing number of PET cameras has increased the popularity of PET tracers used for nuclear imaging. Consequently, there is a growing demand for these radiopharmaceuticals compounds labeled with short-lived radioisotopes for clinical applications. From a research and development tool in the eighties, PET has now grown up to a clinical tool. Moreover, depending of the social welfare, reimbursement of some PET examinations is granted, which accelerates the trend for an extended use of PET tracers. Regulatory affairs try to establish and standardize the control on these radiopharmaceutical compounds produced in a growing number of local radio pharmacies owning a baby cyclotron. On the other hand, the attention of equipment suppliers was brought in the setting up of a total quality control follow up. These efforts were successively achieved by getting for instance the ISO 9001 certificate

Drug interaction with radiopharmaceuticals: effect on the labeling of red blood cells with technetium-99m and on the bioavailability of radiopharmaceuticals

Directory of Open Access Journals (Sweden)

Maria Luisa Gomes

2002-09-01

Full Text Available The evidence that natural and synthetic drugs can affect radiolabeling or bioavailability of radiopharmaceuticals in setting of nuclear medicine clinic is already known. However, this drug interaction with radiopharmaceuticals (DIR is not completely understood. Several authors have described the effect of drugs on the labeling of blood elements with technetium-99m (99mTc and on the biodistribution of radiopharmaceuticals. When the DIR is known, if desirable or undesirable, the natural consequence is a correct diagnosis. However, when it is unknown, it is undesirable and the consequences are the possibility of misdiagnosis and/or the repetition of the examination with an increase of radiation dose to the patient. The possible explanation to the appearance of DIR are (a radiopharmaceutical modification, (b alteration of the labeling efficiency of the radiopharmaceutical, (c modification of the target, (d modification of no target and/or the (e alteration of the binding of the radiopharmaceutical on the blood proteins. The effect of drugs on the labeling of blood elements with 99mTc might be explained by (i a direct inhibition (chelating action of the stannous and pertechnetate ions, (ii damage induced in the plasma membrane, (iii competition of the cited ions for the same binding sites, (iv possible generation of reactive oxygen species that could oxidize the stannous ion and/or (v direct oxidation of the stannous ion. In conclusion, the development of biological models to study the DIR is highly relevant.A evidência de que drogas naturais ou sintéticas podem afetar a radiomarcação ou a biodisponibilidade de radiofármacos nos procedimentos de medicina nuclear já é bem conhecida. Entretanto, essa interação de droga com radiofármacos (IDR não está completamente compreendida. Vários autores têm descrito o efeito de drogas na marcação de elementos sanguíneos com tecnécio-99m (99mTce na biodistribuição de radiofármacos. Quando a

A Study on the Quality Control of {sup 18}F-FDG Radiopharmaceutical

Energy Technology Data Exchange (ETDEWEB)

Kim, Ssang Tae [CareCamp Inc., Seoul (Korea, Republic of); Yong, Chul Soon [Yeungnam University, Gyeongsan (Korea, Republic of); Han, Eun Ok [Daegu Health College, Daegu (Korea, Republic of)

2010-12-15

The types of test items which were recorded in this test report of quality control domestic {sup 18}F-FDG radiopharmaceutical which consisted of 13 different types: appearance, half-life, radioactive heterokaryosis, radiochemical Confirmation (measure of Rf value), radiochemical Purity, Ethanol, Acetonitrile, Kryptofix, Aluminium, pH, Endotoxin, aseptic test, and radioactivity·ml-1. The record was fully recorded in 'appearance', 'radioactive heterokaryosis', 'pH', 'Endotoxin', and 'aseptic test'. In 'half-life', 'radiochemical Confirmation (measure of Rf value), 'radiochemical Purity', 'Ethanol', 'Acetonitrile', 'Kryptofix', 'Aluminium', 'radioactivity·ml-1', there were differences in records of each manufacturing business on radioactive medicine and medical supplies. The result of the test showed all 13 items of quality control test were 100% suitable on the basis of recorded data. There were more radiopharmaceutical made in the laboratory than in hospitals and businesses and in for result of suitability test, the laboratory showed higher suitability than did the hospitals or businesses. Domestically, there are differences of the test report items in the safety of radiopharmaceutical of each facility, and since it is not standardized, supplements are needed. To submit standardized test reports of quality guarantee in radiopharmaceutical, GMP of U.S. and CE Mark of Europe should be referred as well as receiving advice from professionals to standardize as suitable domestic standard.

Preparation and in vitro evaluation of 177Lu-iPSMA-RGD as a new heterobivalent radiopharmaceutical

International Nuclear Information System (INIS)

Escudero-Castellanos, Alondra; Universidad Autonoma del Estado de Mexico, Toluca, Estado de Mexico; Ocampo-Garcia, B.E.; Ferro-Flores, Guillermina; Santos-Cuevas, C.L.; Isaac-Olive, Keila; Olmos-Ortiz, Andrea; Garcia-Quiroz, Janice; Garcia-Becerra, Rocio; Diaz, Lorenza

2017-01-01

This study aimed to synthesize a new 177 Lu-iPSMA-RGD heterobivalent radiopharmaceutical, as well as to assess the in vitro radiopharmaceutical potential to target cancer cells overexpressing PSMA and α(v) β(3) integrins. The radiotracer prepared with a radiochemical purity of 98.8 ± 1.0% showed stability in human serum, specific recognition with suitable affinity to PSMA and α(v)β(3) integrins, and capability to inhibit cancer cell proliferation and VEGF signaling (antiangiogenic effect). Results warrant further preclinical studies to establish the 177 Lu-iPSMA-RGD potential as a dual therapeutic radiopharmaceutical. (author)

2. Semi-annual progress report 1980, no 17

International Nuclear Information System (INIS)

1981-01-01

This semi-annual report deals with the experimental research carried out at the Departement de Recherche Fondamentale de Grenoble (fission, nuclear spectroscopy, heavy ion reactions, physical metallurgy, magnetism, organic molecules, theoretical chemistry, molecular physical chemistry, cellular biology, vegetal biology) [fr

Determination of radiochemistry purity and pH of radiopharmaceutical in Northeast nuclear medicine services

International Nuclear Information System (INIS)

Andrade, Wellington; Santos, Poliane; Lima, Fernando de Andrade; Lima, Fabiana Farias de

2013-01-01

The radiopharmaceutical is a chemical compound associated with a radionuclide, which is selected so that meets the need cf diagnosis and capable of producing quality images. Drugs labeled with 99m Tc radionuclide kits consist of lyophilized, and be handled by the nuclear medicine services (NMS) must pass tests as the resolution of ANVISA (RDC 38) published in 2008. Among these tests are those of radiochemical purity and pH determination. This study evaluated the radiochemical purity of radiopharmaceuticals and pH SMN manipulated in the Northeast. The radiochemical purity (RCP) was determined by thin layer chromatography, which were used Whatman ® and silica gel, with dimensions of 1 x 10 cm, as stationary phase, and solvents indicated in the inserts of manufacturers. The chromatographic strips were placed in sealed containers so as not to touch the walls thereof. After the chromatographic run, the tape was cut every centimeter and the activities determined in doses of each calibrator NMS. The pH of the radiopharmaceutical was assessed through the use of universal pH paper (Merck®) and obtained staining compared with its color scale. The results showed (hat 82.6% and 100% of the radiopharmaceuticals of the samples were within the limits recommended by international pharmacopoeias for radiochemical purity and pl-l, respectively. There is then the need to include in routine tests indicated SMN by ANVISA. Well, they can detect possible problems in the marking of radiopharmaceuticals administered to the patient and avoid inappropriate material. (author)

The quality of 99mTc-radiopharmaceuticals - a basic requirement in the diagnostic nuclear medicine

International Nuclear Information System (INIS)

Ivanova, S.; Popsavova, H.; Kostadinova, I.

2011-01-01

Development and application of new high quality radiopharmaceuticals (RP) are of a great significance for the development in nuclear medicine. The high quality of the radiopharmaceuticals has a major influence on the accuracy of nuclear medical examinations. Therefore, a good knowledge and application if various control methods, is essential. Radiochemical impurities affect the quality of RP most significantly and they can appear at every stage of the preparation. The aim of this review is to present the literature information concerning the quality of the most commonly used radiopharmaceuticals, labeled with 99m Tc, and all requirements for them, i.e. radiochemical, radionuclide and chemical purity. This is well-known fact that metastable isotope of Technetium is golden standard for diagnostics in nuclear medicine. Research shows that about 80% of approx. 25 million nuclear medical studies a year are performed with this radionuclide. According to the European Pharmacopoeia and to the leaflets provided with the kits, radiochemical purity must exceed 95%. The main radiochemical impurities in 99m Tc-radiopharmaceuticals are free pertechnetate ( 99m TcO 4 - ), whose presence causes accumulation of RP in the thyroid gland, stomach, gastrointestinal tract, or the salivary glands, leading to a wrong diagnosis, and reduced hydrolyzed technetium, which causes visualization of the reticulo-endothelial system. This paper contains information about the authors' experience with analyses of the radiochemical purity of the two most commonly used radiopharmaceuticals in Bulgaria - for bone and renal scintigraphy (MDA and DTPA). An Instant Thin-Layer Chromatography (ITLC) is used for this purpose. It is concluded that the high quality of the applied 99m Tc-radiopharmaceuticals can be guaranteed only with both selection of renowned manufactures, recognized by EU, and a routine daily control of the labeling and generator eluate, meeting all requirements of the manufacturer and

Radiopharmaceuticals. 40 years is nothing

International Nuclear Information System (INIS)

Hager, Alfredo A.

2006-01-01

The nuclear medicine is today a medical speciality recognized and practised in the whole world. The birth was in the middle of the 20th century in the use of molecules or drugs marked with a radionuclide (radiopharmaceutical), for the diagnostic studies in vivo or in vitro, to obtain a therapeutic effect. Early in the decade of 70, its development and evolution was accentuated thanks to electronics, the contribution of new instruments for detection of diagnosis by images (gamma camera) and to the emergence of new radionuclide (in particular, 99m Tc). (author) [es

Parameter estimation and compartmental modelling for individualization of therapeutic dosage of radiopharmaceuticals

International Nuclear Information System (INIS)

Giussani, A.; Cantone, C.

2001-01-01

A successful application of radiopharmaceuticals for therapy requires a patient-specific optimization of the administration activity. The intention of this contribution is to show how this is possible with a relatively limited effort, by combining an optimized experimental schedule for the collection of the anatomic and physiological data of interest and a rigorous mathematical analysis. The benefits of such an optimization will concern not only the success of the therapy, but also the radiological protection of the patients and could even be translated in a more cost-effective usage of the radiopharmaceutical available. (author)

Metabolic radiopharmaceutical therapy in nuclear medicine; Terapia metabolica mediante radiofarmacos en medicina nuclear

Energy Technology Data Exchange (ETDEWEB)

Reguera, L.; Lozano, M. L.; Alonso, J. C.

2016-08-01

In 1986 the National Board of Medical Specialties defined the specialty of nuclear medicine as a medical specialty that uses radioisotopes for prevention, diagnosis, therapy and medical research. Nowadays, treatment with radiopharmaceuticals has reached a major importance within of nuclear medicine. The ability to treat tumors with radiopharmaceutical, Radiation selective therapy has become a first line alternative. In this paper, the current situation of the different therapies that are sued in nuclear medicine, is reviewed. (Author)

Influence of sweeteners in the biodistribution of radiopharmaceutical ...

African Journals Online (AJOL)

Influence of sweeteners in the biodistribution of radiopharmaceutical and laboratory tests in rats. Michelly Pires Queiroz, Vanessa Santos de Arruda Barbosa, Cecília Maria de Carvalho Xavier Holanda, Janette Monroy Osório, Tarciso Bruno Montenegro Sampaio, Christina da Silva Camillo, Aldo Cunha Medeiros, Marília ...

Relation between water chemistry and operational safety

International Nuclear Information System (INIS)

Oliveira, M.F. de.

1991-01-01

This report describes the relation between chemistry/radiochemistry and operational safety, the technics bases for chemical and radiochemical parameters and an analysis of the Annual Report of Angra I Operation and OSRAT Mission report to 1989 in this area too. Furthermore it contains the transcription of the technical Specifications related to the chemistry and radiochemistry for Angra I. (author)

IKO Annual Report 1976

International Nuclear Information System (INIS)

1977-01-01

The IKO Annual Report of 1976 relates their progress in different projects and project fields. The fields covered include electron scattering, pion and muon physics, theory, radio- and nuclear chemistry, technical department, MEA, nuclear reactions and nuclear spectroscopy

Radiological investigation in the outside area of expedition's room during radiopharmaceuticals' expedition

International Nuclear Information System (INIS)

Reina, Luiz C.; Monteiro, Ilka H.T.S.; Silva, Joao Carlos P. da; Teixeira, Danilo L.; Pedro, C.R.; Santos, J. Regis dos

2013-01-01

Radiopharmaceuticals produced in IEN - Instituto de Engenharia Nuclear of the Brazilian Nuclear Energy Commission, are issued by the radiation protection team, which is responsible for preparing and issuing the packaged documentation required for movement in modal transportation. The documents are: Invoice , Shipper's Declaration of Radioactive Material , Shipper's Declaration of Dangerous Goods - (form IATA ) , Emergency Sheet, sketch of packed. All this documentation is inserted in an envelope of emergency. The Department of Radiological Protection is responsible for issuing such documents except the invoice that is issued by the Commercial Sector (Setcom). A employee of this sector is responsible for delivering it to the shipment sector. The preparation of packaged and documentation is performed in a room located in the building of Radiopharmaceutical Division. The vehicles which are used in the transport are parked outside this building, where are monitored after commissioning of packaged. The present study aims to evaluate potential and occupational radiation risks of people in transit or remain in the area where radioactive material circulates due to the shipment of radiopharmaceuticals for the classification of the area during the operation of dispatch

188Re radiopharmaceuticals for radiosynovectomy: evaluation and comparison of tin colloid, hydroxyapatite and tin-ferric hydroxide macroaggregates

International Nuclear Information System (INIS)

Savio, Eduardo; Ures, María Cristina; Zeledón, Patricia; Trindade, Victoria; Paolino, Andrea; Mockford, Virginia; Malanga, Antonio; Fernández, Marcelo; Gaudiano, Javier

2004-01-01

Radiosynovectomy is a therapy used to relieve pain and inflammation from rheumatoid arthritis and related diseases. In this study three 188 Re particulate compounds were characterized according to their physico-chemical properties and their biological behavior in rabbits. The results were compared in order to establish which was the radiopharmaceutical that better fits the requirements of this kind of radiotherapy. Three radiopharmaceutical formulations, tin colloid, hydroxyapatite particles (HA) and ferric hydroxide macroaggregates coated with tin colloid (FHMA), were physically characterized (number, volume and surface of the particles). For this purpose laser diffraction methodology was used. To evaluate cavity leakage of activity the following studies in New Zealand rabbits were performed: scintigraphic images for 48 hr after intraarticular injection of each radiopharmaceutical, biodistribution at 48 hr and urine samples collection during the first 24 hr post-radiopharmaceutical administration. Labeling procedures for 188 Re-HA and 188 Re-Sn-FHMA were labour intensive while 188 Re-Sn was easily prepared. Furthermore, 188 Re-Sn colloid offered the greatest surface area in the 2–10 microm range and was obtained with a radiochemical purity over 95%, while percentage of bound activity for 188 Re-HA and 188 Re-Sn-FHMA were 55% and 92% respectively. Stability was verified for the three radiopharmaceuticals for 24 hr. Scintigraphic studies and biodistribution in rabbits after intraarticular administration of the radiopharmaceuticals showed relevant activity only in the knee, this being over 90% of the residual activity in the whole body at 48 hr in every case. Renal elimination of 188 Re-Sn colloid and 188 Re-Sn-FHMA was detected by activity measurements in urine samples, during the first 12 hr post-radiopharmaceutical injection. The percentage of activity retained in the knee was 69.1% for 188 Re-Sn colloid, 55.1% for 188 Re-Sn-FHMA and 33.6% for 188 Re-HA. The 188

Advances in nuclear medicine and in radiopharmaceuticals, International meeting in Cabo Frio. Program and abstracts

International Nuclear Information System (INIS)

2002-01-01

The meeting of Advances in Nuclear Medicine and in Radiopharmaceuticals, held in Cabo Frio, Rio de Janeiro State, Brazil, in September 26-28, 2002, has provided an excellent opportunity for the presentation and the discussion of the latest achievements and new trends of nuclear medicine techniques and radiopharmaceuticals for the clinical evaluation of inflammation, infection, oncology and therapy of diseases with radionuclides

Radiation risk in pediatric patients: the need for criteria using radiopharmaceuticals activities

International Nuclear Information System (INIS)

Simas, Felipe; Instituto de Radioprotecao e Dosimetria; Velasques, Silvia M.

2009-01-01

The administration of radionuclides to children for diagnostic procedures should be carried out only if there is a strong clinical indication. The amount of activity administered may be reduced according to body weight, body surface area or other appropriate criteria. In Brazil, activities used for pediatric patients were evaluated (2003-2005) in sixteen selected public and private institutions in Northeast, Southeast and South geographical regions. The present work presents radiopharmaceuticals activities used in Brazil compared with international surveys performed in USA in 2005 and in the European Union in 2007. The activities per patient weight and minimum and maximum activities used per Brazilian installations were compared with those used in USA installations. Per patients, it was calculated the ideal minimum administered activity for each type of radiopharmaceutical by body weight according the Pediatric Dosage Card (PDC) criteria. It was not possible to compare activities for all radiopharmaceuticals used in Brazil because some are not more used outside, e.g. 131 I-NaI, which is replaced by 123 I-NaI for thyroid imaging. The discrepancy between activities used in Brazil compared with those used in USA and Europe may be attributed to the heterogeneity of Brazilian imaging equipment and lack for specific children protocols. The disadvantages for using fractions of adult activities are: necessity of minimum statistical counting for assurance of image quality and dependence upon equipment calibration. It was concluded that is necessary to establish standard criteria for radiopharmaceuticals activities applied to pediatric patients in Brazil and the risks due to additional activities should be estimated individually. (author)

Guidance for nuclear medicine staff on radiopharmaceuticals drug interaction

Directory of Open Access Journals (Sweden)

Ralph Santos-Oliveira

2009-12-01

Full Text Available Numerous drug interactions related to radiopharmaceuticals take place every day in hospitals many of which are not reported or detected. Information concerning this kind of reaction is not abundant, and nuclear medicine staff are usually overwhelmed by this information. To better understand this type of reaction, and to help nuclear medicine staff deal with it, a review of the literature was conducted. The results show that almost all of radiopharmaceuticals marketed around the world present drug interactions with a large variety of compounds. This suggests that a logical framework to make decisions based on reviews incorporating adverse reactions must be created. The review also showed that researchers undertaking a review of literature, or even a systematic review that incorporates drug interactions, must understand the rationale for the suggested methods and be able to implement them in their review. Additionally, a global effort should be made to report as many cases of drug interaction with radiopharmaceuticals as possible. With this, a complete picture of drug interactions with radiopharmaceuticals can be drawn.Diversos casos de interações medicamentosas com radiofármacos ocorrem diariamente na rotina hospitalar, contudo muitos deles não são notificados ou mesmo percebidos. Informações a respeito desse tipo de reação não é abundante e os profissionais da medicina nuclear muitas vezes estão assoberbados por essas informações. De modo a entender esse tipo de reação e auxiliar a medicina nuclear a lidar com essa situação uma revisão da literatura foi realizada. Os resultados mostraram que a totalidade dos radiofármacos comercializados no mundo apresentam interação medicamentosa com uma enorme variedade de outros medicamentos. Dessa forma sugere-se que revisões sobre radiofármacos inclua um capítulo sobre efeitos adversos. Além disso, um esforço mundial para notificar efeitos adversos deve ser realizado, pois somente

A rapid and efficient preparation of [{sup 123}I]radiopharmaceuticals using a small HPLC Rocket[reg] column

Energy Technology Data Exchange (ETDEWEB)

Katsifis, Andrew [Radiopharmaceuticals Division R and D, Australian Nuclear Science and Technology, Organisation, Menai, NSW 2234, Sydney (Australia)]. E-mail: akx@ansto.gov.au; Papazian, Vahan [Radiopharmaceuticals Division R and D, Australian Nuclear Science and Technology, Organisation, Menai, NSW 2234, Sydney (Australia); Jackson, Timothy [Radiopharmaceuticals Division R and D, Australian Nuclear Science and Technology, Organisation, Menai, NSW 2234, Sydney (Australia); Loc' h, Christian [Radiopharmaceuticals Division R and D, Australian Nuclear Science and Technology, Organisation, Menai, NSW 2234, Sydney (Australia)

2006-01-01

A simplified method for the rapid and efficient preparation of [{sup 123}I]radiopharmaceuticals is described. Three radiopharmaceuticals, [{sup 123}I]{beta}-CIT, [{sup 123}I]MIBG and [{sup 123}I]clioquinol, were synthesised and purified as model compounds. The radiotracers were labelled with iodine-123 using electrophilic oxidative conditions and purified by a compact semi-preparative reverse phase column (C-18, 3 {mu}m, 7x53 mm, Alltima Rocket[reg, Alltech] using aqueous-ethanol as HPLC solvents that were directly used for radiopharmaceutical formulation. The radiochemical purity of the radioiodinated tracers as assessed by analytical HPLC was higher than 99% with specific activity higher than 3 GBq/nmol. The total preparation time of a radiotracer ranged from 40 to 60 min and, starting from 3.7 GBq of iodine-123, more than 2.5 GBq of formulated radiopharmaceuticals were available for clinical investigations.

The IAEA Activities on Supporting Development of Therapeutic Radiopharmaceuticals and Capacity Building in Member States

International Nuclear Information System (INIS)

Pillai, M.R.A.; Haji-Saeid, M.; Zaknun, J.; Ramamoorthy, N.

2009-01-01

The IAEA activities on supporting development of therapeutic radiopharmaceuticals are focused on identified radionuclides that can be produced in large quantities and making use of carrier molecules which can be synthesized locally or procured from commercial sources or already available in MS from other related programs. The main emphasis is on 90 Y and 177 Lu based products, which cover the hard beta energy and soft beta energy range respectively, and also since both these radionuclides can be produced in large quantities with very high specific activity and high radionuclidic purity. The services to MS are provided through implementing Coordinated Research Projects (CRP), Technical Cooperation (TC) projects, technical meetings and regional training courses in addition to documenting practically useful technical information related to these products though IAEA publications. The CRP is a group activity in which nearly 15 participants from as many countries come together to work towards an identified objective. Two of the completed CRPs in this area are: (i) Comparative evaluation of therapeutic radiopharmaceuticals (2002-2005) that focussed on the development of 'in vitro' and 'in vivo' techniques for evaluating new generation therapeutic radiopharmaceuticals; and (ii) Development of generator technologies for therapeutic radionuclides (2004-2007) that addressed technologies for 90 Sr/ 90 Y and 188 W/ 188 Re generators and which can be easily adapted by MS. The participants in the CRP on 'Comparative evaluation of therapeutic radiopharmaceuticals' used the somatostatin analogue, DOTATATE as the lead molecule for developing radiopharmaceuticals and testing the efficacy by in vitro biological assays and animal biodistribution studies. A significant outcome of the CRP was that 177 Lu-DOTATATE therapy is now practised in several of the CRP participating countries including Brazil, India, Italy, and Poland. The major outcome of the CRP on 'Development of generator

The IAEA Activities on Supporting Development of Therapeutic Radiopharmaceuticals and Capacity Building in Member States

Energy Technology Data Exchange (ETDEWEB)

Pillai, M R.A.; Haji-Saeid, M; Zaknun, J; Ramamoorthy, N [Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna (Austria)

2009-07-01

The IAEA activities on supporting development of therapeutic radiopharmaceuticals are focused on identified radionuclides that can be produced in large quantities and making use of carrier molecules which can be synthesized locally or procured from commercial sources or already available in MS from other related programs. The main emphasis is on {sup 90}Y and {sup 177}Lu based products, which cover the hard beta energy and soft beta energy range respectively, and also since both these radionuclides can be produced in large quantities with very high specific activity and high radionuclidic purity. The services to MS are provided through implementing Coordinated Research Projects (CRP), Technical Cooperation (TC) projects, technical meetings and regional training courses in addition to documenting practically useful technical information related to these products though IAEA publications. The CRP is a group activity in which nearly 15 participants from as many countries come together to work towards an identified objective. Two of the completed CRPs in this area are: (i) Comparative evaluation of therapeutic radiopharmaceuticals (2002-2005) that focussed on the development of 'in vitro' and 'in vivo' techniques for evaluating new generation therapeutic radiopharmaceuticals; and (ii) Development of generator technologies for therapeutic radionuclides (2004-2007) that addressed technologies for {sup 90}Sr/{sup 90}Y and {sup 188}W/{sup 188}Re generators and which can be easily adapted by MS. The participants in the CRP on 'Comparative evaluation of therapeutic radiopharmaceuticals' used the somatostatin analogue, DOTATATE as the lead molecule for developing radiopharmaceuticals and testing the efficacy by in vitro biological assays and animal biodistribution studies. A significant outcome of the CRP was that {sup 177}Lu-DOTATATE therapy is now practised in several of the CRP participating countries including Brazil, India, Italy, and Poland. The major outcome of the CRP

Infection imaging with radiopharmaceuticals in the 21st century

Energy Technology Data Exchange (ETDEWEB)

Das, Satya S.; Wareham, David W. [St. Bartholomew' s Hospital, London (United Kingdom). Dept. of Medical Microbiology; Britton, Keith E. [St. Bartholomew' s Hospital, London (United Kingdom). Dept. of Nuclear Medicine; Hall, Anne V. [Harefield Hospital, Middlesex (United Kingdom). Microbiology Dept.

2002-09-01

Infection continues to be a major cause of morbidity and mortality worldwide. Nuclear medicine has an important role in aiding the diagnosis of particularly deep-seated infections such as abscesses, osteomyelitis, septic arthritis, endocarditis, and infections of prosthetic devices. Established techniques such as radiolabelled leucocytes are sensitive and specific for inflammation but do not distinguish between infective and non-infective inflammation. The challenge for Nuclear Medicine in infection imaging in the 21st century is to build on the recent trend towards the development of more infection specific radiopharmaceuticals, such as radiolabelled anti-infectives (e.g. 99 m Tc ciprofloxacin). In addition to aiding early diagnosis of infection, through serial imaging these agents might prove very useful in monitoring the response to and determining the optimum duration of anti-infective therapy. This article reviews the current approach to infection imaging with radiopharmaceuticals nd the future direction it might take. (author)

Infection imaging with radiopharmaceuticals in the 21st century

International Nuclear Information System (INIS)

Das, Satya S.; Wareham, David W.; Britton, Keith E.; Hall, Anne V.

2002-01-01

Infection continues to be a major cause of morbidity and mortality worldwide. Nuclear medicine has an important role in aiding the diagnosis of particularly deep-seated infections such as abscesses, osteomyelitis, septic arthritis, endocarditis, and infections of prosthetic devices. Established techniques such as radiolabelled leucocytes are sensitive and specific for inflammation but do not distinguish between infective and non-infective inflammation. The challenge for Nuclear Medicine in infection imaging in the 21st century is to build on the recent trend towards the development of more infection specific radiopharmaceuticals, such as radiolabelled anti-infectives (e.g. 99 m Tc ciprofloxacin). In addition to aiding early diagnosis of infection, through serial imaging these agents might prove very useful in monitoring the response to and determining the optimum duration of anti-infective therapy. This article reviews the current approach to infection imaging with radiopharmaceuticals nd the future direction it might take. (author)

Public exposure due to the transport of radiopharmaceuticals; Exposicao do publico devido ao transporte de radiofarmacos

Energy Technology Data Exchange (ETDEWEB)

Rodrigues, Demerval L.; Carneiro, Janete C.G.G.; Sanches, Matias P.; Sordi, Gian Maria A.A., E-mail: dlrodri@ipen.b, E-mail: janetegc@ipen.b, E-mail: msanches@ipen.b, E-mail: gsordi@ipen.b [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil)

2011-10-26

This paper estimate the radiological impact resulting from radiopharmaceuticals transport from the IPEN to some destinations defined a priori. So, doses were estimated in the public individuals, which are in the streets and vehicles that transit near the public transport, alongside the itinerary went through by packages, during the realization of radiopharmaceuticals transport

Radioprotection and management of radioactive residues study in the radiopharmaceuticals laboratories

International Nuclear Information System (INIS)

Zidan, Priscila M.; Silva, Maria Isabel B. da

2002-01-01

The 123 I, used in the thyroid cancer diagnoses, is being used at several clinics of nuclear medicine, instead of 131 I. This last one, for presenting half-life 15 times bigger than the first one, causes larger doses to the patient and slower exams. Another subject is the management of the residues generated by radiopharmaceutical laboratories, which requests lager physical space, in the case of 131 I. In the present work, six radiopharmaceutical laboratories of the state of Rio de Janeiro were visited. All of them use the 131 I produced by the Nuclear Engineering Institute. In these visits radioprotection procedures and the management of residues of those laboratories were evaluated, as well as the available infrastructure

Quality assurance of radiopharmaceuticals-specifications and test procedures

International Nuclear Information System (INIS)

Baldas, J.; Bonnyman, J.; Pojer, P.M.

1981-08-01

This report is a compilation of test methods used and specifications adopted for the Radiopharmaceutical Quality Assurance Test Programme conducted by the Australian Radiation Laboratory. In some cases test procedures described have been taken from various Pharmacopoeias or methods published in the literature. In other cases test methods have been developed at the ARL

Environmental Chemistry Division annual report, 1989

International Nuclear Information System (INIS)

Newman, L.

1990-01-01

The research activities making up the programs in the Environmental Chemistry Division of the Department of Applied Science are presented. Some of the more significant accomplishments during 1989 are described and plans for 1990 are discussed briefly. Publications for the period are listed and abstracts are provided. Research objectives and principal investigators are given for each of the active programs. A list of personnel and collaborators during the past year is presented. The support distribution of FY 1989 is approximately 85% from the Department of Energy (65% Office of Health and Environmental Research), and 15% other agencies (principally from the Electric Power Research Institute)

Frequency of adverse reactions to radiopharmaceuticals in Europe

Energy Technology Data Exchange (ETDEWEB)

Hesslewood, S.R.; Keeling, D.H. [Radiopharmacy Department, City Hospital NHS Trust, Dudley Road, Birmingham B18 7QH (United Kingdom)

1997-09-01

A prospective survey was performed in 17 nuclear medicine departments during 1996 in an attempt to provide reliable data on the prevalence of adverse reactions to radiopharmaceuticals. All adverse events following radiopharmaceutical administration were recorded, irrespective of the severity or likelihood of causality, and subsequently analysed using an algorithm developed by Silberstein et al., designed to establish a cause-effect relationship. A prevalence of 11 events per 10{sup 5}administrations was obtained (95% confidence limits 3.3-19.2). No serious of life-threatening events were reported. This rate is slightly higher than that obtained in a larger scale study in the United States (2.3 events per 10 {sup 5}administrations, 95% confidence limits 1.2-3.4). The difference may be due to the decision to include or exclude vasovagal events from the analysis, the way in which the algorithm was used and the comparative size and time scale of the two studies. The prevalence of adverse reactions is approximately 1000-fold than less that occurring with iodinated contrast media and drugs. (orig.). With 2 tabs.

Joint CDRH (Center for Devices and Radiological Health) and state quality-assurance surveys in nuclear medicine: Phase 2 - radiopharmaceuticals

International Nuclear Information System (INIS)

Hamilton, D.R.; Evans, C.D.

1986-08-01

The report discusses survey results on aspects of the quality assurance of radio-pharmaceuticals from 180 nuclear-medicine facilities in the United States. Data were collected from facilities in 8 states. Demographic information about nuclear-medicine operations and quality-assurance programs was gathered by state radiation-control-program personnel. The data collected from the survey show an incomplete acceptance of quality-assurance practices for radiopharmaceuticals. Most of the facilities in the survey indicated that, because an inferior radiopharmaceutical was prepared so infrequently, they did not believe it was cost-effective to perform extensive quality-assurance testing. The Center for Devices and Radiological Health hopes that the information from the survey will stimulate nuclear-medicine professionals and their organizations to encourage appropriate testing of all radiopharmaceuticals

Development of radiopharmaceutical for radiosinovectomy; Desenvolvimento de radiofarmaco para radiosinovectomia

Energy Technology Data Exchange (ETDEWEB)

Couto, Renata Martinussi

2009-07-01

Radiopharmaceuticals prepared with different radionuclides have been used in diagnostic and therapeutic procedures in Nuclear Medicine. The interest in radionuclidic therapy has been increased in last years, with the introduction of new radiopharmaceuticals applied in the destruction of specific cells or to prevent its undesired proliferation. Radiosinovectomy (RSV) is a therapeutic modality that uses radiopharmaceuticals administered in the intra-articular cavity and represents an alternative to the treatment of different arthropaties and, in particular, the arthropaties derived from rheumatoid arthritis and haemophilic. The objective of the present work was to study the labeling of compounds with {sup 90}Y and {sup 177}Lu in order to improve the production conditions and quality control procedures, study the stability of the labeled compounds and preliminary biodistribution studies of the radiopharmaceuticals with potential for RSV applications. The study of the production of {sup 90}Y citrate colloid ({sup 90}Y-Cit) was based in a labeling procedure using {sup 90}Y Cl{sub 3} solution (37 - 54 MBq) that was previously dried, followed by the addition of yttrium nitrate and sodium citrate in p H 7 at 37 deg C for 30 minutes. The production of hydroxyapatite (HA) labeled with {sup 90}Y was based in a labeling procedure using mono hydrated citric acid, yttrium nitrate and {sup 90}Y Cl{sub 3} solution (37 - 370 MBq). The reaction mixture was incubated for 30 minutes at room temperature and the HA was introduced in aqueous medium and the reaction proceed for 30 minutes under strong stirring. {sup 177}Lu-HA was produced using {sup 177}Lu Cl{sub 3} solution (296 MBq), in presence of lutetium oxide in NaCl medium, p H 7, under continuous stirring for 30 minutes at room temperature. Several reaction parameters were studied for the three radiopharmaceuticals. Labeling yield was determined after particles were centrifuged and washed with NaCl 0,9%. Radiochemical purity was

Clinical trials using a radiopharmaceutical investigational drug: What legal environment and what authorizations required?

International Nuclear Information System (INIS)

El-Deeb, G.; Nguon, B.; Tibi, A.; Rizzo-Padoin, N.

2009-01-01

Recent revision of the legal environment for clinical research in France provided an opportunity to review what a hospital needs to carry out clinical trials using a radiopharmaceutical investigational drug. Legal measures concerning radiopharmaceutical investigational drugs are indeed more complex than those of classical clinical trials because of the additional legal provisions governing the use of ionizing radiation. Thus, requirements by the concerned staff (sponsor, pharmacist, person in charge of the nuclear activity) are described here. (authors) [fr

Internal dosimetry of technetium-99m-labelled radiopharmaceuticals used in clinical nuclear medicine

Energy Technology Data Exchange (ETDEWEB)

Roedler, H D [Freie Univ. Berlin (Germany, F.R.). Klinikum Steglitz

1977-01-01

For radiopharmaceuticals labelled with /sup 99m/Tc, which is the most common short-lived radionuclide used in nuclear medicine, the possible dose reduction in comparison to other radionuclides for equal administered activities is deduced from the formalism of absorbed dose calculation and compared to the actually achieved decrease of absorbed dose for the most important radiopharmaceuticals. Absorbed doses per ..mu..Ci of administered activity are tabulated for the gonads, red bone marrow, and critical organs of the adult human, the newborn, and the child of 1, 5, 10, and 15 years.

A 3D high-resolution gamma camera for radiopharmaceutical studies with small animals

CERN Document Server

Loudos, G K; Giokaris, N D; Styliaris, E; Archimandritis, S C; Varvarigou, A D; Papanicolas, C N; Majewski, S; Weisenberger, D; Pani, R; Scopinaro, F; Uzunoglu, N K; Maintas, D; Stefanis, K

2003-01-01

The results of studies conducted with a small field of view tomographic gamma camera based on a Position Sensitive Photomultiplier Tube are reported. The system has been used for the evaluation of radiopharmaceuticals in small animals. Phantom studies have shown a spatial resolution of 2 mm in planar and 2-3 mm in tomographic imaging. Imaging studies in mice have been carried out both in 2D and 3D. Conventional radiopharmaceuticals have been used and the results have been compared with images from a clinically used system.

A Survey on the Usage and Demand of Medical Radioisotope and Radiopharmaceuticals in Malaysia

International Nuclear Information System (INIS)

Muhammad Fakhrurazi Ahmad Fadzil; Siti Selina Abdul Hamid; Siti Najila Mohd Janib; Azahari Kasbollah; Syed Asraf Fahlawi Wafa

2015-01-01

Medical radioisotope is a small quantity of radioactive substance used in safe, cost effective, for the purpose of diagnostic and therapy of various diseases. In Malaysia, the emerging of new nuclear medicine centers or institutions in both government and private sectors rose abruptly for the past few years. Currently, there are no data available on the usage and demand of medical radioisotope or radiopharmaceuticals. Understanding the usage trending and demand of radiopharmaceuticals and medical radioisotope is essential when related to technology changes in order to meet the market size of these radiopharmaceuticals. Survey result found out that the highest demand and the highest usage among all radioisotopes are Technetium-99m and Radioiodine isotopes such as the Iodine-1331, Iodine131 MIBG, Iodine-123 and Iodine-123 MIBG. Currently, most of the medical isotopes and radiopharmaceuticals are currently imported. Technetium-99m is the backbone of nuclear medicine whereby more than 80 % of Nuclear Medicine services utilize this radioisotope. Technetium-99m supply chain is unstable globally and in coming future, two main reactors (Canada and Holland) that produces 60 % of world Molybdenum-99 will shut down the operation and supply of Molybdenum-99 will be disrupted. As for radioiodine services, currently, Iodine-123 can't be obtained in Malaysia and neighboring countries due to its short half-life, Iodine-123 is useful in diagnostic of thyroid related diseases. As for PET services, the highest demands are F-18 FDG and Gallium-68 Generator for the moment. However the survey data still did not include most of the PET centers in the Klang Valley, northern area (Penang) and the new upcoming PET center in Southern Region (Malacca and Johor). It is important for Malaysia to self-produced medical radioisotope and radiopharmaceuticals to meet the market and local demand of these medical isotopes. (author)

Proceedings of the 14. Annual Symposium of the ACIESP

International Nuclear Information System (INIS)

1990-01-01

The works of XIV Annual Symposium of the ACIESP with the topic 'Lanthanides and Actinides Chemistry' are presented, including theme about rare earths separation process, uranium and thorium recovery, physical-chemistry studies, analytical techniques for rare earths determination, etc. (C.G.C.)

Verein fuer Kernverfahrenstechnik und Analytik Rossendorf (VKTA). Annual report 1995

International Nuclear Information System (INIS)

Haefele, W.

1996-04-01

The annual report 1995 presents information from the managing and financial departments and on the activities and achievements of the scientific-technical departments relating to nuclear facilities, radioactive waste management, radioactivity analytics, measurement and management of radioactivity in the environment, radiopharmaceuticals, and safety and radiological protection. The main activities continued to be the management of radwaste resulting from decommissioning of the research reactors and facilities on site; other activities include cooperative activities together with the Siemens company assisting in erection and establishment of isotope production labs in developing countries. There also is an organizational chart of the institution. (DG) [de

SU-E-I-82: PET Radiopharmaceuticals for Prostate Cancer Imaging: A Review

International Nuclear Information System (INIS)

Fernandes, F; Silva, D da; Rodrigues, L

2015-01-01

Purpose: The aim of this work was to review new and clinical practice PET radiopharmaceuticals for prostate cancer imaging. Methods: PET radiopharmaceuticals were reviewed on the main databases. Availability, dosimetry, accuracy and limitations were considered. Results: The following radioisotopes with respective physical half-life and mean positron energy were found: 18 F (109,7 min, 249,8 keV), 89 Zr (78,4 hs, 395,5 keV), 11 C (20,4 min, 385,7 keV) and 68 Ga (67,8 min, 836 keV). 68 Ga was the only one not produced by cyclotron. Radiopharmaceuticals uptake by glucose metabolism ( 18 F-FDG), lipogenesis ( 11 C-Choline and 11 C-Acetate), amino acid transport (Anti- 18 F-FACBC), bone matrix ( 18 F-NaF), prostatespecific membrane antigen ( 68 Ga-PSMA and 89 Zr-J591), CXCR receptors ( 89 Ga-Pentixafor), adrenal receptors ( 18 F-FDHT) and gastrin release peptide receptor (bombesin analogue). Most of radiopharmaceuticals are urinary excretion, so bladder is the critical organ. 11C-choline (pancreas), Anti- 18 FFACBC (liver) and 18 F-FBDC (stomach wall) are the exception. Higher effective dose was seen 18 F-NaF (27 μSv/MBq) while the lowest was 11 CAcetate (3,5 μSv/MBq). Conclusion: Even though 18 F-FDG has a large availability its high urinary excretion and poor uptake to slow growing disease offers weak results for prostate cancer. Better accuracy is obtained when 18 F-NaF is used for bone metastatic investigation although physicians tend to choose bone scintigraphy probably due to its cost and practice. Many guidelines in oncology consider 11 C or 18 F labeled with Choline the gold standard for biochemical relapse after radical treatment. Local, lymph node and distant metastatic relapse can be evaluated at same time with this radiopharmaceutical. There is no consensus over bigger urinary excretion for 18 F labeling. Anti- 18 F-FACBC, 68 Ga-PSMA and 68 Ga-Pentixafor are demonstrating good results but more researches are needed. While PSMA imaging seems to be

Radiopharmaceuticals in positron emission tomography: Radioisotope productions and radiolabelling procedures at the Austin and Repatriation Medical Centre

International Nuclear Information System (INIS)

Tochon-Danguy, H.J.; Sachinidis, J.I.; Chan, J.G.; Cook, M.

1997-01-01

Positron Emission Tomography (PET) is a technique that utilizes positron-emitting radiopharmaceuticals to map the physiology, biochemistry and pharmacology of the human body. Positron-emitting radioisotopes produced in a medical cyclotron are incorporated into compounds that are biologically active in the body. A scanner measures radioactivity emitted from a patient's body and provides cross-sectional images of the distribution of these radiolabelled compounds in the body. It is the purpose of this paper to review the variety of PET radiopharmaceuticals currently produced at the Austin and Repatriation Medical Centre in Melbourne. Radioisotope production, radiolabelling of molecules and quality control of radiopharmaceuticals will be discussed. A few examples of their clinical applications will be shown as well. During the last five years we achieved a reliable routine production of various radiopharmaceuticals labelled with the four most important positron-emitters: oxygen-15 (t, 1/2 =2min), nitrogen-13 (t 1/2 = 10 min), carbon-11 (t 1/2 =20 min) and fluorine-18 (t 1/2 = 110 min). These radiopharmaceuticals include [ 15 O]oxygen, [ 15 O]carbon monoxide, [ 15 O]carbon dioxide, [ 15 O]water, [ 13 N]ammonia, [ 11 C]flumazenil, [ 11 C]SCH23390, [ 18 F]fluoromisonidazole and [ 18 F]fluoro-deoxy-glucose ([ 18 F]FDG). In addition, since the half life of [ 18 F] is almost two hours, regional distribution can be done, and the Austin and Repatriation Medical Centre is currently supplying [ 18 F]FDG in routine to other hospitals. Future new radiopharmaceuticals development include a [ 18 F]thymidine analog to measure cell proliferation and a [ 11 C]pyrroloisoquinoline to visualize serotonergic neuron abnormalities. (authors)

Organic radiopharmaceuticals: recent advances

International Nuclear Information System (INIS)

Wolf, A.P.; Fowler, J.S.

1979-01-01

Organic radiopharmaceuticals are considered in light of accelerator and nuclide production requirements, special problems relating to the carrier-free state, including terminology, of the special technology required to prepare and manipulate these compounds and new trends in compound design and synthesis. The emphasis is on medical cyclotrons and the positron-emitting radionuclides, carbon-11, nitrogen-13, oxygen-15, and fluorine-18. New routes to synthetic precursors and organic compounds of high specific activity labeled with carbon-11, fluorine-18, and iodine-123 including monosaccharides, aromatic amines, neuroleptics, fatty acids, steroids, and other classes of compounds are discussed. Some compounds are considered in terms of the development and evaluation of structure-activity relationships and including some newer concepts such as metabolic trapping. 67 references

The excretion of radiopharmaceuticals in human breast milk: additional data and dosimetry

International Nuclear Information System (INIS)

Rubow, S.; Klopper, J.; Wasserman, H.; Baard, B.; Niekerk, M. van

1994-01-01

The amount of radioactivity excreted in breast milk following administration of 11 different radiopharmaceuticals, has been measured. This report summarises the data collected from 60 patients. An effective decay constant for the series of samples from each patient was calculated. In order to formulate reliable guidelines, we calculated the total activity theoretically excreted in milk until complete decay of the radionuclide. Of the various 99m Tc compounds, pertechnetate clearly reaches the highest concentrations in breast milk. The wide variability of data from different patients who received the same radiopharmaceutical despite identical methods of sample collection and data processing confirms the impression gained from literature that transfer of radionuclides into milk varies greatly between individuals. We believe that for radiation protection purposes, a ''worst case'' approach is the most appropriate. With new data available and the revision of ICRP recommendations, the guidelines applicable when radiopharmaceuticals are administered to breast-feeding mothers are reviewed. The effective dose resulting from close contact between patient and infant was included in these calculations. Breast feeding need not be interrupted after administration of 99m Tc-DISIDA, -sulphur colloid, -gluconate and -methoxyisobutylisonitrile (MIBI). However, after administration of 99m Tc-MIBI, close contact should be restricted. 99m Tc-pyrophosphate and -microspheres require interruption periods of several hours. High activities of 99m Tc-pertechnetate may require interruption longer than 2 days. For pertechnetate and 99m Tc-labelled red blood cells, interruption of breast feeding with measurement of activity in expressed milk samples is recommended. Breast feeding is contra-indicated after administration of 67 Ga and 131 I. General guidelines regarding breast feeding after administration of radiopharmaceuticals are summarised. (orig./MG)

Preparation of carbon 11-labelled radiopharmaceuticals by the use of HPLC method

International Nuclear Information System (INIS)

Berget, G.; Maziere, M.; Godot, J.M.; Sastre, J.; Prenant, C.; Comar, D.

1982-06-01

Various medical examinations and metabolic studies are carried out with carbon 11-labelled radiopharmaceuticals. This radioelement offers a number of advantages: it can be introduced into an organic molecule without changing its properties; the radiation dose delivered to the patient is low (T = 20 mn); since the specific activity obtained is high (0.5 to 2 Ci/μ mole) the injected masses are very small; finally, tomographic images of the distribution of the product in the body may be obtained by the use of positron cameras. However in view of the radioactivities handled on a routine basis the preparations must be carried out without manual intervention, in closed shielded hoods. Synthesis methods and special equipment have been developed. In all cases the reaction mixtures are purified by HPLC, a method chosen for its speed, efficiency, ease of automation and adaptation to any product with a suitable choice of column and eluant. The radiopharmaceuticals are obtained in injectable solution (ethanol-physiological serum, buffered physiological serum) or in a mixture of volatile solvents which are evaporated by nitrogen bubbling and finally sterilised by passage over millipore filter. About ten different radiopharmaceuticals are prepared in this way in the laboratory [fr

Comparative study of radiopharmaceuticals as radiodiagnostic agent of cardiac damage in rats

International Nuclear Information System (INIS)

Gallego Heise, R.

1983-01-01

Six radiopharmaceuticals were screened in a small-animal model as potential infarct-localizing agents. The model used was subcutaneous inyection of isoproterenol (30 mg/kg of body weight) - induced myocardial lesions in rats, similar to an infarct and ischemia in human beings, corroborated by histological findings. The uptake of each radiopharmaceuticals is measured at various times after lesion initiation. The results are expressed as % I.D./g and through the contrast relations between the activity of whole heart of treated rats and the others tissues. The relation damaged heart/normal heart (DH/NH) of the phosphorated radiopharmaceuticals (sup(99m) Tc-PPi, sup(99m) Tc-MDP, sup(113m) In-EDTMP), and 197 Hg-MPG are significatively greater in rats with heart damaged than in the controls animals (undamaged); these were followed by sup(99m) Tc-GH and sup(99m) Tc-DMSA. Sup(99m) Tc-PPi, was the tracer that showed the mot favorable concentration in the lesion and the best target-non target ratios in most of the time intervals. At early time intervals 197 Hg-MPG showed the best DH/NH relation. (Author)

Annual report 1981, annex

International Nuclear Information System (INIS)

1982-01-01

This volume entitled ''Annex to the annual report'' deals in more detail with the scientific works of the I.L.L.: the scientific activity of theoricians; experimental reports on inelastic scattering in simple solids, crystallographic and magnetic structures, fluids and amorphous substances, imperfections, biology, chemistry

Regulatory considerations concerning IND radiopharmaceutical drug products

International Nuclear Information System (INIS)

Nissel, M.

1985-01-01

The Food and Drug Administration is charged by the Food, Drug, and Cosmetic Act, as presently amended, to assure that any drug introduced into interstate commerce is safe and effective for the purposes for which it is labeled. A radiopharmaceutical is, by definition, a new drug unless there is in effect an approved New Drug Application (NDA) for it. Before the data for the NDA are compiled, investigative studies have to be done. Before such studies can be performed in humans, an exemption from the Act is necessary. This exemption, technically the Claimed Exemption for an Investigational New Drug, is termed the IND. Both the scientific and the administrative requirements for an IND are discussed. For radiopharmaceutical drug products (RDP's), the radiation hazards, as well as the pharmacological ones, must be documented. Should the early studies demonstrate a potential for efficacy in a certain condition or disease state, an investigative protocol for an extended clinical trial is presented. The necessary requirements for Institutional Review Board (IRB) approval and consent forms are discussed. For certain research purposes, uniquely for radioactive drugs, an IND is not required for certain specific studies; the requirements for such a research study, conducted under the auspices of an approved radioactive drug research committee, are outlined

New technologies for production of radiopharmaceuticals and other medical preparations

International Nuclear Information System (INIS)

Bazaniak, Z.; Iller, E.; Mikolajczak, R.

2004-01-01

The Radioisotope Centre POLATOM belongs to the group of R and D institutions whose profile of activities comprises, besides applied research work, also manufacturing of a range of products based on implementation of the Centre's own developments. The Centre possesses considerable experience in its area of expertise: forty-six years of manufacturing of various radiation sources and radiopharmaceuticals, performing metrology and analysis of radioactive materials, which makes OBRI a unique R and D unit. The Centre is a chief manufacturer supplier of radiopharmaceuticals for nuclear medicine in Poland, and also an active exporter with a market of several tens countries. The current trends in the Centre activity assume combination of R and D work with practical application of its results for production purposes. The undertaken research topics are studied in co-operation with domestic and foreign scientific institutions. (author)

Analytical Chemistry Division annual progress report: For period ending December 31, 1987

International Nuclear Information System (INIS)

1988-05-01

This report is divided into analytical spectroscopy; radioactive materials analysis; inorganic chemistry; organic chemistry; ORNL environmental programs; quality assurance, safety, and training; supplementary activities; and presentation of research results

Analytical Chemistry Division annual progress report: For period ending December 31, 1987

Energy Technology Data Exchange (ETDEWEB)

1988-05-01

This report is divided into analytical spectroscopy; radioactive materials analysis; inorganic chemistry; organic chemistry; ORNL environmental programs; quality assurance, safety, and training; supplementary activities; and presentation of research results.

Positron emitting nuclides and their synthetic incorporation in radiopharmaceuticals

International Nuclear Information System (INIS)

Fowler, J.S.

1976-01-01

11 C, 13 N, and 15 O has potential applicability to the study of metabolism in humans. Problems in the synthesis of radiopharmaceuticals labeled with 11 C, 13 N, and 18 F are described: quality control, radiation exposure, carboxylic acids, glucose, amines, amino acids, nitrosources, fluoroethanol. 54 references

Report on the 1. research coordination meeting on 'Development of therapeutic radiopharmaceuticals based on {sup 177}Lu for radionuclide therapy'

Energy Technology Data Exchange (ETDEWEB)

NONE

2006-07-01

Radionuclide therapy (RNT) employing radiopharmaceuticals labelled with emitting radionuclides is fast emerging as an important part of nuclear medicine. Radionuclide therapy is effectively utilized for bone pain palliation, thus providing significant improvement in quality of life of patients suffering from pain resulting from bone metastasis. Targeting primary diseases by using specific carrier molecules labelled with radionuclides is also widely investigated and efficacious products have been emerging for the treatment of Lymphoma and Neuroendocrine tumours. In order to ensure the wider use of radiopharmaceuticals, it is essential to carefully consider the choice of radionuclides that together with the carrier molecules will give suitable pharmacokinetic properties and therapeutic efficacy. The criteria for the selection of a radionuclide for radiotherapy are suitable decay characteristics and amenable chemistry. However, the practical considerations in selecting a radionuclide for targeted therapy are availability in high radionuclidic purity as well as high specific activity and low production cost and comfortable delivery logistics. {sup 177}Lu is one of the isotopes emerging as a clear choice for therapy. Worldwide, the isotope is under investigation for approximately 30 different clinical applications, including treatment of colon cancer, metastatic bone cancer, non-Hodgkin's lymphoma, and lung cancer. {sup 177}Lu decays with a half-life of 6.71 d by emission of particles with E{sub max} of 497 keV (78.6%), 384 keV (9.1%) and 176 keV (12.2%). It also emits photons of 113 keV (6.4%) and 208 keV (11%), that are ideally suited for imaging the in-vivo localization and dosimetric calculations applying a gamma camera. The physical half-life of {sup 177}Lu is comparable to that of {sup 131}I, the most widely used therapeutic radionuclide. The long halflife of {sup 177}Lu provides logistic advantage for production, QA/QC of the products as well as feasibility to

VII. Boettstein Colloquium: PET-Radiopharmaceuticals at PSI: achievement and future prospects

International Nuclear Information System (INIS)

Schubiger, P.A.; Beer, H.F.; Blaeuenstein, P.; Leenders, K.E.

1993-01-01

The three sessions of the 1993 Boettstein colloquium dealt with the following topics: - PET-radiopharmaceuticals, - PET-scanning: significance of tracer uptake, - clinical options using PET. 22 papers were presented. figs., refs

VII. Boettstein Colloquium: PET-Radiopharmaceuticals at PSI: achievement and future prospects

Energy Technology Data Exchange (ETDEWEB)

Schubiger, P.A.; Beer, H.F.; Blaeuenstein, P.; Leenders, K.E.

1993-12-31

The three sessions of the 1993 Boettstein colloquium dealt with the following topics: - PET-radiopharmaceuticals, - PET-scanning: significance of tracer uptake, - clinical options using PET. 22 papers were presented. figs., refs.

VII. Boettstein Colloquium: PET-Radiopharmaceuticals at PSI: achievement and future prospects

Energy Technology Data Exchange (ETDEWEB)

Schubiger, P A; Beer, H F; Blaeuenstein, P; Leenders, K E

1994-12-31

The three sessions of the 1993 Boettstein colloquium dealt with the following topics: - PET-radiopharmaceuticals, - PET-scanning: significance of tracer uptake, - clinical options using PET. 22 papers were presented. figs., refs.

Animal models for the evaluation of radiopharmaceuticals to measure brian blood flow and function

International Nuclear Information System (INIS)

Welch, M.J.; Marshall, L.G.I.; Mathias, C.J.

1987-01-01

Several techniques have been utilized to carry out initial evaluation of radiopharmaceuticals labeled with technetium-99m and other radionuclides. The simplest technique is to measure the amount of radioactivity in the brain in rats or mice following the intravenous administration of these compounds; brain uptake and washout of radiopharmaceuticals can be estimated. More sophisticated techniques involve measuring the uptake and egress of the radiopharmaceutical following carotid artery administration in rats of primates. The Oldendorf technique compares a tracer with a standard compound e.g. tritiated water, to measure the brain uptake index of various compounds determined by decapiation at short times following administration. Another technique in which consecutive administrations of the compound to be studied and oxygen-15-labeled water are injected via the carotid artery of primates; the brain extraction and washout of the unknown tracer can be evaluated. The blood flow can be varied by altering the pCO 2 of the animal. Examples will be given and techniques compared

Radiopharmaceutical chelates and method of external imaging

International Nuclear Information System (INIS)

1976-01-01

The preparation of the following chemicals is described: chelates of technetium-99m, cobalt-57, gallium-67, gallium-68, indium-111 or indium-113m and a substituted iminodiacetic acid or an 8-hydroxyquinoline useful as a radiopharmaceutical external imaging agent. The compounds described are suitable for intravenous injection, have an excellent in vivo stability and are good organ seekers. Tin(II) choride or other tin(II) compounds are used as chelating agents

Radiopharmaceuticals in positron emission tomography: Radioisotope productions and radiolabelling procedures at the Austin and Repatriation Medical Centre

Energy Technology Data Exchange (ETDEWEB)

Tochon-Danguy, H.J.; Sachinidis, J.I.; Chan, J.G.; Cook, M. [Austin and Repatriation Medical Centre, Melbourne, VIC (Australia). Centre for Positron Emission Tomography

1997-10-01

Positron Emission Tomography (PET) is a technique that utilizes positron-emitting radiopharmaceuticals to map the physiology, biochemistry and pharmacology of the human body. Positron-emitting radioisotopes produced in a medical cyclotron are incorporated into compounds that are biologically active in the body. A scanner measures radioactivity emitted from a patient`s body and provides cross-sectional images of the distribution of these radiolabelled compounds in the body. It is the purpose of this paper to review the variety of PET radiopharmaceuticals currently produced at the Austin and Repatriation Medical Centre in Melbourne. Radioisotope production, radiolabelling of molecules and quality control of radiopharmaceuticals will be discussed. A few examples of their clinical applications will be shown as well. During the last five years we achieved a reliable routine production of various radiopharmaceuticals labelled with the four most important positron-emitters: oxygen-15 (t,{sub 1/2}=2min), nitrogen-13 (t{sub 1/2}= 10 min), carbon-11 (t{sub 1/2}=20 min) and fluorine-18 (t{sub 1/2}= 110 min). These radiopharmaceuticals include [{sup 15}O]oxygen, [{sup 15}O]carbon monoxide, [{sup 15}O]carbon dioxide, [{sup 15}O]water, [{sup 13}N]ammonia, [{sup 11}C]flumazenil, [{sup 11}C]SCH23390, [{sup 18}F]fluoromisonidazole and [{sup 18}F]fluoro-deoxy-glucose ([{sup 18}F]FDG). In addition, since the half life of [{sup 18}F] is almost two hours, regional distribution can be done, and the Austin and Repatriation Medical Centre is currently supplying [{sup 18}F]FDG in routine to other hospitals. Future new radiopharmaceuticals development include a [{sup 18}F]thymidine analog to measure cell proliferation and a [{sup 11}C]pyrroloisoquinoline to visualize serotonergic neuron abnormalities. (authors) 23 refs., 2 tabs.

Annual report 1993

International Nuclear Information System (INIS)

1994-01-01

The book is a collection of short communications being a review of the scientific activity of Institute of Nuclear Chemistry and Technology, Warsaw in 1993. The papers are gathered in several branches as follows: radiation chemistry and physics (9); radiochemistry, stable isotopes, nuclear analytical methods, general chemistry (22); radiobiology (6). The last biggest chapter devoted to nuclear technologies and methods is divided into four smaller groups concerning: process engineering (2); material engineering, structural studies, diagnostics (14); radiation technologies (8) and nuclear control systems (4). The annual report of INCT 1993 contains also a general information about the staff and organizations of the Institute, the full list of scientific publications and patents, conferences organized by INCT, Ph.D. and Sc.D. thesis and a list of projects granted by Committee of Scientific Research and other organizations in Poland and elsewhere

Evaluation of quality control of radiopharmaceuticals in Nuclear Medicine service; Avaliacao do controle de qualidade de radiofarmacos em servico de medicina nuclear

Energy Technology Data Exchange (ETDEWEB)

Tavares, Jamille A. Lopes; Lira, Renata F. de, E-mail: jam_alt@hotmail.com, E-mail: renatafariasdelira@hotmail.com [Universidade Federal de Pernambuco (UFPE), Recife (Brazil); Santos, Marcus Aurelio P. dos, E-mail: masantos@cnen.gov.br [Centro Regional de Ciencias Nucleares do Nordeste (CRCN-NE/CNEN-PE), Recife, PE (Brazil)

2014-07-01

Radiopharmaceuticals are a type of pharmaceutical preparation associated with radionuclides with purpose of diagnosis and therapy. Nuclear Medicine Services (NMS) should perform quality control of radiopharmaceuticals according to the recommendations of the manufacturer and scientific evidences accepted by the National Agency Sanitary Surveillance ( Brazilian ANVISA). This study evaluated the quality of the main radiopharmaceuticals in a NMS of the state of Pernambuco in relation to pH and radiochemical purity. The results showed that 96.8% of the radiopharmaceuticals showed radiochemical purity and all pH values were within the range recommended by the American pharmacopoeia. The study found that the quality control when inserted into the NMS, provides important data that allows exclusion of radiopharmaceuticals with low radiochemistry purity, favoring a reliable diagnosis and ensuring good radiation protection practices and biosecurity for patient and occupationally exposed individuals.

Isotope and Nuclear Chemistry Division annual report FY 1986, October 1985-September 1986

International Nuclear Information System (INIS)

Heiken, J.H.

1987-06-01

This report describes progress in the major research and development programs carried out in FY 1986 by the Isotope and Nuclear Chemistry Division. The report includes articles on radiochemical diagnostics and weapons tests; weapons radiochemical diagnostics research and development; other unclassified weapons research; stable and radioactive isotope production and separation; chemical biology and nuclear medicine; element and isotope transport and fixation; actinide and transition metal chemistry; structural chemistry, spectroscopy, and applications; nuclear structure and reactions; irradiation facilities; advanced concepts and technology; and atmospheric chemistry

Isotope and Nuclear Chemistry Division annual report FY 1986, October 1985-September 1986

Energy Technology Data Exchange (ETDEWEB)

Heiken, J.H. (ed.)

1987-06-01

This report describes progress in the major research and development programs carried out in FY 1986 by the Isotope and Nuclear Chemistry Division. The report includes articles on radiochemical diagnostics and weapons tests; weapons radiochemical diagnostics research and development; other unclassified weapons research; stable and radioactive isotope production and separation; chemical biology and nuclear medicine; element and isotope transport and fixation; actinide and transition metal chemistry; structural chemistry, spectroscopy, and applications; nuclear structure and reactions; irradiation facilities; advanced concepts and technology; and atmospheric chemistry.

Handling of radiopharmaceuticals drugs in hot cell: Implementation and validation of new hygiene procedures

International Nuclear Information System (INIS)

Levigoureux, E.; Hoffman, A.; Bolot, C.; Aulagner, G.; Brun, J.

2012-01-01

Exigencies associated with radiopharmaceutical drugs require validation of hygiene procedures. Different bio-cleaning processes were applied. For each, samples were collected from work surface, from preparation field and from the cap of multi-doses vial on agar contact. Twenty-two radiopharmaceutical preparations were inoculated in different liquid media. Results show that modification of bio-cleaning process enables a microbiological contamination reduction (p ≡ 0.0196). All preparations passed the sterility tests. Thus these results enabled the validation of new hygiene process in the radiopharmacy unit. (authors) [fr

Minimising activity and dose with enhanced image quality by radiopharmaceutical administrations

International Nuclear Information System (INIS)

Hoeschen, C.; Mattsson, S.; Cantone, M. C.; Mikuz, M.; Lacasta, C.; Ebel, G.; Clinthorne, N.; Giussani, A.

2010-01-01

Owing to the introduction of new diagnostic procedures, such as computed tomography (CT), positron emission tomography (PET) and single photon emission computed tomography (SPECT), the individual dose caused by medical exposures has grown rapidly in the last years. This is especially a subject to radiation protection for nuclear medical diagnosis, since in this case radiopharmaceuticals are administered to the patient, meaning not only a radiation exposure to the diseased tissue but also to the healthy tissues of large parts of the body. 'Minimizing Activity and Dose with Enhanced Image quality by Radiopharmaceutical Administrations' (MADEIRA) is a project co-funded by the European Commission within the Seventh Euratom Framework Programme that aims to improve three-dimensional (3D) nuclear medical imaging technologies significantly. MADEIRA is aiming to improve the efficacy and safety of 3D PET and SPECT functional imaging by optimising the spatial resolution and the signal-to-noise ratio, improving the knowledge of the temporal variation of the radiopharmaceuticals' uptake in and clearance from tumorous and healthy tissues, and evaluation of the corresponding patient dose. Using an optimised imaging procedure that improves the information gained per unit administered dose, MADEIRA aims especially to reduce the dose to healthy tissues of the patient. In this paper, an overall summary of the current achievements will be presented. (authors)

Preparation of Radiopharmaceuticals Labeled with Metal Radionuclides. Final Report

International Nuclear Information System (INIS)

Welch, M.J.

2012-01-01

The overall goal of this project was to develop methods for the production of metal-based radionuclides, to develop metal-based radiopharmaceuticals and in a limited number of cases, to translate these agents to the clinical situation. Initial work concentrated on the application of the radionuclides of Cu, Cu-60, Cu-61 and Cu-64, as well as application of Ga-68 radiopharmaceuticals. Initially Cu-64 was produced at the Missouri University Research Reactor and experiments carried out at Washington University. A limited number of studies were carried out utilizing Cu-62, a generator produced radionuclide produced by Mallinckrodt Inc. (now Covidien). In these studies, copper-62-labeled pyruvaldehyde Bis(N 4 -methylthiosemicarbazonato)-copper(II) was studied as an agent for cerebral myocardial perfusion. A remote system for the production of this radiopharmaceutical was developed and a limited number of patient studies carried out with this agent. Various other copper radiopharmaceuticals were investigated, these included copper labeled blood imaging agents as well as Cu-64 labeled antibodies. Cu-64 labeled antibodies targeting colon cancer were translated to the human situation. Cu-64 was also used to label peptides (Cu-64 octriatide) and this is one of the first applications of a peptide radiolabeled with a positron emitting metal radionuclide. Investigations were then pursued on the preparation of the copper radionuclides on a small biomedical cyclotron. A system for the production of high specific activity Cu-64 was developed and initially the Cu-64 was utilized to study the hypoxic imaging agent Cu-64 ATSM. Utilizing the same target system, other positron emitting metal radionuclides were produced, these were Y-86 and Ga-66. Radiopharmaceuticals were labeled utilizing both of these radionuclides. Many studies were carried out in animal models on the uptake of Cu-ATSM in hypoxic tissue. The hypothesis is that Cu-ATSM retention in vivo is dependent upon the oxygen

Isotope and Nuclear Chemistry Division annual report FY 1985, October 1984-September 1985

International Nuclear Information System (INIS)

Heiken, J.H.

1986-04-01

This report describes progress in the major research and development programs carried out in FY 1985 by the Isotope and Nuclear Chemistry Division. It covers radiochemical diagnostics of weapons tests; weapons radiochemical diagnostics research and development; other unclassified weapons research; stable and radioactive isotope production, separation, and applications (including biomedical applications); element and isotope transport and fixation; actinide and transition metal chemistry; structural chemistry, spectroscopy, and applications; nuclear structure and reactions; irradiations facilities; advanced analytical techniques; development and applications; atmospheric chemistry and transport; and earth and planetary processes

The 2015 Annual Meeting of SETAC German Language Branch in Zurich (7-10 September, 2015): ecotoxicology and environmental chemistry-from research to application

OpenAIRE

Werner, Inge; Aldrich, Annette; Becker, Benjamin; Becker, Dennis; Brinkmann, Markus; Burkhardt, Michael; Caspers, Norbert; Campiche, Sophie; Chèvre, Nathalie; Düring, Rolf-Alexander; Escher, Beate I.; Fischer, Fabian; Giebner, Sabrina; Heye, Katharina; Hollert, Henner

2016-01-01

This report provides a brief review of the 20th annual meeting of the German Language Branch of the Society of Environmental Toxicology and Chemistry (SETAC GLB) held from September 7th to 10th 2015 at ETH (Swiss Technical University) in Zurich, Switzerland. The event was chaired by Inge Werner, Director of the Swiss Centre for Applied Ecotoxicology (Ecotox Centre) Eawag-EPFL, and organized by a team from Ecotox Centre, Eawag, Federal Office of the Environment, Federal Office of Agriculture, ...

Role of a radiopharmacist in the development of a tumor-localizing radiopharmaceutical

International Nuclear Information System (INIS)

Briner, W.H.

1974-01-01

The development of a new radiopharmaceutical involves heavy responsibility relating to the safety of human lives. Although in past years the primary concern manifested by regulatory agencies was directed toward the radiation characteristics of these agents, more recent attention has been directed to the pharmaceutical quality of radioactive drugs. The technology of radiopharmaceutical design and formulation includes both aspects. Thus radiopharmacists have an exceedingly important role to play in this research and development area, for their training and experience in both the physical and biological sciences, their expertise in pharmaceutical formulation and quality control techniques, and their knowledge of laws and regulations that apply to all drugs can be invaluable. (U.S.)